{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "env: IEX_TOKEN=pk_02f114f931ba4b05978c6a05b390146e\n"
     ]
    }
   ],
   "source": [
    "import pyEX\n",
    "%env IEX_TOKEN=pk_02f114f931ba4b05978c6a05b390146e\n",
    "\n",
    "c = pyEX.Client()\n",
    "# c = pyEX.Client(version='sandbox')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Symbols data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>currency</th>\n",
       "      <th>date</th>\n",
       "      <th>exchange</th>\n",
       "      <th>iexId</th>\n",
       "      <th>isEnabled</th>\n",
       "      <th>name</th>\n",
       "      <th>region</th>\n",
       "      <th>type</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>A</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_46574843354B2D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Agilent Technologies Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AA</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_4238333734532D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Alcoa Corp.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAAU</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>PSE</td>\n",
       "      <td>IEX_474B433136332D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Perth Mint Physical Gold ETF</td>\n",
       "      <td>US</td>\n",
       "      <td>et</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AABA</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NAS</td>\n",
       "      <td>IEX_4E5434354A302D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Altaba Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cef</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAC</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_4843364642592D52</td>\n",
       "      <td>True</td>\n",
       "      <td>AAC Holdings Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       currency       date exchange                 iexId  isEnabled  \\\n",
       "symbol                                                                 \n",
       "A           USD 2019-06-13      NYS  IEX_46574843354B2D52       True   \n",
       "AA          USD 2019-06-13      NYS  IEX_4238333734532D52       True   \n",
       "AAAU        USD 2019-06-13      PSE  IEX_474B433136332D52       True   \n",
       "AABA        USD 2019-06-13      NAS  IEX_4E5434354A302D52       True   \n",
       "AAC         USD 2019-06-13      NYS  IEX_4843364642592D52       True   \n",
       "\n",
       "                                name region type  \n",
       "symbol                                            \n",
       "A          Agilent Technologies Inc.     US   cs  \n",
       "AA                       Alcoa Corp.     US   cs  \n",
       "AAAU    Perth Mint Physical Gold ETF     US   et  \n",
       "AABA                     Altaba Inc.     US  cef  \n",
       "AAC                AAC Holdings Inc.     US   cs  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.symbolsDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Symbols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'symbol': 'A',\n",
       "  'exchange': 'NYS',\n",
       "  'name': 'Agilent Technologies Inc.',\n",
       "  'date': '2019-06-13',\n",
       "  'type': 'cs',\n",
       "  'iexId': 'IEX_46574843354B2D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AA',\n",
       "  'exchange': 'NYS',\n",
       "  'name': 'Alcoa Corp.',\n",
       "  'date': '2019-06-13',\n",
       "  'type': 'cs',\n",
       "  'iexId': 'IEX_4238333734532D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AAAU',\n",
       "  'exchange': 'PSE',\n",
       "  'name': 'Perth Mint Physical Gold ETF',\n",
       "  'date': '2019-06-13',\n",
       "  'type': 'et',\n",
       "  'iexId': 'IEX_474B433136332D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AABA',\n",
       "  'exchange': 'NAS',\n",
       "  'name': 'Altaba Inc.',\n",
       "  'date': '2019-06-13',\n",
       "  'type': 'cef',\n",
       "  'iexId': 'IEX_4E5434354A302D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AAC',\n",
       "  'exchange': 'NYS',\n",
       "  'name': 'AAC Holdings Inc.',\n",
       "  'date': '2019-06-13',\n",
       "  'type': 'cs',\n",
       "  'iexId': 'IEX_4843364642592D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True}]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.symbols()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>currency</th>\n",
       "      <th>date</th>\n",
       "      <th>exchange</th>\n",
       "      <th>iexId</th>\n",
       "      <th>isEnabled</th>\n",
       "      <th>name</th>\n",
       "      <th>region</th>\n",
       "      <th>type</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>A</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_46574843354B2D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Agilent Technologies Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AA</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_4238333734532D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Alcoa Corp.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAAU</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>PSE</td>\n",
       "      <td>IEX_474B433136332D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Perth Mint Physical Gold ETF</td>\n",
       "      <td>US</td>\n",
       "      <td>et</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AABA</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NAS</td>\n",
       "      <td>IEX_4E5434354A302D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Altaba Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cef</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAC</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-06-13</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_4843364642592D52</td>\n",
       "      <td>True</td>\n",
       "      <td>AAC Holdings Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       currency       date exchange                 iexId  isEnabled  \\\n",
       "symbol                                                                 \n",
       "A           USD 2019-06-13      NYS  IEX_46574843354B2D52       True   \n",
       "AA          USD 2019-06-13      NYS  IEX_4238333734532D52       True   \n",
       "AAAU        USD 2019-06-13      PSE  IEX_474B433136332D52       True   \n",
       "AABA        USD 2019-06-13      NAS  IEX_4E5434354A302D52       True   \n",
       "AAC         USD 2019-06-13      NYS  IEX_4843364642592D52       True   \n",
       "\n",
       "                                name region type  \n",
       "symbol                                            \n",
       "A          Agilent Technologies Inc.     US   cs  \n",
       "AA                       Alcoa Corp.     US   cs  \n",
       "AAAU    Perth Mint Physical Gold ETF     US   et  \n",
       "AABA                     Altaba Inc.     US  cef  \n",
       "AAC                AAC Holdings Inc.     US   cs  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.symbolsDF().head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A', 'AA', 'AAAU', 'AABA', 'AAC']"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.symbolsList()[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## IEX Symbols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'symbol': 'A', 'date': '2019-05-07', 'isEnabled': True},\n",
       " {'symbol': 'AA', 'date': '2019-05-07', 'isEnabled': True},\n",
       " {'symbol': 'AAAU', 'date': '2019-05-07', 'isEnabled': True},\n",
       " {'symbol': 'AABA', 'date': '2019-05-07', 'isEnabled': True},\n",
       " {'symbol': 'AAC', 'date': '2019-05-07', 'isEnabled': True}]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.iexSymbols()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>date</th>\n",
       "      <th>isEnabled</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>A</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AA</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAAU</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AABA</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAC</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             date  isEnabled\n",
       "symbol                      \n",
       "A      2019-05-07       True\n",
       "AA     2019-05-07       True\n",
       "AAAU   2019-05-07       True\n",
       "AABA   2019-05-07       True\n",
       "AAC    2019-05-07       True"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.iexSymbolsDF().head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A', 'AA', 'AAAU', 'AABA', 'AAC', 'AADR', 'AAL', 'AAMC', 'AAME', 'AAN']"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.iexSymbolsList()[:10]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## International Symbols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'symbol': 'A',\n",
       "  'exchange': 'NYS',\n",
       "  'name': 'Agilent Technologies Inc.',\n",
       "  'date': '2019-05-07',\n",
       "  'type': 'cs',\n",
       "  'iexId': 'IEX_46574843354B2D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AA',\n",
       "  'exchange': 'NYS',\n",
       "  'name': 'Alcoa Corp.',\n",
       "  'date': '2019-05-07',\n",
       "  'type': 'cs',\n",
       "  'iexId': 'IEX_4238333734532D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AAAAX',\n",
       "  'exchange': 'NAS',\n",
       "  'name': 'DWS Alternative Asset Allocation Fund Class A',\n",
       "  'date': '2019-05-07',\n",
       "  'type': 'oef',\n",
       "  'iexId': 'IEX_4258444437432D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AAADX',\n",
       "  'exchange': 'NAS',\n",
       "  'name': 'Aberdeen Income Builder Fund - Class A',\n",
       "  'date': '2019-05-07',\n",
       "  'type': 'oef',\n",
       "  'iexId': 'IEX_5153364A51302D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True},\n",
       " {'symbol': 'AAAG',\n",
       "  'exchange': 'OTC',\n",
       "  'name': 'AAA Century Group USA Inc.',\n",
       "  'date': '2019-05-07',\n",
       "  'type': 'cs',\n",
       "  'iexId': 'IEX_4A534652444A2D52',\n",
       "  'region': 'US',\n",
       "  'currency': 'USD',\n",
       "  'isEnabled': True}]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.internationalSymbols()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>currency</th>\n",
       "      <th>date</th>\n",
       "      <th>exchange</th>\n",
       "      <th>iexId</th>\n",
       "      <th>isEnabled</th>\n",
       "      <th>name</th>\n",
       "      <th>region</th>\n",
       "      <th>type</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>A</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_46574843354B2D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Agilent Technologies Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AA</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>NYS</td>\n",
       "      <td>IEX_4238333734532D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Alcoa Corp.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAAAX</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>NAS</td>\n",
       "      <td>IEX_4258444437432D52</td>\n",
       "      <td>True</td>\n",
       "      <td>DWS Alternative Asset Allocation Fund Class A</td>\n",
       "      <td>US</td>\n",
       "      <td>oef</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAADX</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>NAS</td>\n",
       "      <td>IEX_5153364A51302D52</td>\n",
       "      <td>True</td>\n",
       "      <td>Aberdeen Income Builder Fund - Class A</td>\n",
       "      <td>US</td>\n",
       "      <td>oef</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAAG</th>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>OTC</td>\n",
       "      <td>IEX_4A534652444A2D52</td>\n",
       "      <td>True</td>\n",
       "      <td>AAA Century Group USA Inc.</td>\n",
       "      <td>US</td>\n",
       "      <td>cs</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       currency       date exchange                 iexId  isEnabled  \\\n",
       "symbol                                                                 \n",
       "A           USD 2019-05-07      NYS  IEX_46574843354B2D52       True   \n",
       "AA          USD 2019-05-07      NYS  IEX_4238333734532D52       True   \n",
       "AAAAX       USD 2019-05-07      NAS  IEX_4258444437432D52       True   \n",
       "AAADX       USD 2019-05-07      NAS  IEX_5153364A51302D52       True   \n",
       "AAAG        USD 2019-05-07      OTC  IEX_4A534652444A2D52       True   \n",
       "\n",
       "                                                 name region type  \n",
       "symbol                                                             \n",
       "A                           Agilent Technologies Inc.     US   cs  \n",
       "AA                                        Alcoa Corp.     US   cs  \n",
       "AAAAX   DWS Alternative Asset Allocation Fund Class A     US  oef  \n",
       "AAADX          Aberdeen Income Builder Fund - Class A     US  oef  \n",
       "AAAG                       AAA Century Group USA Inc.     US   cs  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.internationalSymbolsDF().head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A', 'AA', 'AAAAX', 'AAADX', 'AAAG']"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.internationalSymbolsList()[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## FX Symbols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'currencies': [{'code': 'EUR', 'name': 'Euro'},\n",
       "  {'code': 'USD', 'name': 'U.S. Dollar'},\n",
       "  {'code': 'GBP', 'name': 'British Pound'},\n",
       "  {'code': 'AUD', 'name': 'Australian Dollar'},\n",
       "  {'code': 'JPY', 'name': 'Japanese Yen'},\n",
       "  {'code': 'CNY', 'name': 'Chinese Yuan Renminbi'},\n",
       "  {'code': 'CAD', 'name': 'Canadian Dollar'},\n",
       "  {'code': 'CHF', 'name': 'Swiss Franc'},\n",
       "  {'code': 'ARS', 'name': 'Argentine Peso'},\n",
       "  {'code': 'BGN', 'name': 'Bulgarian Lev'},\n",
       "  {'code': 'BRL', 'name': 'Brazilian Real'},\n",
       "  {'code': 'CLP', 'name': 'Chilean Peso'},\n",
       "  {'code': 'COP', 'name': 'Colombian Peso'},\n",
       "  {'code': 'CZK', 'name': 'Czech Koruna'},\n",
       "  {'code': 'DKK', 'name': 'Danish Krone'},\n",
       "  {'code': 'HKD', 'name': 'Hong Kong Dollar'},\n",
       "  {'code': 'HUF', 'name': 'Hungarian Forint'},\n",
       "  {'code': 'IDR', 'name': 'Indonesian Rupiah'},\n",
       "  {'code': 'ILS', 'name': 'Israeli New Shekel'},\n",
       "  {'code': 'INR', 'name': 'Indian Rupee'},\n",
       "  {'code': 'KRW', 'name': 'Korean Won'},\n",
       "  {'code': 'KZT', 'name': 'Kazakhstan Tenge'},\n",
       "  {'code': 'MXN', 'name': 'Mexican Peso'},\n",
       "  {'code': 'MYR', 'name': 'Malaysian Ringgit'},\n",
       "  {'code': 'NOK', 'name': 'Norwegian Krone'},\n",
       "  {'code': 'NZD', 'name': 'New Zealand Dollar'},\n",
       "  {'code': 'PEN', 'name': 'Peruvian Nuevo Sol'},\n",
       "  {'code': 'PHP', 'name': 'Philippine Peso'},\n",
       "  {'code': 'PLN', 'name': 'Polish Zloty'},\n",
       "  {'code': 'RON', 'name': 'Romanian Leu'},\n",
       "  {'code': 'RUB', 'name': 'Russian Ruble'},\n",
       "  {'code': 'SEK', 'name': 'Swedish Krona'},\n",
       "  {'code': 'SGD', 'name': 'Singapore Dollar'},\n",
       "  {'code': 'THB', 'name': 'Thai Baht'},\n",
       "  {'code': 'TRY', 'name': 'Turkish Lira'},\n",
       "  {'code': 'TWD', 'name': 'Taiwan Dollar'},\n",
       "  {'code': 'UAH', 'name': 'Ukrainian Hryvna'},\n",
       "  {'code': 'VND', 'name': 'Vietnamese Dong'},\n",
       "  {'code': 'ZAR', 'name': 'South African Rand'},\n",
       "  {'code': 'HRK', 'name': 'Croatian Kuna'},\n",
       "  {'code': 'RSD', 'name': 'Serbian Dinar'}],\n",
       " 'pairs': [{'fromCurrency': 'EUR', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'GBP', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'GBP'},\n",
       "  {'fromCurrency': 'AUD', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'AUD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'CNY'},\n",
       "  {'fromCurrency': 'CNY', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'CAD'},\n",
       "  {'fromCurrency': 'CAD', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'CHF'},\n",
       "  {'fromCurrency': 'CHF', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'GBP'},\n",
       "  {'fromCurrency': 'GBP', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'CHF'},\n",
       "  {'fromCurrency': 'CHF', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'ARS'},\n",
       "  {'fromCurrency': 'ARS', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'BGN'},\n",
       "  {'fromCurrency': 'BGN', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'BRL'},\n",
       "  {'fromCurrency': 'BRL', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'CLP'},\n",
       "  {'fromCurrency': 'CLP', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'COP'},\n",
       "  {'fromCurrency': 'COP', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'CZK'},\n",
       "  {'fromCurrency': 'CZK', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'DKK'},\n",
       "  {'fromCurrency': 'DKK', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'HKD'},\n",
       "  {'fromCurrency': 'HKD', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'HUF'},\n",
       "  {'fromCurrency': 'HUF', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'IDR'},\n",
       "  {'fromCurrency': 'IDR', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'ILS'},\n",
       "  {'fromCurrency': 'ILS', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'INR'},\n",
       "  {'fromCurrency': 'INR', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'KRW'},\n",
       "  {'fromCurrency': 'KRW', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'KZT'},\n",
       "  {'fromCurrency': 'KZT', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'MXN'},\n",
       "  {'fromCurrency': 'MXN', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'MYR'},\n",
       "  {'fromCurrency': 'MYR', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'NOK'},\n",
       "  {'fromCurrency': 'NOK', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'NZD', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'NZD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'PEN'},\n",
       "  {'fromCurrency': 'PEN', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'PHP'},\n",
       "  {'fromCurrency': 'PHP', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'PLN'},\n",
       "  {'fromCurrency': 'PLN', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'RON'},\n",
       "  {'fromCurrency': 'RON', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'RUB'},\n",
       "  {'fromCurrency': 'RUB', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'SEK'},\n",
       "  {'fromCurrency': 'SEK', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'SGD'},\n",
       "  {'fromCurrency': 'SGD', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'THB'},\n",
       "  {'fromCurrency': 'THB', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'TRY'},\n",
       "  {'fromCurrency': 'TRY', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'TWD'},\n",
       "  {'fromCurrency': 'TWD', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'UAH'},\n",
       "  {'fromCurrency': 'UAH', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'VND'},\n",
       "  {'fromCurrency': 'VND', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'USD', 'toCurrency': 'ZAR'},\n",
       "  {'fromCurrency': 'ZAR', 'toCurrency': 'USD'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'AUD'},\n",
       "  {'fromCurrency': 'AUD', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'BGN'},\n",
       "  {'fromCurrency': 'BGN', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'CAD'},\n",
       "  {'fromCurrency': 'CAD', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'CNY'},\n",
       "  {'fromCurrency': 'CNY', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'CZK'},\n",
       "  {'fromCurrency': 'CZK', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'DKK'},\n",
       "  {'fromCurrency': 'DKK', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'HRK'},\n",
       "  {'fromCurrency': 'HRK', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'HUF'},\n",
       "  {'fromCurrency': 'HUF', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'INR'},\n",
       "  {'fromCurrency': 'INR', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'KRW'},\n",
       "  {'fromCurrency': 'KRW', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'KZT'},\n",
       "  {'fromCurrency': 'KZT', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'NOK'},\n",
       "  {'fromCurrency': 'NOK', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'NZD'},\n",
       "  {'fromCurrency': 'NZD', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'PLN'},\n",
       "  {'fromCurrency': 'PLN', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'RON'},\n",
       "  {'fromCurrency': 'RON', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'RSD'},\n",
       "  {'fromCurrency': 'RSD', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'RUB'},\n",
       "  {'fromCurrency': 'RUB', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'SEK'},\n",
       "  {'fromCurrency': 'SEK', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'TRY'},\n",
       "  {'fromCurrency': 'TRY', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'UAH'},\n",
       "  {'fromCurrency': 'UAH', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'EUR', 'toCurrency': 'ZAR'},\n",
       "  {'fromCurrency': 'ZAR', 'toCurrency': 'EUR'},\n",
       "  {'fromCurrency': 'CAD', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'CAD'},\n",
       "  {'fromCurrency': 'CHF', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'CHF'},\n",
       "  {'fromCurrency': 'NZD', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'NZD'},\n",
       "  {'fromCurrency': 'NOK', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'NOK'},\n",
       "  {'fromCurrency': 'ZAR', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'ZAR'},\n",
       "  {'fromCurrency': 'GBP', 'toCurrency': 'AUD'},\n",
       "  {'fromCurrency': 'AUD', 'toCurrency': 'GBP'},\n",
       "  {'fromCurrency': 'GBP', 'toCurrency': 'CHF'},\n",
       "  {'fromCurrency': 'CHF', 'toCurrency': 'GBP'},\n",
       "  {'fromCurrency': 'AUD', 'toCurrency': 'JPY'},\n",
       "  {'fromCurrency': 'JPY', 'toCurrency': 'AUD'},\n",
       "  {'fromCurrency': 'AUD', 'toCurrency': 'CAD'},\n",
       "  {'fromCurrency': 'CAD', 'toCurrency': 'AUD'}]}"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.fxSymbols()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>name</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>code</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>EUR</th>\n",
       "      <td>Euro</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>USD</th>\n",
       "      <td>U.S. Dollar</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>GBP</th>\n",
       "      <td>British Pound</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AUD</th>\n",
       "      <td>Australian Dollar</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>JPY</th>\n",
       "      <td>Japanese Yen</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   name\n",
       "code                   \n",
       "EUR                Euro\n",
       "USD         U.S. Dollar\n",
       "GBP       British Pound\n",
       "AUD   Australian Dollar\n",
       "JPY        Japanese Yen"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dfs = c.fxSymbolsDF()\n",
    "dfs[0].head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>fromCurrency</th>\n",
       "      <th>toCurrency</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>EUR</td>\n",
       "      <td>USD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>USD</td>\n",
       "      <td>EUR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>GBP</td>\n",
       "      <td>USD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>USD</td>\n",
       "      <td>GBP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>AUD</td>\n",
       "      <td>USD</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  fromCurrency toCurrency\n",
       "0          EUR        USD\n",
       "1          USD        EUR\n",
       "2          GBP        USD\n",
       "3          USD        GBP\n",
       "4          AUD        USD"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dfs[1].head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['EUR', 'USD', 'GBP', 'AUD', 'JPY']"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "l = c.fxSymbolsList()\n",
    "l[0][:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['EURUSD', 'USDEUR', 'GBPUSD', 'USDGBP', 'AUDUSD']"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "l[1][:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Options Symbols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['FLIC', 'TMQ-CT', 'GHM', 'MAS', 'HOMB']"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "d = c.optionsSymbols()\n",
    "list(d.keys())[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>expirations</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>A</th>\n",
       "      <td>[201905, 201906, 201908, 201911, 202001, 202101]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AA</th>\n",
       "      <td>[201905, 201906, 201907, 201910, 202001, 202101]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AABA</th>\n",
       "      <td>[201905, 201906, 201907, 201910, 202001, 202101]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAC</th>\n",
       "      <td>[201905, 201906, 201909, 201912]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAL</th>\n",
       "      <td>[201905, 201906, 201908, 201909, 201911, 20191...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                            expirations\n",
       "A      [201905, 201906, 201908, 201911, 202001, 202101]\n",
       "AA     [201905, 201906, 201907, 201910, 202001, 202101]\n",
       "AABA   [201905, 201906, 201907, 201910, 202001, 202101]\n",
       "AAC                    [201905, 201906, 201909, 201912]\n",
       "AAL   [201905, 201906, 201908, 201909, 201911, 20191..."
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.optionsSymbolsDF().head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A', 'AA', 'AABA', 'AAC', 'AAL']"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.optionsSymbolsList()[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## International Exchanges"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'exchange': 'ADS',\n",
       "  'region': 'AE',\n",
       "  'description': 'Abu Dhabi Securities Exchange',\n",
       "  'mic': 'XADS',\n",
       "  'exchangeSuffix': '-DH'},\n",
       " {'exchange': 'BRU',\n",
       "  'region': 'BE',\n",
       "  'description': 'Euronext Brussels',\n",
       "  'mic': 'XBRU',\n",
       "  'exchangeSuffix': '-BB'},\n",
       " {'exchange': 'ETR',\n",
       "  'region': 'DE',\n",
       "  'description': 'XETRA',\n",
       "  'mic': 'XETR',\n",
       "  'exchangeSuffix': '-GY'},\n",
       " {'exchange': 'PAR',\n",
       "  'region': 'FR',\n",
       "  'description': 'Euronext Paris',\n",
       "  'mic': 'XPAR',\n",
       "  'exchangeSuffix': '-FP'},\n",
       " {'exchange': 'LON',\n",
       "  'region': 'GB',\n",
       "  'description': 'London Stock Exchange',\n",
       "  'mic': 'XLON',\n",
       "  'exchangeSuffix': '-LN'}]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.internationalExchanges()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>description</th>\n",
       "      <th>exchange</th>\n",
       "      <th>exchangeSuffix</th>\n",
       "      <th>mic</th>\n",
       "      <th>region</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Abu Dhabi Securities Exchange</td>\n",
       "      <td>ADS</td>\n",
       "      <td>-DH</td>\n",
       "      <td>XADS</td>\n",
       "      <td>AE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Euronext Brussels</td>\n",
       "      <td>BRU</td>\n",
       "      <td>-BB</td>\n",
       "      <td>XBRU</td>\n",
       "      <td>BE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>XETRA</td>\n",
       "      <td>ETR</td>\n",
       "      <td>-GY</td>\n",
       "      <td>XETR</td>\n",
       "      <td>DE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Euronext Paris</td>\n",
       "      <td>PAR</td>\n",
       "      <td>-FP</td>\n",
       "      <td>XPAR</td>\n",
       "      <td>FR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>London Stock Exchange</td>\n",
       "      <td>LON</td>\n",
       "      <td>-LN</td>\n",
       "      <td>XLON</td>\n",
       "      <td>GB</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     description exchange exchangeSuffix   mic region\n",
       "0  Abu Dhabi Securities Exchange      ADS            -DH  XADS     AE\n",
       "1              Euronext Brussels      BRU            -BB  XBRU     BE\n",
       "2                          XETRA      ETR            -GY  XETR     DE\n",
       "3                 Euronext Paris      PAR            -FP  XPAR     FR\n",
       "4          London Stock Exchange      LON            -LN  XLON     GB"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.internationalExchangesDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## US Exchanges"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'mic': 'ARCX',\n",
       "  'name': 'NYSE Arca',\n",
       "  'longName': 'NYSE ARCA',\n",
       "  'tapeId': 'P',\n",
       "  'oatsId': 'XP',\n",
       "  'type': 'equities'},\n",
       " {'mic': 'EDGX',\n",
       "  'name': 'Cboe EDGX',\n",
       "  'longName': 'Cboe EDGX US Equities Exchange',\n",
       "  'tapeId': 'K',\n",
       "  'oatsId': 'XK',\n",
       "  'type': 'equities'},\n",
       " {'mic': 'BATS',\n",
       "  'name': 'Cboe BZX',\n",
       "  'longName': 'Cboe BZX US Equities Exchange',\n",
       "  'tapeId': 'Z',\n",
       "  'oatsId': 'XZ',\n",
       "  'type': 'equities'},\n",
       " {'mic': 'BATY',\n",
       "  'name': 'Cboe BYX',\n",
       "  'longName': 'Cboe BYX US Equities Exchange',\n",
       "  'tapeId': 'Y',\n",
       "  'oatsId': 'XY',\n",
       "  'type': 'equities'},\n",
       " {'mic': 'EDGA',\n",
       "  'name': 'Cboe EDGA',\n",
       "  'longName': 'Cboe EDGA US Equities Exchange',\n",
       "  'tapeId': 'J',\n",
       "  'oatsId': 'XJ',\n",
       "  'type': 'equities'}]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.exchanges()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>longName</th>\n",
       "      <th>mic</th>\n",
       "      <th>name</th>\n",
       "      <th>oatsId</th>\n",
       "      <th>tapeId</th>\n",
       "      <th>type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NYSE ARCA</td>\n",
       "      <td>ARCX</td>\n",
       "      <td>NYSE Arca</td>\n",
       "      <td>XP</td>\n",
       "      <td>P</td>\n",
       "      <td>equities</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cboe EDGX US Equities Exchange</td>\n",
       "      <td>EDGX</td>\n",
       "      <td>Cboe EDGX</td>\n",
       "      <td>XK</td>\n",
       "      <td>K</td>\n",
       "      <td>equities</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Cboe BZX US Equities Exchange</td>\n",
       "      <td>BATS</td>\n",
       "      <td>Cboe BZX</td>\n",
       "      <td>XZ</td>\n",
       "      <td>Z</td>\n",
       "      <td>equities</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Cboe BYX US Equities Exchange</td>\n",
       "      <td>BATY</td>\n",
       "      <td>Cboe BYX</td>\n",
       "      <td>XY</td>\n",
       "      <td>Y</td>\n",
       "      <td>equities</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Cboe EDGA US Equities Exchange</td>\n",
       "      <td>EDGA</td>\n",
       "      <td>Cboe EDGA</td>\n",
       "      <td>XJ</td>\n",
       "      <td>J</td>\n",
       "      <td>equities</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                         longName   mic       name oatsId tapeId      type\n",
       "0                       NYSE ARCA  ARCX  NYSE Arca     XP      P  equities\n",
       "1  Cboe EDGX US Equities Exchange  EDGX  Cboe EDGX     XK      K  equities\n",
       "2   Cboe BZX US Equities Exchange  BATS   Cboe BZX     XZ      Z  equities\n",
       "3   Cboe BYX US Equities Exchange  BATY   Cboe BYX     XY      Y  equities\n",
       "4  Cboe EDGA US Equities Exchange  EDGA  Cboe EDGA     XJ      J  equities"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.exchangesDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## US Holidays"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'date': '2019-05-27', 'settlementDate': '2019-05-29'}]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.holidays()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>date</th>\n",
       "      <th>settlementDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2019-05-27</td>\n",
       "      <td>2019-05-29</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        date settlementDate\n",
       "0 2019-05-27     2019-05-29"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.holidaysDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Sectors"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'name': 'Electronic Technology'},\n",
       " {'name': 'Distribution Services'},\n",
       " {'name': 'Health Technology'},\n",
       " {'name': 'Commercial Services'},\n",
       " {'name': 'Industrial Services'}]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.sectors()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Electronic Technology</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Distribution Services</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Health Technology</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Commercial Services</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Industrial Services</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                    name\n",
       "0  Electronic Technology\n",
       "1  Distribution Services\n",
       "2      Health Technology\n",
       "3    Commercial Services\n",
       "4    Industrial Services"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.sectorsDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Tags"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'name': 'Electronic Technology'},\n",
       " {'name': 'Distribution Services'},\n",
       " {'name': 'Commercial Services'},\n",
       " {'name': 'Health Technology'},\n",
       " {'name': 'Industrial Services'}]"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.tags()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Electronic Technology</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Distribution Services</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Commercial Services</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Health Technology</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Industrial Services</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                    name\n",
       "0  Electronic Technology\n",
       "1  Distribution Services\n",
       "2    Commercial Services\n",
       "3      Health Technology\n",
       "4    Industrial Services"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.tagsDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data Points API"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'key': 'DGS10',\n",
       "  'weight': 1,\n",
       "  'description': '10-Year Treasury Rate (daily)',\n",
       "  'lastUpdated': '2019-05-07T06:00:00+00:00'},\n",
       " {'key': 'DGS2',\n",
       "  'weight': 1,\n",
       "  'description': '2-Year Treasury Rate (daily)',\n",
       "  'lastUpdated': '2019-05-07T06:00:02+00:00'},\n",
       " {'key': 'DGS1',\n",
       "  'weight': 1,\n",
       "  'description': '1-Year Treasury Rate (daily)',\n",
       "  'lastUpdated': '2019-05-07T06:00:03+00:00'},\n",
       " {'key': 'DGS30',\n",
       "  'weight': 1,\n",
       "  'description': '30-Year Treasury Rate (daily)',\n",
       "  'lastUpdated': '2019-05-07T06:00:04+00:00'},\n",
       " {'key': 'DGS5',\n",
       "  'weight': 1,\n",
       "  'description': '5-Year Treasury Rate (daily)',\n",
       "  'lastUpdated': '2019-05-07T06:00:05+00:00'}]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.points()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>description</th>\n",
       "      <th>key</th>\n",
       "      <th>lastUpdated</th>\n",
       "      <th>weight</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10-Year Treasury Rate (daily)</td>\n",
       "      <td>DGS10</td>\n",
       "      <td>2019-05-07 06:00:00+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2-Year Treasury Rate (daily)</td>\n",
       "      <td>DGS2</td>\n",
       "      <td>2019-05-07 06:00:02+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1-Year Treasury Rate (daily)</td>\n",
       "      <td>DGS1</td>\n",
       "      <td>2019-05-07 06:00:03+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>30-Year Treasury Rate (daily)</td>\n",
       "      <td>DGS30</td>\n",
       "      <td>2019-05-07 06:00:04+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5-Year Treasury Rate (daily)</td>\n",
       "      <td>DGS5</td>\n",
       "      <td>2019-05-07 06:00:05+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     description    key               lastUpdated  weight\n",
       "0  10-Year Treasury Rate (daily)  DGS10 2019-05-07 06:00:00+00:00       1\n",
       "1   2-Year Treasury Rate (daily)   DGS2 2019-05-07 06:00:02+00:00       1\n",
       "2   1-Year Treasury Rate (daily)   DGS1 2019-05-07 06:00:03+00:00       1\n",
       "3  30-Year Treasury Rate (daily)  DGS30 2019-05-07 06:00:04+00:00       1\n",
       "4   5-Year Treasury Rate (daily)   DGS5 2019-05-07 06:00:05+00:00       1"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.pointsDF().head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2.49"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.points(key='DGS10')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>description</th>\n",
       "      <th>key</th>\n",
       "      <th>lastUpdated</th>\n",
       "      <th>weight</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Quote: latestPrice</td>\n",
       "      <td>QUOTE-LATESTPRICE</td>\n",
       "      <td>2019-05-07 20:29:16+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Quote: latestVolume</td>\n",
       "      <td>QUOTE-LATESTVOLUME</td>\n",
       "      <td>2019-05-07 20:29:16+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Quote: latestUpdate</td>\n",
       "      <td>QUOTE-LATESTUPDATE</td>\n",
       "      <td>2019-05-07 20:29:16+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Quote: change</td>\n",
       "      <td>QUOTE-CHANGE</td>\n",
       "      <td>2019-05-07 20:29:16+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Quote: changePercent</td>\n",
       "      <td>QUOTE-CHANGEPERCENT</td>\n",
       "      <td>2019-05-07 20:29:16+00:00</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            description                  key               lastUpdated  weight\n",
       "0    Quote: latestPrice    QUOTE-LATESTPRICE 2019-05-07 20:29:16+00:00       1\n",
       "1   Quote: latestVolume   QUOTE-LATESTVOLUME 2019-05-07 20:29:16+00:00       1\n",
       "2   Quote: latestUpdate   QUOTE-LATESTUPDATE 2019-05-07 20:29:16+00:00       1\n",
       "3         Quote: change         QUOTE-CHANGE 2019-05-07 20:29:16+00:00       1\n",
       "4  Quote: changePercent  QUOTE-CHANGEPERCENT 2019-05-07 20:29:16+00:00       1"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.pointsDF('aapl').head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "202.86"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.points('aapl', 'QUOTE-LATESTPRICE')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Stock API"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "symbol = 'AAPL'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Advanced Stats"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'week52change': 0.125945,\n",
       " 'week52high': 233.47,\n",
       " 'week52low': 142,\n",
       " 'marketcap': 959233158400,\n",
       " 'employees': 132000,\n",
       " 'day200MovingAvg': 192.36,\n",
       " 'day50MovingAvg': 191.93,\n",
       " 'float': 4594455231,\n",
       " 'avg10Volume': 29695469,\n",
       " 'avg30Volume': 27470517.9,\n",
       " 'ttmEPS': 11.99,\n",
       " 'ttmDividendRate': 2.92,\n",
       " 'companyName': 'Apple, Inc.',\n",
       " 'sharesOutstanding': 4601080000,\n",
       " 'maxChangePercent': 205.130117,\n",
       " 'year5ChangePercent': 1.463761,\n",
       " 'year2ChangePercent': 0.362525,\n",
       " 'year1ChangePercent': 0.125945,\n",
       " 'ytdChangePercent': 0.320162,\n",
       " 'month6ChangePercent': -0.007002,\n",
       " 'month3ChangePercent': 0.219609,\n",
       " 'month1ChangePercent': 0.041879,\n",
       " 'day30ChangePercent': 0.104588,\n",
       " 'day5ChangePercent': 0.03892,\n",
       " 'nextDividendDate': '2019-05-10',\n",
       " 'dividendYield': 0.014006139677666923,\n",
       " 'nextEarningsDate': '2019-07-22',\n",
       " 'exDividendDate': '2019-05-10',\n",
       " 'peRatio': 16.92,\n",
       " 'beta': 1.454167231727185,\n",
       " 'totalCash': 66301000000,\n",
       " 'currentDebt': 20748000000,\n",
       " 'revenue': 265809000000,\n",
       " 'grossProfit': 101983000000,\n",
       " 'totalRevenue': 265809000000,\n",
       " 'EBITDA': 80342000000,\n",
       " 'revenuePerShare': 0.02,\n",
       " 'revenuePerEmployee': 2013704.55,\n",
       " 'debtToEquity': 1.07,\n",
       " 'profitMargin': 0.22396156638789508,\n",
       " 'enterpriseValue': 1022460690000,\n",
       " 'enterpriseValueToRevenue': 3.85,\n",
       " 'priceToSales': 3.67,\n",
       " 'priceToBook': 8.95249664852959,\n",
       " 'forwardPERatio': 18.14,\n",
       " 'pegRatio': -1.76,\n",
       " 'peHigh': '19.635828427249788',\n",
       " 'peLow': '11.942809083263246'}"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.advancedStats(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>EBITDA</th>\n",
       "      <th>avg10Volume</th>\n",
       "      <th>avg30Volume</th>\n",
       "      <th>beta</th>\n",
       "      <th>companyName</th>\n",
       "      <th>currentDebt</th>\n",
       "      <th>day200MovingAvg</th>\n",
       "      <th>day30ChangePercent</th>\n",
       "      <th>day50MovingAvg</th>\n",
       "      <th>day5ChangePercent</th>\n",
       "      <th>...</th>\n",
       "      <th>totalRevenue</th>\n",
       "      <th>ttmDividendRate</th>\n",
       "      <th>ttmEPS</th>\n",
       "      <th>week52change</th>\n",
       "      <th>week52high</th>\n",
       "      <th>week52low</th>\n",
       "      <th>year1ChangePercent</th>\n",
       "      <th>year2ChangePercent</th>\n",
       "      <th>year5ChangePercent</th>\n",
       "      <th>ytdChangePercent</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>80342000000</td>\n",
       "      <td>29695469</td>\n",
       "      <td>27470517.9</td>\n",
       "      <td>1.454167</td>\n",
       "      <td>Apple, Inc.</td>\n",
       "      <td>20748000000</td>\n",
       "      <td>192.36</td>\n",
       "      <td>0.104588</td>\n",
       "      <td>191.93</td>\n",
       "      <td>0.03892</td>\n",
       "      <td>...</td>\n",
       "      <td>265809000000</td>\n",
       "      <td>2.92</td>\n",
       "      <td>11.99</td>\n",
       "      <td>0.125945</td>\n",
       "      <td>233.47</td>\n",
       "      <td>142</td>\n",
       "      <td>0.125945</td>\n",
       "      <td>0.362525</td>\n",
       "      <td>1.463761</td>\n",
       "      <td>0.320162</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows  48 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        EBITDA  avg10Volume  avg30Volume      beta  companyName  currentDebt  \\\n",
       "0  80342000000     29695469   27470517.9  1.454167  Apple, Inc.  20748000000   \n",
       "\n",
       "   day200MovingAvg  day30ChangePercent  day50MovingAvg  day5ChangePercent  \\\n",
       "0           192.36            0.104588          191.93            0.03892   \n",
       "\n",
       "   ...  totalRevenue  ttmDividendRate  ttmEPS  week52change  week52high  \\\n",
       "0  ...  265809000000             2.92   11.99      0.125945      233.47   \n",
       "\n",
       "  week52low  year1ChangePercent  year2ChangePercent  year5ChangePercent  \\\n",
       "0       142            0.125945            0.362525            1.463761   \n",
       "\n",
       "   ytdChangePercent  \n",
       "0          0.320162  \n",
       "\n",
       "[1 rows x 48 columns]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.advancedStatsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Balance Sheet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'balancesheet': [{'reportDate': '2019-03-31',\n",
       "   'currentCash': 38329000000,\n",
       "   'shortTermInvestments': 42104000000,\n",
       "   'receivables': 15085000000,\n",
       "   'inventory': 4884000000,\n",
       "   'otherCurrentAssets': 11751000000,\n",
       "   'currentAssets': 123346000000,\n",
       "   'longTermInvestments': 146807000000,\n",
       "   'propertyPlantEquipment': 38746000000,\n",
       "   'goodwill': 0,\n",
       "   'intangibleAssets': None,\n",
       "   'otherAssets': 33099000000,\n",
       "   'totalAssets': 341998000000,\n",
       "   'accountsPayable': 30443000000,\n",
       "   'currentLongTermDebt': 10505000000,\n",
       "   'otherCurrentLiabilities': 40900000000,\n",
       "   'totalCurrentLiabilities': 93772000000,\n",
       "   'longTermDebt': 90201000000,\n",
       "   'otherLiabilities': 6279000000,\n",
       "   'minorityInterest': 0,\n",
       "   'totalLiabilities': 236138000000,\n",
       "   'commonStock': 42801000000,\n",
       "   'retainedEarnings': 64558000000,\n",
       "   'treasuryStock': None,\n",
       "   'capitalSurplus': None,\n",
       "   'shareholderEquity': 105860000000,\n",
       "   'netTangibleAssets': 105860000000}]}"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.balanceSheet(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>accountsPayable</th>\n",
       "      <th>capitalSurplus</th>\n",
       "      <th>commonStock</th>\n",
       "      <th>currentAssets</th>\n",
       "      <th>currentCash</th>\n",
       "      <th>currentLongTermDebt</th>\n",
       "      <th>goodwill</th>\n",
       "      <th>intangibleAssets</th>\n",
       "      <th>inventory</th>\n",
       "      <th>longTermDebt</th>\n",
       "      <th>...</th>\n",
       "      <th>propertyPlantEquipment</th>\n",
       "      <th>receivables</th>\n",
       "      <th>retainedEarnings</th>\n",
       "      <th>shareholderEquity</th>\n",
       "      <th>shortTermInvestments</th>\n",
       "      <th>totalAssets</th>\n",
       "      <th>totalCurrentLiabilities</th>\n",
       "      <th>totalLiabilities</th>\n",
       "      <th>treasuryStock</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>reportDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-03-31</th>\n",
       "      <td>30443000000</td>\n",
       "      <td>None</td>\n",
       "      <td>42801000000</td>\n",
       "      <td>123346000000</td>\n",
       "      <td>38329000000</td>\n",
       "      <td>10505000000</td>\n",
       "      <td>0</td>\n",
       "      <td>None</td>\n",
       "      <td>4884000000</td>\n",
       "      <td>90201000000</td>\n",
       "      <td>...</td>\n",
       "      <td>38746000000</td>\n",
       "      <td>15085000000</td>\n",
       "      <td>64558000000</td>\n",
       "      <td>105860000000</td>\n",
       "      <td>42104000000</td>\n",
       "      <td>341998000000</td>\n",
       "      <td>93772000000</td>\n",
       "      <td>236138000000</td>\n",
       "      <td>None</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows  27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            accountsPayable capitalSurplus  commonStock  currentAssets  \\\n",
       "reportDate                                                               \n",
       "2019-03-31      30443000000           None  42801000000   123346000000   \n",
       "\n",
       "            currentCash  currentLongTermDebt  goodwill intangibleAssets  \\\n",
       "reportDate                                                                \n",
       "2019-03-31  38329000000          10505000000         0             None   \n",
       "\n",
       "             inventory  longTermDebt  ...  propertyPlantEquipment  \\\n",
       "reportDate                            ...                           \n",
       "2019-03-31  4884000000   90201000000  ...             38746000000   \n",
       "\n",
       "            receivables  retainedEarnings  shareholderEquity  \\\n",
       "reportDate                                                     \n",
       "2019-03-31  15085000000       64558000000       105860000000   \n",
       "\n",
       "            shortTermInvestments   totalAssets  totalCurrentLiabilities  \\\n",
       "reportDate                                                                \n",
       "2019-03-31           42104000000  341998000000              93772000000   \n",
       "\n",
       "            totalLiabilities  treasuryStock  symbol  \n",
       "reportDate                                           \n",
       "2019-03-31      236138000000           None    AAPL  \n",
       "\n",
       "[1 rows x 27 columns]"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.balanceSheetDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Book"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'quote': {'symbol': 'AAPL',\n",
       "  'companyName': 'Apple, Inc.',\n",
       "  'calculationPrice': 'close',\n",
       "  'open': 205.86,\n",
       "  'openTime': 1557235800311,\n",
       "  'close': 202.86,\n",
       "  'closeTime': 1557259200243,\n",
       "  'high': 207.417,\n",
       "  'low': 200.825,\n",
       "  'latestPrice': 202.86,\n",
       "  'latestSource': 'Close',\n",
       "  'latestTime': 'May 7, 2019',\n",
       "  'latestUpdate': 1557259200243,\n",
       "  'latestVolume': 38382396,\n",
       "  'iexRealtimePrice': 202.89,\n",
       "  'iexRealtimeSize': 100,\n",
       "  'iexLastUpdated': 1557259199899,\n",
       "  'delayedPrice': 202.86,\n",
       "  'delayedPriceTime': 1557259201283,\n",
       "  'extendedPrice': 203.08,\n",
       "  'extendedChange': 0.22,\n",
       "  'extendedChangePercent': 0.00108,\n",
       "  'extendedPriceTime': 1557260091760,\n",
       "  'previousClose': 208.48,\n",
       "  'change': -5.62,\n",
       "  'changePercent': -0.02696,\n",
       "  'iexMarketPercent': 0.022655255810502293,\n",
       "  'iexVolume': 869563,\n",
       "  'avgTotalVolume': 27470518,\n",
       "  'iexBidPrice': 0,\n",
       "  'iexBidSize': 0,\n",
       "  'iexAskPrice': 0,\n",
       "  'iexAskSize': 0,\n",
       "  'marketCap': 933375088800,\n",
       "  'peRatio': 16.92,\n",
       "  'week52High': 233.47,\n",
       "  'week52Low': 142,\n",
       "  'ytdChange': 0.293202},\n",
       " 'bids': [],\n",
       " 'asks': [],\n",
       " 'trades': [{'price': 202.89,\n",
       "   'size': 100,\n",
       "   'tradeId': 1369002144,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259199899},\n",
       "  {'price': 202.89,\n",
       "   'size': 100,\n",
       "   'tradeId': 1369002130,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259199899},\n",
       "  {'price': 202.85,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368943918,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259199769},\n",
       "  {'price': 202.83,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368817668,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259199419},\n",
       "  {'price': 202.76,\n",
       "   'size': 300,\n",
       "   'tradeId': 1368669281,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': True,\n",
       "   'timestamp': 1557259199027},\n",
       "  {'price': 202.75,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368668777,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259199027},\n",
       "  {'price': 202.75,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368668745,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259199027},\n",
       "  {'price': 202.79,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368549344,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259198487},\n",
       "  {'price': 202.79,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368549338,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259198487},\n",
       "  {'price': 202.82,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368496168,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259198202},\n",
       "  {'price': 202.82,\n",
       "   'size': 12,\n",
       "   'tradeId': 1368271085,\n",
       "   'isISO': False,\n",
       "   'isOddLot': True,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197370},\n",
       "  {'price': 202.82,\n",
       "   'size': 12,\n",
       "   'tradeId': 1368271035,\n",
       "   'isISO': False,\n",
       "   'isOddLot': True,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197370},\n",
       "  {'price': 202.86,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368225389,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197202},\n",
       "  {'price': 202.86,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368225371,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197202},\n",
       "  {'price': 202.89,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368160699,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197052},\n",
       "  {'price': 202.89,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368160648,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197052},\n",
       "  {'price': 202.82,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368110917,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197002},\n",
       "  {'price': 202.82,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368110875,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259197002},\n",
       "  {'price': 202.76,\n",
       "   'size': 100,\n",
       "   'tradeId': 1368094554,\n",
       "   'isISO': False,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259196891},\n",
       "  {'price': 202.79,\n",
       "   'size': 100,\n",
       "   'tradeId': 1367963797,\n",
       "   'isISO': True,\n",
       "   'isOddLot': False,\n",
       "   'isOutsideRegularHours': False,\n",
       "   'isSinglePriceCross': False,\n",
       "   'isTradeThroughExempt': False,\n",
       "   'timestamp': 1557259196401}],\n",
       " 'systemEvent': {'systemEvent': 'M', 'timestamp': 1557259200001}}"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.book(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>avgTotalVolume</th>\n",
       "      <th>calculationPrice</th>\n",
       "      <th>change</th>\n",
       "      <th>changePercent</th>\n",
       "      <th>close</th>\n",
       "      <th>closeTime</th>\n",
       "      <th>companyName</th>\n",
       "      <th>delayedPrice</th>\n",
       "      <th>delayedPriceTime</th>\n",
       "      <th>extendedChange</th>\n",
       "      <th>...</th>\n",
       "      <th>previousClose</th>\n",
       "      <th>price</th>\n",
       "      <th>size</th>\n",
       "      <th>symbol</th>\n",
       "      <th>timestamp</th>\n",
       "      <th>tradeId</th>\n",
       "      <th>type</th>\n",
       "      <th>week52High</th>\n",
       "      <th>week52Low</th>\n",
       "      <th>ytdChange</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>27470518.0</td>\n",
       "      <td>close</td>\n",
       "      <td>-5.62</td>\n",
       "      <td>-0.02696</td>\n",
       "      <td>202.86</td>\n",
       "      <td>2019-05-07 20:00:00.243</td>\n",
       "      <td>Apple, Inc.</td>\n",
       "      <td>202.86</td>\n",
       "      <td>2019-05-07 20:00:01.283</td>\n",
       "      <td>0.22</td>\n",
       "      <td>...</td>\n",
       "      <td>208.48</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>quote</td>\n",
       "      <td>233.47</td>\n",
       "      <td>142.0</td>\n",
       "      <td>0.293202</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>202.89</td>\n",
       "      <td>100.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>2019-05-07 19:59:59.899</td>\n",
       "      <td>1.369002e+09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>202.89</td>\n",
       "      <td>100.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>2019-05-07 19:59:59.899</td>\n",
       "      <td>1.369002e+09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>202.85</td>\n",
       "      <td>100.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>2019-05-07 19:59:59.769</td>\n",
       "      <td>1.368944e+09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>202.83</td>\n",
       "      <td>100.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>2019-05-07 19:59:59.419</td>\n",
       "      <td>1.368818e+09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  48 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   avgTotalVolume calculationPrice  change  changePercent   close  \\\n",
       "0      27470518.0            close   -5.62       -0.02696  202.86   \n",
       "0             NaN              NaN     NaN            NaN     NaN   \n",
       "1             NaN              NaN     NaN            NaN     NaN   \n",
       "2             NaN              NaN     NaN            NaN     NaN   \n",
       "3             NaN              NaN     NaN            NaN     NaN   \n",
       "\n",
       "                closeTime  companyName  delayedPrice        delayedPriceTime  \\\n",
       "0 2019-05-07 20:00:00.243  Apple, Inc.        202.86 2019-05-07 20:00:01.283   \n",
       "0                     NaT          NaN           NaN                     NaT   \n",
       "1                     NaT          NaN           NaN                     NaT   \n",
       "2                     NaT          NaN           NaN                     NaT   \n",
       "3                     NaT          NaN           NaN                     NaT   \n",
       "\n",
       "   extendedChange  ...  previousClose   price   size  symbol  \\\n",
       "0            0.22  ...         208.48     NaN    NaN    AAPL   \n",
       "0             NaN  ...            NaN  202.89  100.0    AAPL   \n",
       "1             NaN  ...            NaN  202.89  100.0    AAPL   \n",
       "2             NaN  ...            NaN  202.85  100.0    AAPL   \n",
       "3             NaN  ...            NaN  202.83  100.0    AAPL   \n",
       "\n",
       "                timestamp       tradeId   type  week52High week52Low  \\\n",
       "0                     NaT           NaN  quote      233.47     142.0   \n",
       "0 2019-05-07 19:59:59.899  1.369002e+09    NaN         NaN       NaN   \n",
       "1 2019-05-07 19:59:59.899  1.369002e+09    NaN         NaN       NaN   \n",
       "2 2019-05-07 19:59:59.769  1.368944e+09    NaN         NaN       NaN   \n",
       "3 2019-05-07 19:59:59.419  1.368818e+09    NaN         NaN       NaN   \n",
       "\n",
       "   ytdChange  \n",
       "0   0.293202  \n",
       "0        NaN  \n",
       "1        NaN  \n",
       "2        NaN  \n",
       "3        NaN  \n",
       "\n",
       "[5 rows x 48 columns]"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.bookDF(symbol).head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cashflow"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'cashflow': [{'reportDate': '2019-03-31',\n",
       "   'netIncome': 11561000000,\n",
       "   'depreciation': 3040000000,\n",
       "   'changesInReceivables': 2992000000,\n",
       "   'changesInInventories': 70000000,\n",
       "   'cashChange': -4954000000,\n",
       "   'cashFlow': 11155000000,\n",
       "   'capitalExpenditures': -2363000000,\n",
       "   'investments': 15749000000,\n",
       "   'investingActivityOther': 56000000,\n",
       "   'totalInvestingCashFlows': 13348000000,\n",
       "   'dividendsPaid': -3443000000,\n",
       "   'netBorrowings': -2506000000,\n",
       "   'otherFinancingCashFlows': -196000000,\n",
       "   'cashFlowFinancing': -29457000000,\n",
       "   'exchangeRateEffect': None}]}"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.cashFlow(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>capitalExpenditures</th>\n",
       "      <th>cashChange</th>\n",
       "      <th>cashFlow</th>\n",
       "      <th>cashFlowFinancing</th>\n",
       "      <th>changesInInventories</th>\n",
       "      <th>changesInReceivables</th>\n",
       "      <th>depreciation</th>\n",
       "      <th>dividendsPaid</th>\n",
       "      <th>exchangeRateEffect</th>\n",
       "      <th>investingActivityOther</th>\n",
       "      <th>investments</th>\n",
       "      <th>netBorrowings</th>\n",
       "      <th>netIncome</th>\n",
       "      <th>otherFinancingCashFlows</th>\n",
       "      <th>totalInvestingCashFlows</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>reportDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-03-31</th>\n",
       "      <td>-2363000000</td>\n",
       "      <td>-4954000000</td>\n",
       "      <td>11155000000</td>\n",
       "      <td>-29457000000</td>\n",
       "      <td>70000000</td>\n",
       "      <td>2992000000</td>\n",
       "      <td>3040000000</td>\n",
       "      <td>-3443000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>56000000</td>\n",
       "      <td>15749000000</td>\n",
       "      <td>-2506000000</td>\n",
       "      <td>11561000000</td>\n",
       "      <td>-196000000</td>\n",
       "      <td>13348000000</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            capitalExpenditures  cashChange     cashFlow  cashFlowFinancing  \\\n",
       "reportDate                                                                    \n",
       "2019-03-31          -2363000000 -4954000000  11155000000       -29457000000   \n",
       "\n",
       "            changesInInventories  changesInReceivables  depreciation  \\\n",
       "reportDate                                                             \n",
       "2019-03-31              70000000            2992000000    3040000000   \n",
       "\n",
       "            dividendsPaid  exchangeRateEffect  investingActivityOther  \\\n",
       "reportDate                                                              \n",
       "2019-03-31    -3443000000                 NaN                56000000   \n",
       "\n",
       "            investments  netBorrowings    netIncome  otherFinancingCashFlows  \\\n",
       "reportDate                                                                     \n",
       "2019-03-31  15749000000    -2506000000  11561000000               -196000000   \n",
       "\n",
       "            totalInvestingCashFlows symbol  \n",
       "reportDate                                  \n",
       "2019-03-31              13348000000   AAPL  "
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.cashFlowDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Collections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\u001b[0;31mSignature:\u001b[0m       \u001b[0mc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcollections\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmeth\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m<\u001b[0m\u001b[0mfunction\u001b[0m \u001b[0mcollections\u001b[0m \u001b[0mat\u001b[0m \u001b[0;36m0x119c3bf28\u001b[0m\u001b[0;34m>\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
       "\u001b[0;31mCall signature:\u001b[0m  \u001b[0mc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcollections\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
       "\u001b[0;31mType:\u001b[0m            partial\n",
       "\u001b[0;31mString form:\u001b[0m     functools.partial(<bound method Client.bind of <pyEX.client.Client object at 0x1195fca58>>, meth=<function collections at 0x119c3bf28>)\n",
       "\u001b[0;31mFile:\u001b[0m            /usr/local/Cellar/python/3.7.3/Frameworks/Python.framework/Versions/3.7/lib/python3.7/functools.py\n",
       "\u001b[0;31mDocstring:\u001b[0m      \n",
       "Returns an array of quote objects for a given collection type. Currently supported collection types are sector, tag, and list\n",
       "\n",
       "\n",
       "https://iexcloud.io/docs/api/#collections\n",
       "\n",
       "Args:\n",
       "    tag (string);  Sector, Tag, or List\n",
       "    collectionName (string);  Associated name for tag\n",
       "    token (string); Access token\n",
       "    version (string); API version\n",
       "\n",
       "Returns:\n",
       "    dict: result\n",
       "\u001b[0;31mClass docstring:\u001b[0m\n",
       "partial(func, *args, **keywords) - new function with partial application\n",
       "of the given arguments and keywords.\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "c.collections?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\u001b[0;31mSignature:\u001b[0m      \n",
       "\u001b[0mc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcollectionsDF\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\u001b[0m\n",
       "\u001b[0;34m\u001b[0m    \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\n",
       "\u001b[0;34m\u001b[0m    \u001b[0mmeth\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m<\u001b[0m\u001b[0mfunction\u001b[0m \u001b[0mcollectionsDF\u001b[0m \u001b[0mat\u001b[0m \u001b[0;36m0x119e58048\u001b[0m\u001b[0;34m>\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\n",
       "\u001b[0;34m\u001b[0m    \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\n",
       "\u001b[0;34m\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
       "\u001b[0;31mCall signature:\u001b[0m  \u001b[0mc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcollectionsDF\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
       "\u001b[0;31mType:\u001b[0m            partial\n",
       "\u001b[0;31mString form:\u001b[0m     functools.partial(<bound method Client.bind of <pyEX.client.Client object at 0x1195fca58>>, meth=<function collectionsDF at 0x119e58048>)\n",
       "\u001b[0;31mFile:\u001b[0m            /usr/local/Cellar/python/3.7.3/Frameworks/Python.framework/Versions/3.7/lib/python3.7/functools.py\n",
       "\u001b[0;31mDocstring:\u001b[0m      \n",
       "Returns an array of quote objects for a given collection type. Currently supported collection types are sector, tag, and list\n",
       "\n",
       "\n",
       "https://iexcloud.io/docs/api/#collections\n",
       "\n",
       "Args:\n",
       "    tag (string);  Sector, Tag, or List\n",
       "    collectionName (string);  Associated name for tag\n",
       "    token (string); Access token\n",
       "    version (string); API version\n",
       "\n",
       "Returns:\n",
       "    DataFrame: result\n",
       "\u001b[0;31mClass docstring:\u001b[0m\n",
       "partial(func, *args, **keywords) - new function with partial application\n",
       "of the given arguments and keywords.\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "c.collectionsDF?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Company"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'companyName': 'Apple, Inc.',\n",
       " 'exchange': 'NASDAQ',\n",
       " 'industry': 'Telecommunications Equipment',\n",
       " 'website': 'http://www.apple.com',\n",
       " 'description': 'Designs, manufactures, and markets mobile communication, media devices, personal computers, and portable digital music players',\n",
       " 'CEO': 'Timothy Donald Cook',\n",
       " 'securityName': 'Apple Inc.',\n",
       " 'issueType': 'cs',\n",
       " 'sector': 'Electronic Technology',\n",
       " 'employees': 132000,\n",
       " 'tags': ['Electronic Technology', 'Telecommunications Equipment']}"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.company(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CEO</th>\n",
       "      <th>companyName</th>\n",
       "      <th>description</th>\n",
       "      <th>employees</th>\n",
       "      <th>exchange</th>\n",
       "      <th>industry</th>\n",
       "      <th>issueType</th>\n",
       "      <th>sector</th>\n",
       "      <th>securityName</th>\n",
       "      <th>tags</th>\n",
       "      <th>website</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>AAPL</th>\n",
       "      <td>Timothy Donald Cook</td>\n",
       "      <td>Apple, Inc.</td>\n",
       "      <td>Designs, manufactures, and markets mobile comm...</td>\n",
       "      <td>132000</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>Telecommunications Equipment</td>\n",
       "      <td>cs</td>\n",
       "      <td>Electronic Technology</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>[Electronic Technology, Telecommunications Equ...</td>\n",
       "      <td>http://www.apple.com</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        CEO  companyName  \\\n",
       "symbol                                     \n",
       "AAPL    Timothy Donald Cook  Apple, Inc.   \n",
       "\n",
       "                                              description  employees exchange  \\\n",
       "symbol                                                                          \n",
       "AAPL    Designs, manufactures, and markets mobile comm...     132000   NASDAQ   \n",
       "\n",
       "                            industry issueType                 sector  \\\n",
       "symbol                                                                  \n",
       "AAPL    Telecommunications Equipment        cs  Electronic Technology   \n",
       "\n",
       "       securityName                                               tags  \\\n",
       "symbol                                                                   \n",
       "AAPL     Apple Inc.  [Electronic Technology, Telecommunications Equ...   \n",
       "\n",
       "                     website  \n",
       "symbol                        \n",
       "AAPL    http://www.apple.com  "
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.companyDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Delayed Quote"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'delayedPrice': 203.08,\n",
       " 'high': 207.417,\n",
       " 'low': 200.825,\n",
       " 'delayedSize': 5,\n",
       " 'delayedPriceTime': 1557260100013,\n",
       " 'totalVolume': 38370354,\n",
       " 'processedTime': 1557261004110}"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.delayedQuote(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>delayedPrice</th>\n",
       "      <th>delayedPriceTime</th>\n",
       "      <th>delayedSize</th>\n",
       "      <th>high</th>\n",
       "      <th>low</th>\n",
       "      <th>processedTime</th>\n",
       "      <th>totalVolume</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>AAPL</th>\n",
       "      <td>203.08</td>\n",
       "      <td>2019-05-07 20:15:00.013</td>\n",
       "      <td>5</td>\n",
       "      <td>207.417</td>\n",
       "      <td>200.825</td>\n",
       "      <td>1970-01-01 00:25:57.261004110</td>\n",
       "      <td>38370354</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        delayedPrice        delayedPriceTime  delayedSize     high      low  \\\n",
       "symbol                                                                        \n",
       "AAPL          203.08 2019-05-07 20:15:00.013            5  207.417  200.825   \n",
       "\n",
       "                       processedTime  totalVolume  \n",
       "symbol                                             \n",
       "AAPL   1970-01-01 00:25:57.261004110     38370354  "
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.delayedQuoteDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Dividends"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'exDate': '2019-05-10',\n",
       "  'paymentDate': '2019-05-16',\n",
       "  'recordDate': '2019-05-13',\n",
       "  'declaredDate': '2019-04-30',\n",
       "  'amount': 0.77,\n",
       "  'flag': 'Increase',\n",
       "  'currency': 'USD',\n",
       "  'description': 'Apple Hikes Quarterly Dividend 5.5%',\n",
       "  'frequency': 'Quarterly',\n",
       "  'date': '2019-05-07'},\n",
       " {'exDate': '2019-02-08',\n",
       "  'paymentDate': '2019-02-14',\n",
       "  'recordDate': '2019-02-11',\n",
       "  'declaredDate': '2019-01-29',\n",
       "  'amount': 0.73,\n",
       "  'flag': 'No Change QoQ',\n",
       "  'currency': 'USD',\n",
       "  'description': 'Apple Declares Quarterly Dividend of $0.73 Per Share',\n",
       "  'frequency': 'Quarterly',\n",
       "  'date': '2019-05-07'}]"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.dividends(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>amount</th>\n",
       "      <th>currency</th>\n",
       "      <th>date</th>\n",
       "      <th>declaredDate</th>\n",
       "      <th>description</th>\n",
       "      <th>flag</th>\n",
       "      <th>frequency</th>\n",
       "      <th>paymentDate</th>\n",
       "      <th>recordDate</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>exDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-05-10</th>\n",
       "      <td>0.77</td>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>2019-04-30</td>\n",
       "      <td>Apple Hikes Quarterly Dividend 5.5%</td>\n",
       "      <td>Increase</td>\n",
       "      <td>Quarterly</td>\n",
       "      <td>2019-05-16</td>\n",
       "      <td>2019-05-13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-02-08</th>\n",
       "      <td>0.73</td>\n",
       "      <td>USD</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>2019-01-29</td>\n",
       "      <td>Apple Declares Quarterly Dividend of $0.73 Per...</td>\n",
       "      <td>No Change QoQ</td>\n",
       "      <td>Quarterly</td>\n",
       "      <td>2019-02-14</td>\n",
       "      <td>2019-02-11</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            amount currency       date declaredDate  \\\n",
       "exDate                                                \n",
       "2019-05-10    0.77      USD 2019-05-07   2019-04-30   \n",
       "2019-02-08    0.73      USD 2019-05-07   2019-01-29   \n",
       "\n",
       "                                                  description           flag  \\\n",
       "exDate                                                                         \n",
       "2019-05-10                Apple Hikes Quarterly Dividend 5.5%       Increase   \n",
       "2019-02-08  Apple Declares Quarterly Dividend of $0.73 Per...  No Change QoQ   \n",
       "\n",
       "            frequency paymentDate recordDate  \n",
       "exDate                                        \n",
       "2019-05-10  Quarterly  2019-05-16 2019-05-13  \n",
       "2019-02-08  Quarterly  2019-02-14 2019-02-11  "
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.dividendsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Earnings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'earnings': [{'actualEPS': 2.46,\n",
       "   'consensusEPS': 2.36,\n",
       "   'announceTime': 'AMC',\n",
       "   'numberOfEstimates': 34,\n",
       "   'EPSSurpriseDollar': 0.1,\n",
       "   'EPSReportDate': '2019-04-30',\n",
       "   'fiscalPeriod': 'Q1 2019',\n",
       "   'fiscalEndDate': '2019-03-31',\n",
       "   'yearAgo': 2.73,\n",
       "   'yearAgoChangePercent': -0.0989}]}"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.earnings(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>EPSSurpriseDollar</th>\n",
       "      <th>actualEPS</th>\n",
       "      <th>announceTime</th>\n",
       "      <th>consensusEPS</th>\n",
       "      <th>fiscalEndDate</th>\n",
       "      <th>fiscalPeriod</th>\n",
       "      <th>numberOfEstimates</th>\n",
       "      <th>yearAgo</th>\n",
       "      <th>yearAgoChangePercent</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>EPSReportDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-04-30</th>\n",
       "      <td>0.1</td>\n",
       "      <td>2.46</td>\n",
       "      <td>AMC</td>\n",
       "      <td>2.36</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>Q1 2019</td>\n",
       "      <td>34</td>\n",
       "      <td>2.73</td>\n",
       "      <td>-0.0989</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               EPSSurpriseDollar  actualEPS announceTime  consensusEPS  \\\n",
       "EPSReportDate                                                            \n",
       "2019-04-30                   0.1       2.46          AMC          2.36   \n",
       "\n",
       "              fiscalEndDate fiscalPeriod  numberOfEstimates  yearAgo  \\\n",
       "EPSReportDate                                                          \n",
       "2019-04-30       2019-03-31      Q1 2019                 34     2.73   \n",
       "\n",
       "               yearAgoChangePercent symbol  \n",
       "EPSReportDate                               \n",
       "2019-04-30                  -0.0989   AAPL  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.earningsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Earnings Today"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'bto': [{'consensusEPS': '0.09',\n",
       "   'announceTime': 'BTO',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q1 2019',\n",
       "   'fiscalEndDate': '2019-03-31',\n",
       "   'symbol': 'CPGVY',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'CPGVY',\n",
       "    'companyName': 'CG Power & Industrial Solutions Ltd.',\n",
       "    'calculationPrice': 'previousclose',\n",
       "    'open': None,\n",
       "    'openTime': None,\n",
       "    'close': None,\n",
       "    'closeTime': None,\n",
       "    'high': None,\n",
       "    'low': None,\n",
       "    'latestPrice': None,\n",
       "    'latestSource': 'N/A',\n",
       "    'latestTime': 'N/A',\n",
       "    'latestUpdate': None,\n",
       "    'latestVolume': 0,\n",
       "    'iexRealtimePrice': None,\n",
       "    'iexRealtimeSize': None,\n",
       "    'iexLastUpdated': None,\n",
       "    'delayedPrice': None,\n",
       "    'delayedPriceTime': None,\n",
       "    'extendedPrice': None,\n",
       "    'extendedChange': None,\n",
       "    'extendedChangePercent': None,\n",
       "    'extendedPriceTime': None,\n",
       "    'previousClose': None,\n",
       "    'change': None,\n",
       "    'changePercent': None,\n",
       "    'iexMarketPercent': None,\n",
       "    'iexVolume': None,\n",
       "    'avgTotalVolume': None,\n",
       "    'iexBidPrice': None,\n",
       "    'iexBidSize': None,\n",
       "    'iexAskPrice': None,\n",
       "    'iexAskSize': None,\n",
       "    'marketCap': None,\n",
       "    'peRatio': None,\n",
       "    'week52High': 0,\n",
       "    'week52Low': 0,\n",
       "    'ytdChange': 0}}],\n",
       " 'amc': [{'consensusEPS': '5.19',\n",
       "   'announceTime': 'AMC',\n",
       "   'numberOfEstimates': 31,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'AVGO',\n",
       "   'reportDate': '2019-06-12',\n",
       "   'quote': {'symbol': 'AVGO',\n",
       "    'companyName': 'Broadcom, Inc.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 281.52,\n",
       "    'openTime': 1560432600943,\n",
       "    'close': 279.73,\n",
       "    'closeTime': 1560369600575,\n",
       "    'high': 282.89,\n",
       "    'low': 277.41,\n",
       "    'latestPrice': 278.05,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:51:28 AM',\n",
       "    'latestUpdate': 1560441088647,\n",
       "    'latestVolume': 1011386,\n",
       "    'iexRealtimePrice': 278.05,\n",
       "    'iexRealtimeSize': 60,\n",
       "    'iexLastUpdated': 1560441088647,\n",
       "    'delayedPrice': 277.75,\n",
       "    'delayedPriceTime': 1560440345331,\n",
       "    'extendedPrice': 281.6,\n",
       "    'extendedChange': 3.55,\n",
       "    'extendedChangePercent': 0.01277,\n",
       "    'extendedPriceTime': 1560432516931,\n",
       "    'previousClose': 279.73,\n",
       "    'change': -1.68,\n",
       "    'changePercent': -0.00601,\n",
       "    'iexMarketPercent': 0.022085534108639036,\n",
       "    'iexVolume': 22337,\n",
       "    'avgTotalVolume': 2925420,\n",
       "    'iexBidPrice': 245,\n",
       "    'iexBidSize': 100,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 110064980300,\n",
       "    'peRatio': 17.95,\n",
       "    'week52High': 323.2,\n",
       "    'week52Low': 197.45,\n",
       "    'ytdChange': 0.097418}},\n",
       "  {'consensusEPS': '0.01',\n",
       "   'announceTime': 'AMC',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'MMMB',\n",
       "   'reportDate': '2019-06-12',\n",
       "   'quote': {'symbol': 'MMMB',\n",
       "    'companyName': \"MamaMancini's Holdings, Inc.\",\n",
       "    'calculationPrice': 'previousclose',\n",
       "    'open': None,\n",
       "    'openTime': None,\n",
       "    'close': None,\n",
       "    'closeTime': None,\n",
       "    'high': None,\n",
       "    'low': None,\n",
       "    'latestPrice': 0.5625,\n",
       "    'latestSource': 'Previous close',\n",
       "    'latestTime': 'June 12, 2019',\n",
       "    'latestUpdate': 1560312000000,\n",
       "    'latestVolume': 0,\n",
       "    'iexRealtimePrice': None,\n",
       "    'iexRealtimeSize': None,\n",
       "    'iexLastUpdated': None,\n",
       "    'delayedPrice': None,\n",
       "    'delayedPriceTime': None,\n",
       "    'extendedPrice': None,\n",
       "    'extendedChange': None,\n",
       "    'extendedChangePercent': None,\n",
       "    'extendedPriceTime': None,\n",
       "    'previousClose': 0.5625,\n",
       "    'change': 0,\n",
       "    'changePercent': 0,\n",
       "    'iexMarketPercent': None,\n",
       "    'iexVolume': None,\n",
       "    'avgTotalVolume': 13017,\n",
       "    'iexBidPrice': None,\n",
       "    'iexBidSize': None,\n",
       "    'iexAskPrice': None,\n",
       "    'iexAskSize': None,\n",
       "    'marketCap': 17924625,\n",
       "    'peRatio': 40.76,\n",
       "    'week52High': 1.25,\n",
       "    'week52Low': 0.33,\n",
       "    'ytdChange': -0.147081}}],\n",
       " 'other': [{'consensusEPS': '-0.04',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 10,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'HEXO',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'HEXO',\n",
       "    'companyName': 'HEXO Corp.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 6.18,\n",
       "    'openTime': 1560432600091,\n",
       "    'close': 6.45,\n",
       "    'closeTime': 1560369600065,\n",
       "    'high': 6.2,\n",
       "    'low': 5.88,\n",
       "    'latestPrice': 5.93,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:52:20 AM',\n",
       "    'latestUpdate': 1560441140818,\n",
       "    'latestVolume': 5497166,\n",
       "    'iexRealtimePrice': 5.93,\n",
       "    'iexRealtimeSize': 100,\n",
       "    'iexLastUpdated': 1560441140818,\n",
       "    'delayedPrice': 5.935,\n",
       "    'delayedPriceTime': 1560440350234,\n",
       "    'extendedPrice': 6.16,\n",
       "    'extendedChange': 0.23,\n",
       "    'extendedChangePercent': 0.03879,\n",
       "    'extendedPriceTime': 1560432600686,\n",
       "    'previousClose': 6.45,\n",
       "    'change': -0.52,\n",
       "    'changePercent': -0.08062,\n",
       "    'iexMarketPercent': 0.004538520393962998,\n",
       "    'iexVolume': 24949,\n",
       "    'avgTotalVolume': 4067398,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 5.94,\n",
       "    'iexAskSize': 200,\n",
       "    'marketCap': 1247885480,\n",
       "    'peRatio': -52.39,\n",
       "    'week52High': 8.4,\n",
       "    'week52Low': 3.02,\n",
       "    'ytdChange': 0.5986739999999999}},\n",
       "  {'consensusEPS': '-0.57',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q1 2019',\n",
       "   'fiscalEndDate': '2019-03-31',\n",
       "   'symbol': 'TUFN',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'TUFN',\n",
       "    'companyName': 'Tufin Software Technologies Ltd.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 22.45,\n",
       "    'openTime': 1560432604115,\n",
       "    'close': 22.17,\n",
       "    'closeTime': 1560369891355,\n",
       "    'high': 23.39,\n",
       "    'low': 20.65,\n",
       "    'latestPrice': 20.6,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:41:32 AM',\n",
       "    'latestUpdate': 1560440492032,\n",
       "    'latestVolume': 357532,\n",
       "    'iexRealtimePrice': 20.6,\n",
       "    'iexRealtimeSize': 300,\n",
       "    'iexLastUpdated': 1560440492032,\n",
       "    'delayedPrice': 20.9,\n",
       "    'delayedPriceTime': 1560440301195,\n",
       "    'extendedPrice': 22.74,\n",
       "    'extendedChange': 2.14,\n",
       "    'extendedChangePercent': 0.10388,\n",
       "    'extendedPriceTime': 1560432586019,\n",
       "    'previousClose': 22.17,\n",
       "    'change': -1.57,\n",
       "    'changePercent': -0.07082,\n",
       "    'iexMarketPercent': 0.035761833905776266,\n",
       "    'iexVolume': 12786,\n",
       "    'avgTotalVolume': 148066,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 22.04,\n",
       "    'iexAskSize': 100,\n",
       "    'marketCap': 668202200,\n",
       "    'peRatio': None,\n",
       "    'week52High': 24.89,\n",
       "    'week52Low': 18.05,\n",
       "    'ytdChange': 0.08991299999999999}},\n",
       "  {'consensusEPS': '0.46',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 5,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'CNR',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'CNR',\n",
       "    'companyName': 'Cornerstone Building Brands, Inc.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 4.26,\n",
       "    'openTime': 1560432600160,\n",
       "    'close': 4.24,\n",
       "    'closeTime': 1560369721192,\n",
       "    'high': 4.41,\n",
       "    'low': 4.24,\n",
       "    'latestPrice': 4.355,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:54:03 AM',\n",
       "    'latestUpdate': 1560441243829,\n",
       "    'latestVolume': 188039,\n",
       "    'iexRealtimePrice': 4.355,\n",
       "    'iexRealtimeSize': 200,\n",
       "    'iexLastUpdated': 1560441243829,\n",
       "    'delayedPrice': 4.345,\n",
       "    'delayedPriceTime': 1560440351031,\n",
       "    'extendedPrice': 0,\n",
       "    'extendedChange': None,\n",
       "    'extendedChangePercent': None,\n",
       "    'extendedPriceTime': 1560460212047,\n",
       "    'previousClose': 4.24,\n",
       "    'change': 0.115,\n",
       "    'changePercent': 0.02712,\n",
       "    'iexMarketPercent': 0.041252080685389735,\n",
       "    'iexVolume': 7757,\n",
       "    'avgTotalVolume': 1073638,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 4.36,\n",
       "    'iexAskSize': 200,\n",
       "    'marketCap': 546613470,\n",
       "    'peRatio': 11.29,\n",
       "    'week52High': 22.59,\n",
       "    'week52Low': 4.2,\n",
       "    'ytdChange': -0.411291}},\n",
       "  {'consensusEPS': '0.03',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q1 2019',\n",
       "   'fiscalEndDate': '2019-03-31',\n",
       "   'symbol': 'SECO',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'SECO',\n",
       "    'companyName': 'Secoo Holding Ltd.',\n",
       "    'calculationPrice': 'sip',\n",
       "    'open': 8.03,\n",
       "    'openTime': 1560432600273,\n",
       "    'close': 7.75,\n",
       "    'closeTime': 1560369600567,\n",
       "    'high': 8.25,\n",
       "    'low': 7.858,\n",
       "    'latestPrice': 8.03,\n",
       "    'latestSource': '15 minute delayed price',\n",
       "    'latestTime': '11:39:14 AM',\n",
       "    'latestUpdate': 1560440354792,\n",
       "    'latestVolume': 121547,\n",
       "    'iexRealtimePrice': 8.04,\n",
       "    'iexRealtimeSize': 1094,\n",
       "    'iexLastUpdated': 1560440106981,\n",
       "    'delayedPrice': 8.03,\n",
       "    'delayedPriceTime': 1560440354792,\n",
       "    'extendedPrice': 8.09,\n",
       "    'extendedChange': 0.06,\n",
       "    'extendedChangePercent': 0.00747,\n",
       "    'extendedPriceTime': 1560432478589,\n",
       "    'previousClose': 7.75,\n",
       "    'change': 0.28,\n",
       "    'changePercent': 0.03613,\n",
       "    'iexMarketPercent': 0.06856606909261438,\n",
       "    'iexVolume': 8334,\n",
       "    'avgTotalVolume': 87770,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': None,\n",
       "    'peRatio': 17.73,\n",
       "    'week52High': 15.48,\n",
       "    'week52Low': 7.03,\n",
       "    'ytdChange': -0.10466800000000001}},\n",
       "  {'consensusEPS': '-0.99',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 4,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'PTE',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'PTE',\n",
       "    'companyName': 'PolarityTE, Inc.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 5.55,\n",
       "    'openTime': 1560432600453,\n",
       "    'close': 5.54,\n",
       "    'closeTime': 1560369600201,\n",
       "    'high': 5.75,\n",
       "    'low': 5.4,\n",
       "    'latestPrice': 5.52,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:45:49 AM',\n",
       "    'latestUpdate': 1560440749730,\n",
       "    'latestVolume': 120309,\n",
       "    'iexRealtimePrice': 5.52,\n",
       "    'iexRealtimeSize': 100,\n",
       "    'iexLastUpdated': 1560440749730,\n",
       "    'delayedPrice': 5.477,\n",
       "    'delayedPriceTime': 1560440175356,\n",
       "    'extendedPrice': 5.6,\n",
       "    'extendedChange': 0.08,\n",
       "    'extendedChangePercent': 0.01449,\n",
       "    'extendedPriceTime': 1560432599135,\n",
       "    'previousClose': 5.54,\n",
       "    'change': -0.02,\n",
       "    'changePercent': -0.00361,\n",
       "    'iexMarketPercent': 0.005037029648654714,\n",
       "    'iexVolume': 606,\n",
       "    'avgTotalVolume': 428467,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 138927360,\n",
       "    'peRatio': -0.89,\n",
       "    'week52High': 41.22,\n",
       "    'week52Low': 4.96,\n",
       "    'ytdChange': -0.634768}},\n",
       "  {'consensusEPS': '0.13',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'CODA',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'CODA',\n",
       "    'companyName': 'Coda Octopus Group, Inc.',\n",
       "    'calculationPrice': 'sip',\n",
       "    'open': 12.12,\n",
       "    'openTime': 1560432600774,\n",
       "    'close': 9.71,\n",
       "    'closeTime': 1560369600405,\n",
       "    'high': 14.852,\n",
       "    'low': 11.7,\n",
       "    'latestPrice': 13.877,\n",
       "    'latestSource': '15 minute delayed price',\n",
       "    'latestTime': '11:39:05 AM',\n",
       "    'latestUpdate': 1560440345508,\n",
       "    'latestVolume': 2697449,\n",
       "    'iexRealtimePrice': 14.02,\n",
       "    'iexRealtimeSize': 2,\n",
       "    'iexLastUpdated': 1560439545986,\n",
       "    'delayedPrice': 13.877,\n",
       "    'delayedPriceTime': 1560440345508,\n",
       "    'extendedPrice': 12.15,\n",
       "    'extendedChange': -1.727,\n",
       "    'extendedChangePercent': -0.12445,\n",
       "    'extendedPriceTime': 1560432534572,\n",
       "    'previousClose': 9.71,\n",
       "    'change': 4.167,\n",
       "    'changePercent': 0.42915,\n",
       "    'iexMarketPercent': 0.0040256553506665,\n",
       "    'iexVolume': 10859,\n",
       "    'avgTotalVolume': 211342,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 147984328,\n",
       "    'peRatio': 23.04,\n",
       "    'week52High': 19.2,\n",
       "    'week52Low': 3.4,\n",
       "    'ytdChange': 1.050185}},\n",
       "  {'consensusEPS': '-0.11',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q1 2019',\n",
       "   'fiscalEndDate': '2019-03-31',\n",
       "   'symbol': 'ACST',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'ACST',\n",
       "    'companyName': 'Acasti Pharma, Inc.',\n",
       "    'calculationPrice': 'sip',\n",
       "    'open': 0.8854,\n",
       "    'openTime': 1560432600879,\n",
       "    'close': 0.875,\n",
       "    'closeTime': 1560369600256,\n",
       "    'high': 0.8998,\n",
       "    'low': 0.895,\n",
       "    'latestPrice': 0.895,\n",
       "    'latestSource': '15 minute delayed price',\n",
       "    'latestTime': '11:19:26 AM',\n",
       "    'latestUpdate': 1560439166180,\n",
       "    'latestVolume': 12273,\n",
       "    'iexRealtimePrice': 0,\n",
       "    'iexRealtimeSize': 0,\n",
       "    'iexLastUpdated': 0,\n",
       "    'delayedPrice': 0.895,\n",
       "    'delayedPriceTime': 1560439166180,\n",
       "    'extendedPrice': 0.875,\n",
       "    'extendedChange': -0.02,\n",
       "    'extendedChangePercent': -0.02235,\n",
       "    'extendedPriceTime': 1560285115945,\n",
       "    'previousClose': 0.875,\n",
       "    'change': 0.02,\n",
       "    'changePercent': 0.02286,\n",
       "    'iexMarketPercent': None,\n",
       "    'iexVolume': 0,\n",
       "    'avgTotalVolume': 205483,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 1.25,\n",
       "    'iexAskSize': 100,\n",
       "    'marketCap': 69901290,\n",
       "    'peRatio': -0.94,\n",
       "    'week52High': 1.8,\n",
       "    'week52Low': 0.4333,\n",
       "    'ytdChange': -0.004918000000000002}},\n",
       "  {'consensusEPS': '0.16',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q1 2019',\n",
       "   'fiscalEndDate': '2019-03-31',\n",
       "   'symbol': 'CRWS',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'CRWS',\n",
       "    'companyName': 'Crown Crafts, Inc.',\n",
       "    'calculationPrice': 'sip',\n",
       "    'open': 4.9,\n",
       "    'openTime': 1560432600725,\n",
       "    'close': 4.8,\n",
       "    'closeTime': 1560369600313,\n",
       "    'high': 5.05,\n",
       "    'low': 4.9,\n",
       "    'latestPrice': 5.02,\n",
       "    'latestSource': '15 minute delayed price',\n",
       "    'latestTime': '11:28:50 AM',\n",
       "    'latestUpdate': 1560439730801,\n",
       "    'latestVolume': 23100,\n",
       "    'iexRealtimePrice': 0,\n",
       "    'iexRealtimeSize': 0,\n",
       "    'iexLastUpdated': 0,\n",
       "    'delayedPrice': 5.02,\n",
       "    'delayedPriceTime': 1560439730801,\n",
       "    'extendedPrice': 4.9,\n",
       "    'extendedChange': -0.12,\n",
       "    'extendedChangePercent': -0.0239,\n",
       "    'extendedPriceTime': 1560430131119,\n",
       "    'previousClose': 4.8,\n",
       "    'change': 0.22,\n",
       "    'changePercent': 0.04583,\n",
       "    'iexMarketPercent': None,\n",
       "    'iexVolume': 0,\n",
       "    'avgTotalVolume': 54801,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 50817460,\n",
       "    'peRatio': 10.39,\n",
       "    'week52High': 6.25,\n",
       "    'week52Low': 4.01,\n",
       "    'ytdChange': -0.144726}},\n",
       "  {'consensusEPS': '-1.35',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 2,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'ONCS',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'ONCS',\n",
       "    'companyName': 'OncoSec Medical, Inc.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 2.8,\n",
       "    'openTime': 1560432600516,\n",
       "    'close': 2.8,\n",
       "    'closeTime': 1560369600453,\n",
       "    'high': 2.85,\n",
       "    'low': 2.8,\n",
       "    'latestPrice': 2.835,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:42:53 AM',\n",
       "    'latestUpdate': 1560440573973,\n",
       "    'latestVolume': 96945,\n",
       "    'iexRealtimePrice': 2.835,\n",
       "    'iexRealtimeSize': 100,\n",
       "    'iexLastUpdated': 1560440573973,\n",
       "    'delayedPrice': 2.84,\n",
       "    'delayedPriceTime': 1560440028293,\n",
       "    'extendedPrice': 2.9,\n",
       "    'extendedChange': 0.065,\n",
       "    'extendedChangePercent': 0.02293,\n",
       "    'extendedPriceTime': 1560432598042,\n",
       "    'previousClose': 2.8,\n",
       "    'change': 0.035,\n",
       "    'changePercent': 0.0125,\n",
       "    'iexMarketPercent': 0.00850997988550209,\n",
       "    'iexVolume': 825,\n",
       "    'avgTotalVolume': 277410,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 18373295,\n",
       "    'peRatio': -0.41,\n",
       "    'week52High': 19.6,\n",
       "    'week52Low': 2.3,\n",
       "    'ytdChange': -0.560019}},\n",
       "  {'consensusEPS': '-0.08',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'FRAN',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'FRAN',\n",
       "    'companyName': \"Francesca's Holdings Corp.\",\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 0.505,\n",
       "    'openTime': 1560432600953,\n",
       "    'close': 0.505,\n",
       "    'closeTime': 1560369600480,\n",
       "    'high': 0.505,\n",
       "    'low': 0.482,\n",
       "    'latestPrice': 0.4811,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:50:47 AM',\n",
       "    'latestUpdate': 1560441047122,\n",
       "    'latestVolume': 228449,\n",
       "    'iexRealtimePrice': 0.4811,\n",
       "    'iexRealtimeSize': 100,\n",
       "    'iexLastUpdated': 1560441047122,\n",
       "    'delayedPrice': 0.4821,\n",
       "    'delayedPriceTime': 1560440226378,\n",
       "    'extendedPrice': 0.52,\n",
       "    'extendedChange': 0.0389,\n",
       "    'extendedChangePercent': 0.08086,\n",
       "    'extendedPriceTime': 1560432583173,\n",
       "    'previousClose': 0.505,\n",
       "    'change': -0.0239,\n",
       "    'changePercent': -0.04733,\n",
       "    'iexMarketPercent': 0.00043773446152095216,\n",
       "    'iexVolume': 100,\n",
       "    'avgTotalVolume': 678135,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 16746610,\n",
       "    'peRatio': 1.12,\n",
       "    'week52High': 8.48,\n",
       "    'week52Low': 0.442,\n",
       "    'ytdChange': -0.380223}},\n",
       "  {'consensusEPS': '-0.10',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 1,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'CHKE',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'CHKE',\n",
       "    'companyName': 'Cherokee, Inc.',\n",
       "    'calculationPrice': 'sip',\n",
       "    'open': 0.72,\n",
       "    'openTime': 1560432600891,\n",
       "    'close': 0.766,\n",
       "    'closeTime': 1560369600200,\n",
       "    'high': 0.82,\n",
       "    'low': 0.72,\n",
       "    'latestPrice': 0.82,\n",
       "    'latestSource': '15 minute delayed price',\n",
       "    'latestTime': '11:38:36 AM',\n",
       "    'latestUpdate': 1560440316677,\n",
       "    'latestVolume': 5000,\n",
       "    'iexRealtimePrice': 0,\n",
       "    'iexRealtimeSize': 0,\n",
       "    'iexLastUpdated': 0,\n",
       "    'delayedPrice': 0.82,\n",
       "    'delayedPriceTime': 1560440316677,\n",
       "    'extendedPrice': 0.77,\n",
       "    'extendedChange': -0.05,\n",
       "    'extendedChangePercent': -0.06098,\n",
       "    'extendedPriceTime': 1560432522145,\n",
       "    'previousClose': 0.766,\n",
       "    'change': 0.054,\n",
       "    'changePercent': 0.0705,\n",
       "    'iexMarketPercent': None,\n",
       "    'iexVolume': 0,\n",
       "    'avgTotalVolume': 20201,\n",
       "    'iexBidPrice': 0,\n",
       "    'iexBidSize': 0,\n",
       "    'iexAskPrice': 0,\n",
       "    'iexAskSize': 0,\n",
       "    'marketCap': 13075720,\n",
       "    'peRatio': -0.92,\n",
       "    'week52High': 1.25,\n",
       "    'week52Low': 0.38,\n",
       "    'ytdChange': 0.543577}},\n",
       "  {'consensusEPS': '-2.25',\n",
       "   'announceTime': 'DMT',\n",
       "   'numberOfEstimates': 4,\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-04-30',\n",
       "   'symbol': 'FCEL',\n",
       "   'reportDate': '2019-06-13',\n",
       "   'quote': {'symbol': 'FCEL',\n",
       "    'companyName': 'FuelCell Energy, Inc.',\n",
       "    'calculationPrice': 'tops',\n",
       "    'open': 0.47,\n",
       "    'openTime': 1560432600218,\n",
       "    'close': 0.5103,\n",
       "    'closeTime': 1560369600564,\n",
       "    'high': 0.5222,\n",
       "    'low': 0.4101,\n",
       "    'latestPrice': 0.4301,\n",
       "    'latestSource': 'IEX real time price',\n",
       "    'latestTime': '11:47:03 AM',\n",
       "    'latestUpdate': 1560440823108,\n",
       "    'latestVolume': 3484060,\n",
       "    'iexRealtimePrice': 0.4301,\n",
       "    'iexRealtimeSize': 100,\n",
       "    'iexLastUpdated': 1560440823108,\n",
       "    'delayedPrice': 0.4349,\n",
       "    'delayedPriceTime': 1560440346630,\n",
       "    'extendedPrice': 0.46,\n",
       "    'extendedChange': 0.0299,\n",
       "    'extendedChangePercent': 0.06952,\n",
       "    'extendedPriceTime': 1560432584435,\n",
       "    'previousClose': 0.5103,\n",
       "    'change': -0.0802,\n",
       "    'changePercent': -0.15716,\n",
       "    'iexMarketPercent': 0.002944840215151289,\n",
       "    'iexVolume': 10260,\n",
       "    'avgTotalVolume': 2401743,\n",
       "    'iexBidPrice': 0.36,\n",
       "    'iexBidSize': 300,\n",
       "    'iexAskPrice': 0.4251,\n",
       "    'iexAskSize': 700,\n",
       "    'marketCap': 6573648,\n",
       "    'peRatio': -0.04,\n",
       "    'week52High': 22.44,\n",
       "    'week52Low': 0.201,\n",
       "    'ytdChange': -1.08212}}]}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.earningsToday()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>EPSReportDate</th>\n",
       "      <th>EPSSurpriseDollar</th>\n",
       "      <th>actualEPS</th>\n",
       "      <th>announceTime</th>\n",
       "      <th>consensusEPS</th>\n",
       "      <th>fiscalEndDate</th>\n",
       "      <th>fiscalPeriod</th>\n",
       "      <th>numberOfEstimates</th>\n",
       "      <th>quote.avgTotalVolume</th>\n",
       "      <th>quote.calculationPrice</th>\n",
       "      <th>...</th>\n",
       "      <th>quote.peRatio</th>\n",
       "      <th>quote.previousClose</th>\n",
       "      <th>quote.symbol</th>\n",
       "      <th>quote.week52High</th>\n",
       "      <th>quote.week52Low</th>\n",
       "      <th>quote.ytdChange</th>\n",
       "      <th>reportDate</th>\n",
       "      <th>when</th>\n",
       "      <th>yearAgo</th>\n",
       "      <th>yearAgoChangePercent</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>ENIC</th>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BTO</td>\n",
       "      <td>74.82</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>Q1 2019</td>\n",
       "      <td>1.0</td>\n",
       "      <td>316735.0</td>\n",
       "      <td>sip</td>\n",
       "      <td>...</td>\n",
       "      <td>10.80</td>\n",
       "      <td>4.86</td>\n",
       "      <td>ENIC</td>\n",
       "      <td>6.00</td>\n",
       "      <td>4.17</td>\n",
       "      <td>-0.039023</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>bto</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>HENKY</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>-0.05</td>\n",
       "      <td>1.50013</td>\n",
       "      <td>BTO</td>\n",
       "      <td>1.55</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>Q1 2019</td>\n",
       "      <td>5.0</td>\n",
       "      <td>47502.0</td>\n",
       "      <td>previousclose</td>\n",
       "      <td>...</td>\n",
       "      <td>9.18</td>\n",
       "      <td>24.48</td>\n",
       "      <td>HENKY</td>\n",
       "      <td>29.62</td>\n",
       "      <td>22.12</td>\n",
       "      <td>-0.001122</td>\n",
       "      <td>NaT</td>\n",
       "      <td>bto</td>\n",
       "      <td>1.470080</td>\n",
       "      <td>0.0204</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>WF</th>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BTO</td>\n",
       "      <td>2.07</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>Q1 2019</td>\n",
       "      <td>2.0</td>\n",
       "      <td>16784.0</td>\n",
       "      <td>sip</td>\n",
       "      <td>...</td>\n",
       "      <td>4.58</td>\n",
       "      <td>35.72</td>\n",
       "      <td>WF</td>\n",
       "      <td>42.76</td>\n",
       "      <td>32.05</td>\n",
       "      <td>-0.130996</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>bto</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>RACE</th>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BTO</td>\n",
       "      <td>0.94</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>Q1 2019</td>\n",
       "      <td>7.0</td>\n",
       "      <td>364960.0</td>\n",
       "      <td>sip</td>\n",
       "      <td>...</td>\n",
       "      <td>28.16</td>\n",
       "      <td>132.33</td>\n",
       "      <td>RACE</td>\n",
       "      <td>149.85</td>\n",
       "      <td>93.85</td>\n",
       "      <td>0.381309</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>bto</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>RDSMY</th>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>-0.02</td>\n",
       "      <td>0.31346</td>\n",
       "      <td>BTO</td>\n",
       "      <td>0.33</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>Q1 2019</td>\n",
       "      <td>7.0</td>\n",
       "      <td>104561.0</td>\n",
       "      <td>previousclose</td>\n",
       "      <td>...</td>\n",
       "      <td>15.29</td>\n",
       "      <td>27.67</td>\n",
       "      <td>RDSMY</td>\n",
       "      <td>29.09</td>\n",
       "      <td>19.45</td>\n",
       "      <td>0.384192</td>\n",
       "      <td>NaT</td>\n",
       "      <td>bto</td>\n",
       "      <td>0.588161</td>\n",
       "      <td>-0.4671</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  50 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       EPSReportDate EPSSurpriseDollar  actualEPS announceTime consensusEPS  \\\n",
       "symbol                                                                        \n",
       "ENIC             NaT               NaN        NaN          BTO        74.82   \n",
       "HENKY     2019-05-07             -0.05    1.50013          BTO         1.55   \n",
       "WF               NaT               NaN        NaN          BTO         2.07   \n",
       "RACE             NaT               NaN        NaN          BTO         0.94   \n",
       "RDSMY     2019-05-07             -0.02    0.31346          BTO         0.33   \n",
       "\n",
       "       fiscalEndDate fiscalPeriod  numberOfEstimates  quote.avgTotalVolume  \\\n",
       "symbol                                                                       \n",
       "ENIC      2019-03-31      Q1 2019                1.0              316735.0   \n",
       "HENKY     2019-03-31      Q1 2019                5.0               47502.0   \n",
       "WF        2019-03-31      Q1 2019                2.0               16784.0   \n",
       "RACE      2019-03-31      Q1 2019                7.0              364960.0   \n",
       "RDSMY     2019-03-31      Q1 2019                7.0              104561.0   \n",
       "\n",
       "       quote.calculationPrice  ...  quote.peRatio  quote.previousClose  \\\n",
       "symbol                         ...                                       \n",
       "ENIC                      sip  ...          10.80                 4.86   \n",
       "HENKY           previousclose  ...           9.18                24.48   \n",
       "WF                        sip  ...           4.58                35.72   \n",
       "RACE                      sip  ...          28.16               132.33   \n",
       "RDSMY           previousclose  ...          15.29                27.67   \n",
       "\n",
       "        quote.symbol  quote.week52High quote.week52Low  quote.ytdChange  \\\n",
       "symbol                                                                    \n",
       "ENIC            ENIC              6.00            4.17        -0.039023   \n",
       "HENKY          HENKY             29.62           22.12        -0.001122   \n",
       "WF                WF             42.76           32.05        -0.130996   \n",
       "RACE            RACE            149.85           93.85         0.381309   \n",
       "RDSMY          RDSMY             29.09           19.45         0.384192   \n",
       "\n",
       "        reportDate  when   yearAgo  yearAgoChangePercent  \n",
       "symbol                                                    \n",
       "ENIC    2019-05-07   bto       NaN                   NaN  \n",
       "HENKY          NaT   bto  1.470080                0.0204  \n",
       "WF      2019-05-07   bto       NaN                   NaN  \n",
       "RACE    2019-05-07   bto       NaN                   NaN  \n",
       "RDSMY          NaT   bto  0.588161               -0.4671  \n",
       "\n",
       "[5 rows x 50 columns]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.earningsTodayDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Effective Spread"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "ename": "PyEXception",
     "evalue": "('Response 403 - ', 'The API key provided is not valid.')",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mPyEXception\u001b[0m                               Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-13-e3761beeeffa>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mspread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msymbol\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/Repos/pyEX/pyEX/client.py\u001b[0m in \u001b[0;36mbind\u001b[0;34m(self, meth, *args, **kwargs)\u001b[0m\n\u001b[1;32m    316\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    317\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mbind\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmeth\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 318\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mmeth\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtoken\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_token\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_version\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    319\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    320\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0maccount\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/stocks.py\u001b[0m in \u001b[0;36mspread\u001b[0;34m(symbol, token, version)\u001b[0m\n\u001b[1;32m    787\u001b[0m     \"\"\"\n\u001b[1;32m    788\u001b[0m     \u001b[0m_raiseIfNotStr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msymbol\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 789\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0m_getJson\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'stock/'\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0msymbol\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0;34m'/effective-spread'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    790\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    791\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/common.py\u001b[0m in \u001b[0;36m_getJson\u001b[0;34m(url, token, version)\u001b[0m\n\u001b[1;32m    104\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mversion\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m'sandbox'\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    105\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0m_getJsonIEXCloudSandbox\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 106\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0m_getJsonIEXCloud\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    107\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0m_getJsonOrig\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    108\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/common.py\u001b[0m in \u001b[0;36m_getJsonIEXCloud\u001b[0;34m(url, token, version)\u001b[0m\n\u001b[1;32m    123\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstatus_code\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m200\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    124\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mjson\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 125\u001b[0;31m     \u001b[0;32mraise\u001b[0m \u001b[0mPyEXception\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Response %d - '\u001b[0m \u001b[0;34m%\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstatus_code\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtext\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    126\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    127\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mPyEXception\u001b[0m: ('Response 403 - ', 'The API key provided is not valid.')"
     ]
    }
   ],
   "source": [
    "c.spread(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "ename": "PyEXception",
     "evalue": "('Response 403 - ', 'The API key provided is not valid.')",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mPyEXception\u001b[0m                               Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-14-cfac350caf85>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mspreadDF\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msymbol\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/Repos/pyEX/pyEX/client.py\u001b[0m in \u001b[0;36mbind\u001b[0;34m(self, meth, *args, **kwargs)\u001b[0m\n\u001b[1;32m    316\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    317\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mbind\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmeth\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 318\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mmeth\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtoken\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_token\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_version\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    319\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    320\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0maccount\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/stocks.py\u001b[0m in \u001b[0;36mspreadDF\u001b[0;34m(symbol, token, version)\u001b[0m\n\u001b[1;32m    816\u001b[0m         \u001b[0mDataFrame\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    817\u001b[0m     \"\"\"\n\u001b[0;32m--> 818\u001b[0;31m     \u001b[0mdf\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpd\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mDataFrame\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mspread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msymbol\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    819\u001b[0m     \u001b[0m_toDatetime\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdf\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    820\u001b[0m     \u001b[0m_reindex\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdf\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'venue'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/stocks.py\u001b[0m in \u001b[0;36mspread\u001b[0;34m(symbol, token, version)\u001b[0m\n\u001b[1;32m    787\u001b[0m     \"\"\"\n\u001b[1;32m    788\u001b[0m     \u001b[0m_raiseIfNotStr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msymbol\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 789\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0m_getJson\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'stock/'\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0msymbol\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0;34m'/effective-spread'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    790\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    791\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/common.py\u001b[0m in \u001b[0;36m_getJson\u001b[0;34m(url, token, version)\u001b[0m\n\u001b[1;32m    104\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mversion\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m'sandbox'\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    105\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0m_getJsonIEXCloudSandbox\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 106\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0m_getJsonIEXCloud\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mversion\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    107\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0m_getJsonOrig\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    108\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/Repos/pyEX/pyEX/common.py\u001b[0m in \u001b[0;36m_getJsonIEXCloud\u001b[0;34m(url, token, version)\u001b[0m\n\u001b[1;32m    123\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstatus_code\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m200\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    124\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mjson\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 125\u001b[0;31m     \u001b[0;32mraise\u001b[0m \u001b[0mPyEXception\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Response %d - '\u001b[0m \u001b[0;34m%\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstatus_code\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtext\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    126\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    127\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mPyEXception\u001b[0m: ('Response 403 - ', 'The API key provided is not valid.')"
     ]
    }
   ],
   "source": [
    "c.spreadDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Estimates"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'estimates': [{'consensusEPS': 2.1,\n",
       "   'announceTime': 'AMC',\n",
       "   'numberOfEstimates': 38,\n",
       "   'reportDate': '2019-07-22',\n",
       "   'fiscalPeriod': 'Q2 2019',\n",
       "   'fiscalEndDate': '2019-06-30'}]}"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.estimates(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>announceTime</th>\n",
       "      <th>consensusEPS</th>\n",
       "      <th>fiscalPeriod</th>\n",
       "      <th>numberOfEstimates</th>\n",
       "      <th>reportDate</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>fiscalEndDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-06-30</th>\n",
       "      <td>AMC</td>\n",
       "      <td>2.11</td>\n",
       "      <td>Q2 2019</td>\n",
       "      <td>36</td>\n",
       "      <td>2019-07-22</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              announceTime  consensusEPS fiscalPeriod  numberOfEstimates  \\\n",
       "fiscalEndDate                                                              \n",
       "2019-06-30             AMC          2.11      Q2 2019                 36   \n",
       "\n",
       "              reportDate symbol  \n",
       "fiscalEndDate                    \n",
       "2019-06-30    2019-07-22   AAPL  "
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.estimatesDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Financials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'financials': [{'reportDate': '2019-03-31',\n",
       "   'grossProfit': 21648000000,\n",
       "   'costOfRevenue': 36270000000,\n",
       "   'operatingRevenue': 57918000000,\n",
       "   'totalRevenue': 57918000000,\n",
       "   'operatingIncome': 13242000000,\n",
       "   'netIncome': 11561000000,\n",
       "   'researchAndDevelopment': 3948000000,\n",
       "   'operatingExpense': 44676000000,\n",
       "   'currentAssets': 123346000000,\n",
       "   'totalAssets': 341998000000,\n",
       "   'totalLiabilities': 236138000000,\n",
       "   'currentCash': 38329000000,\n",
       "   'currentDebt': 22429000000,\n",
       "   'shortTermDebt': 22429000000,\n",
       "   'longTermDebt': 90201000000,\n",
       "   'totalCash': 80433000000,\n",
       "   'totalDebt': 112630000000,\n",
       "   'shareholderEquity': 105860000000,\n",
       "   'cashChange': -4954000000,\n",
       "   'cashFlow': 11155000000}]}"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.financials(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cashChange</th>\n",
       "      <th>cashFlow</th>\n",
       "      <th>costOfRevenue</th>\n",
       "      <th>currentAssets</th>\n",
       "      <th>currentCash</th>\n",
       "      <th>currentDebt</th>\n",
       "      <th>grossProfit</th>\n",
       "      <th>longTermDebt</th>\n",
       "      <th>netIncome</th>\n",
       "      <th>operatingExpense</th>\n",
       "      <th>...</th>\n",
       "      <th>operatingRevenue</th>\n",
       "      <th>researchAndDevelopment</th>\n",
       "      <th>shareholderEquity</th>\n",
       "      <th>shortTermDebt</th>\n",
       "      <th>totalAssets</th>\n",
       "      <th>totalCash</th>\n",
       "      <th>totalDebt</th>\n",
       "      <th>totalLiabilities</th>\n",
       "      <th>totalRevenue</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>reportDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-03-31</th>\n",
       "      <td>-4954000000</td>\n",
       "      <td>11155000000</td>\n",
       "      <td>36270000000</td>\n",
       "      <td>123346000000</td>\n",
       "      <td>38329000000</td>\n",
       "      <td>22429000000</td>\n",
       "      <td>21648000000</td>\n",
       "      <td>90201000000</td>\n",
       "      <td>11561000000</td>\n",
       "      <td>44676000000</td>\n",
       "      <td>...</td>\n",
       "      <td>57918000000</td>\n",
       "      <td>3948000000</td>\n",
       "      <td>105860000000</td>\n",
       "      <td>22429000000</td>\n",
       "      <td>341998000000</td>\n",
       "      <td>80433000000</td>\n",
       "      <td>112630000000</td>\n",
       "      <td>236138000000</td>\n",
       "      <td>57918000000</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows  21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            cashChange     cashFlow  costOfRevenue  currentAssets  \\\n",
       "reportDate                                                          \n",
       "2019-03-31 -4954000000  11155000000    36270000000   123346000000   \n",
       "\n",
       "            currentCash  currentDebt  grossProfit  longTermDebt    netIncome  \\\n",
       "reportDate                                                                     \n",
       "2019-03-31  38329000000  22429000000  21648000000   90201000000  11561000000   \n",
       "\n",
       "            operatingExpense  ...  operatingRevenue  researchAndDevelopment  \\\n",
       "reportDate                    ...                                             \n",
       "2019-03-31       44676000000  ...       57918000000              3948000000   \n",
       "\n",
       "            shareholderEquity  shortTermDebt   totalAssets    totalCash  \\\n",
       "reportDate                                                                \n",
       "2019-03-31       105860000000    22429000000  341998000000  80433000000   \n",
       "\n",
       "               totalDebt  totalLiabilities  totalRevenue  symbol  \n",
       "reportDate                                                        \n",
       "2019-03-31  112630000000      236138000000   57918000000    AAPL  \n",
       "\n",
       "[1 rows x 21 columns]"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.financialsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Fund Ownership"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'report_date': 1553990400000,\n",
       "  'entityProperName': 'Vanguard Total Stock Market Index Fund',\n",
       "  'adjHolding': 115271453,\n",
       "  'adjMv': 21895812497,\n",
       "  'reportedHolding': 115271453,\n",
       "  'reportedMv': 21895812497},\n",
       " {'report_date': 1553990400000,\n",
       "  'entityProperName': 'Vanguard 500 Index Fund',\n",
       "  'adjHolding': 86850254,\n",
       "  'adjMv': 16497205747,\n",
       "  'reportedHolding': 86850254,\n",
       "  'reportedMv': 16497205747},\n",
       " {'report_date': 1556582400000,\n",
       "  'entityProperName': 'Spdr S&p 500 Etf',\n",
       "  'adjHolding': 50728910,\n",
       "  'adjMv': 10179770370,\n",
       "  'reportedHolding': 50728910,\n",
       "  'reportedMv': 10179770370},\n",
       " {'report_date': 1546214400000,\n",
       "  'entityProperName': 'Government Pension Fund - Global (the)',\n",
       "  'adjHolding': 45933028,\n",
       "  'adjMv': 7245475837,\n",
       "  'reportedHolding': 45933028,\n",
       "  'reportedMv': 7245475993},\n",
       " {'report_date': 1553990400000,\n",
       "  'entityProperName': 'Vanguard Institutional Index Fund',\n",
       "  'adjHolding': 42377520,\n",
       "  'adjMv': 8049609924,\n",
       "  'reportedHolding': 42377520,\n",
       "  'reportedMv': 8049609924},\n",
       " {'report_date': 1556582400000,\n",
       "  'entityProperName': 'Invesco Qqq Trust',\n",
       "  'adjHolding': 38489317,\n",
       "  'adjMv': 7723651242,\n",
       "  'reportedHolding': 38489317,\n",
       "  'reportedMv': 7723651242},\n",
       " {'report_date': 1553990400000,\n",
       "  'entityProperName': 'Fidelity 500 Index Fund',\n",
       "  'adjHolding': 35045571,\n",
       "  'adjMv': 6656906211,\n",
       "  'reportedHolding': 35045571,\n",
       "  'reportedMv': 6656906211},\n",
       " {'report_date': 1556582400000,\n",
       "  'entityProperName': 'Ishares Tr. - Core S&p 500 Etf',\n",
       "  'adjHolding': 32560950,\n",
       "  'adjMv': 6534005837,\n",
       "  'reportedHolding': 32560950,\n",
       "  'reportedMv': 6534005837},\n",
       " {'report_date': 1548892800000,\n",
       "  'entityProperName': 'Blackrock (japan) Ishares Core Msci Kokusai Etf (1657)',\n",
       "  'adjHolding': 30589798,\n",
       "  'adjMv': 5091365979,\n",
       "  'reportedHolding': 30589798,\n",
       "  'reportedMv': 1323161},\n",
       " {'report_date': 1553990400000,\n",
       "  'entityProperName': 'Vanguard Growth Index Fund',\n",
       "  'adjHolding': 29248944,\n",
       "  'adjMv': 5555836913,\n",
       "  'reportedHolding': 29248944,\n",
       "  'reportedMv': 5555836913}]"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.fundOwnership(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>adjHolding</th>\n",
       "      <th>adjMv</th>\n",
       "      <th>entityProperName</th>\n",
       "      <th>report_date</th>\n",
       "      <th>reportedHolding</th>\n",
       "      <th>reportedMv</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>115271453</td>\n",
       "      <td>21895812497</td>\n",
       "      <td>Vanguard Total Stock Market Index Fund</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>115271453</td>\n",
       "      <td>21895812497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>86850254</td>\n",
       "      <td>16497205747</td>\n",
       "      <td>Vanguard 500 Index Fund</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>86850254</td>\n",
       "      <td>16497205747</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>50728910</td>\n",
       "      <td>10179770370</td>\n",
       "      <td>Spdr S&amp;p 500 Etf</td>\n",
       "      <td>2019-04-30</td>\n",
       "      <td>50728910</td>\n",
       "      <td>10179770370</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>45933028</td>\n",
       "      <td>7245475837</td>\n",
       "      <td>Government Pension Fund - Global (the)</td>\n",
       "      <td>2018-12-31</td>\n",
       "      <td>45933028</td>\n",
       "      <td>7245475993</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>42377520</td>\n",
       "      <td>8049609924</td>\n",
       "      <td>Vanguard Institutional Index Fund</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>42377520</td>\n",
       "      <td>8049609924</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>38489317</td>\n",
       "      <td>7723651242</td>\n",
       "      <td>Invesco Qqq Trust</td>\n",
       "      <td>2019-04-30</td>\n",
       "      <td>38489317</td>\n",
       "      <td>7723651242</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>35045571</td>\n",
       "      <td>6656906211</td>\n",
       "      <td>Fidelity 500 Index Fund</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>35045571</td>\n",
       "      <td>6656906211</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>32560950</td>\n",
       "      <td>6534005837</td>\n",
       "      <td>Ishares Tr. - Core S&amp;p 500 Etf</td>\n",
       "      <td>2019-04-30</td>\n",
       "      <td>32560950</td>\n",
       "      <td>6534005837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>30589798</td>\n",
       "      <td>5091365979</td>\n",
       "      <td>Blackrock (japan) Ishares Core Msci Kokusai Et...</td>\n",
       "      <td>2019-01-31</td>\n",
       "      <td>30589798</td>\n",
       "      <td>1323161</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>29248944</td>\n",
       "      <td>5555836913</td>\n",
       "      <td>Vanguard Growth Index Fund</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>29248944</td>\n",
       "      <td>5555836913</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   adjHolding        adjMv                                   entityProperName  \\\n",
       "0   115271453  21895812497             Vanguard Total Stock Market Index Fund   \n",
       "1    86850254  16497205747                            Vanguard 500 Index Fund   \n",
       "2    50728910  10179770370                                   Spdr S&p 500 Etf   \n",
       "3    45933028   7245475837             Government Pension Fund - Global (the)   \n",
       "4    42377520   8049609924                  Vanguard Institutional Index Fund   \n",
       "5    38489317   7723651242                                  Invesco Qqq Trust   \n",
       "6    35045571   6656906211                            Fidelity 500 Index Fund   \n",
       "7    32560950   6534005837                     Ishares Tr. - Core S&p 500 Etf   \n",
       "8    30589798   5091365979  Blackrock (japan) Ishares Core Msci Kokusai Et...   \n",
       "9    29248944   5555836913                         Vanguard Growth Index Fund   \n",
       "\n",
       "  report_date  reportedHolding   reportedMv  \n",
       "0  2019-03-31        115271453  21895812497  \n",
       "1  2019-03-31         86850254  16497205747  \n",
       "2  2019-04-30         50728910  10179770370  \n",
       "3  2018-12-31         45933028   7245475993  \n",
       "4  2019-03-31         42377520   8049609924  \n",
       "5  2019-04-30         38489317   7723651242  \n",
       "6  2019-03-31         35045571   6656906211  \n",
       "7  2019-04-30         32560950   6534005837  \n",
       "8  2019-01-31         30589798      1323161  \n",
       "9  2019-03-31         29248944   5555836913  "
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.fundOwnershipDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Historical Prices"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'date': '2019-04-08',\n",
       "  'open': 196.42,\n",
       "  'close': 200.1,\n",
       "  'high': 200.23,\n",
       "  'low': 196.34,\n",
       "  'volume': 25881697,\n",
       "  'uOpen': 196.42,\n",
       "  'uClose': 200.1,\n",
       "  'uHigh': 200.23,\n",
       "  'uLow': 196.34,\n",
       "  'uVolume': 25881697,\n",
       "  'change': 0,\n",
       "  'changePercent': 0,\n",
       "  'label': 'Apr 8',\n",
       "  'changeOverTime': 0},\n",
       " {'date': '2019-04-09',\n",
       "  'open': 200.32,\n",
       "  'close': 199.5,\n",
       "  'high': 202.85,\n",
       "  'low': 199.23,\n",
       "  'volume': 35768237,\n",
       "  'uOpen': 200.32,\n",
       "  'uClose': 199.5,\n",
       "  'uHigh': 202.85,\n",
       "  'uLow': 199.23,\n",
       "  'uVolume': 35768237,\n",
       "  'change': -0.6,\n",
       "  'changePercent': -0.2999,\n",
       "  'label': 'Apr 9',\n",
       "  'changeOverTime': -0.002999},\n",
       " {'date': '2019-04-10',\n",
       "  'open': 198.68,\n",
       "  'close': 200.62,\n",
       "  'high': 200.74,\n",
       "  'low': 198.18,\n",
       "  'volume': 21695288,\n",
       "  'uOpen': 198.68,\n",
       "  'uClose': 200.62,\n",
       "  'uHigh': 200.74,\n",
       "  'uLow': 198.18,\n",
       "  'uVolume': 21695288,\n",
       "  'change': 1.12,\n",
       "  'changePercent': 0.5614,\n",
       "  'label': 'Apr 10',\n",
       "  'changeOverTime': 0.002599},\n",
       " {'date': '2019-04-11',\n",
       "  'open': 200.85,\n",
       "  'close': 198.95,\n",
       "  'high': 201,\n",
       "  'low': 198.44,\n",
       "  'volume': 20900808,\n",
       "  'uOpen': 200.85,\n",
       "  'uClose': 198.95,\n",
       "  'uHigh': 201,\n",
       "  'uLow': 198.44,\n",
       "  'uVolume': 20900808,\n",
       "  'change': -1.67,\n",
       "  'changePercent': -0.8324,\n",
       "  'label': 'Apr 11',\n",
       "  'changeOverTime': -0.005747},\n",
       " {'date': '2019-04-12',\n",
       "  'open': 199.2,\n",
       "  'close': 198.87,\n",
       "  'high': 200.14,\n",
       "  'low': 196.21,\n",
       "  'volume': 27760668,\n",
       "  'uOpen': 199.2,\n",
       "  'uClose': 198.87,\n",
       "  'uHigh': 200.14,\n",
       "  'uLow': 196.21,\n",
       "  'uVolume': 27760668,\n",
       "  'change': -0.08,\n",
       "  'changePercent': -0.0402,\n",
       "  'label': 'Apr 12',\n",
       "  'changeOverTime': -0.006147},\n",
       " {'date': '2019-04-15',\n",
       "  'open': 198.58,\n",
       "  'close': 199.23,\n",
       "  'high': 199.85,\n",
       "  'low': 198.01,\n",
       "  'volume': 17536646,\n",
       "  'uOpen': 198.58,\n",
       "  'uClose': 199.23,\n",
       "  'uHigh': 199.85,\n",
       "  'uLow': 198.01,\n",
       "  'uVolume': 17536646,\n",
       "  'change': 0.36,\n",
       "  'changePercent': 0.181,\n",
       "  'label': 'Apr 15',\n",
       "  'changeOverTime': -0.004348},\n",
       " {'date': '2019-04-16',\n",
       "  'open': 199.46,\n",
       "  'close': 199.25,\n",
       "  'high': 201.37,\n",
       "  'low': 198.56,\n",
       "  'volume': 25696385,\n",
       "  'uOpen': 199.46,\n",
       "  'uClose': 199.25,\n",
       "  'uHigh': 201.37,\n",
       "  'uLow': 198.56,\n",
       "  'uVolume': 25696385,\n",
       "  'change': 0.02,\n",
       "  'changePercent': 0.01,\n",
       "  'label': 'Apr 16',\n",
       "  'changeOverTime': -0.004248},\n",
       " {'date': '2019-04-17',\n",
       "  'open': 199.54,\n",
       "  'close': 203.13,\n",
       "  'high': 203.38,\n",
       "  'low': 198.61,\n",
       "  'volume': 28906780,\n",
       "  'uOpen': 199.54,\n",
       "  'uClose': 203.13,\n",
       "  'uHigh': 203.38,\n",
       "  'uLow': 198.61,\n",
       "  'uVolume': 28906780,\n",
       "  'change': 3.88,\n",
       "  'changePercent': 1.9473,\n",
       "  'label': 'Apr 17',\n",
       "  'changeOverTime': 0.015142},\n",
       " {'date': '2019-04-18',\n",
       "  'open': 203.12,\n",
       "  'close': 203.86,\n",
       "  'high': 204.15,\n",
       "  'low': 202.52,\n",
       "  'volume': 24195766,\n",
       "  'uOpen': 203.12,\n",
       "  'uClose': 203.86,\n",
       "  'uHigh': 204.15,\n",
       "  'uLow': 202.52,\n",
       "  'uVolume': 24195766,\n",
       "  'change': 0.73,\n",
       "  'changePercent': 0.3594,\n",
       "  'label': 'Apr 18',\n",
       "  'changeOverTime': 0.018791},\n",
       " {'date': '2019-04-22',\n",
       "  'open': 202.83,\n",
       "  'close': 204.53,\n",
       "  'high': 204.94,\n",
       "  'low': 202.34,\n",
       "  'volume': 19439545,\n",
       "  'uOpen': 202.83,\n",
       "  'uClose': 204.53,\n",
       "  'uHigh': 204.94,\n",
       "  'uLow': 202.34,\n",
       "  'uVolume': 19439545,\n",
       "  'change': 0.67,\n",
       "  'changePercent': 0.3287,\n",
       "  'label': 'Apr 22',\n",
       "  'changeOverTime': 0.022139},\n",
       " {'date': '2019-04-23',\n",
       "  'open': 204.43,\n",
       "  'close': 207.48,\n",
       "  'high': 207.75,\n",
       "  'low': 203.9,\n",
       "  'volume': 23322991,\n",
       "  'uOpen': 204.43,\n",
       "  'uClose': 207.48,\n",
       "  'uHigh': 207.75,\n",
       "  'uLow': 203.9,\n",
       "  'uVolume': 23322991,\n",
       "  'change': 2.95,\n",
       "  'changePercent': 1.4423,\n",
       "  'label': 'Apr 23',\n",
       "  'changeOverTime': 0.036882},\n",
       " {'date': '2019-04-24',\n",
       "  'open': 207.36,\n",
       "  'close': 207.16,\n",
       "  'high': 208.48,\n",
       "  'low': 207.05,\n",
       "  'volume': 17540609,\n",
       "  'uOpen': 207.36,\n",
       "  'uClose': 207.16,\n",
       "  'uHigh': 208.48,\n",
       "  'uLow': 207.05,\n",
       "  'uVolume': 17540609,\n",
       "  'change': -0.32,\n",
       "  'changePercent': -0.1542,\n",
       "  'label': 'Apr 24',\n",
       "  'changeOverTime': 0.035282},\n",
       " {'date': '2019-04-25',\n",
       "  'open': 206.83,\n",
       "  'close': 205.28,\n",
       "  'high': 207.76,\n",
       "  'low': 205.12,\n",
       "  'volume': 18543206,\n",
       "  'uOpen': 206.83,\n",
       "  'uClose': 205.28,\n",
       "  'uHigh': 207.76,\n",
       "  'uLow': 205.12,\n",
       "  'uVolume': 18543206,\n",
       "  'change': -1.88,\n",
       "  'changePercent': -0.9075,\n",
       "  'label': 'Apr 25',\n",
       "  'changeOverTime': 0.025887},\n",
       " {'date': '2019-04-26',\n",
       "  'open': 204.9,\n",
       "  'close': 204.3,\n",
       "  'high': 205,\n",
       "  'low': 202.12,\n",
       "  'volume': 18649102,\n",
       "  'uOpen': 204.9,\n",
       "  'uClose': 204.3,\n",
       "  'uHigh': 205,\n",
       "  'uLow': 202.12,\n",
       "  'uVolume': 18649102,\n",
       "  'change': -0.98,\n",
       "  'changePercent': -0.4774,\n",
       "  'label': 'Apr 26',\n",
       "  'changeOverTime': 0.02099},\n",
       " {'date': '2019-04-29',\n",
       "  'open': 204.4,\n",
       "  'close': 204.61,\n",
       "  'high': 205.97,\n",
       "  'low': 203.86,\n",
       "  'volume': 22204716,\n",
       "  'uOpen': 204.4,\n",
       "  'uClose': 204.61,\n",
       "  'uHigh': 205.97,\n",
       "  'uLow': 203.86,\n",
       "  'uVolume': 22204716,\n",
       "  'change': 0.31,\n",
       "  'changePercent': 0.1517,\n",
       "  'label': 'Apr 29',\n",
       "  'changeOverTime': 0.022539},\n",
       " {'date': '2019-04-30',\n",
       "  'open': 203.06,\n",
       "  'close': 200.67,\n",
       "  'high': 203.4,\n",
       "  'low': 199.11,\n",
       "  'volume': 46534923,\n",
       "  'uOpen': 203.06,\n",
       "  'uClose': 200.67,\n",
       "  'uHigh': 203.4,\n",
       "  'uLow': 199.11,\n",
       "  'uVolume': 46534923,\n",
       "  'change': -3.94,\n",
       "  'changePercent': -1.9256,\n",
       "  'label': 'Apr 30',\n",
       "  'changeOverTime': 0.002849},\n",
       " {'date': '2019-05-01',\n",
       "  'open': 209.88,\n",
       "  'close': 210.52,\n",
       "  'high': 215.31,\n",
       "  'low': 209.23,\n",
       "  'volume': 64827328,\n",
       "  'uOpen': 209.88,\n",
       "  'uClose': 210.52,\n",
       "  'uHigh': 215.31,\n",
       "  'uLow': 209.23,\n",
       "  'uVolume': 64827328,\n",
       "  'change': 9.85,\n",
       "  'changePercent': 4.9086,\n",
       "  'label': 'May 1',\n",
       "  'changeOverTime': 0.052074},\n",
       " {'date': '2019-05-02',\n",
       "  'open': 209.84,\n",
       "  'close': 209.15,\n",
       "  'high': 212.65,\n",
       "  'low': 208.13,\n",
       "  'volume': 31996324,\n",
       "  'uOpen': 209.84,\n",
       "  'uClose': 209.15,\n",
       "  'uHigh': 212.65,\n",
       "  'uLow': 208.13,\n",
       "  'uVolume': 31996324,\n",
       "  'change': -1.37,\n",
       "  'changePercent': -0.6508,\n",
       "  'label': 'May 2',\n",
       "  'changeOverTime': 0.045227},\n",
       " {'date': '2019-05-03',\n",
       "  'open': 210.89,\n",
       "  'close': 211.75,\n",
       "  'high': 211.84,\n",
       "  'low': 210.23,\n",
       "  'volume': 20892378,\n",
       "  'uOpen': 210.89,\n",
       "  'uClose': 211.75,\n",
       "  'uHigh': 211.84,\n",
       "  'uLow': 210.23,\n",
       "  'uVolume': 20892378,\n",
       "  'change': 2.6,\n",
       "  'changePercent': 1.2431,\n",
       "  'label': 'May 3',\n",
       "  'changeOverTime': 0.058221},\n",
       " {'date': '2019-05-06',\n",
       "  'open': 204.29,\n",
       "  'close': 208.48,\n",
       "  'high': 208.84,\n",
       "  'low': 203.5,\n",
       "  'volume': 32443113,\n",
       "  'uOpen': 204.29,\n",
       "  'uClose': 208.48,\n",
       "  'uHigh': 208.84,\n",
       "  'uLow': 203.5,\n",
       "  'uVolume': 32443113,\n",
       "  'change': -3.27,\n",
       "  'changePercent': -1.5443,\n",
       "  'label': 'May 6',\n",
       "  'changeOverTime': 0.041879}]"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.chart(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>change</th>\n",
       "      <th>changeOverTime</th>\n",
       "      <th>changePercent</th>\n",
       "      <th>close</th>\n",
       "      <th>high</th>\n",
       "      <th>label</th>\n",
       "      <th>low</th>\n",
       "      <th>open</th>\n",
       "      <th>uClose</th>\n",
       "      <th>uHigh</th>\n",
       "      <th>uLow</th>\n",
       "      <th>uOpen</th>\n",
       "      <th>uVolume</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>date</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-04-08</th>\n",
       "      <td>0.00</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0000</td>\n",
       "      <td>200.10</td>\n",
       "      <td>200.23</td>\n",
       "      <td>Apr 8</td>\n",
       "      <td>196.34</td>\n",
       "      <td>196.42</td>\n",
       "      <td>200.10</td>\n",
       "      <td>200.23</td>\n",
       "      <td>196.34</td>\n",
       "      <td>196.42</td>\n",
       "      <td>25881697</td>\n",
       "      <td>25881697</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-09</th>\n",
       "      <td>-0.60</td>\n",
       "      <td>-0.002999</td>\n",
       "      <td>-0.2999</td>\n",
       "      <td>199.50</td>\n",
       "      <td>202.85</td>\n",
       "      <td>Apr 9</td>\n",
       "      <td>199.23</td>\n",
       "      <td>200.32</td>\n",
       "      <td>199.50</td>\n",
       "      <td>202.85</td>\n",
       "      <td>199.23</td>\n",
       "      <td>200.32</td>\n",
       "      <td>35768237</td>\n",
       "      <td>35768237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-10</th>\n",
       "      <td>1.12</td>\n",
       "      <td>0.002599</td>\n",
       "      <td>0.5614</td>\n",
       "      <td>200.62</td>\n",
       "      <td>200.74</td>\n",
       "      <td>Apr 10</td>\n",
       "      <td>198.18</td>\n",
       "      <td>198.68</td>\n",
       "      <td>200.62</td>\n",
       "      <td>200.74</td>\n",
       "      <td>198.18</td>\n",
       "      <td>198.68</td>\n",
       "      <td>21695288</td>\n",
       "      <td>21695288</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-11</th>\n",
       "      <td>-1.67</td>\n",
       "      <td>-0.005747</td>\n",
       "      <td>-0.8324</td>\n",
       "      <td>198.95</td>\n",
       "      <td>201.00</td>\n",
       "      <td>Apr 11</td>\n",
       "      <td>198.44</td>\n",
       "      <td>200.85</td>\n",
       "      <td>198.95</td>\n",
       "      <td>201.00</td>\n",
       "      <td>198.44</td>\n",
       "      <td>200.85</td>\n",
       "      <td>20900808</td>\n",
       "      <td>20900808</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-12</th>\n",
       "      <td>-0.08</td>\n",
       "      <td>-0.006147</td>\n",
       "      <td>-0.0402</td>\n",
       "      <td>198.87</td>\n",
       "      <td>200.14</td>\n",
       "      <td>Apr 12</td>\n",
       "      <td>196.21</td>\n",
       "      <td>199.20</td>\n",
       "      <td>198.87</td>\n",
       "      <td>200.14</td>\n",
       "      <td>196.21</td>\n",
       "      <td>199.20</td>\n",
       "      <td>27760668</td>\n",
       "      <td>27760668</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-15</th>\n",
       "      <td>0.36</td>\n",
       "      <td>-0.004348</td>\n",
       "      <td>0.1810</td>\n",
       "      <td>199.23</td>\n",
       "      <td>199.85</td>\n",
       "      <td>Apr 15</td>\n",
       "      <td>198.01</td>\n",
       "      <td>198.58</td>\n",
       "      <td>199.23</td>\n",
       "      <td>199.85</td>\n",
       "      <td>198.01</td>\n",
       "      <td>198.58</td>\n",
       "      <td>17536646</td>\n",
       "      <td>17536646</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-16</th>\n",
       "      <td>0.02</td>\n",
       "      <td>-0.004248</td>\n",
       "      <td>0.0100</td>\n",
       "      <td>199.25</td>\n",
       "      <td>201.37</td>\n",
       "      <td>Apr 16</td>\n",
       "      <td>198.56</td>\n",
       "      <td>199.46</td>\n",
       "      <td>199.25</td>\n",
       "      <td>201.37</td>\n",
       "      <td>198.56</td>\n",
       "      <td>199.46</td>\n",
       "      <td>25696385</td>\n",
       "      <td>25696385</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-17</th>\n",
       "      <td>3.88</td>\n",
       "      <td>0.015142</td>\n",
       "      <td>1.9473</td>\n",
       "      <td>203.13</td>\n",
       "      <td>203.38</td>\n",
       "      <td>Apr 17</td>\n",
       "      <td>198.61</td>\n",
       "      <td>199.54</td>\n",
       "      <td>203.13</td>\n",
       "      <td>203.38</td>\n",
       "      <td>198.61</td>\n",
       "      <td>199.54</td>\n",
       "      <td>28906780</td>\n",
       "      <td>28906780</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-18</th>\n",
       "      <td>0.73</td>\n",
       "      <td>0.018791</td>\n",
       "      <td>0.3594</td>\n",
       "      <td>203.86</td>\n",
       "      <td>204.15</td>\n",
       "      <td>Apr 18</td>\n",
       "      <td>202.52</td>\n",
       "      <td>203.12</td>\n",
       "      <td>203.86</td>\n",
       "      <td>204.15</td>\n",
       "      <td>202.52</td>\n",
       "      <td>203.12</td>\n",
       "      <td>24195766</td>\n",
       "      <td>24195766</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-22</th>\n",
       "      <td>0.67</td>\n",
       "      <td>0.022139</td>\n",
       "      <td>0.3287</td>\n",
       "      <td>204.53</td>\n",
       "      <td>204.94</td>\n",
       "      <td>Apr 22</td>\n",
       "      <td>202.34</td>\n",
       "      <td>202.83</td>\n",
       "      <td>204.53</td>\n",
       "      <td>204.94</td>\n",
       "      <td>202.34</td>\n",
       "      <td>202.83</td>\n",
       "      <td>19439545</td>\n",
       "      <td>19439545</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-23</th>\n",
       "      <td>2.95</td>\n",
       "      <td>0.036882</td>\n",
       "      <td>1.4423</td>\n",
       "      <td>207.48</td>\n",
       "      <td>207.75</td>\n",
       "      <td>Apr 23</td>\n",
       "      <td>203.90</td>\n",
       "      <td>204.43</td>\n",
       "      <td>207.48</td>\n",
       "      <td>207.75</td>\n",
       "      <td>203.90</td>\n",
       "      <td>204.43</td>\n",
       "      <td>23322991</td>\n",
       "      <td>23322991</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-24</th>\n",
       "      <td>-0.32</td>\n",
       "      <td>0.035282</td>\n",
       "      <td>-0.1542</td>\n",
       "      <td>207.16</td>\n",
       "      <td>208.48</td>\n",
       "      <td>Apr 24</td>\n",
       "      <td>207.05</td>\n",
       "      <td>207.36</td>\n",
       "      <td>207.16</td>\n",
       "      <td>208.48</td>\n",
       "      <td>207.05</td>\n",
       "      <td>207.36</td>\n",
       "      <td>17540609</td>\n",
       "      <td>17540609</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-25</th>\n",
       "      <td>-1.88</td>\n",
       "      <td>0.025887</td>\n",
       "      <td>-0.9075</td>\n",
       "      <td>205.28</td>\n",
       "      <td>207.76</td>\n",
       "      <td>Apr 25</td>\n",
       "      <td>205.12</td>\n",
       "      <td>206.83</td>\n",
       "      <td>205.28</td>\n",
       "      <td>207.76</td>\n",
       "      <td>205.12</td>\n",
       "      <td>206.83</td>\n",
       "      <td>18543206</td>\n",
       "      <td>18543206</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-26</th>\n",
       "      <td>-0.98</td>\n",
       "      <td>0.020990</td>\n",
       "      <td>-0.4774</td>\n",
       "      <td>204.30</td>\n",
       "      <td>205.00</td>\n",
       "      <td>Apr 26</td>\n",
       "      <td>202.12</td>\n",
       "      <td>204.90</td>\n",
       "      <td>204.30</td>\n",
       "      <td>205.00</td>\n",
       "      <td>202.12</td>\n",
       "      <td>204.90</td>\n",
       "      <td>18649102</td>\n",
       "      <td>18649102</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-29</th>\n",
       "      <td>0.31</td>\n",
       "      <td>0.022539</td>\n",
       "      <td>0.1517</td>\n",
       "      <td>204.61</td>\n",
       "      <td>205.97</td>\n",
       "      <td>Apr 29</td>\n",
       "      <td>203.86</td>\n",
       "      <td>204.40</td>\n",
       "      <td>204.61</td>\n",
       "      <td>205.97</td>\n",
       "      <td>203.86</td>\n",
       "      <td>204.40</td>\n",
       "      <td>22204716</td>\n",
       "      <td>22204716</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-04-30</th>\n",
       "      <td>-3.94</td>\n",
       "      <td>0.002849</td>\n",
       "      <td>-1.9256</td>\n",
       "      <td>200.67</td>\n",
       "      <td>203.40</td>\n",
       "      <td>Apr 30</td>\n",
       "      <td>199.11</td>\n",
       "      <td>203.06</td>\n",
       "      <td>200.67</td>\n",
       "      <td>203.40</td>\n",
       "      <td>199.11</td>\n",
       "      <td>203.06</td>\n",
       "      <td>46534923</td>\n",
       "      <td>46534923</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-01</th>\n",
       "      <td>9.85</td>\n",
       "      <td>0.052074</td>\n",
       "      <td>4.9086</td>\n",
       "      <td>210.52</td>\n",
       "      <td>215.31</td>\n",
       "      <td>May 1</td>\n",
       "      <td>209.23</td>\n",
       "      <td>209.88</td>\n",
       "      <td>210.52</td>\n",
       "      <td>215.31</td>\n",
       "      <td>209.23</td>\n",
       "      <td>209.88</td>\n",
       "      <td>64827328</td>\n",
       "      <td>64827328</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-02</th>\n",
       "      <td>-1.37</td>\n",
       "      <td>0.045227</td>\n",
       "      <td>-0.6508</td>\n",
       "      <td>209.15</td>\n",
       "      <td>212.65</td>\n",
       "      <td>May 2</td>\n",
       "      <td>208.13</td>\n",
       "      <td>209.84</td>\n",
       "      <td>209.15</td>\n",
       "      <td>212.65</td>\n",
       "      <td>208.13</td>\n",
       "      <td>209.84</td>\n",
       "      <td>31996324</td>\n",
       "      <td>31996324</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-03</th>\n",
       "      <td>2.60</td>\n",
       "      <td>0.058221</td>\n",
       "      <td>1.2431</td>\n",
       "      <td>211.75</td>\n",
       "      <td>211.84</td>\n",
       "      <td>May 3</td>\n",
       "      <td>210.23</td>\n",
       "      <td>210.89</td>\n",
       "      <td>211.75</td>\n",
       "      <td>211.84</td>\n",
       "      <td>210.23</td>\n",
       "      <td>210.89</td>\n",
       "      <td>20892378</td>\n",
       "      <td>20892378</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-06</th>\n",
       "      <td>-3.27</td>\n",
       "      <td>0.041879</td>\n",
       "      <td>-1.5443</td>\n",
       "      <td>208.48</td>\n",
       "      <td>208.84</td>\n",
       "      <td>May 6</td>\n",
       "      <td>203.50</td>\n",
       "      <td>204.29</td>\n",
       "      <td>208.48</td>\n",
       "      <td>208.84</td>\n",
       "      <td>203.50</td>\n",
       "      <td>204.29</td>\n",
       "      <td>32443113</td>\n",
       "      <td>32443113</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            change  changeOverTime  changePercent   close    high   label  \\\n",
       "date                                                                        \n",
       "2019-04-08    0.00        0.000000         0.0000  200.10  200.23   Apr 8   \n",
       "2019-04-09   -0.60       -0.002999        -0.2999  199.50  202.85   Apr 9   \n",
       "2019-04-10    1.12        0.002599         0.5614  200.62  200.74  Apr 10   \n",
       "2019-04-11   -1.67       -0.005747        -0.8324  198.95  201.00  Apr 11   \n",
       "2019-04-12   -0.08       -0.006147        -0.0402  198.87  200.14  Apr 12   \n",
       "2019-04-15    0.36       -0.004348         0.1810  199.23  199.85  Apr 15   \n",
       "2019-04-16    0.02       -0.004248         0.0100  199.25  201.37  Apr 16   \n",
       "2019-04-17    3.88        0.015142         1.9473  203.13  203.38  Apr 17   \n",
       "2019-04-18    0.73        0.018791         0.3594  203.86  204.15  Apr 18   \n",
       "2019-04-22    0.67        0.022139         0.3287  204.53  204.94  Apr 22   \n",
       "2019-04-23    2.95        0.036882         1.4423  207.48  207.75  Apr 23   \n",
       "2019-04-24   -0.32        0.035282        -0.1542  207.16  208.48  Apr 24   \n",
       "2019-04-25   -1.88        0.025887        -0.9075  205.28  207.76  Apr 25   \n",
       "2019-04-26   -0.98        0.020990        -0.4774  204.30  205.00  Apr 26   \n",
       "2019-04-29    0.31        0.022539         0.1517  204.61  205.97  Apr 29   \n",
       "2019-04-30   -3.94        0.002849        -1.9256  200.67  203.40  Apr 30   \n",
       "2019-05-01    9.85        0.052074         4.9086  210.52  215.31   May 1   \n",
       "2019-05-02   -1.37        0.045227        -0.6508  209.15  212.65   May 2   \n",
       "2019-05-03    2.60        0.058221         1.2431  211.75  211.84   May 3   \n",
       "2019-05-06   -3.27        0.041879        -1.5443  208.48  208.84   May 6   \n",
       "\n",
       "               low    open  uClose   uHigh    uLow   uOpen   uVolume    volume  \n",
       "date                                                                            \n",
       "2019-04-08  196.34  196.42  200.10  200.23  196.34  196.42  25881697  25881697  \n",
       "2019-04-09  199.23  200.32  199.50  202.85  199.23  200.32  35768237  35768237  \n",
       "2019-04-10  198.18  198.68  200.62  200.74  198.18  198.68  21695288  21695288  \n",
       "2019-04-11  198.44  200.85  198.95  201.00  198.44  200.85  20900808  20900808  \n",
       "2019-04-12  196.21  199.20  198.87  200.14  196.21  199.20  27760668  27760668  \n",
       "2019-04-15  198.01  198.58  199.23  199.85  198.01  198.58  17536646  17536646  \n",
       "2019-04-16  198.56  199.46  199.25  201.37  198.56  199.46  25696385  25696385  \n",
       "2019-04-17  198.61  199.54  203.13  203.38  198.61  199.54  28906780  28906780  \n",
       "2019-04-18  202.52  203.12  203.86  204.15  202.52  203.12  24195766  24195766  \n",
       "2019-04-22  202.34  202.83  204.53  204.94  202.34  202.83  19439545  19439545  \n",
       "2019-04-23  203.90  204.43  207.48  207.75  203.90  204.43  23322991  23322991  \n",
       "2019-04-24  207.05  207.36  207.16  208.48  207.05  207.36  17540609  17540609  \n",
       "2019-04-25  205.12  206.83  205.28  207.76  205.12  206.83  18543206  18543206  \n",
       "2019-04-26  202.12  204.90  204.30  205.00  202.12  204.90  18649102  18649102  \n",
       "2019-04-29  203.86  204.40  204.61  205.97  203.86  204.40  22204716  22204716  \n",
       "2019-04-30  199.11  203.06  200.67  203.40  199.11  203.06  46534923  46534923  \n",
       "2019-05-01  209.23  209.88  210.52  215.31  209.23  209.88  64827328  64827328  \n",
       "2019-05-02  208.13  209.84  209.15  212.65  208.13  209.84  31996324  31996324  \n",
       "2019-05-03  210.23  210.89  211.75  211.84  210.23  210.89  20892378  20892378  \n",
       "2019-05-06  203.50  204.29  208.48  208.84  203.50  204.29  32443113  32443113  "
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.chartDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Income Statement"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'income': [{'reportDate': '2019-03-31',\n",
       "   'totalRevenue': 57918000000,\n",
       "   'costOfRevenue': 36270000000,\n",
       "   'grossProfit': 21648000000,\n",
       "   'researchAndDevelopment': 3948000000,\n",
       "   'sellingGeneralAndAdmin': 4458000000,\n",
       "   'operatingExpense': 44676000000,\n",
       "   'operatingIncome': 13242000000,\n",
       "   'otherIncomeExpenseNet': 551000000,\n",
       "   'ebit': 13242000000,\n",
       "   'interestIncome': 1010000000,\n",
       "   'pretaxIncome': 13793000000,\n",
       "   'incomeTax': 2232000000,\n",
       "   'minorityInterest': 0,\n",
       "   'netIncome': 11561000000,\n",
       "   'netIncomeBasic': 11561000000}]}"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.incomeStatement(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>costOfRevenue</th>\n",
       "      <th>ebit</th>\n",
       "      <th>grossProfit</th>\n",
       "      <th>incomeTax</th>\n",
       "      <th>interestIncome</th>\n",
       "      <th>minorityInterest</th>\n",
       "      <th>netIncome</th>\n",
       "      <th>netIncomeBasic</th>\n",
       "      <th>operatingExpense</th>\n",
       "      <th>operatingIncome</th>\n",
       "      <th>otherIncomeExpenseNet</th>\n",
       "      <th>pretaxIncome</th>\n",
       "      <th>researchAndDevelopment</th>\n",
       "      <th>sellingGeneralAndAdmin</th>\n",
       "      <th>totalRevenue</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>reportDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-03-31</th>\n",
       "      <td>36270000000</td>\n",
       "      <td>13242000000</td>\n",
       "      <td>21648000000</td>\n",
       "      <td>2232000000</td>\n",
       "      <td>1010000000</td>\n",
       "      <td>0</td>\n",
       "      <td>11561000000</td>\n",
       "      <td>11561000000</td>\n",
       "      <td>44676000000</td>\n",
       "      <td>13242000000</td>\n",
       "      <td>551000000</td>\n",
       "      <td>13793000000</td>\n",
       "      <td>3948000000</td>\n",
       "      <td>4458000000</td>\n",
       "      <td>57918000000</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            costOfRevenue         ebit  grossProfit   incomeTax  \\\n",
       "reportDate                                                        \n",
       "2019-03-31    36270000000  13242000000  21648000000  2232000000   \n",
       "\n",
       "            interestIncome  minorityInterest    netIncome  netIncomeBasic  \\\n",
       "reportDate                                                                  \n",
       "2019-03-31      1010000000                 0  11561000000     11561000000   \n",
       "\n",
       "            operatingExpense  operatingIncome  otherIncomeExpenseNet  \\\n",
       "reportDate                                                             \n",
       "2019-03-31       44676000000      13242000000              551000000   \n",
       "\n",
       "            pretaxIncome  researchAndDevelopment  sellingGeneralAndAdmin  \\\n",
       "reportDate                                                                 \n",
       "2019-03-31   13793000000              3948000000              4458000000   \n",
       "\n",
       "            totalRevenue symbol  \n",
       "reportDate                       \n",
       "2019-03-31   57918000000   AAPL  "
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.incomeStatementDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Insider Roster"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'position': 3235000,\n",
       "  'reportDate': 1553990400000,\n",
       "  'entityName': 'WELLCOME TRUST LTD /DIRECT INVESTMENTS/'},\n",
       " {'position': 1147283,\n",
       "  'reportDate': 1551398400000,\n",
       "  'entityName': 'Arthur D. Levinson'},\n",
       " {'position': 878425,\n",
       "  'reportDate': 1546387200000,\n",
       "  'entityName': 'Timothy Donald Cook'},\n",
       " {'position': 419896,\n",
       "  'reportDate': 1533772800000,\n",
       "  'entityName': 'Craig Federighi'},\n",
       " {'position': 164620,\n",
       "  'reportDate': 1554076800000,\n",
       "  'entityName': 'Jeffrey E. Williams'},\n",
       " {'position': 151102,\n",
       "  'reportDate': 1555286400000,\n",
       "  'entityName': \"Deirdre O'Brien\"},\n",
       " {'position': 80696,\n",
       "  'reportDate': 1551398400000,\n",
       "  'entityName': 'Albert Arnold Gore'},\n",
       " {'position': 73455,\n",
       "  'reportDate': 1546214400000,\n",
       "  'entityName': 'SEPIO CAPITAL LLC'},\n",
       " {'position': 65370,\n",
       "  'reportDate': 1522540800000,\n",
       "  'entityName': 'Eduardo H. Cue'},\n",
       " {'position': 61158,\n",
       "  'reportDate': 1534464000000,\n",
       "  'entityName': 'Johny Srouji'}]"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.insiderRoster(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>entityName</th>\n",
       "      <th>position</th>\n",
       "      <th>reportDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>WELLCOME TRUST LTD /DIRECT INVESTMENTS/</td>\n",
       "      <td>3235000</td>\n",
       "      <td>2019-03-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Arthur D. Levinson</td>\n",
       "      <td>1147283</td>\n",
       "      <td>2019-03-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Timothy Donald Cook</td>\n",
       "      <td>878425</td>\n",
       "      <td>2019-01-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Craig Federighi</td>\n",
       "      <td>419896</td>\n",
       "      <td>2018-08-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Jeffrey E. Williams</td>\n",
       "      <td>164620</td>\n",
       "      <td>2019-04-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Deirdre O'Brien</td>\n",
       "      <td>151102</td>\n",
       "      <td>2019-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Albert Arnold Gore</td>\n",
       "      <td>80696</td>\n",
       "      <td>2019-03-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>SEPIO CAPITAL LLC</td>\n",
       "      <td>73455</td>\n",
       "      <td>2018-12-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Eduardo H. Cue</td>\n",
       "      <td>65370</td>\n",
       "      <td>2018-04-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Johny Srouji</td>\n",
       "      <td>61158</td>\n",
       "      <td>2018-08-17</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                entityName  position reportDate\n",
       "0  WELLCOME TRUST LTD /DIRECT INVESTMENTS/   3235000 2019-03-31\n",
       "1                       Arthur D. Levinson   1147283 2019-03-01\n",
       "2                      Timothy Donald Cook    878425 2019-01-02\n",
       "3                          Craig Federighi    419896 2018-08-09\n",
       "4                      Jeffrey E. Williams    164620 2019-04-01\n",
       "5                          Deirdre O'Brien    151102 2019-04-15\n",
       "6                       Albert Arnold Gore     80696 2019-03-01\n",
       "7                        SEPIO CAPITAL LLC     73455 2018-12-31\n",
       "8                           Eduardo H. Cue     65370 2018-04-01\n",
       "9                             Johny Srouji     61158 2018-08-17"
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.insiderRosterDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Insider Summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'reportedTitle': 'Director',\n",
       "  'netTransacted': 1429,\n",
       "  'totalBought': 2950,\n",
       "  'totalSold': -1521,\n",
       "  'fullName': 'Susan Lynne Wagner'},\n",
       " {'reportedTitle': 'Director',\n",
       "  'netTransacted': 1429,\n",
       "  'totalBought': 2950,\n",
       "  'totalSold': -1521,\n",
       "  'fullName': 'James A. Bell'},\n",
       " {'reportedTitle': 'Principal Accounting Officer',\n",
       "  'netTransacted': -6466,\n",
       "  'totalBought': 6917,\n",
       "  'totalSold': -13383,\n",
       "  'fullName': 'Chris Kondo'},\n",
       " {'reportedTitle': 'COO',\n",
       "  'netTransacted': -48989,\n",
       "  'totalBought': 105400,\n",
       "  'totalSold': -154389,\n",
       "  'fullName': 'Jeffrey E. Williams'},\n",
       " {'reportedTitle': 'Director',\n",
       "  'netTransacted': 1429,\n",
       "  'totalBought': 2950,\n",
       "  'totalSold': -1521,\n",
       "  'fullName': 'Andrea Jung'},\n",
       " {'reportedTitle': 'Director',\n",
       "  'netTransacted': -92,\n",
       "  'totalBought': 2950,\n",
       "  'totalSold': -3042,\n",
       "  'fullName': 'Arthur D. Levinson'},\n",
       " {'reportedTitle': 'Director',\n",
       "  'netTransacted': 1429,\n",
       "  'totalBought': 2950,\n",
       "  'totalSold': -1521,\n",
       "  'fullName': 'Robert A. Iger'},\n",
       " {'reportedTitle': 'Director',\n",
       "  'netTransacted': 1429,\n",
       "  'totalBought': 2950,\n",
       "  'totalSold': -1521,\n",
       "  'fullName': 'Ronald D. Sugar'},\n",
       " {'reportedTitle': 'Director',\n",
       "  'netTransacted': 1429,\n",
       "  'totalBought': 37950,\n",
       "  'totalSold': -36521,\n",
       "  'fullName': 'Albert Arnold Gore'},\n",
       " {'reportedTitle': 'SVP, GC and Secretary',\n",
       "  'netTransacted': -7019,\n",
       "  'totalBought': 14371,\n",
       "  'totalSold': -21390,\n",
       "  'fullName': 'Katherine L. Adams'},\n",
       " {'reportedTitle': 'Senior Vice President, CFO',\n",
       "  'netTransacted': -105400,\n",
       "  'totalBought': 105400,\n",
       "  'totalSold': -210800,\n",
       "  'fullName': 'Luca Maestri'},\n",
       " {'reportedTitle': 'Senior Vice President',\n",
       "  'netTransacted': 304602,\n",
       "  'totalBought': 339353,\n",
       "  'totalSold': -34751,\n",
       "  'fullName': \"Deirdre O'Brien\"}]"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.insiderSummary(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>fullName</th>\n",
       "      <th>netTransacted</th>\n",
       "      <th>reportedTitle</th>\n",
       "      <th>totalBought</th>\n",
       "      <th>totalSold</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Susan Lynne Wagner</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>James A. Bell</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Chris Kondo</td>\n",
       "      <td>-6466</td>\n",
       "      <td>Principal Accounting Officer</td>\n",
       "      <td>6917</td>\n",
       "      <td>-13383</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Jeffrey E. Williams</td>\n",
       "      <td>-48989</td>\n",
       "      <td>COO</td>\n",
       "      <td>105400</td>\n",
       "      <td>-154389</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Andrea Jung</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Arthur D. Levinson</td>\n",
       "      <td>-92</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-3042</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Robert A. Iger</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Ronald D. Sugar</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Albert Arnold Gore</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>37950</td>\n",
       "      <td>-36521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Katherine L. Adams</td>\n",
       "      <td>-7019</td>\n",
       "      <td>SVP, GC and Secretary</td>\n",
       "      <td>14371</td>\n",
       "      <td>-21390</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Luca Maestri</td>\n",
       "      <td>-105400</td>\n",
       "      <td>Senior Vice President, CFO</td>\n",
       "      <td>105400</td>\n",
       "      <td>-210800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Deirdre O'Brien</td>\n",
       "      <td>304602</td>\n",
       "      <td>Senior Vice President</td>\n",
       "      <td>339353</td>\n",
       "      <td>-34751</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               fullName  netTransacted                 reportedTitle  \\\n",
       "0    Susan Lynne Wagner           1429                      Director   \n",
       "1         James A. Bell           1429                      Director   \n",
       "2           Chris Kondo          -6466  Principal Accounting Officer   \n",
       "3   Jeffrey E. Williams         -48989                           COO   \n",
       "4           Andrea Jung           1429                      Director   \n",
       "5    Arthur D. Levinson            -92                      Director   \n",
       "6        Robert A. Iger           1429                      Director   \n",
       "7       Ronald D. Sugar           1429                      Director   \n",
       "8    Albert Arnold Gore           1429                      Director   \n",
       "9    Katherine L. Adams          -7019         SVP, GC and Secretary   \n",
       "10         Luca Maestri        -105400    Senior Vice President, CFO   \n",
       "11      Deirdre O'Brien         304602         Senior Vice President   \n",
       "\n",
       "    totalBought  totalSold  \n",
       "0          2950      -1521  \n",
       "1          2950      -1521  \n",
       "2          6917     -13383  \n",
       "3        105400    -154389  \n",
       "4          2950      -1521  \n",
       "5          2950      -3042  \n",
       "6          2950      -1521  \n",
       "7          2950      -1521  \n",
       "8         37950     -36521  \n",
       "9         14371     -21390  \n",
       "10       105400    -210800  \n",
       "11       339353     -34751  "
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.insiderSummaryDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Insider Transactions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'fullName': \"Deirdre O'Brien\",\n",
       "  'reportedTitle': 'Senior Vice President',\n",
       "  'effectiveDate': 1555286400000,\n",
       "  'tranShares': -4154,\n",
       "  'tranPrice': None,\n",
       "  'tranValue': None},\n",
       " {'fullName': \"Deirdre O'Brien\",\n",
       "  'reportedTitle': 'Senior Vice President',\n",
       "  'effectiveDate': 1555286400000,\n",
       "  'tranShares': -5574,\n",
       "  'tranPrice': None,\n",
       "  'tranValue': None},\n",
       " {'fullName': \"Deirdre O'Brien\",\n",
       "  'reportedTitle': 'Senior Vice President',\n",
       "  'effectiveDate': 1555286400000,\n",
       "  'tranShares': -6908,\n",
       "  'tranPrice': None,\n",
       "  'tranValue': None},\n",
       " {'fullName': \"Deirdre O'Brien\",\n",
       "  'reportedTitle': 'Senior Vice President',\n",
       "  'effectiveDate': 1555286400000,\n",
       "  'tranShares': -7334,\n",
       "  'tranPrice': None,\n",
       "  'tranValue': None},\n",
       " {'fullName': \"Deirdre O'Brien\",\n",
       "  'reportedTitle': 'Senior Vice President',\n",
       "  'effectiveDate': 1555286400000,\n",
       "  'tranShares': -10781,\n",
       "  'tranPrice': 199.23,\n",
       "  'tranValue': -2147898.63}]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.insiderTransactions(symbol)[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>fullName</th>\n",
       "      <th>netTransacted</th>\n",
       "      <th>reportedTitle</th>\n",
       "      <th>totalBought</th>\n",
       "      <th>totalSold</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Susan Lynne Wagner</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>James A. Bell</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Chris Kondo</td>\n",
       "      <td>-6466</td>\n",
       "      <td>Principal Accounting Officer</td>\n",
       "      <td>6917</td>\n",
       "      <td>-13383</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Jeffrey E. Williams</td>\n",
       "      <td>-48989</td>\n",
       "      <td>COO</td>\n",
       "      <td>105400</td>\n",
       "      <td>-154389</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Andrea Jung</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Arthur D. Levinson</td>\n",
       "      <td>-92</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-3042</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Robert A. Iger</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Ronald D. Sugar</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>2950</td>\n",
       "      <td>-1521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Albert Arnold Gore</td>\n",
       "      <td>1429</td>\n",
       "      <td>Director</td>\n",
       "      <td>37950</td>\n",
       "      <td>-36521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Katherine L. Adams</td>\n",
       "      <td>-7019</td>\n",
       "      <td>SVP, GC and Secretary</td>\n",
       "      <td>14371</td>\n",
       "      <td>-21390</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Luca Maestri</td>\n",
       "      <td>-105400</td>\n",
       "      <td>Senior Vice President, CFO</td>\n",
       "      <td>105400</td>\n",
       "      <td>-210800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Deirdre O'Brien</td>\n",
       "      <td>304602</td>\n",
       "      <td>Senior Vice President</td>\n",
       "      <td>339353</td>\n",
       "      <td>-34751</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               fullName  netTransacted                 reportedTitle  \\\n",
       "0    Susan Lynne Wagner           1429                      Director   \n",
       "1         James A. Bell           1429                      Director   \n",
       "2           Chris Kondo          -6466  Principal Accounting Officer   \n",
       "3   Jeffrey E. Williams         -48989                           COO   \n",
       "4           Andrea Jung           1429                      Director   \n",
       "5    Arthur D. Levinson            -92                      Director   \n",
       "6        Robert A. Iger           1429                      Director   \n",
       "7       Ronald D. Sugar           1429                      Director   \n",
       "8    Albert Arnold Gore           1429                      Director   \n",
       "9    Katherine L. Adams          -7019         SVP, GC and Secretary   \n",
       "10         Luca Maestri        -105400    Senior Vice President, CFO   \n",
       "11      Deirdre O'Brien         304602         Senior Vice President   \n",
       "\n",
       "    totalBought  totalSold  \n",
       "0          2950      -1521  \n",
       "1          2950      -1521  \n",
       "2          6917     -13383  \n",
       "3        105400    -154389  \n",
       "4          2950      -1521  \n",
       "5          2950      -3042  \n",
       "6          2950      -1521  \n",
       "7          2950      -1521  \n",
       "8         37950     -36521  \n",
       "9         14371     -21390  \n",
       "10       105400    -210800  \n",
       "11       339353     -34751  "
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.insiderTransactionsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Institutional Ownership"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'reportDate': 1553990400000,\n",
       "  'adjHolding': 16434619,\n",
       "  'reportedHolding': 16434619,\n",
       "  'adjMv': 3121755879,\n",
       "  'entityProperName': 'Janus Henderson Group Plc (Subfiler)'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 13191995,\n",
       "  'reportedHolding': 13191995,\n",
       "  'adjMv': 2505819450,\n",
       "  'entityProperName': 'Fisher Asset Management LLC'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 9713927,\n",
       "  'reportedHolding': 9713927,\n",
       "  'adjMv': 1845160434,\n",
       "  'entityProperName': 'The California Public Employees Retirement System'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 8267773,\n",
       "  'reportedHolding': 8267773,\n",
       "  'adjMv': 1570463481,\n",
       "  'entityProperName': 'BMO Harris Bank, NA (Private Bank)'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 8260851,\n",
       "  'reportedHolding': 8260851,\n",
       "  'adjMv': 1569148647,\n",
       "  'entityProperName': 'RhumbLine Advisers LP'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 8134174,\n",
       "  'reportedHolding': 8134174,\n",
       "  'adjMv': 1545086351,\n",
       "  'entityProperName': 'Sanders Capital LLC'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 6414428,\n",
       "  'reportedHolding': 6414428,\n",
       "  'adjMv': 1218420599,\n",
       "  'entityProperName': 'State Board of Administration of Florida Retirement (13F)'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 5179469,\n",
       "  'reportedHolding': 5179469,\n",
       "  'adjMv': 983840137,\n",
       "  'entityProperName': 'Swedbank AB'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 5145938,\n",
       "  'reportedHolding': 5145938,\n",
       "  'adjMv': 977470923,\n",
       "  'entityProperName': 'Raymond James & Associates, Inc.'},\n",
       " {'reportDate': 1553990400000,\n",
       "  'adjHolding': 3994473,\n",
       "  'reportedHolding': 3994473,\n",
       "  'adjMv': 758750146,\n",
       "  'entityProperName': 'Los Angeles Capital Management & Equity Research, Inc.'}]"
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.institutionalOwnership(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>adjHolding</th>\n",
       "      <th>adjMv</th>\n",
       "      <th>entityProperName</th>\n",
       "      <th>reportDate</th>\n",
       "      <th>reportedHolding</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>16434619</td>\n",
       "      <td>3121755879</td>\n",
       "      <td>Janus Henderson Group Plc (Subfiler)</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>16434619</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13191995</td>\n",
       "      <td>2505819450</td>\n",
       "      <td>Fisher Asset Management LLC</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>13191995</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>9713927</td>\n",
       "      <td>1845160434</td>\n",
       "      <td>The California Public Employees Retirement System</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>9713927</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>8267773</td>\n",
       "      <td>1570463481</td>\n",
       "      <td>BMO Harris Bank, NA (Private Bank)</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>8267773</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>8260851</td>\n",
       "      <td>1569148647</td>\n",
       "      <td>RhumbLine Advisers LP</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>8260851</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>8134174</td>\n",
       "      <td>1545086351</td>\n",
       "      <td>Sanders Capital LLC</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>8134174</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6414428</td>\n",
       "      <td>1218420599</td>\n",
       "      <td>State Board of Administration of Florida Retir...</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>6414428</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>5179469</td>\n",
       "      <td>983840137</td>\n",
       "      <td>Swedbank AB</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>5179469</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>5145938</td>\n",
       "      <td>977470923</td>\n",
       "      <td>Raymond James &amp; Associates, Inc.</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>5145938</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>3994473</td>\n",
       "      <td>758750146</td>\n",
       "      <td>Los Angeles Capital Management &amp; Equity Resear...</td>\n",
       "      <td>2019-03-31</td>\n",
       "      <td>3994473</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   adjHolding       adjMv                                   entityProperName  \\\n",
       "0    16434619  3121755879               Janus Henderson Group Plc (Subfiler)   \n",
       "1    13191995  2505819450                        Fisher Asset Management LLC   \n",
       "2     9713927  1845160434  The California Public Employees Retirement System   \n",
       "3     8267773  1570463481                 BMO Harris Bank, NA (Private Bank)   \n",
       "4     8260851  1569148647                              RhumbLine Advisers LP   \n",
       "5     8134174  1545086351                                Sanders Capital LLC   \n",
       "6     6414428  1218420599  State Board of Administration of Florida Retir...   \n",
       "7     5179469   983840137                                        Swedbank AB   \n",
       "8     5145938   977470923                   Raymond James & Associates, Inc.   \n",
       "9     3994473   758750146  Los Angeles Capital Management & Equity Resear...   \n",
       "\n",
       "  reportDate  reportedHolding  \n",
       "0 2019-03-31         16434619  \n",
       "1 2019-03-31         13191995  \n",
       "2 2019-03-31          9713927  \n",
       "3 2019-03-31          8267773  \n",
       "4 2019-03-31          8260851  \n",
       "5 2019-03-31          8134174  \n",
       "6 2019-03-31          6414428  \n",
       "7 2019-03-31          5179469  \n",
       "8 2019-03-31          5145938  \n",
       "9 2019-03-31          3994473  "
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.institutionalOwnershipDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Intraday Prices"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'date': '2019-05-07',\n",
       "  'minute': '09:30',\n",
       "  'label': '09:30 AM',\n",
       "  'high': 206.47,\n",
       "  'low': 205.72,\n",
       "  'average': 205.928,\n",
       "  'volume': 5646,\n",
       "  'notional': 1162672.17,\n",
       "  'numberOfTrades': 56,\n",
       "  'marketHigh': 206.557,\n",
       "  'marketLow': 205.7,\n",
       "  'marketAverage': 205.925,\n",
       "  'marketVolume': 603640,\n",
       "  'marketNotional': 124304727.856,\n",
       "  'marketNumberOfTrades': 1566,\n",
       "  'open': 205.895,\n",
       "  'close': 206.47,\n",
       "  'marketOpen': 205.88,\n",
       "  'marketClose': 206.557,\n",
       "  'changeOverTime': 0,\n",
       "  'marketChangeOverTime': 0},\n",
       " {'date': '2019-05-07',\n",
       "  'minute': '09:31',\n",
       "  'label': '09:31 AM',\n",
       "  'high': 207.37,\n",
       "  'low': 206.565,\n",
       "  'average': 206.934,\n",
       "  'volume': 2895,\n",
       "  'notional': 599074.79,\n",
       "  'numberOfTrades': 30,\n",
       "  'marketHigh': 207.417,\n",
       "  'marketLow': 206.54,\n",
       "  'marketAverage': 207.071,\n",
       "  'marketVolume': 317632,\n",
       "  'marketNotional': 65772420.8479,\n",
       "  'marketNumberOfTrades': 1236,\n",
       "  'open': 206.565,\n",
       "  'close': 207.27,\n",
       "  'marketOpen': 206.6,\n",
       "  'marketClose': 207.134,\n",
       "  'changeOverTime': 0.004885202595081777,\n",
       "  'marketChangeOverTime': 0.005565132936748751},\n",
       " {'date': '2019-05-07',\n",
       "  'minute': '09:32',\n",
       "  'label': '09:32 AM',\n",
       "  'high': 207.04,\n",
       "  'low': 206.5,\n",
       "  'average': 206.697,\n",
       "  'volume': 2300,\n",
       "  'notional': 475403.5,\n",
       "  'numberOfTrades': 19,\n",
       "  'marketHigh': 207.22,\n",
       "  'marketLow': 206.49,\n",
       "  'marketAverage': 206.766,\n",
       "  'marketVolume': 225791,\n",
       "  'marketNotional': 46685865.2891,\n",
       "  'marketNumberOfTrades': 809,\n",
       "  'open': 207.04,\n",
       "  'close': 206.81,\n",
       "  'marketOpen': 207.14,\n",
       "  'marketClose': 206.85,\n",
       "  'changeOverTime': 0.0037343149061808277,\n",
       "  'marketChangeOverTime': 0.004084011169114871},\n",
       " {'date': '2019-05-07',\n",
       "  'minute': '09:33',\n",
       "  'label': '09:33 AM',\n",
       "  'high': 206.96,\n",
       "  'low': 206.68,\n",
       "  'average': 206.813,\n",
       "  'volume': 2297,\n",
       "  'notional': 475049.95,\n",
       "  'numberOfTrades': 25,\n",
       "  'marketHigh': 206.97,\n",
       "  'marketLow': 206.68,\n",
       "  'marketAverage': 206.827,\n",
       "  'marketVolume': 137883,\n",
       "  'marketNotional': 28518003.9585,\n",
       "  'marketNumberOfTrades': 702,\n",
       "  'open': 206.79,\n",
       "  'close': 206.74,\n",
       "  'marketOpen': 206.76,\n",
       "  'marketClose': 206.804,\n",
       "  'changeOverTime': 0.004297618585136508,\n",
       "  'marketChangeOverTime': 0.004380235522641674},\n",
       " {'date': '2019-05-07',\n",
       "  'minute': '09:34',\n",
       "  'label': '09:34 AM',\n",
       "  'high': 206.9,\n",
       "  'low': 206.55,\n",
       "  'average': 206.681,\n",
       "  'volume': 1300,\n",
       "  'notional': 268685.5,\n",
       "  'numberOfTrades': 13,\n",
       "  'marketHigh': 206.9,\n",
       "  'marketLow': 206.53,\n",
       "  'marketAverage': 206.686,\n",
       "  'marketVolume': 80998,\n",
       "  'marketNotional': 16741155.1995,\n",
       "  'marketNumberOfTrades': 490,\n",
       "  'open': 206.9,\n",
       "  'close': 206.66,\n",
       "  'marketOpen': 206.79,\n",
       "  'marketClose': 206.595,\n",
       "  'changeOverTime': 0.00365661784701456,\n",
       "  'marketChangeOverTime': 0.0036955202136700043}]"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.intraday(symbol)[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>average</th>\n",
       "      <th>changeOverTime</th>\n",
       "      <th>close</th>\n",
       "      <th>date</th>\n",
       "      <th>high</th>\n",
       "      <th>label</th>\n",
       "      <th>low</th>\n",
       "      <th>marketAverage</th>\n",
       "      <th>marketChangeOverTime</th>\n",
       "      <th>marketClose</th>\n",
       "      <th>marketHigh</th>\n",
       "      <th>marketLow</th>\n",
       "      <th>marketNotional</th>\n",
       "      <th>marketNumberOfTrades</th>\n",
       "      <th>marketOpen</th>\n",
       "      <th>marketVolume</th>\n",
       "      <th>notional</th>\n",
       "      <th>numberOfTrades</th>\n",
       "      <th>open</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>minute</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>09:30</th>\n",
       "      <td>205.928</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>206.47</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>206.47</td>\n",
       "      <td>09:30 AM</td>\n",
       "      <td>205.720</td>\n",
       "      <td>205.925</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>206.557</td>\n",
       "      <td>206.557</td>\n",
       "      <td>205.70</td>\n",
       "      <td>1.243047e+08</td>\n",
       "      <td>1566</td>\n",
       "      <td>205.88</td>\n",
       "      <td>603640</td>\n",
       "      <td>1162672.17</td>\n",
       "      <td>56</td>\n",
       "      <td>205.895</td>\n",
       "      <td>5646</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>09:31</th>\n",
       "      <td>206.934</td>\n",
       "      <td>0.004885</td>\n",
       "      <td>207.27</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>207.37</td>\n",
       "      <td>09:31 AM</td>\n",
       "      <td>206.565</td>\n",
       "      <td>207.071</td>\n",
       "      <td>0.005565</td>\n",
       "      <td>207.134</td>\n",
       "      <td>207.417</td>\n",
       "      <td>206.54</td>\n",
       "      <td>6.577242e+07</td>\n",
       "      <td>1236</td>\n",
       "      <td>206.60</td>\n",
       "      <td>317632</td>\n",
       "      <td>599074.79</td>\n",
       "      <td>30</td>\n",
       "      <td>206.565</td>\n",
       "      <td>2895</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>09:32</th>\n",
       "      <td>206.697</td>\n",
       "      <td>0.003734</td>\n",
       "      <td>206.81</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>207.04</td>\n",
       "      <td>09:32 AM</td>\n",
       "      <td>206.500</td>\n",
       "      <td>206.766</td>\n",
       "      <td>0.004084</td>\n",
       "      <td>206.850</td>\n",
       "      <td>207.220</td>\n",
       "      <td>206.49</td>\n",
       "      <td>4.668587e+07</td>\n",
       "      <td>809</td>\n",
       "      <td>207.14</td>\n",
       "      <td>225791</td>\n",
       "      <td>475403.50</td>\n",
       "      <td>19</td>\n",
       "      <td>207.040</td>\n",
       "      <td>2300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>09:33</th>\n",
       "      <td>206.813</td>\n",
       "      <td>0.004298</td>\n",
       "      <td>206.74</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>206.96</td>\n",
       "      <td>09:33 AM</td>\n",
       "      <td>206.680</td>\n",
       "      <td>206.827</td>\n",
       "      <td>0.004380</td>\n",
       "      <td>206.804</td>\n",
       "      <td>206.970</td>\n",
       "      <td>206.68</td>\n",
       "      <td>2.851800e+07</td>\n",
       "      <td>702</td>\n",
       "      <td>206.76</td>\n",
       "      <td>137883</td>\n",
       "      <td>475049.95</td>\n",
       "      <td>25</td>\n",
       "      <td>206.790</td>\n",
       "      <td>2297</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>09:34</th>\n",
       "      <td>206.681</td>\n",
       "      <td>0.003657</td>\n",
       "      <td>206.66</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>206.90</td>\n",
       "      <td>09:34 AM</td>\n",
       "      <td>206.550</td>\n",
       "      <td>206.686</td>\n",
       "      <td>0.003696</td>\n",
       "      <td>206.595</td>\n",
       "      <td>206.900</td>\n",
       "      <td>206.53</td>\n",
       "      <td>1.674116e+07</td>\n",
       "      <td>490</td>\n",
       "      <td>206.79</td>\n",
       "      <td>80998</td>\n",
       "      <td>268685.50</td>\n",
       "      <td>13</td>\n",
       "      <td>206.900</td>\n",
       "      <td>1300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        average  changeOverTime   close       date    high     label      low  \\\n",
       "minute                                                                          \n",
       "09:30   205.928        0.000000  206.47 2019-05-07  206.47  09:30 AM  205.720   \n",
       "09:31   206.934        0.004885  207.27 2019-05-07  207.37  09:31 AM  206.565   \n",
       "09:32   206.697        0.003734  206.81 2019-05-07  207.04  09:32 AM  206.500   \n",
       "09:33   206.813        0.004298  206.74 2019-05-07  206.96  09:33 AM  206.680   \n",
       "09:34   206.681        0.003657  206.66 2019-05-07  206.90  09:34 AM  206.550   \n",
       "\n",
       "        marketAverage  marketChangeOverTime  marketClose  marketHigh  \\\n",
       "minute                                                                 \n",
       "09:30         205.925              0.000000      206.557     206.557   \n",
       "09:31         207.071              0.005565      207.134     207.417   \n",
       "09:32         206.766              0.004084      206.850     207.220   \n",
       "09:33         206.827              0.004380      206.804     206.970   \n",
       "09:34         206.686              0.003696      206.595     206.900   \n",
       "\n",
       "        marketLow  marketNotional  marketNumberOfTrades  marketOpen  \\\n",
       "minute                                                                \n",
       "09:30      205.70    1.243047e+08                  1566      205.88   \n",
       "09:31      206.54    6.577242e+07                  1236      206.60   \n",
       "09:32      206.49    4.668587e+07                   809      207.14   \n",
       "09:33      206.68    2.851800e+07                   702      206.76   \n",
       "09:34      206.53    1.674116e+07                   490      206.79   \n",
       "\n",
       "        marketVolume    notional  numberOfTrades     open  volume  \n",
       "minute                                                             \n",
       "09:30         603640  1162672.17              56  205.895    5646  \n",
       "09:31         317632   599074.79              30  206.565    2895  \n",
       "09:32         225791   475403.50              19  207.040    2300  \n",
       "09:33         137883   475049.95              25  206.790    2297  \n",
       "09:34          80998   268685.50              13  206.900    1300  "
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.intradayDF(symbol).head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## IPO Calendar"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'rawData': [{'symbol': 'LCAHU',\n",
       "   'companyName': 'LANDCADIA HOLDINGS II, INC.',\n",
       "   'expectedDate': '2019-05-07',\n",
       "   'leadUnderwriters': ['Jefferies LLC'],\n",
       "   'underwriters': [],\n",
       "   'companyCounsel': ['Winston & Strawn LLP'],\n",
       "   'underwriterCounsel': ['Shearman & Sterling LLP'],\n",
       "   'auditor': 'Continental Stock Transfer & Trust Company',\n",
       "   'market': 'NASDAQ Capital',\n",
       "   'cik': '0001768012',\n",
       "   'address': '1510 WEST LOOP SOUTH',\n",
       "   'city': 'HOUSTON',\n",
       "   'state': 'TX',\n",
       "   'zip': '77027',\n",
       "   'phone': '713-850-1010',\n",
       "   'ceo': 'Tilman J. Fertitta',\n",
       "   'employees': 5,\n",
       "   'url': '',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 25000000,\n",
       "   'priceLow': 10,\n",
       "   'priceHigh': None,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 1000000,\n",
       "   'sharesOverAlloted': 3750000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 31250000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': None,\n",
       "   'netIncome': 0,\n",
       "   'totalAssets': 0,\n",
       "   'totalLiabilities': 0,\n",
       "   'stockholderEquity': 0,\n",
       "   'companyDescription': 'We are a blank check company whose business purpose is to effect a merger, &#10; capital stock exchange, asset acquisition, stock purchase, reorganization or &#10; similar business combination with one or more businesses, which we refer to &#10; throughout this prospectus as our initial business combination. We have not &#10; selected any specific business combination target and we have not, nor has &#10; anyone on our behalf, initiated any substantive discussions, directly or &#10; indirectly, with any business combination target with respect to an initial &#10; business combination with us. While we may pursue an initial business &#10; combination target in any industry, we intend to focus our search on investment &#10; opportunities in the consumer, dining, hospitality, entertainment and gaming &#10; industries, including technology companies operating in these industries. &#10; --- &#10;  &#10; Our executive offices are located at 1510 West Loop South, Houston, Texas 77027, &#10; and our telephone number is (713) 850-1010.',\n",
       "   'businessDescription': 'We are a blank check company whose business purpose is to effect a merger, &#10; capital stock exchange, asset acquisition, stock purchase, reorganization or &#10; similar business combination with one or more businesses, which we refer to &#10; throughout this prospectus as our initial business combination. We have not &#10; selected any specific business combination target and we have not, nor has &#10; anyone on our behalf, initiated any substantive discussions, directly or &#10; indirectly, with any business combination target with respect to an initial &#10; business combination with us. While we may pursue an initial business &#10; combination target in any industry, we intend to focus our search on investment &#10; opportunities in the consumer, dining, hospitality, entertainment and gaming &#10; industries, including technology companies operating in these industries. &#10; --- &#10;  &#10; Our executive offices are located at 1510 West Loop South, Houston, Texas 77027, &#10; and our telephone number is (713) 850-1010.',\n",
       "   'useOfProceeds': 'We are offering 25,000,000 units at an offering price of $10.00 per unit. We &#10; estimate that the net proceeds of this offering together with the funds we will &#10; receive from the sale of the private placement warrants will be used as set &#10; forth in the following table. &#10;  &#10;                                                                                                                     Without           Over-Allotment  &#10;                                                                                                                 Over-Allotment         Option Fully     &#10;                                                                                                                      Option               Exercised       &#10; Gross proceeds                                                                                                                                            &#10; Gross proceeds from units offered to public(1)                                                                    $ 250,000,000         $ 287,500,000     &#10; Gross proceeds from private placement warrants offered in the private placement                                       7,500,000             8,250,000     &#10; Total gross proceeds                                                                                              $ 257,500,000         $ 295,750,000     &#10; Offering expenses(2)                                                                                                                                      &#10; Underwriting commissions (2% of gross proceeds from units offered to public, excluding deferred portion)(3)       $   5,000,000         $   5,750,000     &#10; Legal fees and expenses                                                                                                 300,000               300,000     &#10; Accounting fees and expenses                                                                                             50,000                50,000     &#10; SEC/FINRA Expenses                                                                                                       75,000                75,000     &#10; Travel and road show                                                                                                     25,000                25,000     &#10; Nasdaq listing and filing fees                                                                                           75,000                75,000     &#10; Director and Officer liability insurance premiums                                                                       150,000               150,000     &#10; Printing and engraving expenses                                                                                          50,000                50,000     &#10; Miscellaneous                                                                                                           275,000               275,000     &#10; Total offering expenses (excluding underwriting commissions)                                                      $   1,000,000         $   1,000,000     &#10; Proceeds after offering expenses                                                                                  $ 251,500,000         $ 289,000,000     &#10; Held in trust account(3)                                                                                          $ 250,000,000         $ 287,500,000     &#10; % of public offering size                                                                                                  100%                  100%     &#10; Not held in trust account                                                                                         $   1,500,000         $   1,500,000     &#10;  &#10; The following table shows the estimated use of the approximately $1,500,000 of &#10; net proceeds not held in the trust account.(4) &#10;                                                                                                                                Amount           % of Total     &#10; Legal, accounting, due diligence, travel, and other expenses in connection with any business combination(5)                  $   350,000               23%     &#10; Legal and accounting fees related to regulatory reporting obligations                                                             50,000                3%     &#10; Payment for office space, utilities and secretarial and administrative support ($10,000 per month for up to 24 months)           240,000               16%     &#10; Working capital to cover miscellaneous expenses (including taxes)                                                                860,000               58%     &#10; Total                                                                                                                        $ 1,500,000            100.0%     &#10;  &#10; (1) Includes gross proceeds from this offering of $250,000,000 (or $287,500,000 &#10;     if the underwriters overallotment option is exercised in full). &#10;   &#10; (2) A portion of the offering expenses will be paid from the proceeds of loans &#10;     from our sponsors of up to an aggregate of $300,000 as described in this &#10;     prospectus. As of February 28, 2019, we had not borrowed any amounts (of up &#10;     to $300,000 available to us) under the promissory notes with our sponsors to &#10;     be used for a portion of the expenses of this offering. These amounts will &#10;     be repaid upon completion of this offering out of the offering proceeds that &#10;     has been allocated for the payment of offering expenses (other than &#10;     underwriting commissions). In the event that offering expenses are more than &#10;     as set forth in this table, they will be repaid using a portion of the &#10;     $1,500,000 of offering proceeds not held in the trust account and set aside &#10;     for post-closing working capital expenses. In the event that offering &#10;     expenses are less than set forth in this table, any such amounts will be &#10;     used for post-closing working capital expenses. &#10;   &#10; (3) The underwriters have agreed to defer underwriting commissions equal to 3.5% &#10;     of the gross proceeds of this offering. Upon completion of our initial &#10;     business combination, $8,750,000, which constitutes the underwriters &#10;     deferred commissions (or $10,062,500 if the underwriters over-allotment &#10;     option is exercised in full) will be paid to the underwriters from the funds &#10;     held in the trust account, and the remaining funds, less amounts released to &#10;     the trustee to pay redeeming stockholders, will be released to us and can be &#10;     used to pay all or a portion of the purchase price of the business or &#10;     businesses with which our initial business combination occurs or for general &#10;     corporate purposes, including payment of principal or interest on &#10;     indebtedness incurred in connection with our initial business combination, &#10;     to fund the purchases of other companies or for working capital. The &#10;     underwriters will not be entitled to any interest accrued on the deferred &#10;     underwriting discounts and commissions. &#10;   &#10; (4) These expenses are estimates only and do not include interest which may be &#10;     available to us from the trust account. Our actual expenditures for some or &#10;     all of these items may differ from the estimates set forth herein. For &#10;     example, we may incur greater legal and accounting expenses than our current &#10;     estimates in connection with negotiating and structuring our initial &#10;     business combination based upon the level of complexity of such business &#10;     combination. In the event we identify an initial business combination target &#10;     in a specific industry subject to specific regulations, we may incur &#10;     additional expenses associated with legal due diligence and the engagement &#10;     of special legal counsel. In addition, our staffing needs may vary and as a &#10;     result, we may engage a number of consultants to assist with legal and &#10;     financial due diligence. We do not anticipate any change in our intended use &#10;     of proceeds, other than fluctuations among the current categories of &#10;     allocated expenses, which fluctuations, to the extent they exceed current &#10;     estimates for any specific category of expenses, would not be available for &#10;     our expenses. &#10;   &#10; (5) Includes estimated amounts that may also be used in connection with our &#10;     initial business combination to fund a no shop provision and commitment &#10;     fees for financing. &#10;   &#10; Of the net proceeds of this offering and the sale of the private placement &#10; warrants, $250,000,000 (or $287,500,000 if the underwriters over-allotment &#10; option is exercised in full), including $8,750,000 (or $10,062,500 if the &#10; underwriters over-allotment option is exercised in full) of deferred &#10; underwriting commissions, will be placed in a trust account in the United States &#10; at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company &#10; acting as trustee, and will be invested only in U.S. government treasury bills &#10; with a maturity of 180 days or less or in money market funds meeting certain &#10; conditions under Rule 2a-7 under the Investment Company Act, which invest only &#10; in direct U.S. government treasury obligations. We estimate that the interest &#10; earned on the trust account will be approximately $5,650,000 per year, assuming &#10; an interest rate of 2.26% per year; however, we can provide no assurance &#10; regarding this amount. Except with respect to interest earned on the funds held &#10; in the trust account that may be released to us to pay our tax obligations, the &#10; proceeds from this offering and the sale of the private placement warrants will &#10; not be released from the trust account until the earliest to occur of: (a) the &#10; completion of our initial business combination, (b) the redemption of any public &#10; shares properly submitted in connection with a stockholder vote to amend our &#10; third amended and restated certificate of incorporation to modify the substance &#10; or timing of our obligation to redeem 100% of our public shares if we do not &#10; complete our initial business combination within 24 months from the closing of &#10; this offering or to provide for redemption in connection with a business &#10; combination, and (c) the redemption of our public shares if we are unable to &#10; complete our initial business combination within 24 months from the closing of &#10; this offering, subject to applicable law. &#10;  &#10; The net proceeds released to us from the trust account upon the closing of our &#10; initial business combination may be used as consideration to pay the sellers of &#10; a target business with which we complete our initial business combination. If &#10; our initial business combination is paid for using equity or debt securities, or &#10; not all of the funds released from the trust account are used for payment of the &#10; consideration in connection with our initial business combination, we may use &#10; the balance of the cash released from the trust account following the closing &#10; for general corporate purposes, including for maintenance or expansion of &#10; operations of the post-transaction company, the payment of principal or interest &#10; due on indebtedness incurred in completing our initial business combination, to &#10; fund the purchase of other companies or for working capital. There is no &#10; limitation on our ability to raise funds through the issuance of equity-linked &#10; securities or through loans, advances or other indebtedness in connection with &#10; our initial business combination, including pursuant to forward purchase &#10; agreements or backstop arrangements we may enter into following consummation of &#10; this offering. &#10;  &#10; We believe that amounts not held in trust will be sufficient to pay the costs &#10; and expenses to which such proceeds are allocated. This belief is based on the &#10; fact that while we may begin preliminary due diligence of a target business in &#10; connection with an indication of interest, we intend to undertake in-depth due &#10; diligence, depending on the circumstances of the relevant prospective business &#10; combination, only after we have negotiated and signed a letter of intent or &#10; other preliminary agreement that addresses the terms of an initial business &#10; combination. However, if our estimate of the costs of undertaking in-depth due &#10; diligence and negotiating an initial business combination is less than the &#10; actual amount necessary to do so, we may be required to raise additional &#10; capital, the amount, availability and cost of which is currently &#10; unascertainable. If we are required to seek additional capital, we could seek &#10; such additional capital through loans or additional investments from our &#10; sponsors, members of our management team or their affiliates, but such persons &#10; are not under any obligation to advance funds to, or invest in, us. &#10;  &#10; Commencing on the date of this prospectus, we have agreed to pay FEI a total of  &#10; $10,000 per month for office space, utilities and secretarial and administrative &#10; support. Upon completion of our initial business combination or our liquidation, &#10; we will cease paying these monthly fees. &#10;  &#10; Prior to the closing of this offering, our sponsors have agreed to loan us up to &#10; an aggregate of $300,000 to be used for a portion of the expenses of this &#10; offering. As of February 28, 2019, we had not borrowed any amounts under the &#10; promissory notes with our sponsors to be used for a portion of the expenses of &#10; this offering. These loans are non-interest bearing, unsecured and are due at &#10; the earlier of September 30, 2019 or the closing of this offering. The loan will &#10; be repaid upon the closing of this offering out of offering proceeds not held in &#10; the trust account. &#10;  &#10; In addition, in order to finance transaction costs in connection with an &#10; intended initial business combination, our sponsors or an affiliate of one of &#10; our sponsors or certain of our officers and directors may, but are not obligated &#10; to, loan us funds as may be required. If we complete our initial business &#10; combination, we would repay such loaned amounts out of the proceeds of the trust &#10; account released to us. Otherwise, such loans would be repaid only out of funds &#10; held outside the trust account. In the event that our initial business &#10; combination does not close, we may use a portion of the working capital held &#10; outside the trust account to repay such loaned amounts but no proceeds from our &#10; trust account would be used to repay such loaned amounts. Up to $1,500,000 of &#10; such loans may be convertible into warrants, at a price of $1.50 per warrant at &#10; the option of the lender. The warrants would be identical to the private &#10; placement warrants, including as to exercise price, exercisability and exercise &#10; period. The terms of such loans by our officers and directors, if any, have not &#10; been determined and no written agreements exist with respect to such loans. We &#10; do not expect to seek loans from parties other than our sponsors or an affiliate &#10; of one of our sponsors as we do not believe third parties will be willing to &#10; loan such funds and provide a waiver against any and all rights to seek access &#10; to funds in our trust account. &#10;  &#10; If we seek stockholder approval of our initial business combination and we do &#10; not conduct redemptions in connection with our initial business combination &#10; pursuant to the tender offer rules, our sponsors, initial stockholders, &#10; directors, officers, advisors or their affiliates may purchase shares or public &#10; warrants in privately-negotiated transactions or in the open market, either &#10; prior to or following the completion of our initial business combination. There &#10; is no limit on the number of shares our initial stockholders, directors, &#10; officers, advisors or their affiliates may purchase in such transactions, &#10; subject to compliance with applicable law and Nasdaq rules. However, they have &#10; no current commitments, plans or intentions to engage in such transactions and &#10; have not formulated any terms or conditions for any such transactions. If they &#10; engage in such transactions, they will not make any such purchases when they are &#10; in possession of any material nonpublic information not disclosed to the seller &#10; or if such purchases are prohibited by Regulation M under the Exchange Act. We &#10; do not currently anticipate that such purchases, if any, would constitute a &#10; tender offer subject to the tender offer rules under the Exchange Act or a &#10; going-private transaction subject to the going-private rules under the Exchange &#10; Act; however, if the purchasers determine at the time of any such purchases that &#10; the purchases are subject to such rules, the purchasers will comply with such &#10; rules. Any such purchases will be reported pursuant to Section 13 and Section 16 &#10; of the Exchange Act to the extent such purchasers are subject to such reporting &#10; requirements. None of the funds held in the trust account will be used to &#10; purchase shares or public warrants in such transactions prior to completion of &#10; our initial business combination. &#10;  &#10; The purpose of any such purchases of shares could be to vote such shares in &#10; favor of the initial business combination and thereby increase the likelihood of &#10; obtaining stockholder approval of the initial business combination or to satisfy &#10; a closing condition in an agreement with a target that requires us to have a &#10; minimum net worth or a certain amount of cash at the closing of our initial &#10; business combination, where it appears that such requirement would otherwise not &#10; be met. The purpose of any such purchases of public warrants could be to reduce &#10; the number of public warrants outstanding or to vote such warrants on any &#10; matters submitted to the warrantholders for approval in connection with our &#10; initial business combination. Any such purchases of our securities may result in &#10; the completion of our initial business combination that may not otherwise have &#10; been possible. In addition, if such purchases are made, the public float of &#10; our shares of Class A common stock or warrants may be reduced and the number of &#10; beneficial holders of our securities may be reduced, which may make it difficult &#10; to maintain or obtain the quotation, listing or trading of our securities on a &#10; national securities exchange. &#10;  &#10; We may not redeem our public shares in an amount that would cause our net &#10; tangible assets to be less than $5,000,001 upon consummation of our initial &#10; business combination and after payment of deferred underwriters commissions (so &#10; that we are not subject to the SECs penny stock rules) and the agreement for &#10; our initial business combination may require as a closing condition that we have &#10; a minimum net worth or a certain amount of cash. If too many public stockholders &#10; exercise their redemption rights so that we cannot satisfy the net tangible  &#10; asset requirement or any net worth or cash requirements, we would not proceed &#10; with the redemption of our public shares or the initial business combination, &#10; and instead may search for an alternate business combination. &#10;  &#10; A public stockholder will be entitled to receive funds from the trust account &#10; only upon the earliest to occur of: (i) our completion of an initial business &#10; combination, (ii) the redemption of any public shares properly submitted in &#10; connection with a stockholder vote to amend our third amended and restated &#10; certificate of incorporation to modify the substance or timing of our obligation &#10; to redeem 100% of our public shares if we do not complete our initial business &#10; combination within 24 months from the closing of this offering or to provide for &#10; redemption in connection with a business combination and (iii) the redemption of &#10; our public shares if we are unable to complete our initial business combination &#10; within 24 months following the closing of this offering, subject to applicable &#10; law and as further described herein and any limitations (including, but not &#10; limited to, cash requirements) created by the terms of the proposed initial &#10; business combination. In no other circumstances will a public stockholder have &#10; any right or interest of any kind to or in the trust account. &#10;  &#10; Our sponsors, officers and directors have entered into a letter agreement with &#10; us, pursuant to which they have agreed to waive their redemption rights with &#10; respect to any founder shares and any public shares held by them in connection &#10; with the completion of our initial business combination. In addition, our &#10; initial stockholders have agreed to waive their rights to liquidating &#10; distributions from the trust account with respect to any founder shares held by &#10; them if we fail to complete our initial business combination within the &#10; prescribed time frame. However, if our sponsors or any of our officers, &#10; directors or affiliates acquires public shares in or after this offering, they &#10; will be entitled to liquidating distributions from the trust account with &#10; respect to such public shares if we fail to complete our initial business &#10; combination within the prescribed time frame.',\n",
       "   'competition': 'In identifying, evaluating and selecting a target business for our initial &#10; business combination, we may encounter competition from other entities having a &#10; business objective similar to ours, including other blank check companies, &#10; private equity groups and leveraged buyout funds, public companies and operating &#10; businesses seeking strategic business combinations. Many of these entities are &#10; well established and have extensive experience identifying and effecting &#10; business combinations directly or through affiliates. Moreover, many of these &#10; competitors possess greater financial, technical, human and other resources than &#10; we do. Our ability to acquire larger target businesses will be limited by our &#10; available financial resources. This inherent limitation gives others an &#10; advantage in pursuing the initial business combination of a target business. &#10; Furthermore, our obligation to pay cash in connection with our public &#10; stockholders who exercise their redemption rights may reduce the resources &#10; available to us for our initial business combination and our outstanding &#10; warrants, and the future dilution they potentially represent, may not be viewed &#10; favorably by certain target businesses. Either of these factors may place us at &#10; a competitive disadvantage in successfully negotiating an initial business &#10; combination.',\n",
       "   'amount': 125000000,\n",
       "   'percentOffered': '80.00'},\n",
       "  {'symbol': 'TRVI',\n",
       "   'companyName': 'TREVI THERAPEUTICS, INC.',\n",
       "   'expectedDate': '2019-05-07',\n",
       "   'leadUnderwriters': ['BMO Capital Markets Corp',\n",
       "    'Stifel Nicolaus & Company, Incorporated',\n",
       "    'SVB Leerink LLC'],\n",
       "   'underwriters': ['Needham & Company, LLC'],\n",
       "   'companyCounsel': ['Wilmer Cutler Pickering Hale and Dorr LLP'],\n",
       "   'underwriterCounsel': ['Covington & Burling LLP'],\n",
       "   'auditor': 'Computershare Trust Company, N.A',\n",
       "   'market': 'NASDAQ Global',\n",
       "   'cik': '0001563880',\n",
       "   'address': '195 CHURCH STREET',\n",
       "   'city': 'NEW HAVEN',\n",
       "   'state': 'CT',\n",
       "   'zip': '06510',\n",
       "   'phone': '203-304-2499',\n",
       "   'ceo': 'Jennifer Good',\n",
       "   'employees': 16,\n",
       "   'url': 'www.trevitherapeutics.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 5500000,\n",
       "   'priceLow': 10,\n",
       "   'priceHigh': None,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 2500000,\n",
       "   'sharesOverAlloted': 825000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 17771751,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -20545000,\n",
       "   'totalAssets': 10526000,\n",
       "   'totalLiabilities': 3182000,\n",
       "   'stockholderEquity': -109494000,\n",
       "   'companyDescription': 'We are a clinical-stage biopharmaceutical company focused on the development and &#10; commercialization of nalbuphine ER to treat serious neurologically mediated &#10; conditions. We are currently developing nalbuphine ER for the treatment of &#10; chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, &#10; or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinsons &#10; disease. These conditions share a common pathophysiology that is mediated &#10; through opioid receptors in the central and peripheral nervous systems. Due to &#10; nalbuphines mechanism of action as a modulator of opioid receptors, we believe &#10; it has the potential to be effective in treating each of these conditions. We &#10; are currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, which we &#10; refer to as the PRISM trial, in patients with severe pruritus associated with &#10; prurigo nodularis, and expect to report top-line data from the trial in the &#10; first half of 2020. If successful, we expect that we will use the PRISM trial &#10; and an additional Phase 3 clinical trial that we plan to conduct to support the &#10; submission of a new drug application, or NDA, to the United States Food and Drug &#10; Administration, or FDA, and a marketing authorization application, or MAA, to &#10; the European Medicines Agency, or EMA, for nalbuphine ER for the treatment of &#10; pruritus associated with prurigo nodularis. &#10; --- &#10;  &#10; We were incorporated under the laws of the State of Delaware on March 17, 2011 &#10; under the name Trevi Therapeutics, Inc. Our principal executive offices are &#10; located at 195 Church Street, 14th Floor, New Haven, Connecticut 06510, and our &#10; telephone number is (203) 304-2499. Our website address is &#10; www.trevitherapeutics.com.',\n",
       "   'businessDescription': 'We are a clinical-stage biopharmaceutical company focused on the development and &#10; commercialization of nalbuphine ER to treat serious neurologically mediated &#10; conditions. We are currently developing nalbuphine ER for the treatment of &#10; chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, &#10; or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinsons &#10; disease. These conditions share a common pathophysiology that is mediated &#10; through opioid receptors in the central and peripheral nervous systems. Due to &#10; nalbuphines mechanism of action as a modulator of opioid receptors, we believe &#10; it has the potential to be effective in treating each of these conditions. We &#10; are currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, which we &#10; refer to as the PRISM trial, in patients with severe pruritus associated with &#10; prurigo nodularis, and expect to report top-line data from the trial in the &#10; first half of 2020. If successful, we expect that we will use the PRISM trial &#10; and an additional Phase 3 clinical trial that we plan to conduct to support the &#10; submission of a new drug application, or NDA, to the United States Food and Drug &#10; Administration, or FDA, and a marketing authorization application, or MAA, to &#10; the European Medicines Agency, or EMA, for nalbuphine ER for the treatment of &#10; pruritus associated with prurigo nodularis. &#10;  &#10; Nalbuphine ER is an oral extended release formulation of nalbuphine. Nalbuphine &#10; is a mixed k-opioid receptor agonist and m-opioid receptor antagonist that has &#10; been approved and marketed as an injectable for pain indications for more than &#10; 20 years in the United States and Europe. The k- and m-opioid receptors are &#10; known to be critical mediators of itch, cough and certain movement disorders. &#10; Nalbuphines mechanism of action also mitigates the risk of abuse associated &#10; with m-opioid agonists because it antagonizes, or blocks, the m-opioid receptor. &#10; Nalbuphine is currently the only opioid approved for marketing that is not &#10; classified as a controlled substance in the United States or Europe. &#10;  &#10; We have retained worldwide development and commercial rights for nalbuphine ER  &#10; in all indications. &#10; --- &#10;  &#10; Chronic pruritus, defined as itching lasting longer than six weeks, causes a &#10; number of physical and psychological issues that can substantially impact &#10; patients daily well-being. The urge to scratch can be unbearable and the act of &#10; scratching can remove layers of skin and break the skin barrier, leading to &#10; bleeding and scarring and greatly increasing the risk of infection. Chronic &#10; pruritus can also lead to trouble sleeping, resulting in loss of work &#10; productivity and increased anxiety and depression as patients struggle to &#10; maintain self-control. Chronic pruritus is a hallmark of many dermatologic and &#10; systemic diseases and is the predominant reason that patients with these &#10; diseases experience so much discomfort. A recent report published in the Journal &#10; of the American Academy of Dermatology estimated that up to 26% of the worldwide &#10; population will suffer from chronic pruritus at some point in their lives. &#10; According to the Global Pruritus Therapeutic Market Research Report issued in &#10; 2017, the market for pruritus therapeutics was $10.8 billion in 2016 and is &#10; expected to grow to $14.3 billion in 2022. Despite the large market opportunity &#10; and the severity of chronic pruritus, there are no drugs approved in the United &#10; States or Europe for the treatment of moderate to severe pruritus. Nalbuphine &#10; ERs dual mechanism of action targets opioid receptors located in both the &#10; central and peripheral nervous systems, each of which plays a role in modulating &#10; the sensation of itch. We believe this makes nalbuphine ER a promising potential &#10; therapy for the treatment of chronic pruritus. &#10;  &#10; Nalbuphine ER Clinical Development &#10;  &#10; We have completed clinical trials in two distinct and serious pruritic &#10; conditions, uremic pruritus and pruritus associated with prurigo nodularis, with &#10; over 400 patients treated with different doses of nalbuphine ER in these trials. &#10; Uremic pruritus is a pruritic condition occurring in patients with chronic &#10; kidney disease typically receiving dialysis. Prurigo nodularis is an intensely &#10; pruritic dermatologic condition characterized by the presence of nodular &#10; pruriginous lesions such as papules or plaques. &#10;  &#10; In our Phase 2b/3 clinical trial in uremic pruritus, we enrolled 373 patients &#10; with moderate to severe uremic pruritus. Patients were randomized to one of &#10; three arms: either 108 mg or 54 mg of nalbuphine ER or placebo, each &#10; administered twice daily. The primary endpoint in the trial was the change from &#10; baseline in patients seven-day mean worst itch numerical rating scale, or &#10; WI-NRS, scores, which was met in the 108 mg arm, but not in the 54 mg arm.  &#10; Patients in the 54 mg arm reported a reduction in WI-NRS score that was larger  &#10; than the reduction in the placebo arm, although the difference was not  &#10; statistically significant. The reduction in WI-NRS scores across the three arms &#10; of the trial demonstrated a dose response. &#10;  &#10; In our Phase 2 clinical trial in prurigo nodularis, we enrolled 63 patients with &#10; prurigo nodularis who had moderate to severe pruritus. Patients were randomized &#10; to one of three arms: either 162 mg or 81 mg of nalbuphine ER or placebo, each &#10; administered twice daily. The primary endpoint of the trial was the proportion &#10; of patients reporting at least a 30% reduction from baseline to week 10 in &#10; seven-day mean WI-NRS scores. Although the primary endpoint was not met in &#10; either of the nalbuphine ER arms, a key secondary endpoint of the trial was the &#10; proportion of patients reporting at least a 50% reduction in WI-NRS score from &#10; baseline. In the 162 mg arm, 33% of patients reported at least a 50% reduction &#10; in WI-NRS score as compared to 18% of patients in the placebo arm. The trial met &#10; a key secondary efficacy endpoint, reduction of ItchyQoL scores, in the 162 mg &#10; arm compared to the placebo arm. ItchyQoL measures quality of life improvements &#10; from pruritus reduction. The secondary endpoints of the trial were not powered &#10; for statistical significance. &#10;  &#10; We conducted a post hoc analysis of the data from the 50 patients who completed &#10; the 10-weekcourse of treatment in our Phase 2 clinical trial in prurigo &#10; nodularis, whom we refer to as completers. We believe an analysis of the trial &#10; results of this subset of patients provides informative data regarding &#10; nalbuphine ER because it eliminates the effects of patient discontinuations. In &#10; the trial, 50% of the completers in the 162 mg arm reported at least a 50% &#10; reduction in WI-NRS score from baseline, as compared to 20% of the completers in &#10; the placebo arm, although this analysis was not powered for statistical &#10; significance. As the patients in the 162 mg arm had a mean baseline WI-NRS score &#10; of 8.05, a 50% reduction in WI-NRS score from baseline for patients in this arm &#10; was comparable to a 4-point reduction in WI-NRS score, the primary efficacy &#10; endpoint of our PRISM trial. &#10;  &#10; Based on the results of our prurigo nodularis and uremic pruritus trials and &#10; open label extension trials in both indications, and discussions with the FDA &#10; and European regulatory authorities, we initiated our Phase 2b/3 Pruritus Relief &#10; through Itch Scratch Modulation, or PRISM, trial in September 2018. In designing &#10; the statistical plan for the PRISM trial, we considered the rates of patient &#10; discontinuations we experienced in our earlier trials. We believe that these &#10; discontinuation rates can be reduced through increased patient and physician &#10; education prior to the commencement of dosing. We expect to report top-line data &#10; from the 14-week blinded treatment period of the PRISM trial in the first half &#10; of 2020. We will need to conduct an additional Phase 3 clinical trial to support &#10; the submission of an NDA to the FDA and an MAA to the EMA for nalbuphine ER for &#10; the treatment of pruritus associated with prurigo nodularis. We may initiate &#10; this trial before the PRISM trial is complete. &#10;  &#10; We have also commenced a Phase 1b clinical trial in patients with chronic liver &#10; disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of &#10; nalbuphine ER in this population, with data expected in the second half of 2019. &#10; If positive, we also intend to use data from this trial to support an NDA &#10; submission for nalbuphine ER in prurigo nodularis and commence a Phase 2 &#10; clinical trial for pruritus associated with chronic liver disease. We are not &#10; actively developing nalbuphine ER for uremic pruritus at this time based on our &#10; evaluation of the market dynamics, but may consider resuming development in the &#10; future. &#10;  &#10; As a result of nalbuphines ability to modulate the k- and m-opioid receptors, &#10; which are known to be involved in the pathophysiology of chronic cough in &#10; patients with IPF and in LID in patients with Parkinsons disease, we are also &#10; pursuing the development of nalbuphine ER for each of these indications. In the &#10; first half of 2019, we intend to initiate a Phase 2 clinical trial to evaluate &#10; the safety of nalbuphine ER in patients with IPF, and make an initial assessment &#10; of its efficacy on cough, with data expected in the first half of 2020. Subject &#10; to discussions with the FDA and the submission of an investigational new drug &#10; application for this indication, we also intend to initiate a Phase 2 clinical &#10; trial of nalbuphine ER in the second half of 2019 to evaluate the effect of &#10; nalbuphine ER on LID in patients with Parkinsons disease. &#10; --- &#10;  &#10; We were incorporated under the laws of the State of Delaware on March 17, 2011 &#10; under the name Trevi Therapeutics, Inc. Our principal executive offices are &#10; located at 195 Church Street, 14th Floor, New Haven, Connecticut 06510, and our &#10; telephone number is (203) 304-2499. Our website address is &#10; www.trevitherapeutics.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from our issuance and sale of 5,500,000 shares &#10; of our common stock in this offering will be approximately $48.7 million, or &#10; $56.3 million if the underwriters exercise their option to purchase 825,000 &#10; additional shares in full, assuming an initial public offering price of $10.00 &#10; per share, after deducting underwriting discounts and commissions and estimated &#10; offering expenses payable by us. We also expect to receive net proceeds of $14.0 &#10; million from the sale of shares of our common stock to New Enterprise &#10; Associates, or NEA, in the proposed concurrent private placement, based on the &#10; assumed initial public offering price of $10.00 per share and after deducting &#10; estimated placement agent fees payable by us, for aggregate net proceeds to be &#10; raised by us in this offering and the concurrent private placement of $62.6 &#10; million. Because we have not entered into any definitive agreements with NEA &#10; related to the proposed concurrent private placement, there can be no guarantee &#10; that the proposed concurrent private placement will take place or that the terms &#10; of the proposed concurrent private placement will be consistent with those &#10; assumed in this prospectus. &#10;  &#10; A $1.00 decrease in the assumed initial public offering price of $10.00 per &#10; share would decrease the net proceeds to us from this offering by approximately &#10; $5.1 million, assuming that the number of shares offered by us in this offering, &#10; as set forth on the cover page of this prospectus, remains the same and after &#10; deducting underwriting discounts and commissions and estimated offering expenses &#10; payable by us, and both assuming completion of the proposed concurrent private &#10; placement, the proceeds of which would be unaffected by such decrease, and &#10; deduction of estimated placement agent fees. An increase (decrease) of 1,000,000 &#10; shares in the number of shares offered by us in this offering, as set forth on &#10; the cover page of this prospectus, would increase (decrease) the net proceeds to &#10; us from this offering and the proposed concurrent private placement by &#10; approximately $9.3 million, assuming no change in the assumed initial public &#10; offering price per share and after deducting underwriting discounts and &#10; commissions and estimated offering expenses payable by us, and both assuming &#10; completion of the proposed concurrent private placement and deduction of &#10; estimated placement agent fees. &#10;  &#10; As of December 31, 2018, we had cash and cash equivalents of $7.2 million. We &#10; currently estimate that we will use the net proceeds from this offering, &#10; together with our existing cash and cash equivalents, as follows: &#10;  &#10;  approximately $7.5 million to $13.5 million to fund the development of     &#10;   nalbuphine ER for the treatment of pruritus associated with prurigo nodularis; &#10;  &#10;  approximately $5.0 million to $7.5 million to fund the development of      &#10;   nalbuphine ER for the treatment of pruritus associated with chronic liver  &#10;   disease; &#10;  &#10;  approximately $4.0 million to $8.0 million to fund the development of      &#10;   nalbuphine ER for the treatment of chronic cough in patients with IPF;  &#10;  &#10;  approximately $5.5 million to $7.5 million to fund the development of      &#10;   nalbuphine ER for the treatment of LID in patients with Parkinsons disease; &#10;   and &#10;  &#10;  the remainder for working capital and other general corporate purposes. &#10;  &#10; We currently estimate that, if we receive additional net proceeds of $14.0 &#10; million from the sale of shares of our common stock to NEA in the proposed &#10; concurrent private placement, we will use such net proceeds as follows: &#10;  &#10;  approximately $2.5 to $4.0 million to fund the development of nalbuphine ER &#10;   for the treatment of pruritus associated with prurigo nodularis; &#10;  &#10;  approximately $1.0 to $1.5 million to fund the development of nalbuphine ER &#10;   for the treatment of pruritus associated with chronic liver disease; &#10;  &#10;  approximately $1.0 to $2.0 million to fund the development of nalbuphine ER &#10;   for the treatment of chronic cough in patients with IPF; &#10;  &#10;  approximately $1.5 to $2.5 million to fund the development of nalbuphine ER &#10;   for the treatment of LID in patients with Parkinsons disease; and &#10;  &#10;  the remainder for working capital and other general corporate purposes. &#10;  &#10; Our expected use of the net proceeds from this offering and the net proceeds, if &#10; any, from the proposed concurrent private placement and our existing cash and &#10; cash equivalents represents our intentions based on our current plans and &#10; business conditions, which could change in the future as our plans and business &#10; conditions evolve. The amounts and timing of our actual expenditures may vary &#10; significantly depending on numerous factors, including the progress of our &#10; clinical development of nalbuphine ER, the status of and results from our &#10; clinical trials, including our ongoing PRISM trial as well as the additional &#10; Phase 3 clinical trial we will need to conduct for nalbuphine ER for pruritus &#10; associated with prurigo nodularis, the timing of regulatory submissions and the &#10; outcome of regulatory review, as well as any collaborations that we may enter &#10; into with third parties and any unforeseen cash needs. As a result, we cannot &#10; predict with certainty the expenditures that may be necessary to complete the &#10; clinical development and commercialization of nalbuphine ER for any indication &#10; and our management will retain broad discretion over the application of the net &#10; proceeds from this offering and the net proceeds, if any, from the proposed &#10; concurrent private placement. &#10;  &#10; Based on our current plans, we believe that the anticipated net proceeds from &#10; this offering and the net proceeds, if any, from the proposed concurrent private &#10; placement, together with our existing cash and cash equivalents, will enable us &#10; to fund our operating expenses and capital expenditure requirements through the &#10; end of 2020. In particular, we expect that the anticipated net proceeds from &#10; this offering and the net proceeds, if any, from the proposed concurrent private &#10; placement, together with our existing cash and cash equivalents, will enable us &#10; to complete our ongoing PRISM trial, our ongoing Phase 1b clinical trial in &#10; patients with chronic liver disease, our planned Phase 2 clinical trial for &#10; chronic cough in patients with IPF and our planned Phase 2 clinical trial for &#10; LID in patients with Parkinsons disease. However, we do not expect these funds &#10; will be sufficient to complete the clinical development of nalbuphine ER for &#10; pruritus associated with prurigo nodularis and other indications, commercialize &#10; nalbuphine ER (if we receive regulatory approval) for pruritus associated with &#10; prurigo nodularis and other indications, and pursue the development and &#10; commercialization of any future product candidate. We do not have any committed &#10; external source of funds. Accordingly, we will be required to obtain further &#10; funding through public or private equity offerings, debt financings, &#10; collaborations and licensing arrangements or other sources to complete the &#10; clinical development and commercialization of nalbuphine ER for pruritus &#10; associated with prurigo nodularis or any other indication. &#10;  &#10; Pending our use of the net proceeds from this offering and the net proceeds, if &#10; any, from the proposed concurrent private placement, we intend to invest the net &#10; proceeds in a variety of capital preservation investments, including short-term, &#10; investment-grade,interest-bearing instruments and U.S. government securities.',\n",
       "   'competition': 'The biopharmaceutical industry is intensely competitive and is subject to rapid &#10; and significant change. While we believe that our technology, knowledge, &#10; experience and scientific resources provide us with competitive advantages, we &#10; face potential competition from many sources, including major pharmaceutical, &#10; specialty pharmaceutical and biotechnology companies. If we are able to &#10; successfully develop and commercialize nalbuphine ER, it would compete with &#10; existing therapies and new therapies that may become available in the future. &#10;  &#10; Chronic Pruritus &#10;  &#10; We are developing nalbuphine ER for the treatment of pruritus associated with &#10; prurigo nodularis. Currently, there are no products approved in the United &#10; States or Europe for the treatment of pruritus associated with prurigo &#10; nodularis, however there are many products that are used to help manage pruritus &#10; associated with prurigo nodularis with which we expect that nalbuphine ER would &#10; compete if it is approved in this indication. The most common of these agents &#10; are anti-itch creams and emollients as well as oral or injectable &#10; antihistamines. All of these products have limited degrees of efficacy and are &#10; available generically. Additionally, patients may try several other agents such &#10; as gabapentin and Lyrica (pregabalin), which are prescription medicines approved &#10; for the treatment of seizures and neuropathic pain, naltrexone and UVB light &#10; therapy, generally with limited success. If approved for the treatment of &#10; pruritus associated with prurigo nodularis, we expect that nalbuphine ER might &#10; also compete with product candidates currently in clinical development in this &#10; indication, including serlopitant, an oral neurokinin-1 receptor antagonist &#10; being developed by Menlo Therapeutics that is in Phase 3 clinical trials; &#10; nemolizumab, an anti-interleukin-31 receptor A humanized monoclonal antibody &#10; being developed by Galderma; and KPL-716, a monoclonal antibody targeting &#10; oncostatin M receptor beta being developed by Kiniksa Pharmaceuticals. In &#10; addition, a number of other product candidates are currently in clinical &#10; development to treat other pruritic conditions and nalbuphine ER, if approved &#10; for the treatment of pruritus associated with prurigo nodularis or another &#10; pruritic condition, could face competition from these product candidates. These &#10; product candidates include KORSUVA, a k-opioid receptor agonist being developed &#10; by Cara Therapeutics that is in Phase 3 clinical trials for administration by &#10; injection for uremic pruritus and earlier-stage clinical trials for oral &#10; administration for uremic pruritus and pruritus associated with chronic liver &#10; disease, and tradipitant, an oral neurokinin-1 receptor antagonist being &#10; developed by Vanda Pharmaceuticals that is in Phase 3 clinical trials for &#10; chronic pruritus in patients with atopic dermatitis. &#10;  &#10; If approved for the treatment of pruritus associated with chronic liver disease, &#10; nalbuphine ER may also compete with bile acid sequestrants, such as &#10; cholestyramine, which are used off label and generally as first-line therapy, &#10; although they typically provide only modest relief. Cholestyramine is marketed &#10; as Questran in the United States and as Colestyr, Efensol, Ipocol, Kolestran, &#10; Lipocol, Olestyr, Prevalite or Quantalan in various other countries. Nalbuphine &#10; ER may also complete with second-line therapies such as the antibiotic &#10; rifampicin, naltrexone, the anti-depressant sertraline, as well as phototherapy &#10; and drugs such as gabapentin and Lyrica (pregabalin), which are approved for the &#10; treatment of seizures and neuropathic pain. In addition, it is possible that &#10; therapies to reduce chronic liver disease, such as ursodeoxycholic acid, which &#10; is approved for the treatment of PBC, could reduce the need for therapies to &#10; treat pruritus associated with chronic liver disease. &#10;  &#10; Chronic Cough in Idiopathic Pulmonary Fibrosis &#10;  &#10; If nalbuphine ER is approved for the treatment of chronic cough associated with &#10; idiopathic pulmonary fibrosis, we expect that it would compete with RVT-1601, a &#10; formulation of cromolyn sodium being developed by Respivant Sciences, and expect &#10; that it might also compete with other product candidates currently in &#10; development for the treatment of chronic cough by companies including Merck and &#10; Nerre Therapeutics. In addition, it is possible that product candidates &#10; currently in development for the treatment of IPF could, if approved, reduce the &#10; need for therapies to treat chronic cough associated with IPF. &#10;  &#10; Levodopa-Induced Dyskinesia in Parkinsons Disease &#10;  &#10; If nalbuphine ER is approved for the treatment of LID in patients with &#10; Parkinsons disease, we expect that it would compete with Gocovri, an extended &#10; release capsule formulation of amantadine marketed by Adamas Pharmaceuticals, &#10; and expect that it might also compete with other product candidates currently in &#10; development for the treatment of LID by companies including Lundbeck, Addex &#10; Therapeutics and IRLAB Therapeutics. In addition, it is possible that product &#10; candidates currently in development for the treatment of Parkinsons disease by &#10; companies could, if approved, reduce the need for therapies to treat LID. &#10;  &#10; Many of our competitors and potential competitors, either alone or with their &#10; strategic partners, have substantially greater financial, technical and human &#10; resources and significantly greater experience in the discovery and development &#10; of product candidates, obtaining FDA and other regulatory approvals of products &#10; and commercializing products than we do. Mergers and acquisitions in the &#10; biotechnology and pharmaceutical industries may result in even more resources &#10; being concentrated among a smaller number of our competitors. These competitors &#10; also compete with us in recruiting and retaining qualified scientific and &#10; management personnel and establishing clinical trial sites and enrolling &#10; patients for clinical trials, as well as in acquiring technologies complementary &#10; to, or necessary for, our programs. Smaller or early-stage companies may also &#10; prove to be significant competitors, particularly through collaborative &#10; arrangements with large and established companies. &#10;  &#10; We expect that nalbuphine ER, if approved for marketing, will compete on the &#10; basis of, among other things, efficacy, safety, health-economic benefit, &#10; convenience of administration and delivery, price, the level of generic &#10; competition and the availability of adequate reimbursement from government and &#10; other third-party payors. &#10;  &#10; Our commercial opportunity could be reduced or eliminated if our competitors &#10; develop and commercialize products that are safer, more effective, have fewer or &#10; less severe side effects, are more convenient or are less expensive than &#10; nalbuphine ER. Our competitors also may obtain FDA or other regulatory approval &#10; for their products more rapidly than we may obtain approval for nalbuphine ER, &#10; which could result in our competitors establishing a strong market position &#10; before we are able to enter the market.',\n",
       "   'amount': 27500000,\n",
       "   'percentOffered': '30.95'}],\n",
       " 'viewData': [{'Company': 'LANDCADIA HOLDINGS II, INC.',\n",
       "   'Symbol': 'LCAHU',\n",
       "   'Price': '$10.00',\n",
       "   'Shares': '25,000,000',\n",
       "   'Amount': '125,000,000',\n",
       "   'Float': '31,250,000',\n",
       "   'Percent': '80.00%',\n",
       "   'Market': 'NASDAQ Capital',\n",
       "   'Expected': '2019-05-07',\n",
       "   'quote': {'latestPrice': 10.01, 'changePercent': 0.0009999999999999788}},\n",
       "  {'Company': 'TREVI THERAPEUTICS, INC.',\n",
       "   'Symbol': 'TRVI',\n",
       "   'Price': '$10.00',\n",
       "   'Shares': '5,500,000',\n",
       "   'Amount': '27,500,000',\n",
       "   'Float': '17,771,751',\n",
       "   'Percent': '30.95%',\n",
       "   'Market': 'NASDAQ Global',\n",
       "   'Expected': '2019-05-07',\n",
       "   'quote': {'latestPrice': 7.89, 'changePercent': -0.21100000000000002}}],\n",
       " 'lastUpdate': '2019-05-07'}"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ipoToday()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>address</th>\n",
       "      <th>amount</th>\n",
       "      <th>auditor</th>\n",
       "      <th>businessDescription</th>\n",
       "      <th>ceo</th>\n",
       "      <th>cik</th>\n",
       "      <th>city</th>\n",
       "      <th>companyCounsel</th>\n",
       "      <th>companyDescription</th>\n",
       "      <th>companyName</th>\n",
       "      <th>...</th>\n",
       "      <th>status</th>\n",
       "      <th>stockholderEquity</th>\n",
       "      <th>totalAssets</th>\n",
       "      <th>totalExpenses</th>\n",
       "      <th>totalLiabilities</th>\n",
       "      <th>underwriterCounsel</th>\n",
       "      <th>underwriters</th>\n",
       "      <th>url</th>\n",
       "      <th>useOfProceeds</th>\n",
       "      <th>zip</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>LCAHU</th>\n",
       "      <td>1510 WEST LOOP SOUTH</td>\n",
       "      <td>125000000</td>\n",
       "      <td>Continental Stock Transfer &amp; Trust Company</td>\n",
       "      <td>We are a blank check company whose business pu...</td>\n",
       "      <td>Tilman J. Fertitta</td>\n",
       "      <td>0001768012</td>\n",
       "      <td>HOUSTON</td>\n",
       "      <td>[Winston &amp; Strawn LLP]</td>\n",
       "      <td>We are a blank check company whose business pu...</td>\n",
       "      <td>LANDCADIA HOLDINGS II, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1000000</td>\n",
       "      <td>0</td>\n",
       "      <td>[Shearman &amp; Sterling LLP]</td>\n",
       "      <td>[]</td>\n",
       "      <td></td>\n",
       "      <td>We are offering 25,000,000 units at an offerin...</td>\n",
       "      <td>77027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>TRVI</th>\n",
       "      <td>195 CHURCH STREET</td>\n",
       "      <td>27500000</td>\n",
       "      <td>Computershare Trust Company, N.A</td>\n",
       "      <td>We are a clinical-stage biopharmaceutical comp...</td>\n",
       "      <td>Jennifer Good</td>\n",
       "      <td>0001563880</td>\n",
       "      <td>NEW HAVEN</td>\n",
       "      <td>[Wilmer Cutler Pickering Hale and Dorr LLP]</td>\n",
       "      <td>We are a clinical-stage biopharmaceutical comp...</td>\n",
       "      <td>TREVI THERAPEUTICS, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-109494000</td>\n",
       "      <td>10526000</td>\n",
       "      <td>2500000</td>\n",
       "      <td>3182000</td>\n",
       "      <td>[Covington &amp; Burling LLP]</td>\n",
       "      <td>[Needham &amp; Company, LLC]</td>\n",
       "      <td>www.trevitherapeutics.com</td>\n",
       "      <td>We estimate that the net proceeds from our iss...</td>\n",
       "      <td>06510</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2 rows  39 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                     address     amount  \\\n",
       "symbol                                    \n",
       "LCAHU   1510 WEST LOOP SOUTH  125000000   \n",
       "TRVI       195 CHURCH STREET   27500000   \n",
       "\n",
       "                                           auditor  \\\n",
       "symbol                                               \n",
       "LCAHU   Continental Stock Transfer & Trust Company   \n",
       "TRVI              Computershare Trust Company, N.A   \n",
       "\n",
       "                                      businessDescription                 ceo  \\\n",
       "symbol                                                                          \n",
       "LCAHU   We are a blank check company whose business pu...  Tilman J. Fertitta   \n",
       "TRVI    We are a clinical-stage biopharmaceutical comp...       Jennifer Good   \n",
       "\n",
       "               cik       city                               companyCounsel  \\\n",
       "symbol                                                                       \n",
       "LCAHU   0001768012    HOUSTON                       [Winston & Strawn LLP]   \n",
       "TRVI    0001563880  NEW HAVEN  [Wilmer Cutler Pickering Hale and Dorr LLP]   \n",
       "\n",
       "                                       companyDescription  \\\n",
       "symbol                                                      \n",
       "LCAHU   We are a blank check company whose business pu...   \n",
       "TRVI    We are a clinical-stage biopharmaceutical comp...   \n",
       "\n",
       "                        companyName  ... status  stockholderEquity  \\\n",
       "symbol                               ...                             \n",
       "LCAHU   LANDCADIA HOLDINGS II, INC.  ...  Filed                  0   \n",
       "TRVI       TREVI THERAPEUTICS, INC.  ...  Filed         -109494000   \n",
       "\n",
       "       totalAssets totalExpenses totalLiabilities         underwriterCounsel  \\\n",
       "symbol                                                                         \n",
       "LCAHU            0       1000000                0  [Shearman & Sterling LLP]   \n",
       "TRVI      10526000       2500000          3182000  [Covington & Burling LLP]   \n",
       "\n",
       "                    underwriters                        url  \\\n",
       "symbol                                                        \n",
       "LCAHU                         []                              \n",
       "TRVI    [Needham & Company, LLC]  www.trevitherapeutics.com   \n",
       "\n",
       "                                            useOfProceeds    zip  \n",
       "symbol                                                            \n",
       "LCAHU   We are offering 25,000,000 units at an offerin...  77027  \n",
       "TRVI    We estimate that the net proceeds from our iss...  06510  \n",
       "\n",
       "[2 rows x 39 columns]"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ipoTodayDF()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'rawData': [{'symbol': 'PSN',\n",
       "   'companyName': 'PARSONS CORP',\n",
       "   'expectedDate': '2019-05-08',\n",
       "   'leadUnderwriters': ['BofA Merrill Lynch', 'Goldman Sachs & Co. LLC'],\n",
       "   'underwriters': ['Cowen and Company, LLC',\n",
       "    'Jefferies LLC',\n",
       "    'Morgan Stanley & Co. LLC',\n",
       "    'MUFG Securities Americas Inc.',\n",
       "    'Scotia Capital Markets',\n",
       "    'SunTrust Robinson Humphrey, Inc',\n",
       "    'Wells Fargo Securities, LLC'],\n",
       "   'companyCounsel': ['Latham & Watkins LLP'],\n",
       "   'underwriterCounsel': ['Gibson Dunn and Crutcher LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0000275880',\n",
       "   'address': '5875 TRINITY PKWY #300',\n",
       "   'city': 'CENTREVILLE',\n",
       "   'state': 'VA',\n",
       "   'zip': '20120',\n",
       "   'phone': '703-988-8500',\n",
       "   'ceo': 'Charles L. Harrington',\n",
       "   'employees': 15633,\n",
       "   'url': 'www.parsons.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 18518500,\n",
       "   'priceLow': 26,\n",
       "   'priceHigh': 28,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 9551215,\n",
       "   'sharesOverAlloted': 2777775,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 96657331,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 3560508000,\n",
       "   'netIncome': 222337000,\n",
       "   'totalAssets': 2612578000,\n",
       "   'totalLiabilities': 1657345000,\n",
       "   'stockholderEquity': -967537000,\n",
       "   'companyDescription': 'We are a leading provider of technology-driven solutions in the defense, &#10; intelligence and critical infrastructure markets. We provide technical design &#10; and engineering services and software to address our customers challenges. We &#10; have developed significant expertise and differentiated capabilities in key &#10; areas of cybersecurity, intelligence, defense, military training, connected &#10; communities, physical infrastructure and mobility solutions. By combining our &#10; talented team of professionals and advanced technology, we help solve complex &#10; technical challenges to enable a safer, smarter and more interconnected world. &#10; --- &#10;  &#10; We are a Delaware corporation and commenced our principal operations in 1944. &#10; Our principal executive offices are located at 5875 Trinity Parkway #300, &#10; Centreville, Virginia 20120, and our telephone number is (703) 988-8500. Our &#10; website address is www.parsons.com.',\n",
       "   'businessDescription': 'We are a leading provider of technology-driven solutions in the defense, &#10; intelligence and critical infrastructure markets. We provide technical design &#10; and engineering services and software to address our customers challenges. We &#10; have developed significant expertise and differentiated capabilities in key &#10; areas of cybersecurity, intelligence, defense, military training, connected &#10; communities, physical infrastructure and mobility solutions. By combining our &#10; talented team of professionals and advanced technology, we help solve complex &#10; technical challenges to enable a safer, smarter and more interconnected world. &#10;  &#10; Since our founding 75 years ago, we have built our reputation and business on &#10; our ability to successfully transform and innovate our services while leveraging &#10; cutting-edge technologies in order to expand our offerings. Whether our &#10; customers need a first-of-its-kind advanced missile development and testing &#10; facility, or an artificial intelligence enabled cloud platform to defend against &#10; cybersecurity threats, we deliver for our customers. We seek to grow by offering &#10; our clients innovative solutions supported by research and development, as well &#10; as acquisitions of emerging technologies. We have developed longstanding &#10; relationships with customers such as the U.S. military and intelligence agencies &#10; and state and local governments and agencies. &#10;  &#10; Advances in technology are dramatically shifting the operating landscape across &#10; our markets. Governments and companies are grappling with pressing challenges &#10; ranging from confronting increasingly sophisticated cybersecurity threats to &#10; upgrading aging systems and infrastructure. To address these challenges, our &#10; customers are actively seeking technology-enabled solutions to enhance and &#10; transform their operations and assets. Our wide-ranging capabilities enable us &#10; to provide our services and solutions across the defense, intelligence and &#10; critical infrastructure markets. As a leading technology-driven solutions &#10; provider with a proven track record, we believe we are well positioned to &#10; benefit from these trends and serve our customers evolving needs. We have &#10; capabilities in the following four areas that cut across our segments and &#10; business lines: &#10;  &#10; Systems Integration: We provide engineering services and technology for large &#10; digital and physical systems with high technical complexity. We lead projects &#10; from concept development through design, implementation, testing and &#10; verification, ensuring interoperability of these complex, disparate systems. &#10;  &#10; Software Development: We develop software and systems across many domains and &#10; mission-specific applications. Our experienced software engineers and developers &#10; design, develop, integrate, operate and sustain mission-critical software &#10; applications and systems across cyber, intelligence, defense and commercial &#10; customers. &#10;  &#10; Program Management: We provide expertise and technology to advance our  &#10; customers execution of large, complex projects within their defined time and &#10; cost parameters. &#10;  &#10; Critical Mission Support: We provide a diverse set of technical services to &#10; help our nations military on land, sea, air and space. These services include &#10; mission training, protecting national airspace, fighting infectious diseases, &#10; digitizing the health environment, performing contingency operations and &#10; providing operations and maintenance for physical infrastructure. &#10;  &#10; Our customer relationships, which are based on a long history of successfully &#10; delivering complex technical services, are key to our success. We are often &#10; involved in the early stages of our customers planning processes, which allows &#10; us to efficiently optimize our service delivery model. These relationships, &#10; along with our technical expertise and access to talented human capital, allow &#10; us to successfully deliver solutions that meet our customers demanding &#10; technical and execution requirements. &#10;  &#10; Technology and our people are our most important assets, allowing us to &#10; consistently deliver for our customers and help them solve their most pressing &#10; challenges. Investment in key technological capabilities is core to our business &#10; and helps us to stay at the forefront of the evolving trends across our end &#10; markets. To meet the challenges of tomorrow, we are focusing our technology &#10; investment on cybersecurity, machine learning, big data analytics and cloud &#10; applications. The work of our highly skilled and dedicated employees has enabled &#10; our long track record of continued innovation and execution on behalf of our &#10; customers. Our team of engineers, scientists, programmers and other specialists &#10; include PhDs and certified hackers and a large number of our skilled workforce &#10; hold government security clearances, which provides a significant competitive &#10; advantage for the highly technical and demanding work we perform. &#10;  &#10; We operate in two reporting segments, Federal Solutions and Critical &#10; Infrastructure, with revenue contribution of 41.5% and 58.5%, respectively, and &#10; Adjusted EBITDA contribution of 49.9% and 42.6%, respectively, for fiscal 2018. &#10;  &#10; Federal Solutions: Our Federal Solutions segment is a high-end services and &#10; technology provider to the U.S. government, delivering timely, cost-effective &#10; solutions for mission-critical projects. We provide advanced technologies, &#10; including cybersecurity, missile defense systems, military training, subsurface &#10; munitions detection, military facility modernization, logistics support, &#10; chemical weapon remediation and engineering services. The U.S. government and &#10; its agencies represent substantially all of the revenue of our Federal Solutions &#10; segment. These U.S. government agencies include the Missile Defense Agency, the &#10; United States intelligence community, the U.S. military, the Department of &#10; Energy and the Federal Aviation Administration. &#10;  &#10; Critical Infrastructure: Our Critical Infrastructure segment provides integrated &#10; design and engineering services for complex physical and digital infrastructure &#10; around the globe. We are a technology innovator focused on next generation  &#10; infrastructure. Our capabilities in design and project management allow us to  &#10; deliver significant value to our customers by employing cutting-edge &#10; technologies, improving timelines and reducing costs. We serve a diverse global &#10; customer base including federal, state, municipal and industry customers such as &#10; Los Angeles World Airports, Canadas Metrolinx, Dubais Roads and Transport &#10; Authority and the Port Authority of New York and New Jersey. &#10;  &#10; We have successfully grown our business in each segment and on a consolidated &#10; basis. In fiscal 2018, we generated revenues of $3.6 billion, net income &#10; attributable to Parsons Corporation of $222.3 million and Adjusted EBITDA of &#10; $229.8 million. In fiscal 2018, our Federal Solutions segment had 37.0% &#10; year-over-year revenue growth, or 15.9% excluding the results of Polaris Alpha, &#10; LLC, or Polaris Alpha, which we acquired in May 2018, and our Critical  &#10; Infrastructure segment had 7.5% year-over-year revenue growth. &#10; --- &#10;  &#10; On new contracts and task orders for which we competed, we achieved an overall &#10; win rate of 39.9% in fiscal 2016, 34.9% in fiscal 2017 and 42.9% in fiscal 2018. &#10; As of December 31, 2018, our total backlog was $8.0 billion, an increase of &#10; 24.1% from December 29, 2017. &#10; --- &#10;  &#10; We are a Delaware corporation and commenced our principal operations in 1944. &#10; Our principal executive offices are located at 5875 Trinity Parkway #300, &#10; Centreville, Virginia 20120, and our telephone number is (703) 988-8500. Our &#10; website address is www.parsons.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds to us from the sale of shares of our common &#10; stock in this offering will be approximately $462.9 million, based upon the &#10; assumed initial public offering price of $27.00 per share, which is the midpoint &#10; of the estimated offering price range set forth on the cover page of this &#10; prospectus, and after deducting underwriting discounts and commissions and &#10; estimated offering expenses payable by us. If the underwriters exercise their &#10; option to purchase additional shares in full, we estimate that the net proceeds &#10; to be received by us will be approximately $533.8 million, after deducting &#10; underwriting discounts, commissions and estimated offering expenses payable by &#10; us. &#10;  &#10; A $1.00 increase (decrease) in the assumed initial public offering price of &#10; $27.00 per share would increase (decrease) the net proceeds that we receive from &#10; this offering by approximately $17.5 million, assuming that the number of shares &#10; offered by us, as set forth on the cover page of this prospectus, remains the &#10; same and after deducting the underwriting discounts and commissions and &#10; estimated offering expenses payable by us. Similarly, each increase (decrease) &#10; of 1.0 million in the number of shares offered by us would increase (decrease) &#10; the net proceeds that we receive from this offering by approximately $25.5 &#10; million, assuming that the assumed initial public offering price remains the &#10; same and after deducting the underwriting discounts and commissions and &#10; estimated offering expenses payable by us. &#10;  &#10; The principal purposes of this offering are to increase our capitalization and &#10; financial flexibility, create a public market for our common stock and thereby &#10; enable access to the public equity markets for us and our stockholders. We &#10; intend to use the net proceeds to us from this offering to fund the IPO Dividend &#10; of $52.1 million, repay the outstanding balance of $150.5 million under our Term &#10; Loan and repay outstanding indebtedness under our Revolving Credit Facility. &#10;  &#10; In January 2019, we borrowed $150.0 million under our Term Loan Agreement to &#10; partially finance the OGSystems Acquisition. Our Term Loan is comprised of &#10; Offshore Rate Loans and Base Rate Loans (each as defined in the Term Loan &#10; Agreement), with an initial aggregate principal amount of $150.0 million. The &#10; Offshore Rate Loans bear interest at a rate per annum of LIBOR, divided by 1.00 &#10; minus the Eurodollar Reserve Percentage, plus 1.25%. The Base Rate Loans bear &#10; interest at a rate per annum of the sum of (a) the highest of (1) the &#10; administrative agents reference rate; (2) the rate equal to 1.50% per annum &#10; above the Offshore Rate; and (3) the rate equal to 0.50% per annum above the &#10; latest federal funds rate, plus (b) 0.25%. The Term Loan has a maturity date of &#10; January 3, 2020. We intend to use $150.5 million of our net proceeds from this &#10; offering to repay the outstanding balance under our Term Loan upon the &#10; consummation of this offering. &#10;  &#10; As of December 31, 2018, the outstanding indebtedness under our Revolving Credit &#10; Facility was $180.0 million, which does not include $110.0 million we borrowed &#10; under our Revolving Credit Facility in January 2019 to partially finance the &#10; OGSystems Acquisition. In May 2018, we borrowed $260.0 million under our &#10; Revolving Credit Facility to partially finance the acquisition of Polaris Alpha. &#10; Under the terms of our Credit Agreement, borrowings under our Revolving Credit &#10; Facility bear interest, at our option, at either the Base Rate (as defined in &#10; the Credit Agreement), plus an applicable margin, or LIBOR plus an applicable &#10; margin. The applicable margin for Base Rate loans is a range of 0.125% to 1.00% &#10; and the applicable margin for LIBOR loans is a range of 1.125% to 2.00%, both &#10; based on our leverage ratio at the end of each fiscal quarter. The Credit &#10; Agreement has a maturity date of November 15, 2022. &#10;  &#10; We will have broad discretion over the uses of the net proceeds from this &#10; offering and investors will be relying on the judgment of our management &#10; regarding the application of the net proceeds from this offering. Pending the &#10; use of proceeds from this offering as described above, we plan to invest the net &#10; proceeds that we receive in this offering in short-term and long-term &#10; interest-bearing obligations, including government- and investment-grade debt &#10; securities and money market funds. &#10;  &#10; Affiliates of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo &#10; Securities, LLC, MUFG Securities Americas Inc. and Scotia Capital (USA) Inc. are &#10; each a lender under the Term Loan and Revolving Credit Facility. A portion of &#10; the net proceeds from this offering will be used to repay borrowings under the &#10; Term Loan and Revolving Credit Facility. As a result, we expect more than 5% of &#10; the net proceeds from this offering will be paid to affiliates of each of &#10; Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo Securities, LLC, &#10; MUFG Securities Americas Inc. and Scotia Capital (USA) Inc. Therefore, this &#10; offering is being made in compliance with FINRA Rule 5121. As a result of this &#10; conflict of interest, Goldman Sachs & Co. LLC has agreed to act as the qualified &#10; independent underwriter with respect to this offering.',\n",
       "   'competition': 'The industries we operate in consist of a large number of enterprises ranging &#10; from small, niche-oriented companies to multi-billion dollar corporations that &#10; serve many government and commercial customers. We compete on the basis of our &#10; technical expertise, technological innovation, our ability to deliver &#10; cost-effective multi-faceted services in a timely manner, our reputation and &#10; relationships with our customers, qualified and/or security-clearance personnel, &#10; and pricing. Our main competitors in Federal Solutions are U.S. federal systems &#10; integrators and service providers such as CACI International Inc, Leidos &#10; Holdings, Inc., Science Applications International Corporation, Booz Allen &#10; Hamilton, CSRA Inc., The Raytheon Company, Northrop Grumman Corporation, &#10; Perspecta Inc. and ManTech International Corporation. Our main competitors in &#10; Critical Infrastructure include Jacobs Engineering Group Inc. and Tetra Tech, &#10; Inc., as well as Siemens AG and Cisco Systems, Inc. in the connected communities &#10; market. Large defense firms or technology companies may develop products or &#10; services in the future that could compete with us.',\n",
       "   'amount': 499999500,\n",
       "   'percentOffered': '19.16'},\n",
       "  {'symbol': 'HHR',\n",
       "   'companyName': 'HEADHUNTER GROUP PLC',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Credit Suisse Securities (USA) LLC',\n",
       "    'Goldman Sachs & Co. LLC',\n",
       "    'Morgan Stanley & Co. LLC',\n",
       "    'VTB Capital plc'],\n",
       "   'underwriters': ['BofA Merrill Lynch', 'Sberbank CIB (UK) Limited'],\n",
       "   'companyCounsel': ['Latham & Watkins (London) LLP'],\n",
       "   'underwriterCounsel': ['White and Case LLP'],\n",
       "   'auditor': 'Not Specified',\n",
       "   'market': 'NASDAQ Global Select',\n",
       "   'cik': '0001721181',\n",
       "   'address': 'DOSITHEOU, 42, STROVOLOS',\n",
       "   'city': 'NICOSIA 2028',\n",
       "   'state': '',\n",
       "   'zip': '',\n",
       "   'phone': '357-22-418200',\n",
       "   'ceo': 'Mikhail Zhukov',\n",
       "   'employees': 683,\n",
       "   'url': 'www.hh.ru',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 16304348,\n",
       "   'priceLow': 11,\n",
       "   'priceHigh': 13.5,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 4369364,\n",
       "   'sharesOverAlloted': 2445652,\n",
       "   'shareholderShares': 16304348,\n",
       "   'sharesOutstanding': 50000000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 88063000,\n",
       "   'netIncome': 14867000,\n",
       "   'totalAssets': 192013000,\n",
       "   'totalLiabilities': 148780000,\n",
       "   'stockholderEquity': 42809000,\n",
       "   'companyDescription': 'We are the leading online recruitment platform in Russia and the Commonwealth of &#10; Independent States (CIS) and focus on connecting job seekers with employers. &#10; We offer potential employers and recruiters paid access to our extensive &#10; curriculum vitae (CV) database and job postings platform. We also provide job &#10; seekers and employers with a value added services (VAS) portfolio centered &#10; around their recruitment needs. Our brand and the strength of our platform allow &#10; us to generate significant traffic, over 86% of which was free for us as of &#10; November, 2018 according to our internal data, and we were the third most &#10; visited job and employment website globally as of January 1, 2019, according to &#10; the latest available data from SimilarWeb. Our CV database contained 22.1 &#10; million, 26.4 million and 36.2 million total CVs (excluding Ukraine) as of &#10; December 31, 2016, 2017 and 2018, respectively, the growth partially due to our &#10; acquisition of Job.ru in January 2018, and our platform hosted a daily average &#10; of more than 344,000, 398,000 and 559,000 job postings (excluding Ukraine) in &#10; the years ended December 31, 2016, 2017 and 2018, respectively. For the years &#10; ended December 31, 2016, 2017 and 2018, our platform averaged 16.7 million, &#10; 17.5 million and 20.0 million unique visitors per month, respectively, according &#10; to LiveInternet. &#10; --- &#10;  &#10; We were incorporated in Cyprus on May 28, 2014 under the Cyprus Companies Law, &#10; Cap. 113 as Zemenik Trading Limited, and our registered office is located at 42 &#10; Dositheou Street, Strovolos, Nicosia, Cyprus. On March 1, 2018, Zemenik Trading &#10; Limited was converted from a private limited company incorporated in Cyprus into &#10; a public limited company incorporated in Cyprus, and the Companys name changed, &#10; pursuant to a special resolution at a general meeting of the shareholders, to &#10; HeadHunter Group PLC. The legal effect of this conversion under Cypriot law was &#10; limited to the change of legal form. Following the completion of this offering, &#10; we are considering changing the place of management of HeadHunter Group PLC from &#10; Cyprus to Russia, which will result in HeadHunter Group PLC becoming a Russian &#10; tax resident. &#10;  &#10; The principal executive office of our key operating subsidiary, Headhunter LLC, &#10; is located at 9/10 Godovikova Street, Moscow, 129085 Russia. The telephone &#10; number at this address is +7 495 974-6427. Our website address is www.hh.ru.',\n",
       "   'businessDescription': 'We are the leading online recruitment platform in Russia and the Commonwealth of &#10; Independent States (CIS) and focus on connecting job seekers with employers. &#10; We offer potential employers and recruiters paid access to our extensive &#10; curriculum vitae (CV) database and job postings platform. We also provide job &#10; seekers and employers with a value added services (VAS) portfolio centered &#10; around their recruitment needs. Our brand and the strength of our platform allow &#10; us to generate significant traffic, over 86% of which was free for us as of &#10; November, 2018 according to our internal data, and we were the third most &#10; visited job and employment website globally as of January 1, 2019, according to &#10; the latest available data from SimilarWeb. Our CV database contained 22.1 &#10; million, 26.4 million and 36.2 million total CVs (excluding Ukraine) as of &#10; December 31, 2016, 2017 and 2018, respectively, the growth partially due to our &#10; acquisition of Job.ru in January 2018, and our platform hosted a daily average &#10; of more than 344,000, 398,000 and 559,000 job postings (excluding Ukraine) in &#10; the years ended December 31, 2016, 2017 and 2018, respectively. For the years &#10; ended December 31, 2016, 2017 and 2018, our platform averaged 16.7 million, &#10; 17.5 million and 20.0 million unique visitors per month, respectively, according &#10; to LiveInternet. &#10;  &#10; Our user base consists primarily of job seekers who use our products and &#10; services to discover new career opportunities. The majority of the services we &#10; provide to job seekers are free. Our customer base consists primarily of &#10; businesses using our CV database and job posting service to fill vacancies &#10; inside their organizations. &#10;  &#10; The quality and quantity of CVs in our database attract an increasing number of &#10; customers, which leads to more job seekers turning to us as their primary &#10; recruitment and related services provider, creating a powerful network effect &#10; that has allowed us to continuously solidify our market leadership and increase &#10; the gap between us and our competitors. &#10;  &#10; Our portfolio of recruitment-centric VAS is designed to improve the customer &#10; experience, increase the effectiveness of the recruitment process for our &#10; customer base and enable us to penetrate each link of the recruitment value &#10; chain beginning with sourcing, to engaging, pre-selecting, interviewing and then &#10; onboarding the selected candidates. We are working to further integrate our VAS &#10; features into our core products in order to enhance efficiency throughout the &#10; overall recruitment process, which we believe will increase the value &#10; proposition of our services and improve retention rates and average revenue per &#10; customer. &#10;  &#10; We were founded in 2000 and have successfully established a strong, trusted &#10; brand and the leading market position, which have enabled us to achieve &#10; significant growth in recent years. We had approximately 253,000 paying &#10; customers on our platform for the year ended December 31, 2018. We have a highly &#10; diversified customer base, representing the majority of the industries active in &#10; the Russian economy. Our brand awareness is one of the highest among the Russian &#10; online recruitment players, according to Socis MR Rus, which, coupled with a &#10; nationwide sales force and broad customer reach, creates barriers for new &#10; entrants to our markets. &#10;  &#10; We engage with job seekers and employers via our desktop sites, mobile sites and &#10; mobile applications. Since launch, our mobile applications had been downloaded &#10; 15.3 million times cumulatively as of December 31, 2018, and our mobile  &#10; platforms currently account for the majority of our traffic. Our scalable  &#10; technology platform utilizes an increasingly clear and simple user interface  &#10; enhanced by our search engine, which is powered by artificial intelligence  &#10; (AI) and machine learning algorithms. &#10; --- &#10;  &#10; We were incorporated in Cyprus on May 28, 2014 under the Cyprus Companies Law, &#10; Cap. 113 as Zemenik Trading Limited, and our registered office is located at 42 &#10; Dositheou Street, Strovolos, Nicosia, Cyprus. On March 1, 2018, Zemenik Trading &#10; Limited was converted from a private limited company incorporated in Cyprus into &#10; a public limited company incorporated in Cyprus, and the Companys name changed, &#10; pursuant to a special resolution at a general meeting of the shareholders, to &#10; HeadHunter Group PLC. The legal effect of this conversion under Cypriot law was &#10; limited to the change of legal form. Following the completion of this offering, &#10; we are considering changing the place of management of HeadHunter Group PLC from &#10; Cyprus to Russia, which will result in HeadHunter Group PLC becoming a Russian &#10; tax resident. &#10;  &#10; The principal executive office of our key operating subsidiary, Headhunter LLC, &#10; is located at 9/10 Godovikova Street, Moscow, 129085 Russia. The telephone &#10; number at this address is +7 495 974-6427. Our website address is www.hh.ru.',\n",
       "   'useOfProceeds': 'The Selling Shareholders are selling all of the ADSs being sold in this &#10; offering. Accordingly, we will not receive any proceeds from the sale of ADSs in &#10; this offering. We will bear all costs, fees and expenses in connection with this &#10; offering, which are estimated to be approximately $4.4 million. &#10;  &#10; In connection with the Acquisition, Highworld Investments Limited entered into a &#10; profit sharing arrangement with an affiliate of Ivan Tavrin, and ELQ Investors &#10; VIII Limited in turn entered into a pro rata arrangement with Highworld &#10; Investments Limited, pursuant to which Mr. Tavrins affiliate will receive &#10; approximately 9% of any profit that Highworld Investments Limited and ELQ &#10; Investors VIII Limited realize with regard to their investment in the Company, &#10; including any profit realized upon the sale of its ADSs in this offering. &#10; Pursuant to this arrangement, Mr. Tavrins affiliate will receive approximately &#10; $16.0 million from the sale of ADSs by the Selling Shareholders in this &#10; offering, assuming an initial public offering price per share of $12.25, which &#10; is the midpoint of the price range set forth on the cover page of this &#10; prospectus (or approximately $18.7 million if the underwriters exercise their &#10; option to purchase additional ADSs in full). Neither Mr. Tavrin nor his &#10; affiliate provided services in connection with the Acquisition or to the &#10; Company. Neither Mr. Tavrin nor his affiliate is a shareholder of the Company &#10; and neither has rights in the Company or its shares or with regard to its &#10; management. Instead, the profit sharing arrangement with Mr. Tavrin settles the &#10; Selling Shareholders obligation to Mr. Tavrin arising from his relinquishing a &#10; previously existing position as the preferred purchaser in the Acquisition. Mr. &#10; Tavrin is a well-known Russian telecom, media and technology entrepreneur who &#10; was a founder, shareholder and head of a number of Russian companies. He was CEO &#10; of Megafon from 2012 to 2016. Mr. Tavrin previously held a position on the board &#10; of directors of Mail.Ru (but did not hold such position at the time of the &#10; Acquisition) and affiliates of Highworld Investments Limited have historically &#10; had and continue to have joint investment projects with Mr. Tavrin in other &#10; businesses that are not related to the Company. Neither Mr. Tavrin nor his &#10; affiliate is otherwise affiliated with the Selling Shareholders or the Company, &#10; and the Company has no obligations to Mr. Tavrin or his affiliate.',\n",
       "   'competition': 'We are the largest player in the Russian online recruitment market and offer the &#10; most comprehensive package of HR and recruiting services, supported by the &#10; largest CV database, a well-recognized brand and a growing base of job postings, &#10; as well as by our ability to attract new customers and retain existing ones. We &#10; believe that our scale and position in the Russian online recruitment market &#10; provide a competitive edge over other market participants and help us &#10; successfully sustain and compete for additional market share. &#10;  &#10; The Russian online recruitment market is characterized by a dynamic competitive &#10; landscape and ongoing technological evolution. We face competition mainly from &#10; Russian online job portals, online classifieds platforms with presence in the &#10; jobs vertical and offline media. Our key competitors include Russian online &#10; recruitment services providers such as SuperJob.ru, Zarplata.ru and Rabota.ru, &#10; who also offer access to CV databases and job posting services. In addition, we &#10; face competition from the large Russian general classifieds company Avito, which &#10; is focused on blue collar job seekers and small businesses, monetizing primarily &#10; through a fee-per-job posting model. Our former shareholder, Mail.Ru, runs its &#10; classifieds business under the Youla brand and in 2018, launched a job &#10; aggregation model under this brand, and later in the summer of 2018, allowed &#10; employers to post job vacancies directly on its site for free, and it is &#10; uncertain how this could affect the overall competitive climate. Yandex, another &#10; well-established Internet player in Russia, is currently present in the  &#10; recruitment market via an aggregator platform and might decide to expand its  &#10; presence in the jobs market by directly targeting some or all of our customers. &#10; Over the last two years, we have noticed the emergence of mobile-only startups,  &#10; which target blue collar high turnover professions. These startups are still in  &#10; the early stages, and it is uncertain how they will affect the overall  &#10; competitive climate in Russia. Several new specialized HR technology companies  &#10; are bringing new technologies to recruitment functions and could challenge the  &#10; automation of certain recruitment related functions and have emerged as new  &#10; players, which could gain a larger presence in the market. In certain  &#10; geographies and specific segments, we compete mainly with offline media, such &#10; as local newspapers with a jobs classifieds section. &#10;  &#10; Our international competitors include or may in the future include global &#10; professional networks, such as LinkedIn, job portals and aggregators, such as &#10; Indeed, HR technology companies and players who operate adjacent business &#10; models, including social networks, such as Facebook, and search engines, such as &#10; Google, who recently introduced its enhanced job search user function called &#10; Google for Jobs in Russia. The competition from international players is &#10; currently limited, given that Russia is perceived as a market with strong &#10; domestic Internet players, as well as Russias regulatory regime, compliance &#10; with which entails significant investments and costs, such as the requirement to &#10; store personal data of Russian citizens within Russia as prescribed by the Law &#10; on Personal Data. Notably, access to LinkedIns resources in Russia was blocked &#10; by the Roskomnadzor in November 2016 as a result of LinkedIns failure to  &#10; comply with this regulation. We believe we are advantageously positioned  &#10; against our indirect competitors, such as social networks and search engines. &#10;  &#10; Because our CV database, traffic to our website and the range of additional &#10; services for employers exceed those of our competitors, we view premium pricing &#10; of our services to be justified and sustainable. We have historically been able &#10; to retain our customers and attract new ones while periodically increasing the &#10; prices for our services. &#10;  &#10; The main monetization model adopted in the Russian online recruitment market is &#10; either providing paid access to a CV database, charging a fee per job posting or &#10; a combination thereof. Should some international players, such as Indeed, expand &#10; their operations in Russia and propose to the market an alternative monetisation &#10; model adopted elsewhere, such as CPC, we might be forced to change our business &#10; model accordingly. However, we believe that with successful introduction of our &#10; ClickMe product, which operates on the CPC model, we believe we are well &#10; positioned and prepared for such challenges. &#10;  &#10; The competition in HCM services is largely fragmented and differs across various &#10; types of services. Currently, key competitors in broader HCM space are large &#10; international, such as Oracle and SAP, and local, such as 1C and IBS, IT service &#10; providers, while future competition may arise from growing HR technology &#10; start-up companies, as well as new developing business and monetization models, &#10; such as recruiting chat bots or advertising agencies, providing recruiting &#10; services on cost-per-acquisition basis.',\n",
       "   'amount': 199728263,\n",
       "   'percentOffered': '32.61'},\n",
       "  {'symbol': 'APLT',\n",
       "   'companyName': 'APPLIED THERAPEUTICS INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Citigroup Global Markets Inc',\n",
       "    'Cowen and Company, LLC',\n",
       "    'UBS Investment Bank'],\n",
       "   'underwriters': ['Robert W. Baird & Co. Incorporated'],\n",
       "   'companyCounsel': ['Cooley LLP'],\n",
       "   'underwriterCounsel': ['Davis Polk & Wardwell LLP'],\n",
       "   'auditor': 'Computershare Trust Company, N.A',\n",
       "   'market': 'NASDAQ Global',\n",
       "   'cik': '0001697532',\n",
       "   'address': '340 MADISON AVENUE',\n",
       "   'city': 'NEW YORK',\n",
       "   'state': 'NY',\n",
       "   'zip': '10173',\n",
       "   'phone': '212-220-9319',\n",
       "   'ceo': 'Shoshana Shendelman',\n",
       "   'employees': 9,\n",
       "   'url': 'www.appliedtherapeutics.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 4000000,\n",
       "   'priceLow': 14,\n",
       "   'priceHigh': 16,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 3200000,\n",
       "   'sharesOverAlloted': 600000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 17052202,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -16521000,\n",
       "   'totalAssets': 20246000,\n",
       "   'totalLiabilities': 4428000,\n",
       "   'stockholderEquity': -19592000,\n",
       "   'companyDescription': 'We are a clinical-stage biopharmaceutical company developing a pipeline of novel &#10; product candidates against validated molecular targets in indications of high  &#10; unmet medical need. We focus on molecules and pathways whose role in the disease &#10; process is well known based on prior research, but have previously failed to &#10; yield successful products due to poor efficacy and tolerability. Our unique &#10; approach to drug development leverages recent technological advances to design &#10; improved drugs, employs early use of biomarkers to confirm biological activity &#10; and focuses on abbreviated regulatory pathways. We develop product candidates &#10; with increased potency and selectivity by leveraging recent technological  &#10; advances in high throughput crystallography and in situ structural design. Our &#10; strategy is also informed by early use of biomarkers to confirm biological  &#10; activity and target engagement. The result of this unique multifaceted approach &#10; to drug development is a portfolio of highly specific and selective product  &#10; candidates that we believe are significantly de-risked and can move quickly &#10; through the development process. &#10; --- &#10;  &#10; We were incorporated under the laws of the State of Delaware on January 20,  &#10; 2016. Our principal executive offices are located at 340 Madison Avenue, 19th &#10; Floor, New York, New York 10173, and our telephone number is (212) 220-9226. Our &#10; corporate website address is www.appliedtherapeutics.com.',\n",
       "   'businessDescription': 'We are a clinical-stage biopharmaceutical company developing a pipeline of novel &#10; product candidates against validated molecular targets in indications of high  &#10; unmet medical need. We focus on molecules and pathways whose role in the disease &#10; process is well known based on prior research, but have previously failed to  &#10; yield successful products due to poor efficacy and tolerability. Our unique  &#10; approach to drug development leverages recent technological advances to design &#10; improved drugs, employs early use of biomarkers to confirm biological activity &#10; and focuses on abbreviated regulatory pathways. We develop product candidates  &#10; with increased potency and selectivity by leveraging recent technological  &#10; advances in high throughput crystallography and in situ structural design. Our &#10; strategy is also informed by early use of biomarkers to confirm biological  &#10; activity and target engagement. The result of this unique multifaceted approach &#10; to drug development is a portfolio of highly specific and selective product  &#10; candidates that we believe are significantly de-risked and can move quickly  &#10; through the development process. &#10;  &#10; Our first molecular target is aldose reductase, or AR, the first enzyme and &#10; rate-limiting step in the polyol pathway, an alternative glucose metabolism &#10; pathway. AR is a redox-regulated enzyme that is activated by an altered redox &#10; state within the cell, such as oxidative stress, which occurs during &#10; hyperglycemia and ischemia. AR activity produces excess sorbitol, which causes &#10; osmotic dysregulation within cells and tissues, and is implicated in multiple &#10; diseases. The detrimental consequences of aberrent AR activation include broad &#10; effects, such as mitochondrial dysfunction and cell death, as well as &#10; tissue-specific changes, such as neuronal degeneration in peripheral nerves, &#10; collagen crosslinking and fibrosis in cardiac tissue, and damage to blood &#10; vessels in the lens of the eye. Prior attempts to inhibit this enzyme were &#10; hindered by nonselective, nonspecific inhibition, which resulted in limited &#10; efficacy and significant off-target safety effects. Our AR inhibitor, or ARI, &#10; program currently includes three small molecules, which are all designed to be &#10; potent and selective ARIs, and are engineered to have unique tissue permeability &#10; profiles to target different disease states, including diabetic complications, &#10; heart disease and a rare pediatric metabolic disease. &#10;  &#10; Our lead product candidate, AT-001, is a novel ARI with broad systemic exposure &#10; and peripheral nerve permeability, that we are developing for the treatment of  &#10; diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart, for which no  &#10; treatments are available. DbCM is estimated to afflict 17% of diabetic patients, &#10; equating to an estimated 77 million patients globally. We initially plan to  &#10; target the 50% of these patients who are within the symptomatic stages of  &#10; disease we believe most likely to be responsive to treatment. We are also  &#10; developing AT-001 for diabetic peripheral neuropathy, or DPN, a debilitating &#10; neurodegenerative disease that significantly reduces quality of life, and for &#10; which there are currently no approved treatments in the United States.  &#10; Approximately 50% of the global diabetic population, or 226 million diabetic &#10; patients, suffer from DPN. We recently completed a Phase 1/2 clinical trial  &#10; evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which &#10; no drug-related adverse effects or tolerability issues were observed. This trial &#10; also demonstrated target engagement and proof of biological activity, as  &#10; measured by reduction in sorbitol, a biomarker of AR activity, and NTproBNP, a &#10; marker of cardiac stress. We plan to initiate a Phase 2/3 pivotal clinical trial &#10; of AT-001 for the treatment of DbCM in 2019. We plan to collect data on motor &#10; nerve conduction velocity, or MNCV, in our planned pivotal trial in DbCM  &#10; patients that also have DPN, which we expect will provide a basis for dose &#10; selection in Phase 3 clinical trials of DPN. &#10;  &#10; Our second product candidate, AT-007, is a central nervous system, or CNS,  &#10; penetrant ARI that we are developing for the treatment of galactosemia, a &#10; devastating rare pediatric metabolic disease that affects how the body processes &#10; a simple sugar called galactose, and for which there is no known cure or &#10; approved treatment available. We estimate that the U.S. galactosemia population &#10; is approximately 2,800 patients, based on newborn screening data identifying &#10; 2,500 infants through 2014, and the estimated birth rate of 80 patients per &#10; year. High levels of galactose circulating in the blood and tissues of &#10; galactosemia patients enable AR to convert galactose to a toxic metabolite, &#10; galactitol, which results in long-term complications ranging from CNS &#10; dysfunction to cataracts. We have demonstrated in an animal model of &#10; galactosemia that treatment with AT-007 reduces toxic galactitol levels and &#10; prevents disease complications. We believe that galactosemia may qualify for &#10; accelerated approval, as well as for the rare pediatric disease priority review &#10; voucher, or RPD-PRV, program. Additionally, the U.S. Food and Drug &#10; Administration, or FDA, recently released draft guidance for industry on drug &#10; development for low prevalence, slowly progressing rare metabolic diseases, for &#10; which we believe galactosemia qualifies. The guidance allows for a &#10; biomarker-based development program if clinical efficacy and a link to a &#10; relevant biomarker can be demonstrated in an animal model of disease. We are &#10; currently in late stages of preclinical development and intend to advance AT-007 &#10; into a Phase 1 clinical trial in 2019. &#10;  &#10; We are also developing AT-003, an ARI designed to cross through the back of the &#10; eye when dosed orally, which has demonstrated strong retinal penetrance, for the &#10; treatment of diabetic retinopathy, or DR. DR is an ophthalmic disease that &#10; occurs in diabetic patients and for which treatments are currently limited to &#10; high-cost biologics requiring intravitreal administration. DR afflicts &#10; approximately 35% of diabetic patients, equating to an estimated 158 million &#10; patients globally. DR has been linked to AR activity, including elevations in &#10; sorbitol and subsequent changes in retinal blood vessels, which distorts vision &#10; and leads to permanent blindness. We are currently in late stages of preclinical &#10; development of AT-003. AT-003 displayed significant retinal penetration when &#10; dosed orally in diabetic rats. The drug was observed to be well tolerated with &#10; no adverse effects. Efficacy of AT-003 is currently being explored in two animal &#10; models of DRan ischemic injury model (acute damage) and chronic diabetic &#10; treatment model. We intend to advance AT-003 into a Phase 1 clinical trial in &#10; 2020. &#10;  &#10; Applying our strategy from our ARI program, we have also developed a program &#10; targeting selective inhibition of phosphatidylinositol 3-kinase, or PI3K, &#10; subunits that has resulted in an early-stage oncology pipeline. We expect to &#10; initially target orphan hematological oncology indications, including peripheral &#10; T-cell lymphoma, cutaneous T-cell lymphoma and T-cell acute lymphoblastic &#10; leukemia. We are additionally developing selective alpha/gamma inhibitors to &#10; target solid tumors that constitutively express PI3K alpha. We plan to initiate &#10; our clinical program in these indications in 2020. &#10; --- &#10;  &#10; We were incorporated under the laws of the State of Delaware on January 20,  &#10; 2016. Our principal executive offices are located at 340 Madison Avenue, 19th &#10; Floor, New York, New York 10173, and our telephone number is (212) 220-9226. Our &#10; corporate website address is www.appliedtherapeutics.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds to us from this offering will be approximately &#10; $52.6 million (or approximately $61.0 million if the underwriters exercise in  &#10; full their option to purchase up to 600,000 additional shares of common stock to &#10; cover over-allotments), based on an assumed initial public offering price of  &#10; $15.00 per share, the midpoint of the price range set forth on the cover page of &#10; this prospectus, after deducting estimated underwriting discounts and &#10; commissions and estimated offering expenses payable by us. &#10;  &#10; Each $1.00 increase or decrease in the assumed initial public offering price of &#10; $15.00 per share, the midpoint of the price range set forth on the cover page of &#10; this prospectus, would increase or decrease the net proceeds to us from this &#10; offering by $3.7 million, assuming that the number of shares of common stock &#10; offered by us, as set forth on the cover page of this prospectus, remains the &#10; same and after deducting the estimated underwriting discounts and commissions &#10; and estimated offering expenses payable by us. Similarly, each increase or &#10; decrease of 1.0 million shares of common stock offered by us, would increase or &#10; decrease the net proceeds to us by $14.0 million, assuming the assumed initial &#10; public offering price per share remains the same, and after deducting the &#10; estimated underwriting discounts and commissions. &#10;  &#10; The principal purposes of this offering are to increase our capitalization and &#10; financial flexibility, establish a public market for our common stock and to &#10; facilitate future access to the public equity markets by us, our employees and &#10; our stockholders, obtain additional capital to support our operations and &#10; increase our visibility in the marketplace. &#10;  &#10; We currently intend to use the net proceeds from this offering, together with &#10; our existing cash and cash equivalents, as follows: &#10;  &#10;  approximately $30 million to fund our pivotal Phase 2/3 clinical trial for &#10;   AT-001 for the treatment of diabetic cardiomyopathy; &#10;  &#10;  approximately $5 million to advance AT-007 for the treatment of galactosemia  &#10;   in adults through our planned Phase 1 clinical trial; &#10;  &#10;  approximately $4 million to advance AT-003 for the treatment of diabetic  &#10;   retinopathy into our planned Phase 1 clinical trial; and &#10;  &#10;  the remainder to fund other research and development activities, working  &#10;   capital and other general corporate purposes. &#10;  &#10; We may also use a portion of the remaining net proceeds to in-license, acquire &#10; or invest in complementary businesses, technologies, products or assets.  &#10; However, we have no current commitments or obligations to do so. &#10;  &#10; This expected use of the net proceeds from this offering represents our  &#10; intentions based on our current plans and business conditions, which could &#10; change in the future as our plans and business conditions evolve. Further, due &#10; to the uncertainties inherent in the drug development process, it is difficult &#10; to estimate with certainty the exact amounts of the net proceeds from this &#10; offering that may be used for the above purposes. &#10;  &#10; Our management will have broad discretion over the use of the net proceeds from &#10; this offering, and our investors will be relying on the judgment of our &#10; management regarding the application of the net proceeds of this offering. The &#10; amounts and timing of our expenditures will depend upon numerous factors &#10; including the results of our research and development efforts, the timing and &#10; success of preclinical studies and any ongoing clinical trials or clinical &#10; trials we may commence in the future, the timing of regulatory submissions and &#10; the amount of cash obtained through current and any future collaborations. &#10;  &#10; The expected net proceeds from this offering, together with our cash and cash &#10; equivalents, will not be sufficient for us to fund any of our product candidates &#10; through regulatory approval, and we will need to raise additional capital to &#10; complete the development and commercialization of our product candidates. We &#10; expect to finance our cash needs through a combination of equity offerings, debt &#10; financings and potential collaborations, and license and development agreements. &#10; We have based these estimates on assumptions that may prove to be incorrect, and &#10; we could expend our available capital resources at a rate greater than we  &#10; currently expect. &#10;  &#10; Pending the use of the net proceeds from this offering as described above, we  &#10; intend to invest the net proceeds in a variety of capital preservation  &#10; instruments, including short-term, interest-bearing obligations,  &#10; investment-grade instruments, certificates of deposit or direct or guaranteed &#10; obligations of the U.S. government.',\n",
       "   'competition': 'The pharmaceutical industry is characterized by rapidly advancing technologies, &#10; intense competition and a strong emphasis on proprietary products. While we  &#10; believe that our technology, the expertise of our executive and scientific team, &#10; research, clinical capabilities, development experience and scientific knowledge &#10; provide us with competitive advantages, we face potential competition from many &#10; different sources, including pharmaceutical and biotechnology companies,  &#10; academic institutions and governmental agencies and public and private research &#10; institutions. Product candidates that we successfully develop and commercialize &#10; may compete with existing therapies and new therapies that may become available &#10; in the future. &#10;  &#10; Our competitors may have significantly greater financial resources, established &#10; presence in the market, expertise in research and development, manufacturing,  &#10; preclinical and clinical testing, obtaining regulatory approvals and  &#10; reimbursement and marketing approved products than we do. These competitors also &#10; compete with us in recruiting and retaining qualified scientific, sales, &#10; marketing and management personnel, establishing clinical trial sites and &#10; patient registration for clinical trials, as well as in acquiring technologies &#10; complementary to, or necessary for, our programs. Smaller or early-stage &#10; companies may also prove to be significant competitors, particularly through &#10; collaborative arrangements with large and established companies. &#10;  &#10; There are currently no therapies approved to treat DbCM. Entresto, a drug  &#10; developed by Novartis International AG, or Novartis, is approved for acute heart &#10; failure, which can be caused by many conditions, including DbCM. However, we are &#10; aware that Novartis may be pursuing a label expansion for earlier treatment of &#10; generalized heart failure, which may overlap with our target disease stages in &#10; DbCM. Additionally, sponsors of sodium-glucose cotransporter-2, or SGLT2, &#10; inhibitors are pursuing broad cardiovascular labels in type 2 diabetes patients, &#10; which may include a subset of DbCM patients as part of the larger diabetic &#10; population at risk for heart failure. We are also aware of planned Phase 2 &#10; clinical trials on glucagon-like peptide-1, or GLP-1, agonists in DbCM, as well &#10; as anti-fibrotic therapies in Phase 1 clinical development. Many of these &#10; programs are sponsored by large pharmaceutical companies with a strong presence &#10; in cardiology and metabolic disease. Additionally, stem-cell targeted &#10; initiatives are in various stages of preclinical and early clinical development &#10; to stimulate regeneration of cardiac tissue to counter fibrosis in DbCM. There &#10; have been prior studies demonstrating effectiveness in DbCM of off-label use of &#10; sildenafil, although we do not believe this represents a commercially viable &#10; competitive threat. &#10;  &#10; There are no disease modifying therapies approved to treat DPN outside of Japan, &#10; India and China. In these limited markets, epalrestat, another ARI, is approved &#10; to prevent worsening of DPN, and despite challenges in compliance due to  &#10; frequent dosing three to five times daily, the drugs are generic and offer a low &#10; cost alternative. A more effective therapy with improved tolerability and dosing &#10; may offer an advantage. A re-formulation of proprietary crystalline epalrestat, &#10; BNV-222, is in development for DPN in Russia in a 12-month Phase 2/3 clinical  &#10; trial, which completed enrollment in 2016, but has not yet reported any results. &#10;  &#10; There are currently no therapies approved to treat galactosemia. Due to the &#10; importance of GALK and GALT enzymes within neurons in the CNS, we believe that &#10; enzyme replacement therapy is not an effective approach in this indication. &#10; Additionally, numerous mutations across ethnicities are responsible for loss of &#10; function in GALK or GALT, which presents significant challenges to potential &#10; gene editing approaches. &#10;  &#10; There are several therapies approved to treat severe or late-stage forms of &#10; DR, or proliferative DR, such as diabetic macular edema and proliferative DR, &#10; including anti-VEGF therapies, Lucentis and Eylea, which represents  &#10; approximately 20% of the larger DR population. There are currently no therapies &#10; approved to treat non-proliferative DR, an earlier stage of the disease  &#10; upstream of vessel or capillary proliferation. However, there are significant  &#10; additional clinical development efforts for other mechanistic interventions in &#10; early-stage or for non-proliferative DR. &#10;  &#10; The following table summarizes the current competitive landscape for our initial &#10; target indications: &#10;  &#10; Disease               Product Type                    Stage of Development             &#10; DbCM             Entresto                 Approved for late stages of generalized      &#10;                  (sacubitril/valsartan)   cardiac heart failure; may pursue earlier    &#10;                                           stages of heart failure that may overlap     &#10;                                           with DbCM                                    &#10;                  SGLT2 inhibitors         Approved for glucose control with additional &#10;                                           label claiming cardiovascular benefit in     &#10;                                           diabetics; may achieve specific label in     &#10;                                           DbCM in future studies                       &#10;                  GLP-1 agonists           Approved; additional studies examining       &#10;                                           direct CV benefit in DbCM anticipated        &#10;                  Anti-fibrotic            Preclinical to Phase 1; may prevent collagen &#10;                  therapies                cross-linking and B-catenin remodeling       &#10; DPN              Epalrestat (ARI);        Approved as a generic in Japan, China and    &#10;                                           India                                        &#10;                  BNV-22 epalrestat        Attempt to reformulate as a novel product in &#10;                  reformulation            Russia in Phase 2/3 trial (no information    &#10;                                           available since 2016)                        &#10; Galactosemia                              None identified                              &#10; DR               Anti-VEGFs (Lucentis;    Approved for proliferative forms of DRonly  &#10;                  Eylea)                   20% of DR population                         &#10;                  Other mechanisms         Phase 2a development for non-proliferative   &#10;                                           DR',\n",
       "   'amount': 60000000,\n",
       "   'percentOffered': '23.46'},\n",
       "  {'symbol': 'NXTC',\n",
       "   'companyName': 'NEXTCURE, INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['BofA Merrill Lynch',\n",
       "    'Morgan Stanley & Co. LLC',\n",
       "    'Piper Jaffray & Co.'],\n",
       "   'underwriters': [],\n",
       "   'companyCounsel': ['Hogan Lovells US LLP'],\n",
       "   'underwriterCounsel': ['Cooley LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NASDAQ Global Select',\n",
       "   'cik': '0001661059',\n",
       "   'address': '9000 VIRGINIA MANOR ROAD, SUITE 200',\n",
       "   'city': 'BELTSVILLE',\n",
       "   'state': 'MD',\n",
       "   'zip': '20705',\n",
       "   'phone': '240-399-4900',\n",
       "   'ceo': 'Michael Richman',\n",
       "   'employees': 44,\n",
       "   'url': 'www.nextcure.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 5000000,\n",
       "   'priceLow': 14,\n",
       "   'priceHigh': 16,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 3200000,\n",
       "   'sharesOverAlloted': 750000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 21935381,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -22799000,\n",
       "   'totalAssets': 147628000,\n",
       "   'totalLiabilities': 32349000,\n",
       "   'stockholderEquity': -46944000,\n",
       "   'companyDescription': 'We are a clinical-stage biopharmaceutical company committed to discovering &#10; and developing novel, first-in-class immunomedicines to treat cancer and other &#10; immune-related diseases by restoring normal immune function. We view the immune &#10; system holistically and, rather than target one specific immune cell type, we &#10; focus on understanding biological pathways, the interactions of cells and the &#10; role each interaction plays in an immune response. Through our proprietary &#10; Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, &#10; platform, we study various immune cells to discover and understand targets and &#10; structural components of immune cells and their functional impact in order to &#10; develop immunomedicines. We are focused on patients who do not respond to &#10; current therapies, patients whose cancer progresses despite treatment and &#10; patients with cancer types not adequately addressed by available therapies. We &#10; are committed to discovering and developing first-in-class immunomedicines, &#10; which are immunomedicines that use new or unique mechanisms of action to treat a &#10; medical condition, for these patients. &#10; --- &#10;  &#10; We were incorporated in Delaware in September 2015. Our primary executive &#10; offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland &#10; 20705 and our telephone number is (240) 399-4900. Our website address is &#10; www.nextcure.com.',\n",
       "   'businessDescription': 'We are a clinical-stage biopharmaceutical company committed to discovering &#10; and developing novel, first-in-class immunomedicines to treat cancer and other &#10; immune-related diseases by restoring normal immune function. We view the immune &#10; system holistically and, rather than target one specific immune cell type, we &#10; focus on understanding biological pathways, the interactions of cells and the &#10; role each interaction plays in an immune response. Through our proprietary &#10; Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, &#10; platform, we study various immune cells to discover and understand targets and &#10; structural components of immune cells and their functional impact in order to &#10; develop immunomedicines. We are focused on patients who do not respond to &#10; current therapies, patients whose cancer progresses despite treatment and &#10; patients with cancer types not adequately addressed by available therapies. We &#10; are committed to discovering and developing first-in-class immunomedicines, &#10; which are immunomedicines that use new or unique mechanisms of action to treat a &#10; medical condition, for these patients. &#10;  &#10; Our lead product candidate, NC318, is a first-in-class immunomedicine against a &#10; novel immunomodulatory receptor called Siglec-15, or S15. In October 2018, we &#10; initiated a Phase 1/2 clinical trial of NC318 in patients with advanced or  &#10; metastatic solid tumors. We expect completion of the Phase 1 portion of this  &#10; trial in the fourth quarter of 2019 and completion of the Phase 2 portion in the &#10; fourth quarter of 2020. Our second product candidate, NC410, is a novel  &#10; immunomedicine designed to block immune suppression mediated by an immune  &#10; modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1, or LAIR-1. &#10; We expect to submit an investigational new drug application, or IND, to the U.S. &#10; Food and Drug Administration, or FDA, for NC410 in the first quarter of 2020. &#10;  &#10; Our approach to identifying targets for new immunomedicines is based on our  &#10; FIND-IO platform. FIND-IO embodies a rational approach to the discovery of novel &#10; cell surface and secretory molecules that drive functional immune responses. We &#10; use our immunology knowledge, experience, capabilities and tools we have &#10; developed, including our FIND-IO platform, to support our discovery efforts. We &#10; are working to discover novel targets that play a key role in mediating immune &#10; dysfunction that allows tumors to evade the immune system. We are seeking to &#10; identify and develop immunomedicines that counteract these outcomes and to &#10; further validate and advance our product candidates. We have identified multiple &#10; novel targets using our FIND-IO platform, including those for which certain of &#10; our research programs are being designed to target. In addition, the &#10; immunosuppressive properties of S15, the target of NC318, were discovered using &#10; a predecessor of our FIND-IO platform. &#10;  &#10; The advancement of cancer to late stages indicates a failure of the immune  &#10; system to mount an effective anti-tumor immune response. Immuno-oncology, which &#10; focuses on stimulating the immune system to respond to cancer and includes &#10; checkpoint inhibitors targeting PD-L1, PD-1 and CTLA-4, is one of the most &#10; significant advances in the history of cancer treatment. In 2011, the first &#10; checkpoint inhibitor was approved, and today, despite only a modest breadth of &#10; efficacy, this class of therapies is estimated to have had global sales of more &#10; than $17 billion in 2018 and is predicted to reach more than $33 billion in &#10; global sales by 2022. However, despite the recent success of checkpoint &#10; inhibitors, efficacy has been limited. It is estimated that up to 60% to 70% of &#10; cancer patients, including those with melanoma, renal cell cancer, colorectal &#10; cancer, non-small cell lung cancer, urothelial cancer and head and neck squamous &#10; cell carcinoma, do not respond to single-agent therapy with checkpoint &#10; inhibitors. In addition, some patients develop resistance after initial &#10; treatment with these therapies. As a result, the standard of care in cancer  &#10; today leaves many patients underserved. We believe broader efficacy and more &#10; meaningful clinical responses in oncology may be obtained by focusing on the  &#10; tumor microenvironment, or TME. &#10;  &#10; We are using our FIND-IO platform as our discovery engine to identify targets  &#10; and develop immunomedicines that restore normal immune function in the TME  &#10; through novel mechanisms of action. Since our founding in 2015, we have  &#10; developed, industrialized and optimized our FIND-IO platform based on the  &#10; immunological expertise of our management team and the scientific leadership of &#10; our scientific founder, Dr. Lieping Chen. Our approach in creating the FIND-IO &#10; platform, and how we apply it, reflects our belief in the importance of  &#10; understanding biological pathways of all cells in the immune system and  &#10; restoring normal immune function. The platform uses our proprietary approaches &#10; to assess the suppressive or stimulatory function of immune pathways in T cells &#10; and other immune cells, as measured by effects on proliferation or induction of &#10; molecules known to impact immune responses, such as cytokines, which are &#10; signaling molecules secreted by cells in the immune system that mediate and &#10; regulate immunity and inflammation. We study primary immune cells from healthy &#10; donors and from patients with various diseases, as well as established cell &#10; lines from immune and non-immune cell lineages, including T cell subsets, &#10; monocytes, macrophage subpopulations and cancer cell lines. In oncology, we are &#10; using the FIND-IO platform to discover immunomedicines with the potential to &#10; intervene or modulate interactions of immune cells within the TME to restore &#10; anti-tumor activity. We are also expanding the functional screening approach of &#10; our FIND-IO platform for the identification of novel targets in other serious &#10; illnesses outside of oncology, including autoimmune, inflammatory and &#10; neuro-inflammatory diseases. &#10;  &#10; In November 2018, we entered into a multi-year collaboration agreement with Eli &#10; Lilly and Company, or Lilly, focused on the discovery and development of  &#10; immunomedicines for oncology using our FIND-IO platform. The collaboration seeks &#10; to discover novel cancer targets utilizing our platform and provides that we and &#10; Lilly will each receive options to exclusively develop antibodies resulting from &#10; the collaboration. In connection with the agreement, we received an upfront  &#10; payment of $25.0 million in cash and an equity investment of $15.0 million and &#10; are eligible to receive development and regulatory milestones and sales &#10; milestones in an aggregate of up to $1.4 billion, as well as royalty payments. &#10; --- &#10;  &#10; We were incorporated in Delaware in September 2015. Our primary executive &#10; offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland &#10; 20705 and our telephone number is (240) 399-4900. Our website address is &#10; www.nextcure.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from the sale of shares of our common stock in &#10; this offering will be approximately $66.6 million, or approximately $77.0  &#10; million if the underwriters exercise their option to purchase additional shares &#10; in full, assuming an initial public offering price of $15.00 per share  &#10; (the midpoint of the estimated price range set forth on the cover of this  &#10; prospectus), and after deducting estimated underwriting discounts and  &#10; commissions and estimated offering expenses payable by us. &#10;  &#10; Each $1.00 increase or decrease in the assumed initial public offering price of &#10; $15.00 per share (the midpoint of the estimated price range set forth on the  &#10; cover of this prospectus) would increase or decrease, respectively, the net &#10; proceeds from this offering by approximately $4.7 million, assuming the number &#10; of shares offered by us, as set forth on the cover of this prospectus, remains &#10; the same and after deducting estimated underwriting discounts and commissions &#10; and estimated offering expenses payable by us. We may also increase or decrease &#10; the number of shares we are offering. An increase or decrease of 1.0 million in &#10; the number of shares we are offering would increase or decrease, respectively, &#10; the net proceeds from this offering, after deducting estimated underwriting &#10; discounts and commissions and estimated offering expenses payable by us, by &#10; approximately $14.0 million, assuming the initial public offering price remains &#10; the same. We do not expect that a change in the initial public offering price or &#10; the number of shares offered by us by these amounts would have a material effect &#10; on our intended use of the net proceeds from this offering, although it may &#10; impact the amount of time prior to which we may need to seek additional capital. &#10;  &#10; As of December 31, 2018, we had $135.2 million in cash and cash equivalents. We &#10; intend to use the net proceeds from this offering, together with our existing  &#10; cash and cash equivalents, as follows: &#10;          &#10;  approximately $113.0 million to advance NC318 through completion of our  &#10;   ongoing Phase 1/2 clinical trial in patients with advanced or metastatic &#10;   solid tumors and into a Phase 3 clinical trial; &#10;  &#10;  approximately $31.0 million to advance NC410 through completion of a Phase 1/2 &#10;   clinical trial; and &#10;  &#10;  the remainder for research and development activities related to our FIND-IO &#10;   platform and discovery programs, including advancement of two discovery  &#10;   programs through submission of INDs, personnel expenses, working capital and &#10;   other general corporate purposes, including a $500,000 payment to Yale &#10;   University that is due upon the closing of this offering. &#10;  &#10; Our expected use of the net proceeds from this offering represents our  &#10; intentions based upon our current plans and business conditions, which could &#10; change in the future as our plans and business conditions evolve. As of the date &#10; of this prospectus, we cannot predict with certainty all of the particular uses &#10; for the net proceeds to be received upon the closing of this offering or the &#10; amounts that we will actually spend on the uses set forth above. The amounts and &#10; timing of our actual expenditures and the extent of our research and development &#10; activities may vary significantly depending on numerous factors, including the &#10; progress of our development efforts, the timing and costs associated with the &#10; manufacture and supply of any of our product candidates, and any unforeseen cash &#10; needs. As a result, our management will have broad discretion over the use of &#10; the net proceeds from this offering. &#10;  &#10; Pending the uses described above, we intend to invest the net proceeds from this &#10; offering in interest-bearing, investment-grade securities, certificates of  &#10; deposit or government securities. &#10;  &#10; We believe that our existing cash and cash equivalents, together with the net &#10; proceeds from this offering, will be sufficient to fund our planned operations &#10; into the second half of 2022. We have based this estimate on assumptions that  &#10; may prove to be incorrect, and we could use our available capital resources  &#10; sooner than we currently expect. After this offering, we will require &#10; substantial additional capital in order to continue to advance NC318, NC410 and &#10; future product candidates through preclinical studies, clinical trials,  &#10; regulatory approval and commercialization.',\n",
       "   'competition': \"The biotechnology and pharmaceutical industries, and the immuno-oncology &#10; subsector, are characterized by rapid evolution of technologies, fierce &#10; competition and strong defense of intellectual property. We believe that our &#10; programs, platforms, technology, knowledge, experience and scientific resources &#10; provide us with competitive advantages, but we also face competition from &#10; pharmaceutical and biotechnology companies, academic institutions, governmental &#10; agencies and public and private research institutions, among others. Our &#10; competitors include larger and better funded biopharmaceutical, biotechnology &#10; and therapeutics companies, including companies focused on cancer &#10; immunotherapies, such as Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb &#10; Company, or BMS, Genentech, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., &#10; Novartis AG, Pfizer Inc., Roche Holding Ltd and Sanofi S.A. Moreover, we may &#10; also compete with smaller or earlier-stage companies, universities and other &#10; research institutions that have developed, are developing or may be developing &#10; current and future cancer therapeutics. &#10;  &#10; Product candidates that we successfully develop and commercialize will compete &#10; with a range of therapies that are currently approved and any new therapies that &#10; may become available in the future. Key product features that would affect our &#10; ability to effectively compete with other therapeutics include the efficacy, &#10; safety and convenience of our products. Currently marketed oncology drugs and &#10; therapeutics range from traditional cancer therapies, including chemotherapy, to &#10; antibody-drug conjugates, such as Genentech Inc.'s Kadcyla, to immune checkpoint &#10; inhibitors targeting CTLA-4, such as BMS' Yervoy, and PD-1/PD-L1, such as BMS'  &#10; Opdivo, Merck & Co.'s Keytruda and Genentech's Tecentriq, to T cell-engager  &#10; immunotherapies, such as Amgen's Blincyto. In addition to these marketed  &#10; therapies, numerous compounds are in clinical development for the potential  &#10; treatment of cancer. &#10;  &#10; The availability of reimbursement from government and other third-party payors &#10; will also significantly affect the pricing and competitiveness of our products. &#10; Our competitors may also obtain FDA or other regulatory approval for their &#10; products more rapidly than we may obtain approval for ours, which could result &#10; in our competitors establishing a strong market position before we are able to &#10; enter the market.\",\n",
       "   'amount': 75000000,\n",
       "   'percentOffered': '22.79'},\n",
       "  {'symbol': 'SPFI',\n",
       "   'companyName': 'SOUTH PLAINS FINANCIAL, INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Keefe, Bruyette & Woods, Inc',\n",
       "    \"Sandler O'Neill and Partners, L.P\"],\n",
       "   'underwriters': [],\n",
       "   'companyCounsel': ['Hunton Andrews Kurth LLP'],\n",
       "   'underwriterCounsel': ['Fenimore, Kay, Harrison & Ford, LLP.'],\n",
       "   'auditor': 'Broadridge Corporate Issuer Solutions, Inc',\n",
       "   'market': 'NASDAQ Global Select',\n",
       "   'cik': '0001163668',\n",
       "   'address': '5219 CITY BANK PARKWAY',\n",
       "   'city': 'LUBBOCK',\n",
       "   'state': 'TX',\n",
       "   'zip': '79407-3544',\n",
       "   'phone': '806-792-7101',\n",
       "   'ceo': 'Curtis C. Griffith',\n",
       "   'employees': 684,\n",
       "   'url': 'www.city.bank',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 3380000,\n",
       "   'priceLow': 17.5,\n",
       "   'priceHigh': 19.5,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 1092187,\n",
       "   'sharesOverAlloted': 507000,\n",
       "   'shareholderShares': 680000,\n",
       "   'sharesOutstanding': 17471520,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 170215000,\n",
       "   'netIncome': 29290000,\n",
       "   'totalAssets': 2712745000,\n",
       "   'totalLiabilities': 2499970000,\n",
       "   'stockholderEquity': 154580000,\n",
       "   'companyDescription': 'We are a bank holding company headquartered in Lubbock, Texas, and our &#10; wholly-owned subsidiary, City Bank, is one of the largest independent banks in &#10; West Texas. We have additional banking operations in the Dallas-Fort &#10; Worth-Arlington and El Paso MSAs, as well as in the Greater Houston, College &#10; Station, and Ruidoso and Eastern New Mexico markets. Through City Bank, we &#10; provide a wide range of commercial and consumer financial services to small and &#10; medium-sized businesses and individuals in our market areas. Our principal &#10; business activities include commercial and retail banking, along with insurance, &#10; investment, trust and mortgage services. &#10;  &#10; We had total assets of $2.7 billion, gross loans held for investment of $2.0 &#10; billion, total deposits of $2.3 billion, and total shareholders equity of &#10; $154.6 million as of December 31, 2018. &#10; --- &#10;  &#10; Our principal executive office is located at 5219 City Bank Parkway, Lubbock, &#10; Texas 79407, and our telephone number is (806) 792-7101. Our website address is &#10; www.city.bank.',\n",
       "   'businessDescription': 'We are a bank holding company headquartered in Lubbock, Texas, and our &#10; wholly-owned subsidiary, City Bank, is one of the largest independent banks in &#10; West Texas. We have additional banking operations in the Dallas-Fort &#10; Worth-Arlington and El Paso MSAs, as well as in the Greater Houston, College &#10; Station, and Ruidoso and Eastern New Mexico markets. Through City Bank, we &#10; provide a wide range of commercial and consumer financial services to small and &#10; medium-sized businesses and individuals in our market areas. Our principal &#10; business activities include commercial and retail banking, along with insurance, &#10; investment, trust and mortgage services. &#10;  &#10; We had total assets of $2.7 billion, gross loans held for investment of $2.0 &#10; billion, total deposits of $2.3 billion, and total shareholders equity of &#10; $154.6 million as of December 31, 2018. &#10; --- &#10;  &#10; Our principal executive office is located at 5219 City Bank Parkway, Lubbock, &#10; Texas 79407, and our telephone number is (806) 792-7101. Our website address is &#10; www.city.bank.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds to us from this offering, after deducting &#10; underwriting discounts and estimated offering expenses, will be approximately &#10; $45.6 million, based on an assumed public offering price of $18.50 per share &#10; (the midpoint of the price range set forth on the cover page of this &#10; prospectus). Each $1.00 increase or decrease in the assumed public offering &#10; price of $18.50 per share would increase or decrease the net proceeds to us from &#10; this offering by approximately $2.5 million. We will not receive any proceeds &#10; from the sale of shares of our common stock by the selling shareholder. &#10;  &#10; We intend to use the net proceeds to us from this offering, which we estimate to &#10; be approximately $45.6 million (after deducting underwriting discounts and the &#10; estimated offering expenses) to support future growth of our business, including &#10; through strategic acquisitions and organic growth, and for general corporate &#10; purposes. &#10;  &#10; Our management will retain broad discretion to allocate the net proceeds of this &#10; offering. The precise amounts and timing of our use of the proceeds will depend &#10; upon market conditions and other factors.',\n",
       "   'competition': 'The banking and financial services industry is highly competitive, and we &#10; compete with a wide range of financial institutions within our markets, &#10; including local, regional and national commercial banks and credit unions. We &#10; also compete with mortgage companies, trust companies, brokerage firms, consumer &#10; finance companies, mutual funds, securities firms, insurance companies, &#10; third-party payment processors, financial technology companies and other &#10; financial intermediaries for certain of our products and services. Some of our &#10; competitors are not subject to the regulatory restrictions and level of &#10; regulatory supervision applicable to us. &#10;  &#10; Interest rates on loans and deposits, as well as prices on fee-based services, &#10; are typically significant competitive factors within the banking and financial &#10; services industry. Many of our competitors are much larger financial &#10; institutions that have greater financial resources than we do and compete &#10; aggressively for market share. These competitors attempt to gain market share &#10; through their financial product mix, pricing strategies and banking center &#10; locations. Other important competitive factors in our industry and markets &#10; include office locations and hours, quality of customer service, community &#10; reputation, continuity of personnel and services, capacity and willingness to &#10; extend credit, and ability to offer excellent banking products and services. &#10; While we seek to remain competitive with respect to fees charged, interest rates &#10; and pricing, we believe that our broad suite of financial solutions, our &#10; high-quality customer service culture, our positive reputation and our &#10; long-standing community relationships will enable us to compete successfully &#10; within our markets and enhance our ability to attract and retain customers.',\n",
       "   'amount': 62530000,\n",
       "   'percentOffered': '19.35'},\n",
       "  {'symbol': 'MEC',\n",
       "   'companyName': 'MAYVILLE ENGINEERING COMPANY, INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Citigroup Global Markets Inc',\n",
       "    'Jefferies LLC',\n",
       "    'Robert W. Baird & Co. Incorporated'],\n",
       "   'underwriters': ['UBS Investment Bank', 'William Blair and Co., L.L.C.'],\n",
       "   'companyCounsel': ['Foley & Lardner LLP'],\n",
       "   'underwriterCounsel': ['Latham & Watkins LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0001766368',\n",
       "   'address': '715 SOUTH STREET',\n",
       "   'city': 'MAYVILLE',\n",
       "   'state': 'WI',\n",
       "   'zip': '53050',\n",
       "   'phone': '920-387-4500',\n",
       "   'ceo': 'Robert D. Kamphuis',\n",
       "   'employees': 3100,\n",
       "   'url': 'www.mecinc.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 6250000,\n",
       "   'priceLow': 19,\n",
       "   'priceHigh': 21,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 2700000,\n",
       "   'sharesOverAlloted': 937500,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 19693484,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 354526000,\n",
       "   'netIncome': 17935000,\n",
       "   'totalAssets': 391725000,\n",
       "   'totalLiabilities': 288736000,\n",
       "   'stockholderEquity': -30817000,\n",
       "   'companyDescription': 'MEC is a leading U.S.-based value-added manufacturing partner that provides a &#10; broad range of prototyping and tooling, production fabrication, coating, &#10; assembly and aftermarket components. Our customers operate in diverse end &#10; markets, including heavy- and medium-duty commercial vehicles, construction, &#10; powersports, agriculture, military and other end markets. We have developed &#10; long-standing relationships with our blue chip customers based upon a high level &#10; of experience, trust and confidence. We Make Things Simple by providing a &#10; diverse set of process offerings and a one stop shop for end-to-end solutions &#10; with benefits throughout the entire product lifecycle, including front-end &#10; collaboration in design and prototyping, product manufacturing, aftermarket &#10; components and ancillary supply chain benefits. Founded in 1945 and &#10; headquartered in Mayville, WI, we are a leading Tier I U.S. supplier of highly &#10; engineered components to original equipment manufacturer, which we sometimes &#10; refer to as an OEM, customers with leading positions in their respective &#10; markets. We are focused on producing the highest quality components using &#10; complex processes at the lowest cost by working with customers throughout the &#10; product design and development process to establish optimal solutions. Our &#10; engineering expertise and technical know-how allows us to add value through &#10; every product redevelopment cycle (generally every three to five years for our &#10; customers). According to The Fabricator, we have been ranked as the largest &#10; fabricator in the United States for the past eight years in a row (20112018). &#10; We are more than two times the size of our next largest competitor, based on The &#10; Fabricators projections for 2018 revenue for metal fabricating companies. &#10; --- &#10;  &#10; We are a Wisconsin corporation and commenced operations in 1945. Our principal &#10; operating offices are located at 715 South Street, Mayville, Wisconsin 53050, &#10; and our phone number is (920) 387-4500. Our website address is www.mecinc.com.',\n",
       "   'businessDescription': 'MEC is a leading U.S.-based value-added manufacturing partner that provides a &#10; broad range of prototyping and tooling, production fabrication, coating, &#10; assembly and aftermarket components. Our customers operate in diverse end &#10; markets, including heavy- and medium-duty commercial vehicles, construction, &#10; powersports, agriculture, military and other end markets. We have developed &#10; long-standing relationships with our blue chip customers based upon a high level &#10; of experience, trust and confidence. We Make Things Simple by providing a &#10; diverse set of process offerings and a one stop shop for end-to-end solutions &#10; with benefits throughout the entire product lifecycle, including front-end &#10; collaboration in design and prototyping, product manufacturing, aftermarket &#10; components and ancillary supply chain benefits. Founded in 1945 and &#10; headquartered in Mayville, WI, we are a leading Tier I U.S. supplier of highly &#10; engineered components to original equipment manufacturer, which we sometimes &#10; refer to as an OEM, customers with leading positions in their respective &#10; markets. We are focused on producing the highest quality components using &#10; complex processes at the lowest cost by working with customers throughout the &#10; product design and development process to establish optimal solutions. Our &#10; engineering expertise and technical know-how allows us to add value through &#10; every product redevelopment cycle (generally every three to five years for our &#10; customers). According to The Fabricator, we have been ranked as the largest &#10; fabricator in the United States for the past eight years in a row (20112018). &#10; We are more than two times the size of our next largest competitor, based on The &#10; Fabricators projections for 2018 revenue for metal fabricating companies. &#10;  &#10; Our customers complex products require a unique combination of our capabilities &#10; that allow us to achieve a customized offering to satisfy our customers desired &#10; outcomes. Our capabilities, which include, but are not limited to: metal &#10; fabrication, metal stamping, tube bending and forming, robotic part forming, &#10; robotic welding, resistance welding, five-axis tube and fiber laser cutting and &#10; custom coatings, including high heat and chemical agent resistant coating, or &#10; CARC, painting, are used in a variety of applications and represent the building &#10; blocks of what we produce. &#10; --- &#10;  &#10; Our key customers have globally recognized brands and demand the highest product &#10; quality and expertise. Over our nearly 75-year history, we have developed &#10; capabilities and provide solutions that result in customer loyalty and &#10; long-standing relationships, which we call Experience You Can Trust. We have a &#10; diverse and market-leading customer base that serves broad end markets &#10; representing favorable near- and long-term growth prospects for us. We have a &#10; track record of growth and are well-positioned to increase our market share and &#10; benefit from growth in customer demand as well as consolidate demand across the &#10; end markets that we serve. To help pursue our strategic mission, we have more &#10; than 3,100 employees who are tactically aligned around our core values and will &#10; continue to participate in our employee ownership culture. We are led by an &#10; experienced management team that has contributed to our growth by establishing &#10; deep and long-standing relationships with key customers, and has worked to &#10; expand the customer base both organically and through strategic acquisitions. &#10;  &#10; We maintain an established base of long-standing customers comprised of leading, &#10; blue-chip OEM manufacturers across the United States. Our broad capabilities &#10; offering and track record of producing the highest quality solutions have &#10; allowed us to establish, and subsequently deepen, relationships with additional &#10; products and platforms over time. For example, our more than 40 year &#10; relationship with Deere & Company, which we sometimes refer to as John Deere, &#10; began with a small order of simple stamped parts for a farm tractor in its &#10; agricultural segment that expanded over time and represented 2018 pro forma &#10; sales in excess of $90.0 million across five market segments, representing over &#10; 60 model platforms. We have also been successful in winning customers and &#10; rapidly expanding relationships with high-growth customers by utilizing our &#10; diversified one-stop offering. For instance, our relationship with Volvo Truck &#10; began with fuel tanks and has expanded over the last six years to include &#10; exhaust tubing, new sleeper cab and chassis fabrications and air tanks. Through &#10; the expansion of multiple fabricated components from multiple facilities, we &#10; have been able to deepen our relationship with this customer and solidify our &#10; position as an important strategic sourcing partner. &#10; --- &#10;  &#10; We serve customers through 21 strategically located U.S. facilities across eight &#10; states, with almost three million square feet of manufacturing capacity. Our &#10; expansive footprint enables us to service and maintain strong relationships with &#10; existing key customers across the United States with a local presence, as well &#10; as target new customer opportunities. We have a proven track record of improving &#10; financial results by thoroughly understanding our capabilities and the markets &#10; we serve, and aligning our people and resources to optimize results. Coupled &#10; with our focus on market alignment and execution, we constantly strive to &#10; improve and refine capabilities and capacities. In addition, the ongoing &#10; investment in flexible, re-deployable automation allows us to expand output &#10; while reducing cost and improving quality, productivity and consistency for &#10; margin enhancement and market leading competitiveness. Through this continuum of &#10; activities, we have generated approximately $34.3 million in improved results &#10; from the beginning of 2014 through December 31, 2018. &#10;  &#10; Our leading market position, embedded customer relationships with leading OEMs, &#10; unique value proposition and proven acquisition strategy has allowed us to &#10; achieve attractive financial performance and has positioned us for further &#10; growth. Our historical financial success is a function of our engineering &#10; expertise, extensive manufacturing capabilities, limited commodity exposure, &#10; investment in automation and embedded relationships with the contractual ability &#10; to pass input costs through prices. We believe we are poised to grow through &#10; economic cycles due to our: &#10;  &#10; . market positioning and reputation; &#10;  &#10; . product breadth; &#10;  &#10; . flexible and re-deployable capital investment in automation and process    &#10;   capabilities; and                                                          &#10;  &#10; . our geographic, end market and product diversification. &#10;  &#10; Our diversified profile today best positions us for stability and leading market &#10; performance through all phases of an economic cycle. &#10; --- &#10;  &#10; We are a Wisconsin corporation and commenced operations in 1945. Our principal &#10; operating offices are located at 715 South Street, Mayville, Wisconsin 53050, &#10; and our phone number is (920) 387-4500. Our website address is www.mecinc.com.',\n",
       "   'useOfProceeds': 'We estimate that our net proceeds from this offering, after deducting estimated &#10; underwriting discounts and commissions and approximately $2.7 million of &#10; estimated offering expenses payable by us, will be $113.55 million, assuming an &#10; initial public offering price of $20.00 per share (the midpoint of the range set &#10; forth on the cover of this prospectus). We intend to use these net proceeds to &#10; repay our outstanding indebtedness and for general corporate purposes (which may &#10; include future acquisitions and/or setting funds aside in a deferred &#10; compensation trust to cover part or all of our deferred compensation &#10; obligations). We are continuously reviewing possible acquisitions, however, as &#10; of the date of this prospectus, we have no current plan or agreements in place &#10; with respect to any future acquisitions. &#10;  &#10; At March 31, 2019, we had total borrowings of $95.0 million outstanding under &#10; the Term Loans, $25.0 million outstanding under the Subordinated Term Loan and &#10; $66.4 million outstanding under the Revolving Loan with an average interest rate &#10; of 5.7% on outstanding borrowings. At March 31, 2019, the interest rates on our &#10; Term Loan A, Real Estate Term Loan, Subordinated Term Loan and Revolving Loan &#10; were 4.75%, 4.75%, 11.59% and 4.75%, respectively. &#10;  &#10; A $1.00 increase or decrease in the assumed initial public offering price per &#10; share of our common stock would cause our net proceeds from this offering to &#10; increase or decrease by approximately $5.81 million, assuming the number of &#10; shares of our common stock offered by us remains the same and after deducting &#10; the estimated underwriting discounts and commissions and offering expenses &#10; payable by us. Each increase or decrease of 100,000 shares in the number of &#10; shares offered by us at the assumed initial public offering price per share of &#10; our common stock would increase or decrease our net proceeds from this offering &#10; by $1.86 million after deducting the estimated underwriting discounts and &#10; commissions and offering expenses payable by us.',\n",
       "   'competition': 'We participate in a highly fragmented market with competitors in each of the end &#10; markets we serve ranging in size from small companies focused on a single &#10; capability or end market, to large multi-disciplinary companies. While there can &#10; be instances of intense competition from specific end markets, we believe that &#10; we have been able to effectively compete, and maintain competitive advantages on &#10; the basis of our: &#10;  &#10; . scale and product offering with the ability to cross-sell and provide our  &#10;   customers with a one-stop solution; &#10;  &#10; . broad manufacturing capability and flexibility to fulfill requests that &#10;   require complex solutions; &#10;  &#10; . customer service with our highly skilled and knowledgeable workforce able to &#10;   provide consultative advice; and &#10;  &#10; . regionalized geographic focus provides a defensible position from both &#10;   foreign and domestic competitors as our customers continue to take a       &#10;   regionalized approach to production, which provides a shorter supply chain &#10;   with greater flexibility.',\n",
       "   'amount': 125000000,\n",
       "   'percentOffered': '31.74'},\n",
       "  {'symbol': 'CRTX',\n",
       "   'companyName': 'CORTEXYME, INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['BofA Merrill Lynch',\n",
       "    'Credit Suisse Securities (USA) LLC'],\n",
       "   'underwriters': ['Canaccord Genuity LLC', 'JMP Securities LLC'],\n",
       "   'companyCounsel': ['Orrick, Herrington & Sutcliffe LLP'],\n",
       "   'underwriterCounsel': ['Latham & Watkins LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NASDAQ Global Select',\n",
       "   'cik': '0001662774',\n",
       "   'address': '269 EAST GRAND AVE',\n",
       "   'city': 'SOUTH SAN FRANCISCO',\n",
       "   'state': 'CA',\n",
       "   'zip': '94080',\n",
       "   'phone': '415-910-5717',\n",
       "   'ceo': 'Casey C. Lynch',\n",
       "   'employees': 19,\n",
       "   'url': 'www.cortexyme.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 4412000,\n",
       "   'priceLow': 16,\n",
       "   'priceHigh': 18,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 2113507,\n",
       "   'sharesOverAlloted': 661800,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 26013334,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -12476000,\n",
       "   'totalAssets': 72877000,\n",
       "   'totalLiabilities': 1457000,\n",
       "   'stockholderEquity': -32626000,\n",
       "   'companyDescription': 'We are a clinical stage biopharmaceutical company pioneering a novel &#10; disease-modifying therapeutic approach to treat what we believe to be a key &#10; underlying cause of Alzheimers and other degenerative diseases. Our approach is &#10; based on the seminal discovery of the presence of Porphyromonas gingivalis, or &#10; P. gingivalis, and its secreted toxic virulence factor proteases, called &#10; gingipains, in the brains of greater than 90% of more than 100 Alzheimers &#10; patients observed across multiple studies to date. Additionally, we have &#10; observed that P. gingivalis infection causes Alzheimers pathology in animal &#10; models, and these effects have been successfully treated with a gingipain &#10; inhibitor in preclinical studies. Our proprietary lead drug candidate, COR388, &#10; is an orally-administered, brain-penetrating small molecule gingipain inhibitor. &#10; COR388 was well-tolerated with no concerning safety signals in our Phase 1a and &#10; Phase 1b clinical trials conducted to date, which enrolled a total of 67 &#10; subjects, including nine patients with mild to moderate Alzheimers disease. We &#10; initiated a global Phase 2/3 clinical trial of COR388, called the GAIN trial, in &#10; mild to moderate Alzheimers patients in April 2019 and expect top-line results &#10; by the end of 2021. &#10; --- &#10;  &#10; We were incorporated in Delaware on June 20, 2012. Our principal executive &#10; offices are located at 269 East Grand Avenue, South San Francisco, CA 94080. Our &#10; telephone number at that location is (415) 910-5717. Our corporate website &#10; address is www.cortexyme.com.',\n",
       "   'businessDescription': 'We are a clinical stage biopharmaceutical company pioneering a novel &#10; disease-modifying therapeutic approach to treat what we believe to be a key &#10; underlying cause of Alzheimers and other degenerative diseases. Our approach is &#10; based on the seminal discovery of the presence of Porphyromonas gingivalis, or &#10; P. gingivalis, and its secreted toxic virulence factor proteases, called &#10; gingipains, in the brains of greater than 90% of more than 100 Alzheimers &#10; patients observed across multiple studies to date. Additionally, we have &#10; observed that P. gingivalis infection causes Alzheimers pathology in animal &#10; models, and these effects have been successfully treated with a gingipain &#10; inhibitor in preclinical studies. Our proprietary lead drug candidate, COR388, &#10; is an orally-administered, brain-penetrating small molecule gingipain inhibitor. &#10; COR388 was well-tolerated with no concerning safety signals in our Phase 1a and &#10; Phase 1b clinical trials conducted to date, which enrolled a total of 67 &#10; subjects, including nine patients with mild to moderate Alzheimers disease. We &#10; initiated a global Phase 2/3 clinical trial of COR388, called the GAIN trial, in &#10; mild to moderate Alzheimers patients in April 2019 and expect top-line results &#10; by the end of 2021. &#10;  &#10; Understanding the Foundation of Our Therapeutic Approach &#10;  &#10; P. gingivalis is an intracellular bacterial pathogen, and its gingipains are &#10; essential for P. gingivalis survival and pathogenicity. Our new understanding of &#10; the P. gingivalis brain infection and associated gingipain production, which we &#10; have observed to cause Alzheimers pathology in animal models, provides a new &#10; opportunity for successful upstream treatment of all aspects of Alzheimers &#10; disease pathology. Significant evidence in the last decade has shown that &#10; neurodegenerative diseases, including Alzheimers disease, are linked to a &#10; dysfunctional immune system. Furthermore, the pathology of Alzheimers disease &#10; has been shown in studies to be consistent with that of infection, including, &#10; for example, the pathological presence of amyloid beta, which recently has been &#10; characterized as an antimicrobial peptide produced in response to infection. &#10;  &#10; In preclinical mouse models, we and others have demonstrated that P. gingivalis &#10; is capable of accessing the brain and that its presence causes characteristic &#10; pathology observed in the brain of Alzheimers patients, including amyloid beta &#10; production, inflammation and neurodegeneration. P. gingivalis and gingipains  &#10; have been observed in the brains of greater than 90% of more than 100  &#10; Alzheimers patients across multiple studies conducted by our team both  &#10; independently and in collaboration with academic institutions. &#10;  &#10; COR388 for the Treatment of Alzheimers Disease &#10;  &#10; COR388 is the first and only selective inhibitor of gingipain activity being &#10; investigated in clinical trials for the treatment of Alzheimers disease. COR388 &#10; is designed to target an upstream driver of multiple Alzheimers pathological &#10; pathways, including amyloid beta production, inflammation and neurodegeneration, &#10; in contrast to mechanisms of action targeting downstream effects, such as &#10; amyloid plaques and tau tangles, which have been largely unsuccessful in &#10; clinical trials to date. Accordingly, we believe COR388 could represent a &#10; disease-modifying therapy for the chronic treatment of Alzheimers disease. &#10;  &#10; Our Phase 1a and Phase 1b clinical trials enrolled a total of 67 subjects, &#10; including nine patients with mild to moderate Alzheimers disease. In these &#10; placebo-controlled trials, COR388 was well-tolerated with no concerning safety &#10; signals. In the Alzheimers patients treated with COR388 for 28 days, we found &#10; changes in a number of pharmacodynamic biomarkers associated with Alzheimers &#10; disease, including RANTES, an inflammatory marker, and Apolipoprotein protein E, &#10; or ApoE, a target for gingipains. For example, fragments of ApoE in the cerebral &#10; spinal fluid, or CSF, were reduced compared to placebo, and blood levels of &#10; RANTES were significantly reduced. In addition, data from the Alzheimers &#10; patients treated with COR388 in our Phase 1b clinical trial showed improvements &#10; across several exploratory cognitive tests, such as Mean Mini-Mental State Exam, &#10; Cambridge Neuropsychological Test Automated Battery composite and Winterlight &#10; speech-based cognitive assessment. These improvements in cognitive tests should &#10; be interpreted with caution because they were not all statistically significant. &#10; We identified bacterial DNA from P. gingivalis in the CSF of all nine &#10; Alzheimers patients, and this finding is supported by additional data from &#10; larger studies conducted by our team both independently and in collaboration &#10; with academic institutions. Moreover, we observed that COR388 successfully &#10; penetrated the blood-brain barrier. In addition, in our preclinical studies, we &#10; observed that COR388 reduced bacterial load in the brain, reduced amyloid beta &#10; levels, protected neurons and reduced markers of neuroinflammation. &#10;  &#10; We believe that the development of this compound represents a new paradigm for &#10; potential disease modification in Alzheimers disease, based on our published &#10; and unpublished data, as well as a large body of third-party research. We plan &#10; to enroll approximately 570 mild to moderate Alzheimers patients in our Phase &#10; 2/3 GAIN trial, or GingipAIN inhibitor for treatment of Alzheimers disease &#10; trial, to evaluate safety and efficacy after one year of treatment as measured &#10; on key endpoints that have previously supported regulatory approval of drugs for &#10; Alzheimers disease, including the Alzheimers disease Assessment &#10; Scale-Cognitive Subscale 11, or ADAS-Cog11. We maintain rights to COR388 and &#10; hold issued U.S. patents providing composition of matter coverage through 2035 &#10; and pending U.S. and foreign patent applications, which, if issued, could extend &#10; coverage. &#10; --- &#10;  &#10; We were incorporated in Delaware on June 20, 2012. Our principal executive &#10; offices are located at 269 East Grand Avenue, South San Francisco, CA 94080. Our &#10; telephone number at that location is (415) 910-5717. Our corporate website &#10; address is www.cortexyme.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from our issuance and sale of shares of our &#10; common stock in this offering will be approximately $67.6 million, assuming an &#10; initial public offering price of $17.00 per share, which is the midpoint of the &#10; estimated price range set forth on the cover page of this prospectus, and after &#10; deducting underwriting discounts and commissions and estimated offering expenses &#10; payable by us. If the underwriters exercise in full their option to purchase &#10; additional shares, we estimate that the net proceeds from this offering will be &#10; approximately $78.1 million. &#10;  &#10; A $1.00 increase (decrease) in the assumed initial public offering price of &#10; $17.00 per share, which is the midpoint of the price range set forth on the  &#10; cover page of this prospectus, would increase (decrease) our net proceeds from &#10; this offering by approximately $4.1 million, assuming that the number of shares &#10; offered by us, as set forth on the cover page of this prospectus, remains the &#10; same, and after deducting the underwriting discounts and commissions and &#10; estimated offering expenses payable by us. We may also increase (decrease) the &#10; number of shares of common stock we are offering. An increase (decrease) of &#10; 1.0 million shares in the number of shares of common stock offered would &#10; increase (decrease) our net proceeds from this offering by approximately &#10; $15.8 million, assuming the initial public offering price remains the same, and &#10; after deducting the underwriting discounts and commissions and estimated &#10; offering expenses payable to us. &#10;  &#10; We intend to use the net proceeds from this offering to fund our global Phase &#10; 2/3 GAIN clinical trial for COR388, and to support future clinical and &#10; preclinical activities, manufacturing and development of our library of &#10; compounds, as well as for working capital and general corporate purposes, which &#10; may include the costs of operating as a public company. &#10;  &#10; We estimate that our current capital resources, along with the net proceeds from &#10; this offering, will be sufficient to fund our operating expenses and capital &#10; expenditure requirements through 2021, including through the completion and the &#10; announcement of the top-line results of our Phase 2/3 GAIN trial. However, the &#10; net proceeds from this offering, together with our current cash, will not be &#10; sufficient for us to fund the development of COR388 through regulatory approval, &#10; and we will need to raise additional capital to complete the development and &#10; commercialization of COR388. At this time, we cannot predict with certainty the &#10; amount of capital needed to complete the development and commercialization of &#10; COR388, but we anticipate seeking additional capital in the future to fund such &#10; capital needs through further equity offerings and/or debt borrowings. We cannot &#10; guarantee that we will be able to raise additional capital on reasonable terms &#10; or at all. &#10;  &#10; This expected use of the net proceeds from this offering represents our &#10; intentions based upon our current plans and business conditions. As of the date &#10; of this prospectus, we cannot predict with certainty all of the particular uses &#10; for the net proceeds to be received upon the closing of this offering or the &#10; amounts that we will actually spend on the uses set forth above. &#10;  &#10; The amounts and timing of our actual expenditures and the extent of our Phase &#10; 2/3 GAIN trial and research and development activities may vary significantly &#10; depending on numerous factors, including the progress of our development &#10; efforts, the status of and results from any preclinical or clinical trials we &#10; may commence in the future, our ability to take advantage of expedited programs &#10; or to obtain regulatory approval for any other drug candidates we may identify &#10; and pursue, the timing and costs associated with the manufacture and supply of &#10; any other drug candidates we may identify and pursue for clinical development or &#10; commercialization, and any unforeseen cash needs. As a result, our management &#10; will retain broad discretion over the allocation of the net proceeds from this &#10; offering. &#10;  &#10; We intend to invest the net proceeds in a variety of capital preservation &#10; investments, including short-term, investment-grade, interest-bearing &#10; instruments and U.S. government securities.',\n",
       "   'competition': 'We face competition from a number of different sources, including large and &#10; specialty pharmaceutical and biotechnology companies, academic research &#10; institutions, governmental agencies and public and private research &#10; institutions. We believe that the key competitive factors affecting the success &#10; of COR388 and any other drug candidates will include efficacy, safety profile, &#10; method of administration, cost, level of promotional activity and intellectual &#10; property protection. We know of no competitors developing clinical stage &#10; therapeutics targeting P. gingivalis or gingipains for the chronic treatment of &#10; Alzheimers disease. &#10;  &#10; Our drug candidates, if successfully developed and approved, will compete with &#10; current therapies approved for the treatment of Alzheimers disease, which to &#10; date have been primarily targeted at treating the symptoms of such diseases &#10; rather than halting or slowing the progression of the disease. However, in &#10; addition to such currently approved therapies, we believe that our drug &#10; candidates, if approved, may also compete with other potential therapies &#10; intended to halt or slow the progression of neurodegenerative disease that are &#10; being developed by a number of companies and institutions, including but not &#10; limited to potentially disease modifying therapeutics that are being developed &#10; by several large and specialty pharmaceutical and biotechnology companies, &#10; including AbbVie Inc., Biogen Inc., Celgene Corporation, Eli Lilly and Company, &#10; Eisai Co., Ltd., Merck & Company, Inc., Novartis AG and Roche Holding AG &#10; (including Genentech, its wholly owned subsidiary), as well as companies &#10; pursuing a dysfunctional immune system approach to Alzheimers disease or other &#10; types of therapies.',\n",
       "   'amount': 75004000,\n",
       "   'percentOffered': '16.96'},\n",
       "  {'symbol': 'AXLA',\n",
       "   'companyName': 'AXCELLA HEALTH INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Goldman Sachs & Co. LLC',\n",
       "    'J.P. Morgan Securities LLC',\n",
       "    'SVB Leerink LLC'],\n",
       "   'underwriters': [],\n",
       "   'companyCounsel': ['Goodwin Procter LLP'],\n",
       "   'underwriterCounsel': ['Latham & Watkins LLP'],\n",
       "   'auditor': 'Computershare Trust Company, N.A',\n",
       "   'market': 'NASDAQ Global',\n",
       "   'cik': '0001633070',\n",
       "   'address': '840 MEMORIAL DRIVE',\n",
       "   'city': 'CAMBRIDGE',\n",
       "   'state': 'MA',\n",
       "   'zip': '02139',\n",
       "   'phone': '617-868-0949',\n",
       "   'ceo': 'William Hinshaw',\n",
       "   'employees': 49,\n",
       "   'url': 'www.axcellahealth.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 3571428,\n",
       "   'priceLow': 20,\n",
       "   'priceHigh': 22,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 1940000,\n",
       "   'sharesOverAlloted': 535714,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 22988359,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -36069000,\n",
       "   'totalAssets': 81844000,\n",
       "   'totalLiabilities': 33755000,\n",
       "   'stockholderEquity': -149753000,\n",
       "   'companyDescription': 'We are a biotechnology company pioneering the research and development of novel &#10; multifactorial interventions to support health and address dysregulated  &#10; metabolism across a broad spectrum of consumers and patients who have limited &#10; options. Our AXA Candidates are generated from our proprietary, human-focused &#10; AXA Development Platform and harness the power of endogenous metabolic &#10; modulators, or EMMs, a broad family of molecules that fundamentally impact and &#10; regulate human metabolism. &#10; --- &#10;  &#10; We were incorporated in August 2008 under the laws of the state of Delaware  &#10; under the name Newco LS16, Inc. Our name was changed to Axcella Health Inc. in &#10; June 2016. Our principal executive offices are located at 840 Memorial Drive, &#10; Cambridge, MA 02139, and our phone number is (857) 320-2200. Our website address &#10; is www.axcellahealth.com.',\n",
       "   'businessDescription': 'We are a biotechnology company pioneering the research and development of novel &#10; multifactorial interventions to support health and address dysregulated  &#10; metabolism across a broad spectrum of consumers and patients who have limited &#10; options. Our AXA Candidates are generated from our proprietary, human-focused &#10; AXA Development Platform and harness the power of endogenous metabolic &#10; modulators, or EMMs, a broad family of molecules that fundamentally impact and &#10; regulate human metabolism. &#10;  &#10; Using our AXA Development Platform, we have rapidly generated a pipeline of AXA &#10; Candidates that are novel compositions of EMMs engineered in distinct ratios and &#10; designed to target and maximize the fundamental role that EMMs play in  &#10; regulating multiple metabolic functions. Our AXA Candidates are administered &#10; orally and anchored by amino acids, which have a history of safe use as food. As &#10; such, we expect our AXA Candidates may also be combinable with other modalities. &#10; We believe our current dataset supports the potential of our AXA Candidates to &#10; safely modulate the metabolic pathways they target. These features may make them &#10; an attractive development opportunity with significant commercial potential. &#10;  &#10; In 2018, we completed three Non-IND, IRB-Approved Clinical Studies. In all three &#10; studies, our AXA Candidates were generally found to be well tolerated, and we  &#10; generated positive normal structure and function data indicating potential  &#10; metabolic modulation. We believe generating this rich human dataset at this &#10; early stage of development (i) eliminates the translational uncertainty &#10; associated with transitioning from animal studies to human studies, (ii) enables &#10; us to make high-insight, capital-efficient development decisions and  &#10; (iii) potentially increases the probability of success for these AXA Candidates. &#10; For AXA Candidates we decide to develop under an IND, we will discuss with the  &#10; FDA our ability to use data generated from our Non-IND, IRB-Approved Clinical  &#10; Studies to begin Phase II or potential registrational Clinical Trials. &#10;  &#10; On March 6, 2019, we had a face-to-face pre-IND meeting with the FDA for  &#10; AXA1665, our lead AXA Candidate, during which we discussed clinical endpoints, &#10; assessment tools and other matters relating to a potential IND-opening Clinical &#10; Trial for AXA1665 in hepatic encephalopathy, or HE. After meeting with the FDA, &#10; we made a decision to pursue a drug development path for AXA1665. Under the &#10; planned IND, the initial indication would be for the treatment of HE, with time &#10; to breakthrough episode of overt HE event as the primary endpoint and key &#10; secondary muscle-related endpoints. We anticipate interacting with the FDA again &#10; prior to a formal IND submission for AXA1665. We anticipate initiating a &#10; Clinical Trial in the second half of 2020 for AXA1665 that we believe could &#10; potentially serve as a registrational (pivotal) trial to support the submission &#10; of a New Drug Application, or NDA. &#10; --- &#10;  &#10; We were founded in 2008 by Flagship Labs, the institutional innovation foundry  &#10; of Flagship Pioneering. A team comprising innovators and entrepreneurs Dr. David &#10; Berry, Dr. Geoffrey von Maltzahn and Dr. Noubar Afeyan started exploring the  &#10; potential medical applications of diverse, orally-consumed proteins. The work &#10; of this team led to the understanding that specific amino acid combinations at  &#10; different ratios have the potential to drive profound biological effects in both &#10; health and disease by impactingdysregulated metabolic pathways and  &#10; multi-compartmental biology. With this transformational new approach, we are  &#10; harnessing the potential for orally-administered EMM compositions to drive  &#10; cellularbiology in a specific and reproducible manner with the goal of  &#10; delivering safe interventions for patients or consumers.  &#10; --- &#10;  &#10; We were incorporated in August 2008 under the laws of the state of Delaware  &#10; under the name Newco LS16, Inc. Our name was changed to Axcella Health Inc. in &#10; June 2016. Our principal executive offices are located at 840 Memorial Drive, &#10; Cambridge, MA 02139, and our phone number is (857) 320-2200. Our website address &#10; is www.axcellahealth.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds to us from the sale of the shares of our &#10; common stock in this offering will be approximately $66.6 million, or &#10; approximately $77.1 million if the underwriters exercise their option to &#10; purchase additional shares in full, based upon an assumed initial public &#10; offering price of $21.00 per share, the midpoint of the price range set forth on &#10; the cover page of this prospectus, after deducting estimated underwriting &#10; discounts and commissions and estimated offering expenses payable by us. &#10;  &#10; A $1.00 increase (decrease) in the assumed initial public offering price of  &#10; $21.00 per share, the midpoint of the price range set forth on the cover page of &#10; this prospectus, would increase (decrease) the net proceeds to us from this &#10; offering by approximately $3.3 million, assuming the number of shares offered by &#10; us, as set forth on the cover page of this prospectus, remains the same. &#10; Similarly, an increase (decrease) of 1,000,000 shares in the number of shares &#10; offered by us would increase (decrease) the net proceeds to us from this &#10; offering by approximately $19.5 million, assuming that the assumed initial &#10; public offering price remains the same. We do not expect that a change in the &#10; initial public offering price or the number of shares by these amounts would &#10; have a material effect on our uses of the proceeds from this offering, although &#10; it may accelerate the time at which we will need to seek additional capital. &#10;  &#10; We currently expect to use the net proceeds from this offering, together with &#10; our cash and cash equivalents as of March 31, 2019, as follows: &#10;  &#10;  approximately $90.0 million to advance our current liver (AXA1665, AXA1125 and &#10;   AXA1957) and other programs, including through additional Non-IND,  &#10;   IRB-Approved Clinical Studies, potential IND filing(s) and the ensuing &#10;   Clinical Trials, including our planned IND filing and Clinical Trial for &#10;   AXA1665, and infrastructure to support our pipeline; &#10;  &#10;  approximately $30.0 million to advance our AXA Development Platform discovery &#10;   efforts, intellectual property and associated infrastructure; and &#10;   &#10;  the remainder, if any, for working capital and other general corporate  &#10;   purposes. &#10;  &#10; As of March 31, 2019, we had $66.7 million of cash and cash equivalents on hand, &#10; based on preliminary unaudited information and management estimates for the  &#10; three months ended March 31, 2019. Based on our current plans, we believe our  &#10; cash and cash equivalents as of March 31, 2019, together with the net proceeds &#10; from this offering, will be sufficient to fund our operating expenses and  &#10; capital expenditure requirements through the second quarter of 2021. With our &#10; cash and cash equivalents as of March 31, 2019 and the net proceeds of this  &#10; offering, we expect to be able to complete ongoing and planned Non-IND &#10; IRB-Approved Clinical Studies numbered AXA1665-002, AXA1125-003, AXA1957-002 and &#10; AXA4010-001; and file an IND for a Phase IIb/III AXA1665 Clinical Trial in HE, &#10; including if it is a registrational study. We have based these estimates on &#10; assumptions that may prove to be incorrect, and we could use our available &#10; capital resources sooner than we currently expect. In any event, we will require &#10; additional funding to be able to complete any Clinical Trial in HE, and we do &#10; not yet have any committed source of funding for this Clinical Trial. We may &#10; satisfy our future cash needs through the sale of equity securities, debt &#10; financings, working capital lines of credit, corporate collaborations or license &#10; agreements, grant funding, interest income earned on invested cash balances, or &#10; a combination of one or more of these sources. &#10;  &#10; We cannot specify with certainty all of the particular uses for the net proceeds &#10; to be received upon the completion of this offering. Due to uncertainties  &#10; inherent in the development process, it is difficult to estimate the exact &#10; amounts of the net proceeds that will be used for any particular purpose. We may &#10; use our existing cash, cash equivalents and the future payments, if any,  &#10; generated from any future collaboration agreements to fund our operations, &#10; either of which may alter the amount of net proceeds used for a particular &#10; purpose. In addition, the amount, allocation and timing of our actual  &#10; expenditures will depend upon numerous factors, including the results of our &#10; research and development efforts, the timing and success of our Non-IND,  &#10; IRB-Approved Clinical Studies and Clinical Trials and the timing of regulatory &#10; submissions. Accordingly, we will have broad discretion in using these proceeds. &#10;  &#10; Pending their uses, we plan to invest the net proceeds of this offering in &#10; short-term, interest-bearing, investment-grade instruments, certificates of &#10; deposit or direct or guaranteed obligations of the U.S. government.',\n",
       "   'competition': 'The biotechnology and pharmaceutical industries utilize rapidly advancing &#10; technologies and are characterized by intense competition. There is also a &#10; strong emphasis on intellectual property and proprietary products. &#10;  &#10; We believe that our pioneering research in establishing EMM compositions for &#10; drug or non-drug pathways such as non-drug products, coupled with our  &#10; capabilities across our AXA Candidate platform technology, product design, &#10; development pathway and manufacturing provide us with a competitive advantage. &#10; However, we will continue to face competition from different sources, including &#10; major pharmaceutical companies, biotechnology companies, consumer health product &#10; companies, academic institutions, government agencies, public and private &#10; research institutions, consumer nutritional supplement or conventional consumer &#10; health manufacturers and manufacturers of amino acids and other EMMs. For any &#10; products that we eventually commercialize, we will not only compete with &#10; existing products but also with new products that may become available in the &#10; future, such as microbiome products. &#10;  &#10; We compete in the consumer health, pharmaceutical and biotechnology industries. &#10; There are additional companies that are working on modulating specific metabolic &#10; pathways involved in various health and disease conditions, although we are not &#10; aware of any company creating AXA Candidate-like products with multifactorial &#10; activity. Companies with clinical programs that could compete with our AXA  &#10; Candidates include Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals,  &#10; Inc., Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Co., Esperion  &#10; Therapeutics, Inc., Viking Therapeutics, Inc., Scholar Rock Holding Corporation, &#10; NGM Biopharmaceuticals Inc., Genfit SA and Kaleido Biosciences, Inc., among  &#10; others. &#10;  &#10; Finally, we anticipate competing with the largest consumer health companies and &#10; nutritional pharmaceutical and amino acid companies in the world, such as Nestl &#10; Health Science S.A., Abbott Laboratories, Johnson & Johnson, The Procter &  &#10; Gamble Company, and Ajinomoto Co., Inc., all of which are currently conducting &#10; research in competitive indications or may be interested in using amino acids  &#10; and other EMMs as drugs or nutritional supplements.',\n",
       "   'amount': 74999988,\n",
       "   'percentOffered': '15.54'},\n",
       "  {'symbol': 'MIST',\n",
       "   'companyName': 'MILESTONE PHARMACEUTICALS INC.',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Cowen and Company, LLC',\n",
       "    'Jefferies LLC',\n",
       "    'Piper Jaffray & Co.'],\n",
       "   'underwriters': ['Oppenheimer & Co. Inc.'],\n",
       "   'companyCounsel': ['Cooley LLP'],\n",
       "   'underwriterCounsel': ['Wilmer Cutler Pickering Hale and Dorr LLP'],\n",
       "   'auditor': 'Computer Share Investor Services, Inc',\n",
       "   'market': 'NASDAQ Global',\n",
       "   'cik': '0001408443',\n",
       "   'address': '1111 DR. FREDERIK-PHILIPS BLVD',\n",
       "   'city': 'MONTREAL H4M 2X6',\n",
       "   'state': '',\n",
       "   'zip': '',\n",
       "   'phone': '(514) 336-0444',\n",
       "   'ceo': 'Joseph Oliveto',\n",
       "   'employees': 23,\n",
       "   'url': 'www.milestonepharma.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 5000000,\n",
       "   'priceLow': 14,\n",
       "   'priceHigh': 16,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 2700000,\n",
       "   'sharesOverAlloted': 750000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 23147589,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -23185000,\n",
       "   'totalAssets': 88081000,\n",
       "   'totalLiabilities': 4533000,\n",
       "   'stockholderEquity': -55210000,\n",
       "   'companyDescription': \"We are a Phase 3 clinical-stage biopharmaceutical company dedicated to &#10; developing and commercializing etripamil for the treatment of cardiovascular &#10; indications. Etripamil is a novel, potent and short-acting calcium channel &#10; blocker that we designed and are developing as a rapid-onset nasal spray to be &#10; administered by the patient to terminate episodes of paroxysmal supraventricular &#10; tachycardia, or PSVT, as they occur. PSVT is a rapid heart rate condition that &#10; starts and stops without warning, often experienced by patients with symptoms &#10; including palpitations, sweating, chest pressure or pain, shortness of breath, &#10; sudden onset of fatigue, lightheadedness or dizziness, fainting and anxiety. &#10; Calcium channel blockers have long been approved for the treatment of PSVT as &#10; well as other cardiac conditions. For episodes of PSVT, however, calcium channel &#10; blockers are administered intravenously under medical supervision, usually in &#10; the emergency department. Etripamil's combination of convenient delivery, rapid &#10; onset and short duration of action has the potential to shift the current &#10; treatment paradigm away from the burdensome and costly emergency department &#10; setting. If approved, we believe that etripamil will be the first &#10; self-administered therapy for the rapid termination of episodes of PSVT wherever &#10; and whenever they occur. &#10; --- &#10;  &#10; We were incorporated under the laws of the province of Qubec in 2003. Our &#10; principal executive offices are located at 1111 Dr. Frederik-Philips Blvd., &#10; Suite 420, Montral, Qubec, Canada H4M 2X6, and our telephone number is &#10; (514) 336-0444. In January 2017, we incorporated our wholly owned subsidiary, &#10; Milestone Pharmaceuticals USA, Inc., a Delaware corporation. Our corporate &#10; website address is www.milestonepharma.com.\",\n",
       "   'businessDescription': \"We are a Phase 3 clinical-stage biopharmaceutical company dedicated to &#10; developing and commercializing etripamil for the treatment of cardiovascular &#10; indications. Etripamil is a novel, potent and short-acting calcium channel &#10; blocker that we designed and are developing as a rapid-onset nasal spray to be &#10; administered by the patient to terminate episodes of paroxysmal supraventricular &#10; tachycardia, or PSVT, as they occur. PSVT is a rapid heart rate condition that &#10; starts and stops without warning, often experienced by patients with symptoms &#10; including palpitations, sweating, chest pressure or pain, shortness of breath, &#10; sudden onset of fatigue, lightheadedness or dizziness, fainting and anxiety. &#10; Calcium channel blockers have long been approved for the treatment of PSVT as &#10; well as other cardiac conditions. For episodes of PSVT, however, calcium channel &#10; blockers are administered intravenously under medical supervision, usually in &#10; the emergency department. Etripamil's combination of convenient delivery, rapid &#10; onset and short duration of action has the potential to shift the current &#10; treatment paradigm away from the burdensome and costly emergency department &#10; setting. If approved, we believe that etripamil will be the first &#10; self-administered therapy for the rapid termination of episodes of PSVT wherever &#10; and whenever they occur. &#10;  &#10; We completed our Phase 2 clinical trial of etripamil for the treatment of PSVT &#10; in the United States and Canada, with results published in the Journal of the &#10; American College of Cardiology. Investigators reported an 87% termination rate &#10; of PSVT within 15 minutes at the dose selected for Phase 3 versus a 35% &#10; termination rate for placebo. We are actively recruiting patients for a Phase 3 &#10; clinical trial of etripamil, which may serve as a single pivotal efficacy trial, &#10; and we expect top-line data in the first half of 2020. In addition to the &#10; efficacy trial, our Phase 3 clinical program for etripamil for PSVT includes two &#10; open-label safety studies, one of which we initiated in December 2018, and the &#10; other we expect to initiate in the second half of 2019. We are also planning to &#10; initiate a Phase 2 clinical trial in the second half of 2019 in atrial &#10; fibrillation, another rapid heart rate condition, and expect to subsequently &#10; initiate an additional Phase 2 clinical trial in angina to establish &#10; proof-of-concept for the broader use of etripamil in 2020. &#10; --- &#10;  &#10; We were incorporated under the laws of the province of Qubec in 2003. Our &#10; principal executive offices are located at 1111 Dr. Frederik-Philips Blvd., &#10; Suite 420, Montral, Qubec, Canada H4M 2X6, and our telephone number is &#10; (514) 336-0444. In January 2017, we incorporated our wholly owned subsidiary, &#10; Milestone Pharmaceuticals USA, Inc., a Delaware corporation. Our corporate &#10; website address is www.milestonepharma.com.\",\n",
       "   'useOfProceeds': 'We estimate that the net proceeds to us from this offering will be approximately &#10; $67.0 million (or approximately $77.5 million if the underwriters exercise in &#10; full their option to purchase up to 750,000 additional common shares), based on &#10; an assumed initial public offering price of $15.00 per share, the midpoint of &#10; the price range set forth on the cover page of this prospectus, after deducting &#10; estimated underwriting discounts and commissions and estimated offering expenses &#10; payable by us. &#10;  &#10; Each $1.00 increase or decrease in the assumed initial public offering price of &#10; $15.00 per share, the midpoint of the price range set forth on the cover page of &#10; this prospectus, would increase or decrease the net proceeds to us from this &#10; offering by $4.7 million, assuming that the number of common shares offered by &#10; us, as set forth on the cover page of this prospectus, remains the same and &#10; after deducting the estimated underwriting discounts and commissions and &#10; estimated offering expenses payable by us. Similarly, each increase or decrease &#10; of 1.0 million in the number of common shares offered by us, as set forth on the &#10; cover of this prospectus, would increase or decrease the net proceeds to us by &#10; $14.0 million, assuming the assumed initial public offering price per share &#10; remains the same and after deducting the estimated underwriting discounts and &#10; commissions and estimated offering expenses payable by us. &#10;  &#10; The principal purposes of this offering are to increase our capitalization and &#10; financial flexibility, establish a public market for our common shares and to &#10; facilitate future access to the public equity markets by us, our employees and &#10; our shareholders, obtain additional capital to support our operations and &#10; increase our visibility in the marketplace. &#10;  &#10; As of December 31, 2018, we had cash, cash equivalents and short-term &#10; investments of $86.0 million. We currently intend to use the net proceeds from &#10; this offering, together with our existing cash, cash equivalents and short-term &#10; investments, as follows: &#10;  &#10; . approximately $85.0 million for our Phase 3 clinical trials of etripamil in &#10;   PSVT; &#10;  &#10; . approximately $20.0 million for pre-commercialization activities; &#10;  &#10; . approximately $6.0 million for our Phase 2 clinical trials of etripamil in &#10;   atrial fibrillation and angina; and &#10;  &#10; . the remainder to fund other research and development activities, working &#10;   capital and other general corporate purposes. &#10;  &#10; We may also use a portion of the remaining net proceeds to in-license, acquire &#10; or invest in complementary businesses, technologies, products or assets. &#10; However, we have no current commitments or obligations to do so. &#10;  &#10; This expected use of the net proceeds from this offering represents our &#10; intentions based on our current plans and business conditions, which could &#10; change in the future as our plans and business conditions evolve. Further, due &#10; to the uncertainties inherent in the drug development process, it is difficult &#10; to estimate with certainty the exact amounts of the net proceeds from this &#10; offering that may be used for the above purposes. &#10;  &#10; Our management will have broad discretion over the use of the net proceeds from &#10; this offering, and our investors will be relying on the judgment of our &#10; management regarding the application of the net proceeds of this offering. The &#10; amounts and timing of our expenditures will depend upon numerous factors &#10; including the results of our research and development efforts, the timing and &#10; success of preclinical studies and any ongoing clinical trials or clinical &#10; trials we may commence in the future, the timing of regulatory submissions and &#10; the amount of cash obtained through current and any future collaborations. &#10;  &#10; While we anticipate that the amount of funds allocated for the Phase 3 clinical &#10; trials of PSVT will be sufficient to complete the Phase 3 clinical trials as &#10; currently planned, we expect that we will need to raise additional funds to &#10; complete the regulatory approval and commercialization of etripamil for PSVT. We &#10; also anticipate that the amount of funds allocated for the planned Phase 2 &#10; clinical trials of etripamil in atrial fibrillation and angina will be  &#10; sufficient to complete such trials. However, we expect that we will need to &#10; raise additional capital to continue the clinical development, regulatory  &#10; approval and commercialization of etripamil in these or any other indications, &#10; or to pursue the development and commercialization of any other product  &#10; candidates. We expect to finance our cash needs through a combination of equity &#10; offerings, debt financings and potential collaborations, and license and  &#10; development agreements. We have based these estimates on assumptions that may &#10; prove to be incorrect, and we could expend our available capital resources at a &#10; rate greater than we currently expect. &#10;  &#10; Pending the use of the net proceeds from this offering as described above, we &#10; intend to invest the net proceeds in a variety of capital preservation &#10; instruments, including short-term, interest-bearing obligations, &#10; investment-grade instruments, certificates of deposit or direct or guaranteed &#10; obligations of the U.S. and Canadian governments.',\n",
       "   'competition': 'Drug development is highly competitive and subject to rapid and significant &#10; technological advancements. Our ability to compete will significantly depend &#10; upon our ability to complete necessary clinical trials and regulatory approval &#10; processes, and effectively market any drug that we may successfully develop. Our &#10; current and potential future competitors include pharmaceutical and &#10; biotechnology companies, academic institutions and government agencies. The &#10; primary competitive factors that will affect the commercial success of etripamil &#10; or any other product candidate for which we may receive marketing approval &#10; include efficacy, safety, tolerability, dosing convenience, price, coverage and &#10; reimbursement. Many of our existing or potential competitors have substantially &#10; greater financial, technical and human resources than we do and significantly &#10; greater experience in the discovery and development of product candidates, as &#10; well as in obtaining regulatory approvals of those product candidates in the &#10; United States and in foreign countries. &#10;  &#10; Our current and potential future competitors may also have significantly more &#10; experience commercializing drugs that have been approved for marketing. Mergers &#10; and acquisitions in the pharmaceutical and biotechnology industries could result &#10; in even more resources being concentrated among a small number of our &#10; competitors. &#10;  &#10; Accordingly, our competitors may be more successful than us in obtaining &#10; regulatory approval for therapies and in achieving widespread market acceptance &#10; of their drugs. It is also possible that a competitor may develop a cure or more &#10; effective treatment method for the diseases we are targeting, which could render &#10; our current or future product candidates non-competitive or obsolete, or reduce &#10; the demand for our product candidates before we can recover our development and &#10; commercialization expenses. &#10;  &#10; We are not aware of any approved drug or drug in clinical development for a &#10; patient self-administered treatment to terminate PSVT episodes. InCarda &#10; Therapeutics, Inc., or InCarda, is developing InRhythm, an inhaled version of &#10; flecainide, in preclinical development. To our knowledge, there are no other &#10; treatments in development for acute episodic treatment of PSVT. In the acute &#10; setting, IV treatments of generic drugs such as adenosine, verapamil and &#10; diltiazem, are routinely given. Additionally, some practitioners prescribe oral &#10; medications, such as calcium channel blockers, beta blockers and &#10; anti-arrhythmics to be taken at the onset of an episode. However, these &#10; interventions are not acutely effective. &#10;  &#10; For atrial fibrillation, there are a number of marketed generic anti-arrhythmic &#10; drugs that are used for chronic and/or acute rate control, such as metoprolol, &#10; propranolol, esmolol, pindolol, atenolol, nadolol, verapamil and diltiazem. &#10; There are also several drugs under development for atrial fibrillation, &#10; including: Ranexa (ranolazine), a sodium channel blocker in Phase 2 (ex-U.S.) &#10; from Gilead Sciences, Inc., or Gilead; Gencaro (bucindolol hydrochloride), a &#10; beta blocker in Phase 2 from ARCA biopharma, Inc.. &#10;  &#10; For acute relief of angina symptoms, approved drugs include short-acting &#10; nitrates such as nitroglycerin, isosorbide dinitrate, and pentaerythritol. We &#10; are not aware of any approved drug or drug in clinical development for &#10; rapid-onset, short-acting treatment for coronary spasm.',\n",
       "   'amount': 75000000,\n",
       "   'percentOffered': '21.60'},\n",
       "  {'symbol': 'DEACU',\n",
       "   'companyName': 'DIAMOND EAGLE ACQUISITION CORP. \\\\ DE',\n",
       "   'expectedDate': '2019-05-09',\n",
       "   'leadUnderwriters': ['Deutsche Bank Securities Inc.',\n",
       "    'Goldman Sachs & Co. LLC'],\n",
       "   'underwriters': ['Northland Securities, Inc'],\n",
       "   'companyCounsel': ['Winston & Strawn LLP'],\n",
       "   'underwriterCounsel': ['Skadden, Arps, Slate, Meagher & Flom LLP'],\n",
       "   'auditor': 'Continental Stock Transfer & Trust Company',\n",
       "   'market': 'NASDAQ Capital',\n",
       "   'cik': '0001772757',\n",
       "   'address': '2121 AVENUE OF THE STARS',\n",
       "   'city': 'LOS ANGELES',\n",
       "   'state': 'CA',\n",
       "   'zip': '90067',\n",
       "   'phone': '310-209-7280',\n",
       "   'ceo': 'Jeff Sagansky',\n",
       "   'employees': 2,\n",
       "   'url': '',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 35000000,\n",
       "   'priceLow': 10,\n",
       "   'priceHigh': None,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 750000,\n",
       "   'sharesOverAlloted': 5250000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 43750000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -675,\n",
       "   'totalAssets': 26733,\n",
       "   'totalLiabilities': 2408,\n",
       "   'stockholderEquity': 24325,\n",
       "   'companyDescription': 'We are a blank check company whose business purpose is to effect a merger, &#10; capital stock exchange, asset acquisition, stock purchase, reorganization or &#10; similar business combination with one or more businesses, which we refer to &#10; throughout this prospectus as our initial business combination. We have not &#10; selected any specific business combination target and we have not, nor has &#10; anyone on our behalf, engaged in any substantive discussions, directly or &#10; indirectly, with any business combination target with respect to an initial &#10; business combination with us. &#10;  &#10; Our efforts to identify a prospective initial business combination target will &#10; not be limited to a particular industry, sector or geographic region. While we &#10; may pursue an initial business combination opportunity in any industry or &#10; sector, we intend to capitalize on the ability of our management team to &#10; identify, acquire and operate a business or businesses that can benefit from our &#10; management teams established global relationships and operating experience. Our &#10; management team has extensive experience in identifying and executing strategic &#10; investments globally and has done so successfully in a number of sectors, &#10; including media and entertainment. Our amended and restated certificate of &#10; incorporation prohibits us from effectuating a business combination with another &#10; blank check company or similar company with nominal operations. &#10; --- &#10;  &#10; Our executive offices are located at 2121 Avenue of the Stars, Suite 2300, Los &#10; Angeles, CA 90067, and our telephone number is (310) 209-7280.',\n",
       "   'businessDescription': 'We are a blank check company whose business purpose is to effect a merger, &#10; capital stock exchange, asset acquisition, stock purchase, reorganization or &#10; similar business combination with one or more businesses, which we refer to &#10; throughout this prospectus as our initial business combination. We have not &#10; selected any specific business combination target and we have not, nor has &#10; anyone on our behalf, engaged in any substantive discussions, directly or &#10; indirectly, with any business combination target with respect to an initial &#10; business combination with us. &#10;  &#10; Our efforts to identify a prospective initial business combination target will &#10; not be limited to a particular industry, sector or geographic region. While we &#10; may pursue an initial business combination opportunity in any industry or &#10; sector, we intend to capitalize on the ability of our management team to &#10; identify, acquire and operate a business or businesses that can benefit from our &#10; management teams established global relationships and operating experience. Our &#10; management team has extensive experience in identifying and executing strategic &#10; investments globally and has done so successfully in a number of sectors, &#10; including media and entertainment. Our amended and restated certificate of &#10; incorporation prohibits us from effectuating a business combination with another &#10; blank check company or similar company with nominal operations. &#10; --- &#10;  &#10; Our executive offices are located at 2121 Avenue of the Stars, Suite 2300, Los &#10; Angeles, CA 90067, and our telephone number is (310) 209-7280.',\n",
       "   'useOfProceeds': 'We are offering 35,000,000 units at an offering price of  $10.00 per unit. We &#10; estimate that the net proceeds of this offering together with the funds we will &#10; receive from the sale of the private placement warrants will be used as set &#10; forth in the following table. &#10;  &#10;                                                                                          Without           Over-allotment    &#10;                                                                                      Over-allotment            Option        &#10;                                                                                          Option               Exercised       &#10; Gross proceeds                                                                                                                &#10; Gross proceeds from units offered to public(1)                                        $ 350,000,000         $ 402,500,000     &#10; Gross proceeds from private placement warrants offered in the private placement           8,500,000             9,550,000     &#10; Total gross proceeds                                                                  $ 358,500,000         $ 412,050,000     &#10; Estimated offering expenses(2)                                                                                                &#10; Underwriting commissions (2.0% of gross proceeds from units offered to                                                       &#10; public, excluding deferred portion)(3)                                                $   7,000,000         $   8,050,000     &#10; Legal fees and expenses                                                                     300,000               300,000     &#10; Printing and engraving expenses                                                              40,000                40,000     &#10; Accounting fees and expenses                                                                 40,000                40,000     &#10; SEC/FINRA Expenses                                                                          110,000               110,000     &#10; Travel and road show                                                                         50,000                50,000     &#10; Nasdaq listing and filing fees                                                               75,000                75,000     &#10; Directors and officers insurance                                                            100,000               100,000     &#10; Miscellaneous                                                                                35,000                35,000     &#10; Total offering expenses (other than underwriting commissions)                         $     750,000         $     750,000     &#10; Proceeds after estimated offering expenses                                            $ 350,750,000         $ 403,250,000     &#10; Held in trust account(3)                                                              $ 350,000,000         $ 402,500,000     &#10; % of public offering size                                                                      100%                  100%     &#10; Not held in trust account                                                             $     750,000         $     750,000     &#10;   &#10; The following table shows the use of the approximately $750,000 of net proceeds &#10; not held in the trust account(4) &#10;  &#10;                                                                                                                     Amount          % of Total     &#10; Legal, accounting, due diligence, travel, and other expenses in connection with any business combination(5)          200,000             26.7%     &#10; Legal and accounting fees related to regulatory reporting obligations                                                 50,000              6.7%     &#10; Nasdaq and other regulatory fees                                                                                      75,000             10.0%     &#10; Payment for office space, secretarial and administrative services                                                    360,000             48.0%     &#10; Consulting, travel and miscellaneous expenses incurred during search for initial business combination target          50,000              6.7%     &#10; Working capital to cover miscellaneous expenses                                                                       15,000              2.0%     &#10; Total                                                                                                              $ 750,000            100.0%     &#10;                                                                                                                                                    &#10; (1) Includes amounts payable to public stockholders who properly redeem their  &#10;     shares in connection with our successful completion of our initial business &#10;     combination. &#10;   &#10; (2) A portion of the offering expenses have been paid from the proceeds of loans &#10;     from our sponsor of up to $300,000 as described in this prospectus. These  &#10;     loans will be repaid upon completion of this offering out of the $750,000 of &#10;     offering proceeds that has been allocated for the payment of offering  &#10;     expenses other than underwriting commissions. In the event that offering  &#10;     expenses are less than set forth in this table, any such amounts will be  &#10;     used for post-closing working capital expenses. &#10;   &#10; (3) The underwriters have agreed to defer underwriting commissions of 3.5% of  &#10;     the gross proceeds of this offering. Upon and concurrently with the  &#10;     completion of our initial business combination, up to $12,250,000, which  &#10;     constitutes the underwriters deferred commissions (or up to $14,087,500 if &#10;     the underwriters over-allotment option is exercised in full) will be paid  &#10;     to the underwriters from the funds held in the trust account. The remaining &#10;     funds, less amounts released to the trustee to pay redeeming stockholders,  &#10;     will be released to us and can be used to pay all or a portion of the  &#10;     purchase price of the business or businesses with which our initial business &#10;     combination occurs or for general corporate purposes, including payment of &#10;     principal or interest on indebtedness incurred in connection with our  &#10;     initial business combination, to fund the purchases of other companies or  &#10;     for working capital. The underwriters will not be entitled to any interest  &#10;     accrued on the deferred underwriting discounts and commissions. &#10;   &#10; (4) These expenses are estimates only. Our actual expenditures for some or all  &#10;     of these items may differ from the estimates set forth herein. For example, &#10;     we may incur greater legal and accounting expenses than our current  &#10;     estimates in connection with negotiating and structuring our initial  &#10;     business combination based upon the level of complexity of such business  &#10;     combination. In the event we identify a business combination target in a  &#10;     specific industry subject to specific regulations, we may incur additional &#10;     expenses associated with legal due diligence and the engagement of special &#10;     legal counsel. In addition, our staffing needs may vary and as a result, we &#10;     may engage a number of consultants to assist with legal and financial due &#10;     diligence. We do not anticipate any change in our intended use of proceeds, &#10;     other than fluctuations among the current categories of allocated expenses, &#10;     which fluctuations, to the extent they exceed current estimates for any  &#10;     specific category of expenses, would not be available for our expenses. The &#10;     amount in the table above does not include interest available to us from the &#10;     trust account. The proceeds held in the trust account will be invested only &#10;     in U.S. government treasury obligations with a maturity of 185 days or less &#10;     or in money market funds meeting certain conditions under Rule 2a-7 under  &#10;     the Investment Company Act which invest only in direct U.S. government  &#10;     treasury obligations. We estimate the interest earned on the trust account &#10;     will be approximately $5,250,000 per year, assuming an interest rate of &#10;     1.5% per year; however, we can provide no assurances regarding this amount. &#10;   &#10; (5) Includes estimated amounts that may also be used in connection with our  &#10;     initial business combination to fund a no shop provision and commitment &#10;     fees for financing. &#10;   &#10; Nasdaq rules provide that at least 90% of the gross proceeds from this offering &#10; and the sale of the private placement warrants be deposited in a trust account. &#10; Of the $358.5 million in gross proceeds we receive from this offering and the &#10; sale of the private placement warrants described in this prospectus, or &#10; $412.05 million if the underwriters over-allotment option is exercised in full, &#10; $350 million ($10.00 per unit), or $402.5 million if the underwriters &#10; over-allotment option is exercised in full ($10.00 per unit), will be deposited &#10; into a trust account with Continental Stock Transfer & Trust Company acting as &#10; trustee, after deducting $7 million in underwriting discounts and commissions &#10; payable upon the closing of this offering (or $8.05 million if the underwriters &#10; over-allotment option is exercised in full) and an aggregate of $1.5 million to &#10; pay expenses in connection with the closing of this offering and for working &#10; capital following this offering. The proceeds held in the trust account will be &#10; invested only in U.S. government treasury bills with a maturity of 185 days or &#10; less or in money market funds meeting certain conditions under Rule 2a-7 under &#10; the Investment Company Act which invest only in direct U.S. government treasury &#10; obligations. We estimate the interest earned on the trust account will be &#10; approximately $5,250,000 per year, assuming an interest rate of 1.5% per year; &#10; however, we can provide no assurances regarding this amount. We expect that the &#10; interest earned on the trust account will be sufficient to pay income taxes. We &#10; will not be permitted to withdraw any of the principal or interest held in the &#10; trust account, except for the withdrawal of interest to fund our working capital &#10; requirements (subject to an annual limit of  $250,000) and/or to pay our taxes, &#10; until the earliest of  (i) the completion of our initial business combination, &#10; (ii) the redemption of our public shares if we are unable to complete our &#10; initial business combination within 24 months from the closing of this offering, &#10; subject to applicable law, and (iii) the redemption of our public shares &#10; properly submitted in connection with a stockholder vote to approve an amendment &#10; to our amended and restated certificate of incorporation to modify the substance &#10; or timing of our obligation to provide for the redemption of our public shares &#10; in connection with an initial business combination or to redeem 100% of our  &#10; public shares if we have not consummated our initial business combination within &#10; 24 months from the closing of this offering. &#10;  &#10; The net proceeds held in the trust account may be used as consideration to pay &#10; the sellers of a target business with which we ultimately complete our initial &#10; business combination. If our initial business combination is paid for using &#10; equity or debt securities, or not all of the funds released from the trust &#10; account are used for payment of the consideration in connection with our initial &#10; business combination, we may apply the balance of the cash released from the &#10; trust account for general corporate purposes, including for maintenance or &#10; expansion of operations of the post-transaction company, the payment of &#10; principal or interest due on indebtedness incurred in completing our initial &#10; business combination, to fund the purchase of other companies or for working &#10; capital. There is no limitation on our ability to raise funds privately or &#10; through loans, advances or other indebtedness in connection with our initial &#10; business combination, including pursuant to forward purchase agreements we may &#10; enter into following consummation of this offering. However, our amended and &#10; restated certificate of incorporation provides that, following this offering and &#10; prior to the consummation of our initial business combination, we will be &#10; prohibited from issuing additional securities that would entitle the holders &#10; thereof to (i) receive funds from the trust account or (ii) vote as a class with &#10; our public shares (a) on any initial business combination or (b) to approve an &#10; amendment to our amended and restated certificate of incorporation to (x) extend &#10; the time we have to consummate a business combination beyond 24 months from the &#10; closing of this offering or (y) amend the foregoing provisions. &#10;  &#10; We believe that amounts not held in trust will be sufficient to pay the costs &#10; and expenses to which such proceeds are allocated. This belief is based on the &#10; fact that while we may begin preliminary due diligence of a target business in &#10; connection with an indication of interest, we intend to undertake in-depth due &#10; diligence, depending on the circumstances of the relevant prospective business &#10; combination, only after we have negotiated and signed a letter of intent or &#10; other preliminary agreement that addresses the terms of a business combination. &#10; However, if our estimate of the costs of undertaking in-depth due diligence and &#10; negotiating a business combination is less than the actual amount necessary to &#10; do so, we may be required to raise additional capital, the amount, availability &#10; and cost of which is currently unascertainable. If we are required to seek &#10; additional capital, we could seek such additional capital through loans or &#10; additional investments from our sponsor, members of our management team or any &#10; of their affiliates, but such persons are not under any obligation to advance &#10; funds to, or invest in, us. &#10;  &#10; We will reimburse an affiliate of our sponsor for office space, secretarial and &#10; administrative services provided to members of our management team, in an amount &#10; not to exceed $15,000 per month in the event such space and/or services are &#10; utilized and we do not pay a third party directly for such services. Upon &#10; completion of our initial business combination or our liquidation, we will cease &#10; paying these monthly fees. &#10;  &#10; Prior to the closing of this offering, our sponsor has agreed to loan us up to &#10; $300,000 to be used for a portion of the expenses of this offering. These loans &#10; are non-interest bearing, unsecured and are due at the earlier of December 31, &#10; 2019 or the closing of this offering. The loan will be repaid upon the closing &#10; of this offering out of the $750,000 of offering proceeds that has been &#10; allocated to the payment of offering expenses. &#10;  &#10; In addition, in order to finance transaction costs in connection with an &#10; intended initial business combination, our sponsor or an affiliate of our &#10; sponsor or certain of our officers and directors may, but are not obligated to, &#10; loan us funds as may be required. If we complete our initial business &#10; combination, we would repay such loaned amounts. Otherwise, such loans would be &#10; repaid only out of funds held outside the trust account. In the event that our &#10; initial business combination does not close, we may use a portion of the working &#10; capital held outside the trust account to repay such loaned amounts but no &#10; proceeds from our trust account would be used to repay such loaned amounts. Up &#10; to $1,500,000 of such loans may be convertible into warrants of the post &#10; business combination entity at a price of $1.50 per warrant at the option of the &#10; lender. The warrants would be identical to the private placement warrants. &#10; Except as set forth above, the terms of such loans, if any, have not been &#10; determined and no written agreements exist with respect to such loans. Prior to &#10; the completion of our initial business combination, we do not expect to seek  &#10; loans from parties other than our sponsor or an affiliate of our sponsor as we  &#10; do not believe third parties will be willing to loan such funds and provide a  &#10; waiver against any and all rights to seek access to funds in our trust account.',\n",
       "   'competition': 'In identifying, evaluating and selecting a target business for our initial &#10; business combination, we may encounter competition from other entities having a &#10; business objective similar to ours, including other special purpose acquisition &#10; companies, private equity groups and leveraged buyout funds, public companies &#10; and operating businesses seeking strategic acquisitions. Many of these entities &#10; are well established and have extensive experience identifying and effecting &#10; business combinations directly or through affiliates. Moreover, many of these &#10; competitors possess greater financial, technical, human and other resources than &#10; us. Our ability to acquire larger target businesses will be limited by our &#10; available financial resources. This inherent limitation gives others an &#10; advantage in pursuing the acquisition of a target business. Furthermore, our &#10; obligation to pay cash in connection with our public stockholders who exercise &#10; their redemption rights may reduce the resources available to us for our initial &#10; business combination and our outstanding warrants, and the future dilution they &#10; potentially represent, may not be viewed favorably by certain target businesses. &#10; Either of these factors may place us at a competitive disadvantage in &#10; successfully negotiating an initial business combination.',\n",
       "   'amount': 175000000,\n",
       "   'percentOffered': '80.00'},\n",
       "  {'symbol': 'UBER',\n",
       "   'companyName': 'UBER TECHNOLOGIES, INC',\n",
       "   'expectedDate': '2019-05-10',\n",
       "   'leadUnderwriters': ['BofA Merrill Lynch',\n",
       "    'Goldman Sachs & Co. LLC',\n",
       "    'Morgan Stanley & Co. LLC'],\n",
       "   'underwriters': ['Academy Securities, Inc',\n",
       "    'Allen & Company LLC',\n",
       "    'Barclays Capital Inc',\n",
       "    'BTIG, LLC',\n",
       "    'Canaccord Genuity LLC',\n",
       "    'Castle Oak Securities, LP',\n",
       "    'Citigroup Global Markets Inc',\n",
       "    'Cowen and Company, LLC',\n",
       "    'Deutsche Bank Securities Inc.',\n",
       "    'Evercore Group L.L.C',\n",
       "    'HSBC Securities (USA) Inc.',\n",
       "    'JMP Securities LLC',\n",
       "    'Loop Capital Markets, LLC',\n",
       "    'Macquarie Capital (USA) Inc',\n",
       "    'Mischler Financial Group, Inc',\n",
       "    'Mizuho Securities USA LLC',\n",
       "    'Needham & Company, LLC',\n",
       "    'Oppenheimer & Co. Inc.',\n",
       "    'Raymond James and Associates, Inc.',\n",
       "    'RBC Capital Markets, LLC',\n",
       "    'Siebert Cisneros Shank & Co., L.L.C',\n",
       "    'SMBC Nikko Securities America, Inc',\n",
       "    'SunTrust Robinson Humphrey, Inc',\n",
       "    'The Williams Capital Group, L.P',\n",
       "    'TPG Capital BD, LLC',\n",
       "    'William Blair and Co., L.L.C.'],\n",
       "   'companyCounsel': ['Cooley LLP and Covington & Burling LLP'],\n",
       "   'underwriterCounsel': ['Davis Polk & Wardwell LLP'],\n",
       "   'auditor': 'Computershare Trust Company, N.A',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0001543151',\n",
       "   'address': '1455 MARKET ST., 4TH FLOOR',\n",
       "   'city': 'SAN FRANCISCO',\n",
       "   'state': 'CA',\n",
       "   'zip': '94103',\n",
       "   'phone': '415-986-2104',\n",
       "   'ceo': 'Dara Khosrowshahi',\n",
       "   'employees': 22263,\n",
       "   'url': 'www.uber.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 180000000,\n",
       "   'priceLow': 44,\n",
       "   'priceHigh': 50,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 15000000,\n",
       "   'sharesOverAlloted': 27000000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 1676959021,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 11270000000,\n",
       "   'netIncome': 997000000,\n",
       "   'totalAssets': 23988000000,\n",
       "   'totalLiabilities': 17196000000,\n",
       "   'stockholderEquity': -7385000000,\n",
       "   'companyDescription': 'Our mission is to ignite opportunity by setting the world in motion. &#10;  &#10; We believe deeply in our bold mission. Every minute of every day, consumers and &#10; Drivers on our platform can tap a button and get a ride or tap a button and get &#10; work. We revolutionized personal mobility with Ridesharing, and we are &#10; leveraging our platform to redefine the massive meal delivery and logistics &#10; industries. While we have had unparalleled growth at scale, we are just getting &#10; started: only 2% of the population in the 63 countries where we operate used our &#10; offerings in the quarter ended December 31, 2018, based on MAPCs. &#10;  &#10; The foundation of our platform is our massive network, leading technology, &#10; operational excellence, and product expertise. Together, these elements power &#10; movement from point A to point B. &#10;  &#10;  Massive network. Our massive, efficient, and intelligent network consists of &#10;   tens of millions of Drivers, consumers, restaurants, shippers, carriers, and &#10;   dockless e-bikes and e-scooters, as well as underlying data, technology, and &#10;   shared infrastructure. Our network becomes smarter with every trip. In over &#10;   700 cities around the world, our network powers movement at the touch of a &#10;   button for millions, and we hope eventually billions, of people.        &#10;  &#10;  Leading technology. We have built proprietary marketplace, routing, and    &#10;   payments technologies. Marketplace technologies are the core of our deep   &#10;   technology advantage and include demand prediction, matching and dispatching, &#10;   and pricing technologies.                                     &#10;  &#10;  Operational excellence. Our regional on-the-ground operations teams use their &#10;   extensive market-specific knowledge to rapidly launch and scale products in &#10;   cities, support Drivers, consumers, restaurants, shippers, and carriers, and &#10;   build and enhance relationships with cities and regulators.  &#10;  &#10;  Product expertise. Our products are built with the expertise that allows us to &#10;   set the standard for powering movement on-demand, provide platform users with &#10;   a contextual, intuitive interface, continually evolve features and  &#10;   functionality, and deliver safety and trust.  &#10; --- &#10;  &#10; We were founded in 2009 and incorporated as Ubercab, Inc., a Delaware  &#10; corporation, in July 2010. In February 2011, we changed our name to Uber &#10; Technologies, Inc. Our principal executive offices are located at 1455 Market &#10; Street, 4th Floor, San Francisco, California 94103, and our telephone number is &#10; (415) 612-8582. Our website address is www.uber.com.',\n",
       "   'businessDescription': 'Our mission is to ignite opportunity by setting the world in motion. &#10;  &#10; We believe deeply in our bold mission. Every minute of every day, consumers and &#10; Drivers on our platform can tap a button and get a ride or tap a button and get &#10; work. We revolutionized personal mobility with Ridesharing, and we are &#10; leveraging our platform to redefine the massive meal delivery and logistics &#10; industries. While we have had unparalleled growth at scale, we are just getting &#10; started: only 2% of the population in the 63 countries where we operate used our &#10; offerings in the quarter ended December 31, 2018, based on MAPCs. &#10;  &#10; The foundation of our platform is our massive network, leading technology, &#10; operational excellence, and product expertise. Together, these elements power &#10; movement from point A to point B. &#10;  &#10;  Massive network. Our massive, efficient, and intelligent network consists of &#10;   tens of millions of Drivers, consumers, restaurants, shippers, carriers, and &#10;   dockless e-bikes and e-scooters, as well as underlying data, technology, and &#10;   shared infrastructure. Our network becomes smarter with every trip. In over &#10;   700 cities around the world, our network powers movement at the touch of a &#10;   button for millions, and we hope eventually billions, of people.        &#10;  &#10;  Leading technology. We have built proprietary marketplace, routing, and    &#10;   payments technologies. Marketplace technologies are the core of our deep   &#10;   technology advantage and include demand prediction, matching and dispatching, &#10;   and pricing technologies.                                     &#10;  &#10;  Operational excellence. Our regional on-the-ground operations teams use their &#10;   extensive market-specific knowledge to rapidly launch and scale products in &#10;   cities, support Drivers, consumers, restaurants, shippers, and carriers, and &#10;   build and enhance relationships with cities and regulators.  &#10;  &#10;  Product expertise. Our products are built with the expertise that allows us to &#10;   set the standard for powering movement on-demand, provide platform users with &#10;   a contextual, intuitive interface, continually evolve features and  &#10;   functionality, and deliver safety and trust.                           &#10;  &#10; Our Personal Mobility, Uber Eats, and Uber Freight platform offerings each &#10; address large, fragmented markets. &#10;  &#10; Personal Mobility &#10;  &#10; Our Personal Mobility offering includes Ridesharing and New Mobility. &#10; Ridesharing refers to products that connect consumers with Drivers who provide &#10; rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, &#10; minibuses, or taxis. New Mobility refers to products that provide consumers with &#10; access to rides through a variety of modes, including dockless e-bikes and &#10; e-scooters. We aim to provide everyone, everywhere on our platform with access &#10; to a safe, reliable, affordable, and convenient trip within a few minutes of &#10; tapping a button. In the quarter ended December 31, 2018, the average wait time &#10; for a rider to be picked up by a Driver was five minutes. In addition to &#10; powering movement for riders, our platform powers opportunity for Drivers, &#10; fueling the future of independent work by providing Drivers with a reliable and &#10; flexible way to earn money. &#10;  &#10; We are committed to providing consumers with access to the best personal &#10; mobility options to meet their needs. We are investing in new modes of &#10; transportation that enable us to address a wider range of consumer use cases and &#10; represent a significant opportunity to bring additional trips onto our platform. &#10; For example, according to the U.S. Department of Transportation, trips of less &#10; than three miles accounted for 46% of all U.S. vehicle trips in 2017. We believe &#10; that dockless e-bikes and e-scooters address many of these use cases and will &#10; replace a portion of these vehicle trips over time, particularly in urban &#10; environments that suffer from substantial traffic during peak commuting hours. &#10;  &#10; The rapid growth and scale of our Ridesharing products, which to date have &#10; accounted for virtually all of our Personal Mobility offering, demonstrates the &#10; size of our opportunity: &#10;  &#10;  Revenue derived from our Ridesharing products grew from $3.5 billion in 2016 &#10;   to $9.2 billion in 2018.                                              &#10;  &#10;  Gross Bookings derived from our Ridesharing products grew from $18.8 billion &#10;   in 2016 to $41.5 billion in 2018.                                  &#10;  &#10;  Consumers traveled approximately 26 billion miles on our platform in 2018. &#10;  &#10; We believe that Personal Mobility represents a vast, rapidly growing, and &#10; underpenetrated market opportunity. We operate our Personal Mobility offering in &#10; 63 countries with an aggregate population of 4.1 billion people. Through our &#10; Personal Mobility offering, we estimate that our platform served 2% of the &#10; population in these countries based on MAPCs in the quarter ended December 31, &#10; 2018. We estimate that people traveled 4.7 trillion vehicle miles in trips under &#10; 30 miles in these countries in 2018, of which the approximately 26 billion miles &#10; traveled on our platform represent less than 1% penetration. &#10;  &#10; We believe that our Personal Mobility market share and ridesharing category &#10; position are key indicators of our progress towards our massive market &#10; opportunity. We calculate our Personal Mobility market share in a given region &#10; by dividing our Personal Mobility miles traveled by our estimates of the &#10; addressable market in miles traveled in the region. We estimate the size of the &#10; addressable market by multiplying the number of passenger cars in each country &#10; by our country-level estimates of miles traveled per car. Our estimates also &#10; include an estimated 4.4 trillion public transportation miles, which we allocate &#10; to regions based on their share of the population in our addressable market.  &#10; Based on this estimate, our Personal Mobility market share is less than 1% in &#10; every major region of the world where we operate. &#10;  &#10; We calculate our ridesharing category position within a given region by dividing &#10; our Ridesharing Gross Bookings by our estimates of total ridesharing Gross &#10; Bookings generated by us and other companies with similar ridesharing products. &#10; Based on these estimates, we have a leading ridesharing category position in &#10; every major region of the world where we operate, as shown in the graphic below. &#10; We also participate in certain regions through our minority-owned affiliates and &#10; intend to maintain our interests in these minority-owned affiliates to &#10; participate in the expected growth of ridesharing and other modes of personal &#10; mobility in the regions where they operate. &#10; --- &#10;  &#10; Uber Eats &#10;  &#10; Our Uber Eats offering allows consumers to search for and discover local &#10; restaurants, order a meal at the touch of a button, and have the meal delivered &#10; reliably and quickly. We launched our Uber Eats app just over three years ago, &#10; and we believe that Uber Eats has grown to be the largest meal delivery platform &#10; in the world outside of China based on Gross Bookings. We believe that our scale &#10; enables the average delivery time for Uber Eats to be faster than the average &#10; delivery time for our competitors. For the quarter ended December 31, 2018, the &#10; average delivery time was approximately 30 minutes. We believe that Uber Eats &#10; not only leverages, but also increases, the supply of Drivers on our network. &#10; For example, Uber Eats enables Ridesharing Drivers to increase their utilization &#10; and earnings by accessing additional demand for trips during non-peak &#10; Ridesharing times. Uber Eats also expands the pool of Drivers by enabling people &#10; who are not Ridesharing Drivers or who do not have access to &#10; Ridesharing-qualified vehicles to deliver meals on our platform. In addition to &#10; benefiting Drivers and consumers, Uber Eats provides restaurants with an instant &#10; mobile presence and efficient delivery capability, which we believe generates &#10; incremental demand and improves margins for restaurants by enabling them to &#10; serve more consumers without increasing their existing front-of-house expenses. &#10; Of the 91 million MAPCs on our platform, over 15 million received a meal using &#10; Uber Eats in the quarter ended December 31, 2018, tapping into our network of &#10; more than 220,000 restaurants in over 500 cities globally. &#10;  &#10; In connection with our transactions with Grab and Yandex, we contributed our &#10; meal delivery offerings in Southeast Asia and Russia/CIS to Grab and to our &#10; Yandex.Taxi joint venture, respectively, including our partnerships with certain &#10; significant global restaurant chains with operations in those markets. We expect &#10; to benefit from continued growth of the meal delivery industry in the regions &#10; where our minority-owned affiliates operate.   &#10;  &#10; Uber Freight &#10;  &#10; We believe that Uber Freight is revolutionizing the logistics industry. Uber &#10; Freight leverages our proprietary technology, brand awareness, and experience &#10; revolutionizing industries to create a transparent, on-demand marketplace that &#10; seamlessly connects shippers and carriers. &#10;  &#10; The freight industry today is highly fragmented and deeply inefficient. It can &#10; take several hours, sometimes days, for shippers to find a truck and driver for &#10; shipments, with most of the process conducted over the phone or by fax. Uber &#10; Freight greatly reduces friction in the logistics industry by providing an &#10; on-demand platform to automate and accelerate logistics transactions end-to-end. &#10; Uber Freight connects carriers with the most appropriate shipments available on &#10; our platform, and gives carriers upfront, transparent pricing and the ability to &#10; book a shipment with the touch of a button. &#10;  &#10; We serve shippers ranging from small- and medium-sized businesses to global &#10; enterprises by enabling them to create and tender shipments with a few clicks, &#10; secure capacity on demand with upfront pricing, and track those shipments in &#10; real-time from pickup to delivery. We believe that all of these factors &#10; represent significant efficiency improvements over traditional freight brokerage &#10; providers. Since Uber Freights public launch in the United States in May 2017, &#10; we have contracted with over 36,000 carriers that in aggregate have more than &#10; 400,000 drivers and have served over 1,000 shippers, including global &#10; enterprises such as Anheuser-Busch InBev, Niagara, Land OLakes, and &#10; Colgate-Palmolive. Uber Freight has grown to $125 million in revenue for the &#10; quarter ended December 31, 2018. &#10;  &#10; In March 2019, we announced the expansion of our Uber Freight offering into &#10; Europe. Although Europes freight market is one of the largest and most &#10; sophisticated in the world, we believe that European shippers and carriers &#10; experience many of the same pain points in their current operations as U.S. &#10; shippers and carriers. &#10;  &#10; Platform Synergies &#10;  &#10; We intend to continue to invest in new platform offerings that we believe will &#10; further strengthen our platform and existing offerings and fuel multiple &#10; virtuous cycles of growth. &#10;  &#10; We can rapidly launch and scale platform products and offerings by leveraging &#10; our massive network, leading technology, operational excellence, and product &#10; expertise. Furthermore, each new product adds nodes to our network and &#10; strengthens these shared capabilities, enabling us to launch and invest in &#10; additional products more efficiently. For example, Uber Eats is used by many of &#10; the same consumers who use our Ridesharing products, is built on our existing &#10; technology stack, and has grown by leveraging many of the same regional &#10; operations teams that built our Ridesharing products. Similarly, in cities where &#10; we already operate, we can more efficiently launch other products and offerings, &#10; such as dockless e-bikes and e-scooters, by leveraging our existing network of &#10; Drivers and consumers and regional on-the-ground operations teams. As evidence &#10; of the power of our platform, Uber Eats grew to $2.6 billion in Gross Bookings &#10; for the quarter ended December 31, 2018, nearly three years following the launch &#10; of the Uber Eats app, which we believe makes our Uber Eats offering the largest &#10; meal delivery platform in the world outside of China. In addition, each new &#10; product or offering enables us to invest more efficiently because we share &#10; innovations and investments across our platform offerings. These synergies &#10; effectively lower our costs and allow us to invest in a scalable way that &#10; becomes increasingly efficient as we grow with each new product or offering. &#10;  &#10; Each platform offering also increases the value of our platform to platform &#10; users, enabling us to attract new platform users and to deepen engagement with &#10; existing platform users. Both of these dynamics grow our network scale and &#10; liquidity, which further increases the value of our platform to platform users. &#10; For example, Uber Eats attracts new consumers to our network  in the quarter &#10; ended December 31, 2018, 50% of first-time Uber Eats consumers were new to our &#10; platform. Additionally, in the quarter ended December 31, 2018, consumers who &#10; used both Personal Mobility and Uber Eats had 11.5 Trips per month on average, &#10; compared to 4.9 Trips per month on average for consumers who used a single &#10; offering in cities where both Personal Mobility and Uber Eats were offered. &#10; Similarly, having multiple offerings increases our engagement with Drivers. For &#10; example, with Uber Eats, Ridesharing Drivers can access additional demand for &#10; trips during non-peak Ridesharing times to increase their utilization and &#10; earnings. We believe that these trends will continue as we further expand Uber &#10; Eats from over 500 cities into nearly 700 cities where we already offer Personal &#10; Mobility. &#10;  &#10; The strength of our leading platform is demonstrated by our performance: &#10;  &#10;  There were 91 million MAPCs for the quarter ended December 31, 2018. &#10;  &#10;  There were 1.5 billion Trips on our platform for the quarter ended December &#10;   31, 2018.                                                         &#10;  &#10;  There were 3.9 million Drivers on our platform for the quarter ended December &#10;   31, 2018.                                                         &#10;  &#10;  Drivers have earned over $78.2 billion on our platform since 2015, as well as &#10;   $1.2 billion in tips since we introduced in-app tipping for Drivers in July &#10;   2017, in each case through December 31, 2018.                         &#10;  &#10;  We had a 9% Core Platform Contribution Margin in 2018.                &#10;  &#10; In 2018, Gross Bookings grew to $49.8 billion, up 45% from $34.4 billion in &#10; 2017. Over the same period, revenue reached $11.3 billion, up 42% from $7.9 &#10; billion in the prior year. Core Platform Adjusted Net Revenue was $9.9 billion &#10; in 2018, up 39% from $7.1 billion in 2017. &#10; --- &#10;  &#10; We were founded in 2009 and incorporated as Ubercab, Inc., a Delaware  &#10; corporation, in July 2010. In February 2011, we changed our name to Uber &#10; Technologies, Inc. Our principal executive offices are located at 1455 Market &#10; Street, 4th Floor, San Francisco, California 94103, and our telephone number is &#10; (415) 612-8582. Our website address is www.uber.com.',\n",
       "   'useOfProceeds': 'We estimate that net proceeds to us from the sale of our common stock in this &#10; offering will be approximately $8.4 billion based on the assumed initial public &#10; offering price of $47.00 per share and after deducting the underwriting &#10; discounts and commissions and estimated offering expenses payable by us. &#10; Additionally, our proceeds from the private placement to PayPal will be &#10; $500 million. We will not receive proceeds from the sale of common stock in this &#10; offering by the selling stockholders. &#10;  &#10; Each $1.00 increase (decrease) in the assumed initial public offering price of &#10; $47.00 per share would increase (decrease) the net proceeds to us from this &#10; offering by approximately $178.2 million, assuming the number of shares of &#10; common stock offered by us, as set forth on the cover page of this prospectus, &#10; remains the same and after deducting the underwriting discounts and commissions &#10; and estimated offering expenses payable by us. Similarly, each increase &#10; (decrease) of 1.0 million shares in the number of shares of common stock offered &#10; by us would increase (decrease) the net proceeds to us from this offering by &#10; approximately $46.5 million, based on the assumed initial public offering price &#10; of $47.00 per share remains the same and after deducting the underwriting &#10; discounts and commissions and estimated offering expenses payable by us. &#10;  &#10; The principal purposes of this offering are to increase our capitalization and &#10; financial flexibility and to create a public market for our common stock. &#10;  &#10; We intend to use the net proceeds we receive from this offering for general &#10; corporate purposes, including working capital, operating expenses, and capital &#10; expenditures. We may also use a portion of the net proceeds to acquire or make &#10; investments in businesses, products, offerings, and technologies, although we do &#10; not have agreements or commitments for any material acquisitions or investments &#10; at this time. &#10;  &#10; We expect to use some of the net proceeds from this offering to satisfy a &#10; portion of the anticipated tax withholding and remittance obligations related to &#10; the settlement of our outstanding RSUs that will vest in connection with this &#10; offering. Based on 76.1 million RSUs outstanding for which the service condition &#10; has been met as of May 1, 2019, and based on the assumed initial public offering &#10; price of $47.00 per share, we estimate that these tax withholding obligations on &#10; the initial settlement date would be approximately $1.4 billion in the &#10; aggregate. Each $1.00 increase in the price of our common stock at the time of &#10; settlement from the assumed initial public offering price of $47.00 per share, &#10; assuming no change in the applicable tax rates, would increase the amount we &#10; would be required to pay to satisfy these obligations by approximately &#10; $29.7 million. Each $1.00 decrease in the price of our common stock at the time &#10; of settlement from the assumed initial public offering price of $47.00 per &#10; share, assuming no change to the applicable tax rates, would decrease the amount &#10; we would be required to pay to satisfy these obligations by approximately &#10; $29.7 million. &#10;  &#10; The expected use of net proceeds from this offering represents our intentions &#10; based upon our present plans and business conditions. We cannot predict with &#10; certainty all of the particular uses for the proceeds of this offering or the &#10; amounts that we will actually spend on the uses set forth above. Accordingly, &#10; our management will have broad discretion in applying the net proceeds of this &#10; offering. The timing and amount of our actual expenditures will be based on many &#10; factors, including cash flows from operations and the anticipated growth of our &#10; business. Pending their use, we intend to invest the net proceeds of this &#10; offering in a variety of capital-preservation investments, including short- and &#10; intermediate-term investments, interest-bearing investments, investment-grade &#10; securities, government securities, and money market funds.',\n",
       "   'competition': 'We face competition in each of our offerings, including: &#10;  &#10;  Personal Mobility. Our Personal Mobility offering competes with personal   &#10;   vehicle ownership and usage, which accounts for the majority of passenger  &#10;   miles in the markets that we serve, and traditional transportation services, &#10;   including taxicab companies and taxi-hailing services, and livery services. In &#10;   addition, public transportation can be a superior substitute to our Personal &#10;   Mobility offering and in many cases, offers a faster and lower-cost travel  &#10;   option in many cities. In Ridesharing, we compete with companies, including &#10;   certain of our minority-owned affiliates, for Drivers and riders, including &#10;   Lyft, OLA, Careem, Didi, Taxify, and our Yandex.Taxi joint venture. Our New &#10;   Mobility products compete for riders in the bike and scooter space, including &#10;   Motivate (an affiliate of Lyft), Lime, Bird, and Skip. We also compete with &#10;   OEMs and other technology companies in the development of autonomous vehicle &#10;   technologies and the deployment of autonomous vehicles, including Waymo, &#10;   Cruise Automation, Tesla, Apple, Zoox, Aptiv, May Mobility, Pronto.ai, Aurora, &#10;   and Nuro, whose offerings may prove more effective than our autonomous vehicle &#10;   technologies. Waymo has already introduced a commercialized ridehailing fleet &#10;   of autonomous vehicles, and it is possible that other of our competitors &#10;   could introduce autonomous vehicle offerings earlier than we will. &#10;  &#10;  Uber Eats. Our Uber Eats offering competes with numerous companies in the meal &#10;   delivery space in various regions for Drivers, consumers, and restaurants, &#10;   including GrubHub, DoorDash, Deliveroo, Swiggy, Postmates, Zomato, Delivery &#10;   Hero, Just Eat, Takeaway.com, and Amazon. Our Uber Eats offering also competes &#10;   with restaurants, meal kit delivery services, grocery delivery services, and &#10;   traditional grocers.                        &#10;  &#10;  Uber Freight. Our Uber Freight offering competes with global and North  &#10;   American freight brokers such as C.H. Robinson, Total Quality Logistics, XPO &#10;   Logistics, Convoy, Echo Global Logistics, Coyote, Transfix, DHL, and NEXT &#10;   Trucking.                                                             &#10;  &#10; We are contractually restricted from competing with our minority-owned &#10; affiliates with respect to certain aspects of our business, including in China &#10; through August 2023, Russia/CIS through February 2025, and Southeast Asia &#10; through the longer of March 2023 or one year after we dispose of all interests &#10; in Grab, while none of our minority-owned affiliates are restricted from &#10; competing with us anywhere in the world. &#10;  &#10; In general, the bases upon which we compete include: &#10;  &#10;  Consumers. We compete to attract, engage, and retain consumers in Personal &#10;   Mobility and Uber Eats. In Personal Mobility, we believe that our ability to &#10;   compete effectively for consumers depends on many factors, including the wait &#10;   time for a ride, fare, ease of payment, reliability of ETA, ability to give &#10;   feedback, availability of dockless e-bikes or e-scooters and receive support, &#10;   and experience of a ride as well as our reputation and the strength of our &#10;   brand. In Uber Eats, we additionally compete on the basis of restaurant &#10;   selection, delivery prices, and reliability of delivery. We also compete for &#10;   shippers in Uber Freight.                    &#10;  &#10;  Drivers and carriers. We seek to attract and retain Drivers in Ridesharing and &#10;   Uber Eats and carriers in Uber Freight. We believe that Drivers and carriers &#10;   can earn more per hour on our platform than other Ridesharing, meal delivery, &#10;   and freight alternatives, given consumer demand, our data, and our marketplace &#10;   liquidity advantages. We recently introduced a Driver rewards program, Uber &#10;   Pro, in beta mode in eight cities in the United States to incentivize them to &#10;   drive with Uber and provide Drivers with the opportunity to receive discounts &#10;   on vehicle maintenance and gas. We are committed to giving Drivers and &#10;   carriers resources to thrive on our platform.               &#10;  &#10;  Network liquidity. We compete to achieve network liquidity through attracting &#10;   Drivers and consumers, and by providing consumers with lower prices to scale &#10;   our platform. At scale, our platform offers consumers lower wait times, lower &#10;   fares, and quicker delivery, and Drivers can earn a higher wage per hour, a &#10;   virtuous cycle that creates a growing liquidity network effect in a city.',\n",
       "   'amount': 8460000000,\n",
       "   'percentOffered': '10.73'},\n",
       "  {'symbol': 'PSTL',\n",
       "   'companyName': 'POSTAL REALTY TRUST, INC.',\n",
       "   'expectedDate': '2019-05-10',\n",
       "   'leadUnderwriters': ['BMO Capital Markets Corp',\n",
       "    'Height Capital Markets, LLC',\n",
       "    'Janney Montgomery Scott LLC',\n",
       "    'Stifel Nicolaus & Company, Incorporated'],\n",
       "   'underwriters': ['B. Riley FBR, Inc', 'D.A. Davidson and Co'],\n",
       "   'companyCounsel': ['Venable LLP and Hunton Andrews Kurth LLP'],\n",
       "   'underwriterCounsel': ['Winston & Strawn LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0001759774',\n",
       "   'address': '75 COLUMBIA AVE',\n",
       "   'city': 'CEDARHURST',\n",
       "   'state': 'NY',\n",
       "   'zip': '11516',\n",
       "   'phone': '576-295-7820',\n",
       "   'ceo': 'Andrew Spodek',\n",
       "   'employees': 0,\n",
       "   'url': 'www.postalrealtytrust.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 5000000,\n",
       "   'priceLow': 19,\n",
       "   'priceHigh': 21,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 6764688,\n",
       "   'sharesOverAlloted': 750000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 5763308,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 7685135,\n",
       "   'netIncome': 1148162,\n",
       "   'totalAssets': 35684432,\n",
       "   'totalLiabilities': 41297845,\n",
       "   'stockholderEquity': -5658006,\n",
       "   'companyDescription': 'We are an internally managed real estate corporation that owns and manages &#10; properties leased to the United States Postal Service, or the USPS. Upon &#10; completion of this offering and the related formation transactions, we will own &#10; and manage an initial portfolio of 271 postal properties located in 41 states &#10; comprising 871,843 net leasable interior square feet, all of which are leased to &#10; the USPS, and through our taxable REIT subsidiary, or TRS, we will provide &#10; fee-based third party property management services for an additional 404 postal &#10; properties leased to the USPS and owned by members of Mr. Spodeks family and &#10; their partners. We believe that we will be one of the largest owners and the &#10; largest manager measured by net leasable square footage of properties that are &#10; leased to the USPS. We will have a right of first offer to purchase 255 of our &#10; 404 managed properties. Our chief executive officer, Andrew Spodek, currently &#10; owns interests in 199 of the 271 initial properties we will own, which he will &#10; contribute to us as part of our formation transactions. Of these 199 properties, &#10; Mr. Spodek controls our 190 Predecessor Properties (as defined below) and has a &#10; non-controlling ownership interest in nine of our Acquisition Properties (as &#10; defined below). Mr. Spodek has been actively engaged in the ownership and &#10; management of postal properties for over 20 years. Upon completion of this &#10; offering and the related formation transactions, Mr. Spodek will own &#10; approximately 29.0% of the fully diluted equity interests in our company. &#10; --- &#10;  &#10; Postal Realty Trust, Inc., a Maryland corporation, was incorporated in November &#10; 2018. Our principal executive offices are located at 75 Columbia Avenue, &#10; Cedarhurst, NY 11516. Our telephone number is (516) 295-7820. We will also &#10; maintain an internet website at www.postalrealtytrust.com.',\n",
       "   'businessDescription': 'We are an internally managed real estate corporation that owns and manages &#10; properties leased to the United States Postal Service, or the USPS. Upon &#10; completion of this offering and the related formation transactions, we will own &#10; and manage an initial portfolio of 271 postal properties located in 41 states &#10; comprising 871,843 net leasable interior square feet, all of which are leased to &#10; the USPS, and through our taxable REIT subsidiary, or TRS, we will provide &#10; fee-based third party property management services for an additional 404 postal &#10; properties leased to the USPS and owned by members of Mr. Spodeks family and &#10; their partners. We believe that we will be one of the largest owners and the &#10; largest manager measured by net leasable square footage of properties that are &#10; leased to the USPS. We will have a right of first offer to purchase 255 of our &#10; 404 managed properties. Our chief executive officer, Andrew Spodek, currently &#10; owns interests in 199 of the 271 initial properties we will own, which he will &#10; contribute to us as part of our formation transactions. Of these 199 properties, &#10; Mr. Spodek controls our 190 Predecessor Properties (as defined below) and has a &#10; non-controlling ownership interest in nine of our Acquisition Properties (as &#10; defined below). Mr. Spodek has been actively engaged in the ownership and &#10; management of postal properties for over 20 years. Upon completion of this &#10; offering and the related formation transactions, Mr. Spodek will own &#10; approximately 29.0% of the fully diluted equity interests in our company. &#10;  &#10; The USPS is an independent agency of the executive branch of the U.S. federal &#10; government that generated $70.6 billion of revenue for its fiscal year ended &#10; September 30, 2018. Article I, Section 8, Clause 7 of the United States &#10; Constitution empowers Congress [t]o establish Post Offices and post Roads, &#10; making the USPS one of the few federal agencies explicitly authorized by the &#10; United States Constitution. The USPS is federally required to provide universal &#10; service to all residents of the United States and its territories, including &#10; rural and isolated areas, and has a monopoly on mail delivery and delivery to &#10; residential and business mailboxes, with delivery to most homes and businesses &#10; six days per week. The USPSs ability to deliver 493 million pieces of mail to &#10; an estimated 159 million delivery points as of September 30, 2018 is driven by a &#10; sophisticated logistics infrastructure of post offices, processing and &#10; distribution centers and annexes. As of September 30, 2018, the USPS managed a &#10; network of over 31,000 properties of which over 23,000 were owned by private &#10; owners and leased to the USPS. We believe that this network of properties is a &#10; critical element of the nations logistics infrastructure that facilitates cost &#10; effective and efficient last mile delivery solutions for the nations largest &#10; e-commerce providers including Amazon, FedEx and UPS. &#10;  &#10; In December 2018, a presidential task force issued a report, which we refer to &#10; as the Task Force Report, evaluating the operations and finances of the USPS. &#10; The Task Force Report stated that the USPSs comprehensive delivery network that &#10; covers every address in the country is a critical part of the nations &#10; infrastructure and that maintaining this critical infrastructure as a national &#10; resource should be considered the primary business objective of the USPS. The &#10; Task Force Report further concluded that the USPS should make accommodating &#10; changes to its pricing, cost, and customer and revenue strategies. &#10;  &#10; In its Annual Report to Congress for the fiscal year ended September 30, 2018, &#10; the USPS reported that it owns nearly 8,400 and leases over 23,000 postal &#10; facilities. Approximately 11.2% of the leased properties are owned by the top &#10; ten private post office owners according to REAC, with the substantial majority &#10; of owners holding a single property. The USPS typically enters into five-year &#10; leases with postal lessors, including us, that are modified double-net leases &#10; pursuant to which the USPS, as tenant, is responsible for utilities and routine &#10; maintenance and reimburses the landlord for property taxes, while the landlord &#10; is responsible for insurance, roof and structure. &#10;  &#10; Our objective is to create stockholder value by generating attractive &#10; risk-adjusted returns through expanding our portfolio of owned and managed &#10; postal properties leased to the USPS. When assessing acquisitions, we look at &#10; properties that we believe are integral to USPS operations with a range of &#10; remaining lease terms. We also seek to acquire properties where we believe our &#10; property management expertise can enhance returns through reducing costs. In &#10; addition, we intend to expand our third-party property management, consulting &#10; and advisory services to enhance revenue and create potential future acquisition &#10; opportunities. We believe the fragmented ownership and specialized nature of &#10; properties leased to the USPS have limited the number and growth of professional &#10; property managers for these properties. &#10; --- &#10;  &#10; Postal Realty Trust, Inc., a Maryland corporation, was incorporated in November &#10; 2018. Our principal executive offices are located at 75 Columbia Avenue, &#10; Cedarhurst, NY 11516. Our telephone number is (516) 295-7820. We will also &#10; maintain an internet website at www.postalrealtytrust.com.',\n",
       "   'useOfProceeds': 'After deducting the underwriting discount and commissions and estimated expenses &#10; of this offering payable by us (including reimbursement of offering related &#10; expenses, including, but not limited to, legal, accounting and IPO consulting &#10; fees, incurred by Mr. Spodek and certain of his affiliates on our behalf), we &#10; expect to receive net proceeds from this offering of approximately $86.2 &#10; million, or approximately $100.2 million if the underwriters overallotment &#10; option is exercised in full, in each case assuming an initial public offering &#10; price of $20.00 per share, which is the midpoint of the price range set forth on &#10; the front cover of this prospectus. A $1.00 increase or decrease in the initial &#10; public offering price per share would increase or decrease, as applicable, the &#10; net proceeds from this offering by approximately $4.65 million, assuming the &#10; number of shares offered by us remains the same. Similarly, an increase or &#10; decrease of 500,000 shares in the number of shares of Class A common stock &#10; offered by us, would increase or decrease the net proceeds from this offering by &#10; approximately $9.3 million, assuming no change in the assumed initial public &#10; offering price per share of $20.00 per share. &#10;  &#10; We intend to contribute the net proceeds of this offering to our operating &#10; partnership in exchange for OP units, and our operating partnership intends to &#10; use the net proceeds received from us as described below: &#10;  &#10; . approximately $33.3 million to acquire our initial properties in our formation  &#10;   transactions;                                                                   &#10;  &#10; . approximately $31.9 million to repay mortgage debt secured by certain of our    &#10;   initial properties; and                                                         &#10;  &#10; . the remainder, if any, for general corporate purposes, including working        &#10;   capital, future acquisitions, transfer taxes and, potentially, paying           &#10;   distributions.                                                                  &#10;  &#10; The following table sets forth information regarding the indebtedness that we &#10; intend to repay with the net proceeds of this offering: &#10;  &#10;                                Amount to be                               &#10;                                 Repaid(1)        Interest Rate(2)       Maturity Date  &#10; Vision Bank                   $ 13,916,028      4.00%, Prime + 0.5 %(3) September 2036 &#10; Atlanta Postal Credit Union   $ 17,194,853                    4.15 %    September 2021 &#10; First Oklahoma Bank           $                4.5%, Prime + 0.25 %(4)  December 2037 &#10; Vision Bank2018              $                 5.00%, Prime +0.5 %(5)   January 2038 &#10; First Oklahoma Bank2018      $    741,495             5.5%, Prime (6)    October 2043 &#10; Total                         $ 31,852,376                                             &#10;  &#10; (1) Amounts based on projected debt principal balances as of closing of this      &#10;     offering.                                                                     &#10;  &#10; (2) Prime refers to the Wall Street Journal Prime Rate. &#10;  &#10; (3) Interest rate resets on September 8, 2021. &#10;  &#10; (4) Interest rate resets on December 31, 2022. &#10;  &#10; (5) Interest rate resets on January 31, 2023. &#10;  &#10; (6) Interest rate resets on October 31, 2023. &#10;  &#10; The proceeds from the indebtedness to be repaid with the proceeds of the &#10; offering were used to finance or re-finance certain of our initial properties. &#10;  &#10; Pending application of the net proceeds of this offering, we intend to invest &#10; the net proceeds in interest-bearing accounts, money market accounts and &#10; interest-bearing securities in a manner that is consistent with our intention to &#10; qualify for taxation as a REIT.',\n",
       "   'competition': 'Our competition is from other property owners in our markets that seek to &#10; attract the USPS as a tenant. Our principal competition for acquisitions is &#10; other owners of postal properties.',\n",
       "   'amount': 100000000,\n",
       "   'percentOffered': '86.76'},\n",
       "  {'symbol': 'SONM',\n",
       "   'companyName': 'SONIM TECHNOLOGIES INC',\n",
       "   'expectedDate': '2019-05-10',\n",
       "   'leadUnderwriters': ['Lake Street Capital Markets, LLC',\n",
       "    'Oppenheimer & Co. Inc.'],\n",
       "   'underwriters': ['National Securities Corp'],\n",
       "   'companyCounsel': ['Cooley LLP'],\n",
       "   'underwriterCounsel': ['Goodwin Procter LLP'],\n",
       "   'auditor': 'American Stock Transfer and Trust Company LLC',\n",
       "   'market': 'NASDAQ Global',\n",
       "   'cik': '0001178697',\n",
       "   'address': '1875 SOUTH GRANT STREET',\n",
       "   'city': 'SAN MATEO',\n",
       "   'state': 'CA',\n",
       "   'zip': '94402',\n",
       "   'phone': '650-378-8100',\n",
       "   'ceo': 'Robert Plaschke',\n",
       "   'employees': 321,\n",
       "   'url': 'www.sonimtech.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 3571429,\n",
       "   'priceLow': 13,\n",
       "   'priceHigh': 15,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 4200000,\n",
       "   'sharesOverAlloted': 535714,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 19509611,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 135665000,\n",
       "   'netIncome': 1277000,\n",
       "   'totalAssets': 67345000,\n",
       "   'totalLiabilities': 62216000,\n",
       "   'stockholderEquity': 5129000,\n",
       "   'companyDescription': 'We are a leading U.S. provider of ultra-rugged mobile phones and accessories &#10; designed specifically for task workers physically engaged in their work &#10; environments, often in mission-critical roles. We currently sell our ruggedized &#10; mobile phones and accessories to three of the four largest wireless carriers in &#10; the United StatesAT&T, Sprint and Verizonas well as the three largest wireless &#10; carriers in CanadaBell, Rogers and Telus Mobility. Our phones and accessories &#10; connect workers with voice, data and workflow applications in two end markets: &#10; industrial enterprise and public sector. &#10; --- &#10;  &#10; We were incorporated in Delaware in August 1999 as NaviSpin.com, Inc. In &#10; December 2001, we changed our name to Sonim Technologies, Inc. Our principal &#10; executive offices are located at 1875 South Grant Street, Suite 750, San Mateo, &#10; California 94402 and our telephone number is (650) 378-8100. Our website address &#10; is www.sonimtech.com.',\n",
       "   'businessDescription': 'We are a leading U.S. provider of ultra-rugged mobile phones and accessories &#10; designed specifically for task workers physically engaged in their work &#10; environments, often in mission-critical roles. We currently sell our ruggedized &#10; mobile phones and accessories to three of the four largest wireless carriers in &#10; the United StatesAT&T, Sprint and Verizonas well as the three largest wireless &#10; carriers in CanadaBell, Rogers and Telus Mobility. Our phones and accessories &#10; connect workers with voice, data and workflow applications in two end markets: &#10; industrial enterprise and public sector. &#10;  &#10; Task workers in these end markets have historically been limited to pen and &#10; paper and single-purpose electronic devices, such as barcode scanners, &#10; location-tracking devices and sensors, to accomplish specific daily tasks. These &#10; single-purpose devices have historically run on proprietary networks, such as &#10; land mobile radio, or LMR, networks, which enable push-to-talk, or PTT, services &#10; for voice communications. We provide Android-based devices that consolidate and &#10; integrate multiple functions into a single ruggedized solution running on &#10; commercial wireless networks at a total cost of ownership that we believe is &#10; significantly lower than comparable offerings with improved productivity and &#10; safety of task workers. &#10;  &#10; Our solutions fall into three main categories: (i) ultra-rugged mobile phones &#10; based on the Android platform that are capable of attaching to both public and &#10; private wireless networks, (ii) industrial-grade accessories and (iii)  &#10; cloud-based software and application services. End customers of our solutions  &#10; include construction, energy and utility, hospitality, logistics, manufacturing, &#10; public sector and transportation entities that primarily purchase our phones and &#10; accessories through their wireless carriers. All of our devices run on the  &#10; Android operating system, providing a familiar and intuitive user interface, and &#10; our smartphones have access to a library of millions of applications available  &#10; through the Google Play Store. We have also implemented dozens of application  &#10; programming interfaces, or APIs, specific to our mobile phones and have  &#10; partnered with over 800 application developers to create a purpose-built  &#10; experience for our end users using these applications on our mobile phones. &#10;  &#10; As of January 2019, we were the only privately held mobile phone provider to &#10; have a stocked product with three of the four largest U.S. wireless carriers: &#10; AT&T, Sprint and Verizon, meaning that these carriers test and certify our &#10; mobile phones on their networks and maintain inventory in their warehouses that &#10; they then sell through their enterprise and retail sales teams to end customers, &#10; often on a subsidized or financed basis. &#10;  &#10; We enter into master sales arrangements with the majority of our channel  &#10; partners (including channel partners contributing over 90% of our total revenues &#10; for the year ended December 31, 2018) under which our partners purchase our &#10; solutions for distribution on a purchase order basis. Under these arrangements, &#10; we and the channel partners determine sales channel distribution in connection &#10; with pricing (including any discounts and price protection) and positioning of &#10; each particular mobile device product. We also offer customer incentives in the &#10; form of funds used for channel marketing, as well as other limited promotional &#10; incentives, such as sales volume incentives, in exchange for retail price  &#10; reductions. We may also offer non-recurring engineering, or NRE, services in the &#10; form of third-party design services relating to the design of materials and  &#10; software licenses used in the manufacturing of our products. &#10; --- &#10;  &#10; We were incorporated in Delaware in August 1999 as NaviSpin.com, Inc. In &#10; December 2001, we changed our name to Sonim Technologies, Inc. Our principal &#10; executive offices are located at 1875 South Grant Street, Suite 750, San Mateo, &#10; California 94402 and our telephone number is (650) 378-8100. Our website address &#10; is www.sonimtech.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from our issuance and sale of shares of common &#10; stock in this offering will be approximately $42.3 million, or approximately &#10; $48.9 million if the underwriters exercise their option to purchase additional &#10; shares of common stock in full, based upon an assumed initial public offering &#10; price of $14.00 per share, which is the midpoint of the price range set forth on &#10; the cover page of this prospectus, after deducting underwriting discounts and &#10; commissions and estimated offering expenses payable by us. We will not receive &#10; any of the proceeds from any sale of shares in this offering by the selling &#10; stockholder. &#10;  &#10; Each $1.00 increase or decrease in the assumed initial public offering price of &#10; $14.00 per share, which is the midpoint of the price range set forth on the &#10; cover page of this prospectus, would increase or decrease, respectively, the &#10; amount of cash and cash equivalents, working capital, total assets and total &#10; stockholders equity by approximately $3.3 million, assuming the number of &#10; shares offered by us, as set forth on the cover page of this prospectus, remains &#10; the same and after deducting underwriting discounts and commissions and &#10; estimated offering expenses payable by us. Similarly, each increase or decrease &#10; of 1.0 million shares of our common stock offered by us would increase or &#10; decrease the amount of cash and cash equivalents, working capital, total assets &#10; and stockholders equity by approximately $13.0 million, assuming an initial &#10; public offering price of $14.00 per share, which is the midpoint of the price &#10; range set forth on the cover page of this prospectus, and after deducting &#10; underwriting discounts and commissions and estimated offering expenses payable &#10; by us. &#10;  &#10; The principal purposes of this offering are to obtain additional capital to &#10; support our operations, establish a public market for our common stock and &#10; thereby enable access to the public equity markets for our employees and &#10; stockholders and increase our visibility in the marketplace. We intend to use &#10; the net proceeds of this offering for general corporate purposes, including &#10; working capital, expanded sales and marketing activities, increased research and &#10; development expenditures and funding our growth strategies. We expect to use &#10; some of the net proceeds from this offering to satisfy anticipated tax &#10; withholding and remittance obligations related to the RSA Settlement in &#10; connection with this offering. Based on approximately 384,000 RSAs that are &#10; expected to be granted and to vest immediately prior to the closing of this &#10; offering, and based on the assumed initial public offering price of $14.00 per &#10; share (the midpoint of the price range set forth on the cover page of this &#10; prospectus), we estimate that these tax withholding obligations upon the RSA &#10; Settlement would be approximately $2.7 million in the aggregate. Each $1.00 &#10; increase or decrease in the price of our common stock at the time of the RSA &#10; Settlement from the assumed initial public offering price of $14.00 per share, &#10; assuming no change in the applicable tax rates, would increase or decrease, &#10; respectively, the amount we would expect to pay by approximately $192,000.  &#10;  &#10; We may use a portion of the net proceeds to prepay principal amounts outstanding &#10; and deferred accrued interest under the B. Riley Convertible Note (including a &#10; prepayment penalty of up to 2.0% of the outstanding principal amount prepaid, &#10; which fee is waived if the total outstanding principal amount following &#10; prepayment does not fall below $10.0 million). The B. Riley Convertible Note has &#10; an interest rate of 10.0% per year, matures on September 1, 2022, and had an &#10; outstanding principal balance, including deferred accrued interest, of $13.0  &#10; million as of December 31, 2018. We may also use a portion of the net proceeds  &#10; to acquire or invest in complimentary businesses, although we currently have no &#10; agreements or understandings with respect to any such acquisitions or  &#10; investments. Pending their application, we intend to invest the net proceeds in &#10; short-term, interest-bearing, investment-grade investments, certificates of &#10; deposit or guaranteed obligations of the U.S. government.',\n",
       "   'competition': 'We operate in a highly competitive environment serving end customers in the &#10; industrial enterprise and public sector markets. These markets are highly  &#10; fragmented, evolving and increasingly competitive. Competition in our industry &#10; is intense and has been characterized by rapidly changing technologies, evolving &#10; industry standards, frequent new product introductions and rapid changes in end &#10; user requirements. &#10;  &#10; We face competition from manufacturers of non-rugged mobile phones such as Apple &#10; Inc. and Samsung Electronics Co. Ltd., to the extent end users decide to &#10; purchase traditional devices for use in environments that we believe are better &#10; suited for ruggedized mobile phones. We also face competition from manufacturers &#10; of rugged mobile phones such as Bullitt Mobile Ltd. and Kyocera Corporation as &#10; well as from large system integrators and manufacturers of private and public &#10; wireless network equipment and devices. Competitors in this space include Harris &#10; Corporation, JVC KENWOOD Corporation, Motorola Solutions, Inc. and Tait &#10; International Limited. For the Data Capture and RFID portion of our product &#10; offerings, competitors include companies that provide a broad portfolio of &#10; barcode scanning products that are suitable for the majority of global market &#10; applications, such as Datalogic USA, Inc., Honeywell International Inc., &#10; Panasonic Corporation and Zebra Technologies Corporation. &#10;  &#10; We believe the principal competitive factors affecting the market for our  &#10; products are the products performance, features (including security features), &#10; quality, design innovation, reliability, price, customer service, reputation in &#10; the industry, brand loyalty and a strong third-party software and accessories &#10; ecosystem. We believe that our strongest competitive advantages are our &#10; products durability and reputation in the industry. In order to compete, we &#10; will be required to continue to respond promptly and effectively to the &#10; challenges of technological changes and our competitors innovations.',\n",
       "   'amount': 50000006,\n",
       "   'percentOffered': '18.31'},\n",
       "  {'symbol': 'HSACU',\n",
       "   'companyName': 'HEALTH SCIENCES ACQUISITIONS CORP',\n",
       "   'expectedDate': '2019-05-10',\n",
       "   'leadUnderwriters': ['Chardan Capital Markets LLC', 'UBS Investment Bank'],\n",
       "   'underwriters': [],\n",
       "   'companyCounsel': ['Loeb and Loeb LLP'],\n",
       "   'underwriterCounsel': ['Kirkland & Ellis LLP'],\n",
       "   'auditor': 'Continental Stock Transfer & Trust Company',\n",
       "   'market': 'NASDAQ Capital',\n",
       "   'cik': '0001764013',\n",
       "   'address': '412 W. 15TH STREET',\n",
       "   'city': 'NEW YORK',\n",
       "   'state': 'NY',\n",
       "   'zip': '10011',\n",
       "   'phone': '646-343-9298',\n",
       "   'ceo': 'Roderick Wong',\n",
       "   'employees': 3,\n",
       "   'url': '',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 10000000,\n",
       "   'priceLow': 10,\n",
       "   'priceHigh': None,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 900000,\n",
       "   'sharesOverAlloted': 1500000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 12500000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': -448,\n",
       "   'totalAssets': 405000,\n",
       "   'totalLiabilities': 380448,\n",
       "   'stockholderEquity': 24552,\n",
       "   'companyDescription': 'We are a blank check company formed under the laws of the State of Delaware on &#10; December 6, 2018. We were formed for the purpose of effecting a merger, share &#10; exchange, asset acquisition, share purchase, reorganization or similar business &#10; combination with one or more businesses, which we refer to throughout this &#10; prospectus as our initial business combination. Although there is no restriction &#10; or limitation on what industry our target operates in, it is our intention to &#10; pursue prospective targets that are focused on healthcare innovation. We &#10; anticipate targeting companies domiciled in North America or Europe that are &#10; developing assets in the biopharma and medical technology sectors, which aligns &#10; with our management teams experience in healthcare investing and drug &#10; development. At the time of preparing this prospectus, we have not identified &#10; any specific business combination, nor has anyone on our behalf initiated or &#10; engaged in any substantive discussions, formal or otherwise, related to such a &#10; transaction. Our efforts to date are limited to organizational activities &#10; related to this offering. &#10; --- &#10;  &#10; Our executive offices are located at 412 West 15th Street, Floor 9 New York, NY &#10; 10011 and our telephone number is (646) 343-9280.',\n",
       "   'businessDescription': 'We are a blank check company formed under the laws of the State of Delaware on &#10; December 6, 2018. We were formed for the purpose of effecting a merger, share &#10; exchange, asset acquisition, share purchase, reorganization or similar business &#10; combination with one or more businesses, which we refer to throughout this &#10; prospectus as our initial business combination. Although there is no restriction &#10; or limitation on what industry our target operates in, it is our intention to &#10; pursue prospective targets that are focused on healthcare innovation. We &#10; anticipate targeting companies domiciled in North America or Europe that are &#10; developing assets in the biopharma and medical technology sectors, which aligns &#10; with our management teams experience in healthcare investing and drug &#10; development. At the time of preparing this prospectus, we have not identified &#10; any specific business combination, nor has anyone on our behalf initiated or &#10; engaged in any substantive discussions, formal or otherwise, related to such a &#10; transaction. Our efforts to date are limited to organizational activities &#10; related to this offering. &#10; --- &#10;  &#10; Our executive offices are located at 412 West 15th Street, Floor 9 New York, NY &#10; 10011 and our telephone number is (646) 343-9280.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds of this offering, in addition to the funds we &#10; will receive from the sale of the private warrants, will be used as set forth in &#10; the following table: &#10;  &#10;                                                                  Without                              &#10;                                                               Over-Allotment         Over-Allotment   &#10;                                                                   Option            Option Exercised  &#10; Gross proceeds                                                                                        &#10; From offering                                                $    100,000,000       $     115,000,000 &#10; From sale of private warrants                                       5,000,000               5,000,000 &#10; Total gross proceeds                                              105,000,000             120,000,000 &#10; Offering expenses(1)                                                                                  &#10; Non-contingent underwriting discount (2.0% of gross                                                   &#10; proceeds from offering)                                             2,000,000 (2)           2,300,000 (2) &#10; Initial Trustee Fee                                                     6,500                   6,500     &#10; Legal fees and expenses                                               275,000                 275,000     &#10; Nasdaq listing fee                                                     55,000                  55,000     &#10; Printing and engraving expenses                                        45,000                  45,000     &#10; Accounting fees and expenses                                           40,000                  40,000     &#10; SEC/FINRA Expenses                                                     31,688                  31,688     &#10; Director & Officer liability insurance premiums                       150,000                 150,000     &#10; Miscellaneous                                                         296,812                 296,812     &#10; Total offering expenses (not including the deferred                                                    &#10; underwriting discount)                                              2,900,000 (3)           3,200,000 (3) &#10;                                                                                                           &#10; Held in the trust account(4)                                 $    100,000,000       $     115,000,000     &#10; Not held in the trust account                                $      2,100,000       $       1,800,000     &#10;  &#10; Use of net proceeds not held in the trust account(5)(6)                                       &#10;                                                                Amount           % of Total    &#10; Legal, accounting and other third-party expenses attendant                                   &#10; to the search for target businesses and to the due                                           &#10; diligence investigation, structuring and negotiation of                                      &#10; our initial business combination                             $   450,000               21.4 % &#10; Legal and accounting fees related to regulatory reporting                                    &#10; obligations                                                      150,000                7.1 % &#10; Consulting, travel and miscellaneous expenses incurred                                       &#10; during search for initial business combination target            100,000                4.8 % &#10; Payment for office space, administrative and support                                         &#10; services                                                         240,000               11.4 % &#10; Nasdaq continued listing fees                                     55,000                2.6 % &#10; Working capital, as necessary                                  1,000,000 (5)           47.6 % &#10; Working capital to cover miscellaneous expenses                  105,000 (5)            5.0 % &#10; Total                                                        $ 2,100,000              100.0 % &#10;  &#10; (1) A portion of the offering expenses, including the SEC registration fee, the &#10;     FINRA filing fee, the non-refundable portion of the Nasdaq listing fee and a &#10;     portion of the legal and audit fees, have been paid from the funds we &#10;     received as loans from our insiders described below. These funds will be &#10;     repaid out of the proceeds of this offering available to us. &#10;  &#10; (2) No discounts or commissions will be paid with respect to the purchase of the &#10;     private warrants. &#10;  &#10; (3) Does not include the deferred underwriting commission payable to Chardan &#10;     Capital Markets LLC in an amount equal to 3.5% of the total gross proceeds &#10;     raised in the offering ($3,500,000, or $4,025,000 if the underwriters &#10;     over-allotment option is exercised in full). &#10;  &#10; (4) The funds held in the trust account may, but need not, be used to pay our &#10;     expenses relating to completing our initial business combination, including &#10;     a deferred underwriting commission payable to Chardan Capital Markets LLC in &#10;     an amount equal to 3.5% of the total gross proceeds raised in the offering &#10;     described below. &#10;  &#10; (5) These expenses are estimates only. Our actual expenditures for some or all &#10;     of these items may differ from the estimates set forth herein. For example, &#10;     we may incur greater legal and accounting expenses than our current &#10;     estimates in connection with negotiating and structuring our initial &#10;     business combination based upon the level of complexity of that business &#10;     combination. We do not anticipate any change in the categories of our &#10;     intended use of proceeds. &#10;  &#10; (6) In the event that the over-allotment option is exercised in full, the amount &#10;     available for working capital, as necessary and working capital to cover &#10;     miscellaneous expenses will be an aggregate of $1,205,000. &#10;  &#10; Certain of our stockholders have committed that they will purchase the private &#10; warrants (for an aggregate purchase price of $5,000,000) from us on a private &#10; placement basis simultaneously with the consummation of this offering. &#10;  &#10; $100,000,000, or $115,000,000 if the over-allotment option is exercised in full, &#10; of net proceeds of this offering and the sale of the private warrants will be &#10; placed in a trust account in the United States at Morgan Stanley Bank, N.A., &#10; maintained by Continental Stock Transfer & Trust Company, as trustee. The funds &#10; held in the trust account will be invested only in United States government &#10; treasury bills, bonds or notes having a maturity of 180 days or less, or in &#10; money market funds meeting the applicable conditions under Rule 2a-7 promulgated &#10; under the Investment Company Act of 1940 and that invest solely in U.S. &#10; treasuries, so that we are not deemed to be an investment company under the &#10; Investment Company Act. Except with respect to interest earned on the funds held &#10; in the trust account that may be released to us to pay our income or other tax &#10; obligations, the proceeds will not be released from the trust account until the &#10; earlier of the completion of our initial business combination or our redemption &#10; of 100% of the outstanding public shares if we have not completed a business &#10; combination in the required time period. The proceeds held in the trust account &#10; may be used as consideration to pay the sellers of a target business with which &#10; we complete our initial business combination to the extent not used to pay &#10; converting stockholders. Any amounts not paid as consideration to the sellers of &#10; the target business may be used to finance operations of the target business. &#10;  &#10; The payment to Health Sciences Holdings, LLC, of a monthly fee of $10,000 is for &#10; general and administrative services including office space, utilities and &#10; secretarial support. However, pursuant to the terms of such agreement, we may &#10; delay payment of such monthly fee upon a determination by our audit committee &#10; that we lack sufficient funds held outside the trust to pay actual or &#10; anticipated expenses in connection with our initial business combination. Any &#10; such unpaid amount will accrue without interest and be due and payable no later &#10; than the date of the consummation of our initial business combination. This &#10; arrangement is being agreed to by Health Sciences Holdings, LLC for our benefit. &#10; We believe that the fee charged by Health Sciences Holdings, LLC is at least as &#10; favorable as we could have obtained from an unaffiliated person. This &#10; arrangement will terminate upon completion of our initial business combination &#10; or the distribution of the trust account to our public stockholders. Other than &#10; the $10,000 per month fee, no compensation of any kind (including finders fees, &#10; consulting fees or other similar compensation) will be paid to our insiders, &#10; members of our management team or any of our or their respective affiliates, for &#10; services rendered to us prior to or in connection with the consummation of our &#10; initial business combination (regardless of the type of transaction that it is). &#10; However, such individuals will receive reimbursement for any out-of-pocket &#10; expenses incurred by them in connection with activities on our behalf, such as &#10; identifying potential target businesses, performing business due diligence on &#10; suitable target businesses and business combinations, as well as traveling to &#10; and from the offices, plants or similar locations of prospective target &#10; businesses to examine their operations. Since the role of present management &#10; after our initial business combination is uncertain, we have no ability to &#10; determine what remuneration, if any, will be paid to those persons after our &#10; initial business combination. &#10;  &#10; The net proceeds from this offering available to us out of trust for our working &#10; capital requirements in searching for our initial business combination will be &#10; approximately $2,100,000 (or $1,800,000 if the over-allotment option is &#10; exercised in full). &#10;  &#10; The allocation of the net proceeds available to us outside of the trust account &#10; represents our best estimate of the intended uses of these funds. In the event &#10; that our assumptions prove to be inaccurate, we may reallocate some of such &#10; proceeds within the above described categories. If our estimate of the costs of &#10; undertaking due diligence and negotiating our initial business combination is &#10; less than the actual amount necessary to do so, we may be required to raise &#10; additional capital, the amount, availability and cost of which is currently &#10; unascertainable. In this event, we could seek such additional capital through &#10; loans or additional investments from our insiders, members of our management &#10; team or third parties, but our insiders, members of our management team or third &#10; parties are not under any obligation to advance funds to, or invest in, us. &#10;  &#10; We will likely use substantially all of the net proceeds of this offering, &#10; including the funds held in the trust account, in connection with our initial &#10; business combination and to pay our expenses relating thereto, including the &#10; deferred underwriting commission payable to Chardan Capital Markets LLC in an &#10; amount equal to 3.5% of the total gross proceeds raised in the offering upon &#10; consummation of our initial business combination. To the extent that our capital &#10; stock is used in whole or in part as consideration to effect our initial &#10; business combination, the proceeds held in the trust account which are not used &#10; to consummate a business combination will be disbursed to the combined company &#10; and will, along with any other net proceeds not expended, be used as working &#10; capital to finance the operations of the target business. Such working capital &#10; funds could be used in a variety of ways, including continuing or expanding the &#10; target business operations, for strategic acquisitions and for marketing, &#10; research and development of existing or new products. &#10;  &#10; To the extent we are unable to consummate a business combination, we will pay &#10; the costs of liquidation from our remaining assets outside of the trust account. &#10; If such funds are insufficient, our insiders have agreed to pay the funds &#10; necessary to complete such liquidation (currently anticipated to be no more than &#10; $15,000) and have agreed not to seek repayment of such expenses. &#10;  &#10; In December 2018, Health Sciences Holdings, LLC loaned us $300,000 to be used to &#10; pay a portion of the expenses of this offering referenced in the line items &#10; above for the SEC registration fee, FINRA filing fee, the non-refundable portion &#10; of the Nasdaq listing fee and a portion of the legal and accounting fees and &#10; expenses. The loans are payable without interest upon the consummation of this &#10; offering. &#10;  &#10; We believe that, upon consummation of this offering, we will have sufficient &#10; available funds to operate for up to the next 24 months, assuming that our &#10; initial business combination is not consummated during that time. However, if &#10; necessary, in order to meet our working capital needs following the consummation &#10; of this offering, our insiders may, but are not obligated to, loan us funds, &#10; from time to time or at any time, in whatever amount they deem reasonable in &#10; their sole discretion. Each loan would be evidenced by a promissory note. The &#10; notes would either be paid upon consummation of our initial business &#10; combination, without interest, or, at the lenders discretion, up to $200,000 of &#10; the notes may be converted upon consummation of our business combination into &#10; additional private warrants at a price of $0.50 per warrant. Our stockholders &#10; have approved the issuance of the private warrants upon conversion of such &#10; notes, to the extent the holder wishes to so convert such notes at the time of &#10; the consummation of our initial business combination. If we do not complete a &#10; business combination, any loans and advances from our insiders or their &#10; affiliates, will be repaid only from amounts remaining outside our trust &#10; account, if any. &#10;  &#10; A public stockholder will be entitled to receive funds from the trust account &#10; only in the event of (1) our redemption of 100% of the outstanding public shares &#10; if we have not completed a business combination in the required time period, (2) &#10; if that public stockholder elects to convert public shares in connection with a &#10; stockholder vote or (3) if that public stockholder sells shares to us in any &#10; tender offer in connection with a proposed business combination. In no other &#10; circumstances will a public stockholder have any right or interest of any kind &#10; to or in the trust account.',\n",
       "   'competition': 'In identifying, evaluating and selecting a target business, we may encounter &#10; intense competition from other entities having a business objective similar to &#10; ours. Many of these entities are well established and have extensive experience &#10; identifying and effecting business combinations directly or through affiliates. &#10; Many of these competitors possess greater technical, human and other resources &#10; than us and our financial resources will be relatively limited when contrasted &#10; with those of many of these competitors. While we believe there may be numerous &#10; potential target businesses that we could complete a business combination with &#10; utilizing the net proceeds of this offering, our ability to compete in &#10; completing a business combination with certain sizable target businesses may be &#10; limited by our available financial resources. &#10;  &#10; The following also may not be viewed favorably by certain target businesses: &#10;  &#10; . our obligation to seek stockholder approval of our initial business &#10;   combination or engage in a tender offer may delay the completion of a &#10;   transaction; &#10;  &#10; . our obligation to convert shares of common stock held by our public &#10;   stockholders may reduce the resources available to us for our initial business &#10;   combination; &#10;  &#10; . our outstanding warrants and the potential future dilution they represent; &#10;  &#10; . our obligation to pay the deferred underwriting commission to Chardan Capital &#10;   Markets LLC upon consummation of our initial business combination; &#10;  &#10; . our obligation to either repay working capital loans that may be made to us by &#10;   our insiders or their affiliates; &#10;  &#10; . our obligation to register the resale of the insider shares, as well as the &#10;   private warrants (and underlying securities) and any shares issued to our &#10;   insiders or their affiliates upon conversion of working capital loans; and &#10;  &#10; . the impact on the target business assets as a result of unknown liabilities &#10;   under the securities laws or otherwise depending on developments involving us &#10;   prior to the consummation of a business combination. &#10;  &#10; Any of these factors may place us at a competitive disadvantage in successfully &#10; negotiating our initial business combination. Our management believes, however, &#10; that our status as a public entity and potential access to the United States &#10; public equity markets may give us a competitive advantage over privately held &#10; entities having a similar business objective as ours in connection with an &#10; initial business combination with a target business with significant growth &#10; potential on favorable terms. &#10;  &#10; If we succeed in effecting our initial business combination, there will be, in &#10; all likelihood, intense competition from competitors of the target business. &#10; Subsequent to our initial business combination, we may not have the resources or &#10; ability to compete effectively.',\n",
       "   'amount': 50000000,\n",
       "   'percentOffered': '80.00'},\n",
       "  {'symbol': 'CPTI',\n",
       "   'companyName': 'CONVERSIONPOINT HOLDINGS, INC.',\n",
       "   'expectedDate': '2019-05-14',\n",
       "   'leadUnderwriters': ['GMP Securities L.P', 'Oppenheimer & Co. Inc.'],\n",
       "   'underwriters': ['D.A. Davidson and Co'],\n",
       "   'companyCounsel': ['Troutman Sanders LLP'],\n",
       "   'underwriterCounsel': ['White and Case LLP'],\n",
       "   'auditor': 'Colonial Stock Transfer Co., Inc',\n",
       "   'market': 'NASDAQ Capital',\n",
       "   'cik': '0001761369',\n",
       "   'address': '840 NEWPORT CENTER DRIVE, SUITE 450',\n",
       "   'city': 'NEWPORT BEACH',\n",
       "   'state': 'CA',\n",
       "   'zip': '92660',\n",
       "   'phone': '(888) 706-6764',\n",
       "   'ceo': 'Robert Tallack',\n",
       "   'employees': 85,\n",
       "   'url': 'www.conversionpoint.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 6153846,\n",
       "   'priceLow': 6,\n",
       "   'priceHigh': 7,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 1500000,\n",
       "   'sharesOverAlloted': 923077,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 28153846,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 39780941,\n",
       "   'netIncome': -33239493,\n",
       "   'totalAssets': 48961064,\n",
       "   'totalLiabilities': 12951634,\n",
       "   'stockholderEquity': 36009430,\n",
       "   'companyDescription': 'Upon the completion of this offering and the consummation of the mergers &#10; described herein, our business will be comprised of the combined businesses of &#10; ConversionPoint Technologies Inc., a Delaware corporation, or ConversionPoint, &#10; and Inuvo, Inc., a Nevada corporation, or Inuvo. &#10;  &#10; Currently, ConversionPoint helps e-commerce companies and brands target, &#10; convert, manage and re-engage their customers using sophisticated online &#10; tracking technology and data analytics. ConversionPoints suite of technologies &#10; manages and optimizes multiple aspects of e-commerce including rich media &#10; content creation, product information management and syndication, audience &#10; targeting, conversion optimization, remarketing, logistics and customer &#10; management. ConversionPoint delivers its technologies to its clients through &#10; software-as-a-service, or SaaS, and uses its technologies to provide managed &#10; digital marketing and e-commerce technology services to brands and advertisers, &#10; which we refer to as managed services. ConversionPoint also uses its own &#10; technologies to sell various products directly to consumers, which we refer to &#10; as e-commerce product sales. &#10;  &#10; Inuvo develops data, analytics and artificial intelligence, or AI, technology &#10; that empowers its clients to execute their business-to-business, or B2B, and &#10; business-to-consumer, or B2C, strategies. These capabilities allow Inuvos &#10; clients to engage with customers and prospects in a manner that drives closer &#10; collaboration through knowledge. These patented technologies have served &#10; household names in industries that have included retail, automotive, insurance, &#10; health care, technology, telecommunications and finance. &#10;  &#10; As a newly-combined company, our mission will be to provide a unified, &#10; end-to-end platform that enables e-commerce companies and brands to target, &#10; convert, manage and re-engage their customers using first-party-data-driven, &#10; AI-powered technology not previously available to small-to-medium-sized &#10; businesses, or SMBs. Our combined business will consist, in part, of &#10; ConversionPoints enterprise grade e-commerce technology, which is currently &#10; used to support over 100 premium online retailers and harnesses first party data &#10; from over 150 million shoppers per month and billions of consumer interactions &#10; across over 860 brands to create optimized product experiences, as well as &#10; Inuvos AI-powered advertising platform and first-party data engine currently &#10; used to create real-time snapshots of highly specific and custom experiences by &#10; consumers. We believe that the combination of ConversionPoints and Inuvos &#10; technologies will allow us to use our combined expertise in customer acquisition &#10; and engagement technology in order to deliver a platform to SMBs that will &#10; empower them to succeed in a fragmented marketplace by creating a modern front &#10; office through the unification of AI, real-time first-party data, targeted &#10; audiences and engaging page experiences that drive increased conversions which &#10; could result in billions of dollars of revenue for these SMBs. &#10;  &#10; Further, as a combined company, we expect to carry out ConversionPoints vision &#10; to simplify the e-commerce experience by integrating Inuvos IntentKey product &#10; into our unified platform. IntentKey is an AI-powered targeting system that &#10; enables campaigns to reach audiences that would typically be missed. &#10; --- &#10;  &#10; We were incorporated in the State of Delaware on November 1, 2018. Our principal &#10; executive offices are located at 840 Newport Center Drive, Suite 450, Newport &#10; Beach, CA 92660. Our telephone number is (888) 706-6764. Our Internet website &#10; address is www.conversionpoint.com. Inuvos principal executive offices are &#10; located at 500 President Clinton Avenue, Suite 300, Little Rock, Arkansas 72201. &#10; Inuvos phone number is (501) 205-8508 and its website is www.inuvo.com.',\n",
       "   'businessDescription': 'Upon the completion of this offering and the consummation of the mergers &#10; described herein, our business will be comprised of the combined businesses of &#10; ConversionPoint Technologies Inc., a Delaware corporation, or ConversionPoint, &#10; and Inuvo, Inc., a Nevada corporation, or Inuvo. &#10;  &#10; Currently, ConversionPoint helps e-commerce companies and brands target, &#10; convert, manage and re-engage their customers using sophisticated online &#10; tracking technology and data analytics. ConversionPoints suite of technologies &#10; manages and optimizes multiple aspects of e-commerce including rich media &#10; content creation, product information management and syndication, audience &#10; targeting, conversion optimization, remarketing, logistics and customer &#10; management. ConversionPoint delivers its technologies to its clients through &#10; software-as-a-service, or SaaS, and uses its technologies to provide managed &#10; digital marketing and e-commerce technology services to brands and advertisers, &#10; which we refer to as managed services. ConversionPoint also uses its own &#10; technologies to sell various products directly to consumers, which we refer to &#10; as e-commerce product sales. &#10;  &#10; Inuvo develops data, analytics and artificial intelligence, or AI, technology &#10; that empowers its clients to execute their business-to-business, or B2B, and &#10; business-to-consumer, or B2C, strategies. These capabilities allow Inuvos &#10; clients to engage with customers and prospects in a manner that drives closer &#10; collaboration through knowledge. These patented technologies have served &#10; household names in industries that have included retail, automotive, insurance, &#10; health care, technology, telecommunications and finance. &#10;  &#10; As a newly-combined company, our mission will be to provide a unified, &#10; end-to-end platform that enables e-commerce companies and brands to target, &#10; convert, manage and re-engage their customers using first-party-data-driven, &#10; AI-powered technology not previously available to small-to-medium-sized &#10; businesses, or SMBs. Our combined business will consist, in part, of &#10; ConversionPoints enterprise grade e-commerce technology, which is currently &#10; used to support over 100 premium online retailers and harnesses first party data &#10; from over 150 million shoppers per month and billions of consumer interactions &#10; across over 860 brands to create optimized product experiences, as well as &#10; Inuvos AI-powered advertising platform and first-party data engine currently &#10; used to create real-time snapshots of highly specific and custom experiences by &#10; consumers. We believe that the combination of ConversionPoints and Inuvos &#10; technologies will allow us to use our combined expertise in customer acquisition &#10; and engagement technology in order to deliver a platform to SMBs that will &#10; empower them to succeed in a fragmented marketplace by creating a modern front &#10; office through the unification of AI, real-time first-party data, targeted &#10; audiences and engaging page experiences that drive increased conversions which &#10; could result in billions of dollars of revenue for these SMBs. &#10;  &#10; Further, as a combined company, we expect to carry out ConversionPoints vision &#10; to simplify the e-commerce experience by integrating Inuvos IntentKey product &#10; into our unified platform. IntentKey is an AI-powered targeting system that &#10; enables campaigns to reach audiences that would typically be missed. The &#10; following are some key facts and statistics regarding IntentKey: &#10;  &#10; . Over 10 years and millions of dollars have been invested in IntentKey &#10;  &#10;   . IntentKeys prospecting engine understands consumer online behavior to &#10;     uncover consumer intent                                                   &#10;  &#10;   . The developers of IntentKey were pioneers in the field of AI, which has been &#10;     refined and optimized over the past 10 years                               &#10;  &#10; . IntentKey learns consumer browsing intent &#10;  &#10;   . IntentKeys AI crawls millions of web sites daily to learn the intentions of &#10;     web pages                                                                  &#10;  &#10;   . 13 million new URLs are added daily to keep up with new trends &#10;  &#10; . IntentKey creates precise customer profiles &#10;  &#10;   . IntentKeys system stores over 500 million anonymous consumer profiles &#10;  &#10;   . IntentKey has 24 million targetable concepts allowing us to target hard to &#10;     find in-market shoppers                                                  &#10;  &#10; . IntentKey provides real time data updates &#10;  &#10;   . 500 million anonymous consumer records are updated continuously to predict  &#10;     consumer purchases                                                         &#10;  &#10; . IntentKeys AI by the numbers &#10;  &#10;   . Over 500 million consumer profiles are updated daily &#10;  &#10;   . AI processes 14 billion ad calls every day to update the profiles in real &#10;     time &#10;  &#10;   . 3.5 billion URLs in IntentKeys portfolio with 12.6 million added daily &#10;  &#10;   . AI is managed in two co-located data centers to handle volume &#10;  &#10;   . 24 million important concepts identified (objects, ideas, emotions, place,  &#10;     etc.)                                                                      &#10;  &#10; We expect to generate revenue from the following three business models: &#10; e-commerce, managed services, and SaaS. As of December 31, 2018, e-commerce &#10; sales generated 18%, managed services generated 79% and SaaS generated 3% of &#10; ConversionPoints total revenues. Once we are a combined company, our goal is to &#10; use our integrated, AI-powered, end-to-end platform to drive revenue and &#10; generate 40% of our revenue from managed services and 60% from SaaS. &#10; --- &#10;  &#10; We were incorporated in the State of Delaware on November 1, 2018. Our principal &#10; executive offices are located at 840 Newport Center Drive, Suite 450, Newport &#10; Beach, CA 92660. Our telephone number is (888) 706-6764. Our Internet website &#10; address is www.conversionpoint.com. Inuvos principal executive offices are &#10; located at 500 President Clinton Avenue, Suite 300, Little Rock, Arkansas 72201. &#10; Inuvos phone number is (501) 205-8508 and its website is www.inuvo.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from our issuance and sale of 6,153,846 shares &#10; of our common stock in this offering will be approximately $35.7 million, &#10; assuming an initial public offering price of $6.50 per share of common stock, &#10; which is the midpoint of the price range set forth on the cover page of this &#10; prospectus, after deducting estimated underwriting discounts and commissions and &#10; estimated offering expenses payable by us. If the underwriters exercise their &#10; option to purchase additional shares in full, we estimate that the net proceeds &#10; from this offering will be approximately $41.3 million, after deducting &#10; estimated underwriting discounts and commissions and estimated offering expenses &#10; payable by us. &#10;  &#10; A $1.00 increase or decrease in the assumed initial public offering price of &#10; $6.50 per share of common stock would increase or decrease the net proceeds from &#10; this offering by approximately $5.7 million, assuming that the number of shares &#10; offered by us, as set forth on the cover page of this prospectus, remains the &#10; same and after deducting the estimated underwriting discounts and commissions. &#10; Similarly, each increase or decrease of $1.0 million in the amount of securities &#10; offered by us would increase or decrease the net proceeds that we receive from &#10; this offering by approximately $6.0 million, assuming the assumed initial public &#10; offering price remains the same and after deducting the estimated underwriting &#10; discounts and commissions. &#10;  &#10; We currently intend to use approximately $15.9 million of the net proceeds from &#10; this offering to satisfy the cash portion of the merger consideration payable to &#10; Inuvo stockholders. We also currently intend to use approximately $8.9 million &#10; for the reduction of indebtedness we incurred for working capital purposes under &#10; (i) the loan agreement with Western Alliance Bank (approximately $1.9 million), &#10; which does not have a maturity date and bears interest at a rate per annum equal &#10; to the prime rate plus 1%, (ii) the SellPoints unsecured subordinated promissory &#10; notes (approximately $3.1 million), which mature on May 31, 2019, and bear &#10; interest at the rate of 10% per annum, (iii) the Loan and Security Agreement &#10; with Montage Capital II, L.P and Partners for Growth IV, L.P. (approximately, &#10; $2.4 million), which matures upon the earlier of the closing of this offering &#10; and May 31, 2020, and bears interest at the rate of 12.25% per annum, (iv) notes &#10; payable to related parties of ConversionPoint (approximately $0.3 million), &#10; which accrue interest at a rate of 8% per annum and are due within 30 days after &#10; the date on which all amounts are repaid to Montage and Partners for Growth &#10; under the Loan and Security Agreement described above, (v) notes payable to &#10; related parties of Inuvo (approximately $0.3 million), which accrue interest at &#10; a rate of 10% per annum and mature on the earlier to occur of a change in &#10; control of Inuvo or November 2, 2019, and (vi) the promissory note issued to CPT &#10; Investments, LLC (approximately $1.0 million), which accrues interest at a rate &#10; of 10% per annum and is due and payable on June 30, 2019. We also intend to use &#10; approximately $10.9 million for general corporate purposes. The principal &#10; reasons for this offering are to increase our capitalization and financial &#10; flexibility, increase our visibility in the marketplace and create a public &#10; market for our shares of common stock. &#10;  &#10; This expected use of net proceeds from this offering represents our intentions &#10; based upon our current plans and business conditions. The amounts and timing of &#10; our actual expenditures may vary significantly depending on numerous factors, &#10; including, among other things, the cash generated by our operations and the rate &#10; of growth, if any, of our business. As a result, our management will retain &#10; broad discretion over the allocation of the net proceeds from this offering. We &#10; may find it necessary or advisable to use the net proceeds from this offering &#10; for other purposes, and we will have broad discretion in the application of net &#10; proceeds. &#10;  &#10; Although it is difficult to predict future liquidity requirements, we believe &#10; that the net proceeds from this offering and our existing cash flow from &#10; operations will be sufficient to fund our operations for the next twelve months. &#10;  &#10; Pending our use of the net proceeds from this offering, we intend to invest the &#10; net proceeds in a variety of capital preservation investments, including &#10; short-term, investment-grade, interest-bearing instruments, certificates of &#10; deposit and direct or guaranteed obligations of the U.S. government. &#10;  &#10; ConversionPoint had negative operating cash flow for the year ended December 31, &#10; 2018. In the future, additional financing may be required to support our &#10; expected investments in our combined business. To the extent we, as a combined &#10; company, have negative cash flow in future periods, we may use a portion of our &#10; general working capital (including the proceeds of this offering) to fund such &#10; negative cash flow.',\n",
       "   'competition': 'The overall market for e-commerce solutions is rapidly evolving, highly &#10; competitive, complex, fragmented with numerous single point solutions, and is &#10; subject to changing technology and shifting customer needs. ConversionPoint &#10; faces significant competition. To maintain and improve ConversionPoints &#10; competitive position, ConversionPoint must keep pace with the evolving needs of &#10; its customers and continue to develop and introduce new modules, features and &#10; services in a timely and efficient manner, and complete the development of its &#10; unified end-to-end e-commerce SaaS platform. &#10;  &#10; ConversionPoint currently competes with established companies, such as &#10; Optimizely and Voluum in the digital media optimization space, WebCollage in the &#10; rich content creation and product information syndication space, Limelight and &#10; Click Funnels in the sales conversion space, AdRoll and Criteo in the &#10; remarketing space, and Narvar and ShipStation in the shipping and logistics &#10; space. &#10;  &#10; ConversionPoint believes the principal competitive factors in its market include &#10; the following: &#10;  &#10;  solution quality, breadth, flexibility and functionality; &#10;  &#10;  level of customer satisfaction and the ability to respond to customer needs   &#10;   rapidly;                                                                      &#10;  &#10;  ability to innovate and develop new or improved products and modules; and &#10;  &#10;  brand awareness and reputation. &#10;  &#10; ConversionPoint believes that it competes favorably with respect to the factors &#10; described above, however, competitors continue to increase their suite of &#10; offerings across e-commerce channels to better compete. A number of competitors &#10; have greater name recognition and are better capitalized than ConversionPoint. &#10; ConversionPoints ability to remain competitive in its market segment depends &#10; upon its ability to innovate and to efficiently provide unique solutions to its &#10; demand and supply customers.',\n",
       "   'amount': 39999999,\n",
       "   'percentOffered': '21.86'},\n",
       "  {'symbol': 'BEER',\n",
       "   'companyName': 'BRICKTOWN BREWERY RESTAURANTS LLC',\n",
       "   'expectedDate': '2019-05-15',\n",
       "   'leadUnderwriters': ['ThinkEquity, a division of Fordham Financial Management, Inc'],\n",
       "   'underwriters': [],\n",
       "   'companyCounsel': ['Ellenoff Grossman & Schole LLP'],\n",
       "   'underwriterCounsel': ['Loeb and Loeb LLP'],\n",
       "   'auditor': 'VStock Transfer, LLC',\n",
       "   'market': 'NASDAQ Capital',\n",
       "   'cik': '0001758951',\n",
       "   'address': '14504 HERTZ QUAIL PARKWAY',\n",
       "   'city': 'OKLAHOMA CITY',\n",
       "   'state': 'OK',\n",
       "   'zip': '73134',\n",
       "   'phone': '(405) 285-5362',\n",
       "   'ceo': 'W.G. Buck Warfield',\n",
       "   'employees': 894,\n",
       "   'url': 'www.bricktownbrewery.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 1875000,\n",
       "   'priceLow': 7,\n",
       "   'priceHigh': 9,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 568543,\n",
       "   'sharesOverAlloted': 281250,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 5000000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 28105402,\n",
       "   'netIncome': -884416,\n",
       "   'totalAssets': 8328615,\n",
       "   'totalLiabilities': 18017910,\n",
       "   'stockholderEquity': -10019782,\n",
       "   'companyDescription': 'We are engaged in the business of developing, owning and operating Bricktown &#10; Brewery and Bricktown Tap House & Kitchen branded restaurants. Bricktown Brewery &#10; and Bricktown Tap House & Kitchen restaurants are multi-tap, casual plus dining &#10; restaurants featuring Bricktown brewed beers (which we brew in-house at one of &#10; our two brewing facilities) and other local beers along with a broad menu &#10; anchored in crafted burgers, artisanal pizza and our take on American comfort &#10; foods. Currently, we own or license restaurants in five states: Oklahoma, Texas, &#10; Arkansas, Kansas and Missouri. As of the date hereof, there are 14 restaurant &#10; units operating under the Bricktown Brewery or Bricktown Tap House & Kitchen &#10; brand, each of which is in secondary and tertiary markets (based on population &#10; size) in its respective state. &#10; --- &#10;  &#10; We were organized originally as a limited liability company under the laws of &#10; the State of Oklahoma in October, 2014 and will convert to a corporation &#10; immediately prior to the effectiveness of the registration statement of which &#10; this prospectus forms a part. Our principal executive office is located at 14504 &#10; Hertz Quail Springs Parkway, Oklahoma City, OK 73134, and our phone number is &#10; (405) 285-5362. We also maintain a website at www.bricktownbrewery.com.',\n",
       "   'businessDescription': 'We are engaged in the business of developing, owning and operating Bricktown &#10; Brewery and Bricktown Tap House & Kitchen branded restaurants. Bricktown Brewery &#10; and Bricktown Tap House & Kitchen restaurants are multi-tap, casual plus dining &#10; restaurants featuring Bricktown brewed beers (which we brew in-house at one of &#10; our two brewing facilities) and other local beers along with a broad menu &#10; anchored in crafted burgers, artisanal pizza and our take on American comfort &#10; foods. Currently, we own or license restaurants in five states: Oklahoma, Texas, &#10; Arkansas, Kansas and Missouri. As of the date hereof, there are 14 restaurant &#10; units operating under the Bricktown Brewery or Bricktown Tap House & Kitchen &#10; brand, each of which is in secondary and tertiary markets (based on population &#10; size) in its respective state. &#10;  &#10; The original Bricktown Brewery restaurant first opened in Oklahoma City, &#10; Oklahoma in 1992 serving local beer and great food with truly friendly &#10; service. Subsequently, we have expanded within Oklahoma and into Kansas, Texas &#10; and Arkansas, with additional licensed restaurants in Oklahoma and Missouri. We &#10; currently own and operate ten restaurants, including a restaurant to be acquired &#10; with the proceeds of this offering. We have licensed the right to open and &#10; operate three additional restaurants which we manage. These three licensed &#10; restaurants are owned by related parties and are not a part of the Company, &#10; although we expect to generate cash from these licensed properties in the future &#10; as described below. We also own 50% of a company that manages and operates &#10; various food and beverage outlets, including a licensed Bricktown Brewery &#10; restaurant at Remington Park, an Oklahoma City racetrack and casino. &#10;  &#10; We are actively looking to expand our business and the number of Company &#10; Restaurants both in the states of Oklahoma, Texas, Kansas and Arkansas in which &#10; we operate and in the Southwest, Midwest, Southeast and Mid-South regions &#10; outside of our current footprint. We are also looking for complimentary &#10; restaurant brands that we may acquire to give us additional synergistic growth &#10; opportunity. &#10;                                       &#10; Each of the Bricktown Brewery and Bricktown Tap House & Kitchen branded &#10; restaurants serves similar fare. Our menu features crafted burgers, artisanal &#10; style pizza and Bricktwisted Comfort Food, our take on American comfort foods. &#10; The prices of our food items range from $3.50 to $16.00 per item which we &#10; believe makes our restaurants appealing to a variety of different guests and for &#10; various dining occasions (including everyday lunch and dinner as well as after &#10; work special occasions). Additionally, each of our Bricktown Brewery locations &#10; serve our own hand-crafted beers as well as a full line up of regional beers &#10; that we sell as local beer. We brew a variety of trademarked beers as well as &#10; non-alcoholic craft root beer at our original Bricktown Brewery location in &#10; downtown Oklahoma City, Oklahoma and at our satellite brewing facility, BTB &#10; Brewing Company, which is also in Oklahoma City, Oklahoma. Because of Texas &#10; state laws, each of our Bricktown Tap House & Kitchen locations feature regional &#10; local beer but do not sell our brewed beers. All restaurants serve a full &#10; complement of distilled spirts, beers and wine. Across the Company Restaurants &#10; in 2018, we had an average customer transaction of $18.10 with a sales ratio of &#10; 76% food and non-alcoholic beverages to 24% alcoholic beverages (of which &#10; Bricktown Brewery beers accounted for approximately one-third of the sales). &#10; --- &#10;  &#10; We were organized originally as a limited liability company under the laws of &#10; the State of Oklahoma in October, 2014 and will convert to a corporation &#10; immediately prior to the effectiveness of the registration statement of which &#10; this prospectus forms a part. Our principal executive office is located at 14504 &#10; Hertz Quail Springs Parkway, Oklahoma City, OK 73134, and our phone number is &#10; (405) 285-5362. We also maintain a website at www.bricktownbrewery.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from the sale of the shares of common stock we &#10; are offering will be approximately $13.2 million based on an assumed offering &#10; price of $8.00 per share (which represents the mid-point of the estimated range &#10; of the initial public offering price shown on the front cover of this &#10; prospectus). If the underwriters fully exercise the over-allotment option, the &#10; net proceeds of the shares we sell will be approximately $15.2 million. Net &#10; proceeds is what we expect to receive after deducting the underwriting discount &#10; and commission and estimated offering expenses payable by us. &#10;  &#10; Each $1.00 increase (decrease) in the assumed offering price of $8.00 would &#10; increase (decrease) the net proceeds to us from this offering by approximately &#10; $1.810 million, after deducting estimated underwriting discount and commission &#10; and estimated offering expenses payable by us, assuming that the number of &#10; shares offered by us, as set forth on the cover page of this prospectus, remains &#10; the same. Each increase of 100,000 shares in the number of shares offered by us &#10; at the assumed public offering price would increase the net proceeds to us in &#10; this offering by approximately $730,000. Similarly, each decrease of 100,000 &#10; shares in the number of shares offered by us at the assumed public offering &#10; price would decrease the net proceeds to us from this offering by approximately &#10; $730,000. A change in the offering price or the number of shares by these &#10; amounts could have a material effect on our uses of the proceeds from this &#10; offering, and it may impact the amount of time prior to which we will need to &#10; seek additional capital. &#10;  &#10; We intend to use the net proceeds of this offering primarily to acquire 71st &#10; Street (as described in more detail elsewhere in this prospectus), repay related &#10; party notes, repay a promissory note held by a non-affiliated individual (such &#10; promissory note matures on December 31, 2019 and bears interest at a rate of 10% &#10; per annum), invest in or acquire companies that are synergistic with or  &#10; complimentary to our business (including, potentially, our licensed restaurants &#10;  though we have no contractual right to acquire these restaurants and there has &#10; not been any negotiation pertaining to the acquisition of such restaurants) and &#10; for working capital and other general corporate purposes. &#10;  &#10; We anticipate an approximate allocation of the use of net proceeds as follows: &#10;  &#10;                                                                $           &#10; Use of Net Proceeds                                      (in millions)*        % &#10; Acquisition of 71st Street                                          .85              6 &#10; Repayment of Related Party Indebtedness                            2.09             16 &#10; Repayment of Promissory Note                                        .15              1 &#10; Acquisition of Synergistic Companies, Working Capital                      &#10; and General                                                                &#10; Corporate Purposes                                                10.11             77 &#10; Total                                                              13.2            100 &#10;  &#10; * Assuming the over-allotment option is not exercised. &#10;  &#10; While we expect to use the net proceeds for the purposes described above, the &#10; amounts and timing of our actual expenditures, other than the acquisition of &#10; 71st Street, will depend upon numerous factors, including the aggregate amount &#10; raised in this offering. The expected net proceeds from the sale of the shares &#10; offered hereby, if added to our current cash and cash equivalents is anticipated &#10; to be sufficient to fund our operations for at least the next 12 months. In the &#10; event that our plans change, our assumptions change or prove to be inaccurate, &#10; or the net proceeds of this offering are less than as set forth herein or &#10; otherwise prove to be insufficient, it may be necessary or advisable to &#10; reallocate proceeds or curtail expansion activities, or we may be required to &#10; seek additional financing or curtail our operations. As a result of the &#10; foregoing, our success will be affected by our discretion and judgment with &#10; respect to the application and allocation of the net proceeds of this offering. &#10;  &#10; Pending their use, we plan to invest the net proceeds from this offering in &#10; short- and intermediate-term, interest-bearing obligations, investment-grade &#10; instruments, certificates of deposit or direct or guaranteed obligations of the &#10; U.S. government.',\n",
       "   'competition': 'The restaurant industry, including the casual dining subset segment is highly &#10; competitive. Bricktown Brewery and Bricktown Tap House & Kitchen compete with a &#10; large number of other varied menu restaurants in the areas in which we operate. &#10; We face significant competition from restaurants in the full service casual &#10; dining, brewpub, and fast casual dining segments of the restaurant industry. &#10; These segments are highly competitive with respect to, among other things, &#10; taste, price, food quality and presentation, beer selection, brewed beers &#10; service, location, and the ambience and condition of each restaurant. Our &#10; competition includes a variety of locally-owned restaurants and national and &#10; regional chains offering dine-in, carry-out, delivery, and catering services. &#10; Among our competitors are a number of multi-unit, multi-market, casual dining &#10; and brewpub restaurant concepts, some of which are expanding nationally. As we &#10; expand, we will face competition from these restaurant concepts as well as new &#10; competitors that strive to compete with our market segments. These competitors &#10; may have, among other things, lower operating costs, better locations, better &#10; facilities, better management, more effective marketing, and more efficient &#10; operations. Many of the restaurants with which Bricktown Brewery and Bricktown &#10; Tap House & Kitchen compete are owned and operated by regional and national &#10; chains, many of which have greater resources and experiences than we do. &#10; Restaurant companies that currently compete with Bricktown in our markets &#10; include Chilis, Applebees, TGIF, Buffalo Wild Wings and other regional, &#10; national and local restaurant groups. Among younger customers, we also face &#10; competition from meal-kit companies such as Blue Apron or Hello Fresh, that &#10; sell prepare at home meals. &#10;  &#10; We believe that Bricktown Brewery and Bricktown Tap House & Kitchen has an &#10; advantage in our proprietary beers, hand crafted quality of our food and the &#10; unusual mix of food items, quality, quantity and price.',\n",
       "   'amount': 15000000,\n",
       "   'percentOffered': '37.50'},\n",
       "  {'symbol': 'PMTG',\n",
       "   'companyName': 'PIMCO MORTGAGE INCOME TRUST INC.',\n",
       "   'expectedDate': '2019-05-16',\n",
       "   'leadUnderwriters': ['Credit Suisse Securities (USA) LLC'],\n",
       "   'underwriters': ['BofA Merrill Lynch',\n",
       "    'Citigroup Global Markets Inc',\n",
       "    'Goldman Sachs & Co. LLC',\n",
       "    'J.P. Morgan Securities LLC',\n",
       "    'JMP Securities LLC',\n",
       "    'JonesTrading Institutional Services LLC',\n",
       "    'Keefe, Bruyette & Woods, Inc',\n",
       "    'Morgan Stanley & Co. LLC',\n",
       "    'Nomura Securities International, Inc.',\n",
       "    'RBC Capital Markets, LLC',\n",
       "    'UBS Investment Bank',\n",
       "    'Wells Fargo Securities, LLC'],\n",
       "   'companyCounsel': ['Latham & Watkins LLP and Venable LLP'],\n",
       "   'underwriterCounsel': ['Clifford Chance US LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0001742691',\n",
       "   'address': 'C/O PIMCO, 650 NEWPORT CENTER DRIVE',\n",
       "   'city': 'NEWPORT BEACH',\n",
       "   'state': 'CA',\n",
       "   'zip': '92660',\n",
       "   'phone': '(949) 720-6000',\n",
       "   'ceo': 'Casey Newell',\n",
       "   'employees': 0,\n",
       "   'url': 'www.pimcoreit.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 50000000,\n",
       "   'priceLow': 20,\n",
       "   'priceHigh': None,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 4075852,\n",
       "   'sharesOverAlloted': 7500000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 50000000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 0,\n",
       "   'netIncome': 0,\n",
       "   'totalAssets': 10000,\n",
       "   'totalLiabilities': 0,\n",
       "   'stockholderEquity': 10000,\n",
       "   'companyDescription': 'We are a newly organized real estate finance company that intends to acquire, &#10; manage and finance, directly or through our subsidiaries, Agency RMBS, MSRs, &#10; Non-Agency RMBS, residential mortgage loans and other real estate-related &#10; assets. We refer to all of the above assets as our Target Assets. We seek to &#10; provide attractive risk-adjusted returns to stockholders over the long term, &#10; primarily through dividends and distributions and secondarily through capital &#10; appreciation. We will seek to employ a flexible and relative value focused &#10; investment strategy and expect to reallocate capital from time to time among our &#10; Target Assets. We believe this flexibility will enable us to more efficiently &#10; manage risk and deliver attractive risk-adjusted returns under a variety of &#10; market conditions and economic cycles. &#10; --- &#10;  &#10; Our principal executive offices are located at 650 Newport Center Drive, Newport &#10; Beach, California 92660. Our telephone number is (949) 720-6000. Our website is &#10; www.pimcoreit.com.',\n",
       "   'businessDescription': 'We are a newly organized real estate finance company that intends to acquire, &#10; manage and finance, directly or through our subsidiaries, Agency RMBS, MSRs, &#10; Non-Agency RMBS, residential mortgage loans and other real estate-related &#10; assets. We refer to all of the above assets as our Target Assets. We seek to &#10; provide attractive risk-adjusted returns to stockholders over the long term, &#10; primarily through dividends and distributions and secondarily through capital &#10; appreciation. We will seek to employ a flexible and relative value focused &#10; investment strategy and expect to reallocate capital from time to time among our &#10; Target Assets. We believe this flexibility will enable us to more efficiently &#10; manage risk and deliver attractive risk-adjusted returns under a variety of &#10; market conditions and economic cycles. &#10;  &#10; We are externally managed and advised by PIMCO, an investment adviser registered &#10; with the Securities and Exchange Commission, or the SEC, pursuant to the &#10; Investment Advisers Act of 1940, as amended, or the Advisers Act. We are &#10; organized as a Maryland corporation. We also intend to operate our business in a &#10; manner that will permit us to maintain one or more exclusions or exemptions from &#10; registration under the Investment Company Act of 1940, as amended, or the 1940 &#10; Act. &#10; --- &#10;  &#10; Our principal executive offices are located at 650 Newport Center Drive, Newport &#10; Beach, California 92660. Our telephone number is (949) 720-6000. Our website is &#10; www.pimcoreit.com.',\n",
       "   'useOfProceeds': 'We estimate that our net proceeds from the initial public offering of our common &#10; stock, after deducting our estimated organizational and offering expenses of &#10; approximately $       million payable by us (including our reimbursement of such &#10; expenses to PIMCO but excluding underwriting discounts and commissions and &#10; $3.6 million of legal costs and expenses paid by PIMCO in connection with this &#10; offering), will be approximately $       million (based on the offering price of &#10; $20.00 per share set forth on the cover of this prospectus). We estimate that &#10; our net proceeds will be approximately $       million if the underwriters &#10; exercise in full their over-allotment option. &#10;  &#10; The underwriters will not be entitled to receive any payment from us at closing. &#10; PIMCO, as our manager, will pay to the underwriters, on our behalf, $       per &#10; share (or     % of the public offering price) for shares sold in this offering &#10; at closing, of which, $       per share (or        % of the public offering &#10; price) will be paid at closing and, only if our gross proceeds from this &#10; offering and future offerings of our common stock and preferred stock equals or &#10; exceeds $       billion, or the Deferral Condition, $       per share (or &#10;       % of the public offering price) will be paid on a deferred basis. If the &#10; Deferral Condition is not satisfied, the underwriters will forego all of the &#10; foregoing deferred payment. The underwriters have agreed to reimburse certain &#10; expenses to PIMCO at closing and upon satisfaction of the Deferral Condition. &#10;  &#10; We intend to use a significant portion of the net proceeds of this offering to &#10; purchase Agency RMBS (including TBAs) and, to a lesser extent over time, Excess &#10; MSRs and residential mortgage loans, subject to our investment guidelines and to &#10; the extent consistent with our intention to qualify for taxation as a REIT and &#10; maintain our exclusion from registration under the 1940 Act. We believe that the &#10; depth and liquidity of the Agency RMBS market, including the TBA market, will &#10; allow us to deploy a significant portion of the net proceeds of this offering in &#10; a relatively short period of time. In particular, upon completion of this &#10; offering, we expect to purchase a significant amount of TBAs in the near term to &#10; accelerate the construction of our initial portfolio, often taking physical &#10; delivery of the underlying Agency RMBS and settling our obligations for cash &#10; provided from this offering and/or with borrowings under repurchase agreements. &#10; However, we may also utilize TBA dollar roll transactions as a means of &#10; investing in and financing Agency RMBS. Although we expect to purchase a &#10; significant amount of TBAs in the near term, we expect to reduce the percentage &#10; of our portfolio that consists of TBAs over time consistent with our intention &#10; to qualify for taxation as a REIT and maintain our exclusion from registration &#10; under the 1940 Act. &#10;  &#10; We expect to use the balance of the proceeds from this offering to acquire other &#10; assets in accordance with our objectives and strategies described in this &#10; prospectus. However, until appropriate assets can be identified for the &#10; proceeds, we may also invest the proceeds from this offering in interest-bearing &#10; or dividend paying short-term investments and/or investment funds that may &#10; invest in similar investments (which subject to the conflicts of interest policy &#10; described below may include funds managed by PIMCO or its affiliates, provided &#10; that any additional fees payable to PIMCO attributable to our equity investment &#10; in such funds are credited against any base management fee payable by us or &#10; otherwise rebated to us), including money market accounts, that are consistent &#10; with our intention to qualify for taxation as a REIT and maintain our exclusion &#10; from registration under the 1940 Act. These interest-bearing short-term &#10; investments are expected to provide a lower net return than we will seek to &#10; achieve from our Target Assets. Additionally, upon the closing of this offering, &#10; we will use $10,000 of the net proceeds to repurchase the 1,000 shares of common &#10; stock held by PIMCO for $10.00 per share, which is the price at which PIMCO &#10; purchased the shares from us.',\n",
       "   'competition': 'Our profitability depends, in large part, on our ability to acquire our Target &#10; Assets at attractive prices. We are subject to significant competition in &#10; acquiring our Target Assets. In particular, we will compete with a variety of &#10; institutional investors, including other REITs, specialty finance companies, &#10; public and private funds, commercial and investment banks, hedge funds, mortgage &#10; bankers, commercial finance and insurance companies, governmental bodies and &#10; other financial institutions. We may also compete with PIMCO and its affiliates &#10; for investment opportunities. In addition, there are several REITs with similar &#10; investment objectives and others may be organized in the future. These other &#10; REITs will increase competition for the available supply of residential mortgage &#10; and other real estate-related assets suitable for purchase or origination. Some &#10; of our anticipated competitors have greater financial resources, access to lower &#10; costs of capital and access to funding sources that may not be available to us, &#10; such as funding from the U.S. government, if we are not eligible to participate &#10; in programs established by the U.S. government. In addition, some of our &#10; competitors are not subject to the operating constraints associated with REIT &#10; tax compliance or maintenance of an exclusion or exemption from the 1940 Act. &#10; Furthermore, some of our competitors may have higher risk tolerances or &#10; different risk assessments, which could allow them to consider a wider variety &#10; of investments, or pay higher prices, than we can. Current market conditions may &#10; attract more competitors, which may increase the competition for our Target &#10; Assets. An increase in the competition for such assets may increase the price of &#10; such assets, which may limit our ability to generate attractive risk-adjusted &#10; returns for our stockholders, thereby adversely affecting the market price of &#10; our common stock. &#10;  &#10; In the face of this competition, we expect to have access to PIMCOs &#10; professionals and their industry experience, which we believe will provide us &#10; with a competitive advantage and help us assess investment risks and determine &#10; appropriate pricing for potential investments. We expect that these &#10; relationships will enable us to compete more efficiently and effectively for &#10; attractive investment opportunities. In addition, we believe that current market &#10; conditions may have adversely affected the financial condition of certain &#10; competitors. Thus, not having a legacy portfolio may also enable us to compete &#10; more effectively for attractive investment opportunities. Although we believe we &#10; are well positioned to compete effectively in each facet of our business, there &#10; can be no assurance that we will be able to achieve our business goals or &#10; expectations due to the extensive competition in our market sector. We operate &#10; in a competitive market for investment opportunities and future competition may &#10; limit our ability to acquire desirable investments in our Target Assets and &#10; could also affect the pricing of these securities.',\n",
       "   'amount': 500000000,\n",
       "   'percentOffered': '100.00'},\n",
       "  {'symbol': 'AVTR',\n",
       "   'companyName': 'AVANTOR, INC.',\n",
       "   'expectedDate': '2019-05-17',\n",
       "   'leadUnderwriters': ['Goldman Sachs & Co. LLC',\n",
       "    'J.P. Morgan Securities LLC',\n",
       "    'Jefferies LLC'],\n",
       "   'underwriters': ['Barclays Capital Inc',\n",
       "    'BofA Merrill Lynch',\n",
       "    'Citigroup Global Markets Inc',\n",
       "    'Cowen and Company, LLC',\n",
       "    'Credit Suisse Securities (USA) LLC',\n",
       "    'Deutsche Bank Securities Inc.',\n",
       "    'Drexel Hamilton, LLC',\n",
       "    'Evercore Group L.L.C',\n",
       "    'Guggenheim Securities, LLC',\n",
       "    'Janney Montgomery Scott LLC',\n",
       "    'KeyBanc Capital Markets Inc',\n",
       "    'Morgan Stanley & Co. LLC',\n",
       "    'Piper Jaffray & Co.',\n",
       "    'PJT Partners LP',\n",
       "    'Raymond James and Associates, Inc.',\n",
       "    'RBC Capital Markets, LLC',\n",
       "    'Robert W. Baird & Co. Incorporated',\n",
       "    'Stephens Inc.',\n",
       "    'Stifel Nicolaus & Company, Incorporated',\n",
       "    'SunTrust Robinson Humphrey, Inc',\n",
       "    'UBS Investment Bank',\n",
       "    'Wells Fargo Securities, LLC',\n",
       "    'William Blair and Co., L.L.C.'],\n",
       "   'companyCounsel': ['Simpson Thacher & Bartlett LLP'],\n",
       "   'underwriterCounsel': ['Ropes & Gray LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0001722482',\n",
       "   'address': 'BUILDING ONE, SUITE 200',\n",
       "   'city': 'RADNOR',\n",
       "   'state': 'PA',\n",
       "   'zip': '19087',\n",
       "   'phone': '(610) 386-1700',\n",
       "   'ceo': 'Michael Stubblefield',\n",
       "   'employees': 12000,\n",
       "   'url': 'ww.avantorinc.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 154000000,\n",
       "   'priceLow': 18,\n",
       "   'priceHigh': 21,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 10400000,\n",
       "   'sharesOverAlloted': 23100000,\n",
       "   'shareholderShares': 100,\n",
       "   'sharesOutstanding': 426444907,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 1480100000,\n",
       "   'netIncome': -6200000,\n",
       "   'totalAssets': 10013900000,\n",
       "   'totalLiabilities': 9221200000,\n",
       "   'stockholderEquity': -3138400000,\n",
       "   'companyDescription': 'We are a leading global provider of mission critical products and services to &#10; customers in the biopharma, healthcare, education & government, and advanced &#10; technologies & applied materials industries. Our comprehensive offerings, which &#10; include materials & consumables, equipment & instrumentation and services & &#10; specialty procurement, are relied upon by our customers, often on a recurring &#10; basis, because they are frequently specified into their research, development &#10; and production processes. These processes are commonly organized into &#10; workflows that define the activities our customers perform each day. We &#10; collaborate closely with our customers to enable them to develop new innovative &#10; products, lower their development and production costs, improve product or &#10; process performance characteristics, and enhance the safety and reliability of &#10; the drugs, devices and other products they produce. In addition to relying on &#10; our products, many customers depend upon our services. Some of these services &#10; are performed by approximately 1,400 of our associates that are co-located with &#10; certain customers, working side-by-side with their scientists every day. Our &#10; local presence combined with our global infrastructure enable and promote &#10; successful relationships with our customers and connect us to over 240,000 of &#10; their locations in over 180 countries. Our mission is to set science in motion &#10; to create a better world. &#10; --- &#10;  &#10; Our principal executive offices are located at the Radnor Corporate Center, &#10; Building One, Suite 200, 100 Matsonford Road, Radnor, Pennsylvania 19087 and our &#10; telephone number is (610) 386-1700. Our website is www.avantorinc.com.',\n",
       "   'businessDescription': 'We are a leading global provider of mission critical products and services to &#10; customers in the biopharma, healthcare, education & government, and advanced &#10; technologies & applied materials industries. Our comprehensive offerings, which &#10; include materials & consumables, equipment & instrumentation and services & &#10; specialty procurement, are relied upon by our customers, often on a recurring &#10; basis, because they are frequently specified into their research, development &#10; and production processes. These processes are commonly organized into &#10; workflows that define the activities our customers perform each day. We &#10; collaborate closely with our customers to enable them to develop new innovative &#10; products, lower their development and production costs, improve product or &#10; process performance characteristics, and enhance the safety and reliability of &#10; the drugs, devices and other products they produce. In addition to relying on &#10; our products, many customers depend upon our services. Some of these services &#10; are performed by approximately 1,400 of our associates that are co-located with &#10; certain customers, working side-by-side with their scientists every day. Our &#10; local presence combined with our global infrastructure enable and promote &#10; successful relationships with our customers and connect us to over 240,000 of &#10; their locations in over 180 countries. Our mission is to set science in motion &#10; to create a better world. &#10;  &#10; The depth and breadth of our portfolio provides our customers a comprehensive &#10; range of products and services and allows us to create customized and integrated &#10; solutions for our customers. Selected offerings sold to our customers in &#10; discovery, research, development and production processes include: &#10;  &#10;  Materials & consumables: Ultra-high purity chemicals and reagents, lab  &#10;   products and supplies, highly specialized formulated silicone materials, &#10;   customized excipients, customized single-use assemblies, process  &#10;   chromatography resins and columns, analytical sample prep kits and education &#10;   and microbiology and clinical trial kits. In 2018, 33% of our revenues were &#10;   from sales of proprietary materials & consumables and 40% of our revenues were &#10;   from third-party materials & consumables; &#10;  &#10;  Equipment & instrumentation: Filtration systems, virus inactivation systems, &#10;   incubators, analytical instruments, evaporators, ultra-low-temperature  &#10;   freezers, biological safety cabinets and critical environment supplies; and &#10;  &#10;  Services & specialty procurement: Onsite lab and production, clinical, &#10;   equipment, procurement and sourcing and biopharmaceutical material scale-up  &#10;   and development services. &#10;  &#10; We have deep expertise in developing, customizing, manufacturing and supplying &#10; products for a wide variety of workflows, allowing us to provide tailored &#10; solutions throughout the lifecycle of our customers products. In aggregate, we &#10; provide approximately six million products, including products we make as well &#10; as products from approximately 4,000 core suppliers across the globe. We &#10; manufacture products that meet or exceed the demanding requirements of our &#10; customers across a number of highly-regulated industries. Our high-purity and &#10; ultra-high purity products, such as our J.T.Baker and SeaStar brand chemicals, &#10; are trusted by life sciences and electronic materials customers around the world &#10; and can be manufactured at purity levels as stringent as one part-per-trillion. &#10; Similarly, our NuSil brand of high-purity, customized silicones has been trusted &#10; for more than thirty years by leading medical device manufacturers and aerospace &#10; companies. &#10;  &#10; We complement our products with a range of value-added services. Each day, our &#10; onsite service associates work side-by-side with our customers to support their &#10; workflows. This close proximity to our customers and their workflows allows our &#10; associates to develop insights into how to serve them better. In certain cases, &#10; customers choose to fully leverage our value-added services and expertise by &#10; outsourcing specialized workflows entirely to us, further connecting us to their &#10; operations and allowing us to identify new business opportunities. We believe &#10; our growing services offering is a competitive advantage that further &#10; differentiates us from our competitors, deepens our relationships with current &#10; customers and enhances our ability to reach new ones. &#10;  &#10; We employ a differentiated innovation model that is informed by our embedded &#10; relationships with our customers and enables us to anticipate and align our &#10; innovation efforts with our customers priorities. We engage with our customers &#10; early in their product development cycles through our 300-person innovation team &#10; to advance our customers programs from research and discovery through &#10; development and commercialization. At each step of our customers workflows, we &#10; share our scientific and workflow expertise to help deliver incremental and &#10; sustainable improvements to existing customer products and processes. These &#10; projects include enhancing product purity and therefore its performance &#10; characteristics, improving product packaging and streamlining workflows. Our &#10; strategic initiatives include the development of new products in emerging areas &#10; of science such as cell and gene therapy. We currently have approximately 1,400 &#10; innovation projects with our customers that address process improvements for &#10; existing products and potential significant new opportunities for us to support. &#10;  &#10; We are a strategic partner to a diverse and sophisticated customer base with &#10; stringent quality and regulatory demands. Our ability to customize products and &#10; processes at scale while meeting these quality and regulatory requirements and &#10; the embedded nature of our business model have made us an integral part of our &#10; customers development programs and broader supply chain. We are incorporated in &#10; over 800 of our customers master access files (MAF) and drug master files &#10; (DMF) that are registered with regulatory authorities around the world. &#10; Additionally, we are able to meet the exacting quality and regulatory &#10; requirements of our advanced technologies & applied materials customers, &#10; including semiconductor manufacturers, by providing materials at purity levels &#10; as stringent as one part-per-trillion. We have developed long-standing &#10; relationships with a global customer base, and generated approximately 36% of &#10; our revenues for the year ended December 31, 2018 from customers with whom we &#10; have 15+ year relationships. In total, in 2018 we believe we served established &#10; leaders and emerging innovators across each of the industries we serve: &#10;  &#10; BIOPHARMA                    HEALTHCARE               EDUCATION & GOVERNMENT       ADVANCED TECHNOLOGIES & &#10;                                                                                       APPLIED  MATERIALS &#10;  &#10; 10 of top 10              10 of top 10 med device    19 of top 20 research          4 of top 5 global &#10;    biotechs and              manufacturers              universities in both          semiconductor &#10;    pharma companies                                     U.S. and Europe               manufacturers    &#10;  &#10; 20 year relationship      10 of top 10 diagnostics    5 of top 5 largest U.S.       4 of top 5  &#10;    with leading              companies                  government research           aerospace & defense  &#10;    biotech trade                                        agencies                      companies &#10;    association &#10;  &#10; The combination of our innovation centers and manufacturing facilities empowers &#10; us to support our customers from the earliest stages of their product innovation &#10; to commercial manufacturing, and provides us multiple opportunities to serve as &#10; a critical partner to them. Our eight regional innovation centers located in &#10; five different countries (including four currently operating in the Asia, Middle &#10; East and Africa (AMEA) region and a fifth which we expect to be operational in &#10; mid-2019), allow us to efficiently support the product development needs of our &#10; diverse customer base. In addition, we have 27 manufacturing facilities, 13 of &#10; which are Current Good Manufacturing Practices (cGMP) compliant and 12 of &#10; which are regulated by the U.S. Food and Drug Administration (FDA) or &#10; comparable foreign regulatory authorities. Led by our globally recognized VWR &#10; brand, we have approximately 150 sales and distribution centers strategically &#10; located to promote supply chain efficiency, enabling us to deliver orders &#10; virtually anywhere in the world, often within 24 to 48 hours. We employ &#10; approximately 3,800 sales and sales support professionals around the world who &#10; are focused on serving our customers through a local presence. Our &#10; professionals comprehensive industry-specific knowledge is supplemented by our &#10; leading online customer platform which affords current and potential customers a &#10; rich, informative and customized user experience and allows us to better address &#10; a global customer base. Many customers choose to directly integrate their &#10; ordering activity with our online platform. We have over 2,500 integrated &#10; connections with our customers and approximately 1,000 integrated connections &#10; with our suppliers to simplify and expedite their transactions with us. In 2018, &#10; approximately 45% of our revenues came from our digital channels. &#10; --- &#10;  &#10; Our 115 year legacy began in 1904 with the founding of the J.T. Baker Chemical &#10; Company. In 2010, Avantor was acquired by affiliates of New Mountain Capital, &#10; LLC (\"New Mountain Capital\"), our sponsor, from Covidien plc. Since then, we &#10; have expanded through a series of large acquisitions across the globe. In 2016, &#10; we acquired NuSil, a leading supplier of high-purity silicone products for the &#10; medical device industry that was founded in 1985. In 2017, we also acquired VWR, &#10; a global manufacturer and distributor of laboratory and production products and &#10; services founded in 1852 that now represents the primary ordering platform for &#10; our customers. Avantor, Inc. was incorporated in Delaware in May 2017 in &#10; anticipation of the VWR Acquisition. &#10;  &#10; Our principal executive offices are located at the Radnor Corporate Center, &#10; Building One, Suite 200, 100 Matsonford Road, Radnor, Pennsylvania 19087 and our &#10; telephone number is (610) 386-1700. Our website is www.avantorinc.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds to us from this offering, after deducting &#10; estimated underwriting discounts and commissions and estimated offering expenses &#10; payable by us, will be approximately $2,889.0 million (or approximately $3,323.7 &#10; million if the underwriters exercise in full their over-allotment option to &#10; purchase additional shares of common stock), assuming an initial public offering &#10; price of $19.50 per share (which is the midpoint of the estimated offering price &#10; range shown on the cover page of this prospectus). &#10;  &#10; We will not receive any of the proceeds from the selling stockholder named in &#10; this prospectus and we will not be required to pay the underwriting discounts &#10; and commissions associated with such sales of shares. The selling stockholder &#10; will receive approximately $1,900.00 of proceeds from this offering. &#10;  &#10; We estimate that the net proceeds to us from the concurrent offering of the &#10; Mandatory Convertible Preferred Stock, if completed, will be approximately &#10; $481.0 million (or approximately $553.4 million if the underwriters of that &#10; offering exercise their over-allotment option to purchase additional shares of &#10; the Mandatory Convertible Preferred Stock in full), in each case after deducting &#10; estimated underwriting discounts and commissions and estimated offering expenses &#10; payable by us. &#10;  &#10; We intend to use approximately $2,629.1 million (including the accumulated and &#10; unpaid dividends and make whole amount) of the net proceeds to us from both &#10; offerings to redeem all outstanding shares of our Existing Senior Preferred &#10; Stock, with any remaining proceeds used to repay $471.2 million and &#10; $269.7 million of outstanding indebtedness under the Dollar Term Loan Facility &#10; and the Euro Term Loan Facility, respectively. The Term Loan Facility matures in &#10; November 2024. The Dollar Term Loan Facility bears interest on the outstanding &#10; unpaid principal amount at a rate equal to an applicable margin plus, at Avantor &#10; Fundings option, either (a) a base rate or (b) a LIBOR rate, in each case &#10; subject to interest rate floors. The Euro Term Loan Facility bears interest on &#10; the outstanding unpaid principal amount at a rate equal to an applicable margin &#10; plus the EURIBO Rate, subject to an interest rate floor. The applicable margin &#10; for the term loans under the Dollar Term Loan Facility, after giving effect to &#10; the Repricing Amendment, is 3.75%, with respect to LIBOR borrowings, and 2.75%, &#10; with respect to base rate borrowings. The applicable margin under the Euro Term &#10; Loan Facility is 3.75%.  &#10;  &#10; A $1.00 increase (decrease) in the assumed initial public offering price of &#10; $19.50 per share, based on the midpoint of the estimated offering price range &#10; shown on the cover page of this prospectus, would increase (decrease) the net &#10; proceeds to us from this offering by approximately $148.6 million, assuming the &#10; number of shares offered by us, shown on the cover page of this prospectus, &#10; remains the same and after deducting estimated underwriting discounts and &#10; commissions and estimated offering expenses payable by us for this offering. An &#10; increase (decrease) of 1,000,000 shares from the expected number of shares to be &#10; sold by us in this offering, assuming no change in the assumed initial public &#10; offering price per share, the midpoint of the estimated offering price range &#10; shown on the cover page of this prospectus, would increase (decrease) our net &#10; proceeds from this offering by $18.8 million. To the extent we raise more &#10; proceeds in this offering than currently estimated, we will repay additional &#10; amounts under the Term Loan Facility. To the extent we raise less proceeds in &#10; this offering than currently estimated, we will reduce the amount we repay under &#10; the Term Loan Facility. &#10;  &#10; Certain affiliates of Goldman Sachs & Co. LLC, an underwriter in this offering, &#10; will receive an aggregate of approximately $421 million following this offering &#10; as a result of currently holding 372,872 shares of our Existing Senior Preferred &#10; Stock and being a lender under the Dollar Term Loan Facility and the Euro Term &#10; Loan Facility, which represents 12.5% of the net proceeds from this offering and &#10; the concurrent offering (or 10.9% of the net proceeds of this offering and the &#10; concurrent offering if the underwriters exercise their over-allotment options in &#10; full in both offerings). &#10;  &#10; To the extent that the underwriters in this offering exercise all or a portion &#10; of their over-allotment option to purchase additional shares of our common stock &#10; or the underwriters in the concurrent offering of Mandatory Convertible &#10; Preferred Stock exercise all or a portion of their over-allotment option to &#10; purchase additional shares of Mandatory Convertible Preferred Stock, the net &#10; proceeds received will be used to repay indebtedness pro rata under the Term &#10; Loan Facility.',\n",
       "   'competition': 'We operate in a highly competitive environment with a diverse and fragmented &#10; base of competitors, many of whom focus on specific regions, customers, and/or &#10; segments. While many customers weigh and balance competitive factors differently &#10; in the industries, many focus upon service and delivery, breadth of product &#10; line, customization capabilities, price, customer support, online capabilities &#10; and the ability to meet the special and local needs of our customers. &#10;  &#10; Competition is driven not only by the product quality and purity across each of &#10; these industries, but also by the adaptability of the supplier as a &#10; developmental and commercial partner. We rely on our scale, expertise, deep &#10; customer access, depth of product and value-added service offerings, marketing &#10; strategies and sales force, acquisition strategy, financial profile and &#10; management team to deliver superior solutions to our customers and provide &#10; extensive market channel access to our suppliers. &#10;  &#10; In each of the industries we serve, we face competition from various players. &#10; Our key competitors include regional as well as global suppliers like BASF, &#10; Bio-Rad, Biomerieux, Cabot Microelectronics, Danaher, DowDuPont, GE Healthcare, &#10; Honeywell, Merck KGaA, Roquette and ThermoFisher Scientific, among others. We &#10; believe that our key advantages include our swift and focused response compared &#10; to those of large multi-segment companies, as well as our global scale and broad &#10; capabilities compared to those of smaller regional companies.',\n",
       "   'amount': 3003000000,\n",
       "   'percentOffered': '36.11'},\n",
       "  {'symbol': 'FSLY',\n",
       "   'companyName': 'FASTLY, INC.',\n",
       "   'expectedDate': '2019-05-17',\n",
       "   'leadUnderwriters': ['BofA Merrill Lynch',\n",
       "    'Citigroup Global Markets Inc',\n",
       "    'Credit Suisse Securities (USA) LLC'],\n",
       "   'underwriters': ['Craig-Hallum Capital Group LLC',\n",
       "    'D.A. Davidson and Co',\n",
       "    'Oppenheimer & Co. Inc.',\n",
       "    'Raymond James and Associates, Inc.',\n",
       "    'Robert W. Baird & Co. Incorporated',\n",
       "    'Stifel Nicolaus & Company, Incorporated',\n",
       "    'William Blair and Co., L.L.C.'],\n",
       "   'companyCounsel': ['Cooley LLP'],\n",
       "   'underwriterCounsel': ['Davis Polk & Wardwell LLP'],\n",
       "   'auditor': 'American Stock Transfer & Trust Company, LLC',\n",
       "   'market': 'NYSE',\n",
       "   'cik': '0001517413',\n",
       "   'address': '475 BRANNAN',\n",
       "   'city': 'SAN FRANCISCO',\n",
       "   'state': 'CA',\n",
       "   'zip': '94107',\n",
       "   'phone': '415-525-3481',\n",
       "   'ceo': 'Artur Bergman',\n",
       "   'employees': 489,\n",
       "   'url': 'www.fastly.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 11250000,\n",
       "   'priceLow': 14,\n",
       "   'priceHigh': 16,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 6000000,\n",
       "   'sharesOverAlloted': 1687500,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 11250000,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 45556000,\n",
       "   'netIncome': -9727000,\n",
       "   'totalAssets': 163735000,\n",
       "   'totalLiabilities': 77749000,\n",
       "   'stockholderEquity': -133598000,\n",
       "   'companyDescription': 'Developers are reinventing the way we live, work, and play online. Yet they &#10; repeatedly encounter innovation barriers when delivering modern digital &#10; experiences. Expectations for digital experiences are at an all-time high; they &#10; must be fast, secure, and highly personalized. If they arent reliable, &#10; end-users simply take their business elsewhere. The challenge today is enabling &#10; developers to deliver a modern digital experience while simultaneously providing &#10; scale, security, and performance. We built our edge cloud platform to solve this &#10; problem. &#10;  &#10; The edge cloud is a new category of Infrastructure as a Service (IaaS) that &#10; enables developers to build, secure, and deliver digital experiences at the edge &#10; of the internet. This service represents the convergence of the Content Delivery &#10; Network (CDN) with functionality that has been traditionally delivered by &#10; hardware-centric appliances such as Application Delivery Controllers (ADC), Web &#10; Application Firewalls (WAF), Bot Detection, and Distributed Denial of Service &#10; (DDoS) solutions. It also includes the emergence of a new, but growing edge &#10; computing market which aims to move compute power and logic as close to the &#10; end-user as possible. The edge cloud uses the emerging cloud computing, &#10; serverless paradigm in which the cloud provider runs the server and dynamically &#10; manages the allocation of machine resources. When milliseconds matter, &#10; processing at the edge is an ideal way to handle highly dynamic and &#10; time-sensitive data. The edge cloud complements data center, central cloud, and &#10; hybrid solutions. &#10;  &#10; Our mission is to fuel the next modern digital experience by providing &#10; developers with a programmable and reliable edge cloud platform that they adopt &#10; as their own. &#10;  &#10; Organizations must keep up with complex and ever-evolving end-user requirements. &#10; We help them surpass their end-users expectations by powering fast, secure, and &#10; scalable digital experiences. We built a powerful edge cloud platform, designed &#10; from the ground up to be programmable and support agile software development. We &#10; believe our platform gives our customers a significant competitive advantage, &#10; whether they were born into the digital age or are just embarking on their &#10; digital transformation journey. Our platform consists of three key components: a &#10; programmable edge, a software-defined modern network, and a philosophy of &#10; customer empowerment. Our programmable edge provides developers with real-time &#10; visibility and control where they can write and deploy code to push application &#10; logic to the edge. It supports modern application delivery processes, freeing &#10; developers to innovate without constraints. Our software-defined modern network &#10; is built for the software-defined future. It is powerful, efficient, and &#10; flexible, designed to enable us to rapidly scale to meet the needs of the most &#10; demanding customers and never be a barrier to their growth. Our 45 terabit edge &#10; network is located in 60 uniquely designed points-of-presence (POPs) across the &#10; world as of March 31, 2019. Finally, being developers ourselves, we empower &#10; customers to build great things while supporting their efforts through &#10; frictionless tools and a deeply technical support team that facilitates ongoing &#10; collaboration. &#10; --- &#10;  &#10; We were initially incorporated under the laws of the State of Delaware in March &#10; 2011 under the name SkyCache, Inc. We changed our name to Fastly, Inc. in May &#10; 2012. &#10;  &#10; Our principal executive offices are located at 475 Brannan Street, Suite 300, &#10; San Francisco, California 94107. Our telephone number is 1-844-432-7859. Our &#10; website address is www.fastly.com.',\n",
       "   'businessDescription': 'Developers are reinventing the way we live, work, and play online. Yet they &#10; repeatedly encounter innovation barriers when delivering modern digital &#10; experiences. Expectations for digital experiences are at an all-time high; they &#10; must be fast, secure, and highly personalized. If they arent reliable, &#10; end-users simply take their business elsewhere. The challenge today is enabling &#10; developers to deliver a modern digital experience while simultaneously providing &#10; scale, security, and performance. We built our edge cloud platform to solve this &#10; problem. &#10;  &#10; The edge cloud is a new category of Infrastructure as a Service (IaaS) that &#10; enables developers to build, secure, and deliver digital experiences at the edge &#10; of the internet. This service represents the convergence of the Content Delivery &#10; Network (CDN) with functionality that has been traditionally delivered by &#10; hardware-centric appliances such as Application Delivery Controllers (ADC), Web &#10; Application Firewalls (WAF), Bot Detection, and Distributed Denial of Service &#10; (DDoS) solutions. It also includes the emergence of a new, but growing edge &#10; computing market which aims to move compute power and logic as close to the &#10; end-user as possible. The edge cloud uses the emerging cloud computing, &#10; serverless paradigm in which the cloud provider runs the server and dynamically &#10; manages the allocation of machine resources. When milliseconds matter, &#10; processing at the edge is an ideal way to handle highly dynamic and &#10; time-sensitive data. The edge cloud complements data center, central cloud, and &#10; hybrid solutions. &#10;  &#10; Our mission is to fuel the next modern digital experience by providing &#10; developers with a programmable and reliable edge cloud platform that they adopt &#10; as their own. &#10;  &#10; Organizations must keep up with complex and ever-evolving end-user requirements. &#10; We help them surpass their end-users expectations by powering fast, secure, and &#10; scalable digital experiences. We built a powerful edge cloud platform, designed &#10; from the ground up to be programmable and support agile software development. We &#10; believe our platform gives our customers a significant competitive advantage, &#10; whether they were born into the digital age or are just embarking on their &#10; digital transformation journey. Our platform consists of three key components: a &#10; programmable edge, a software-defined modern network, and a philosophy of &#10; customer empowerment. Our programmable edge provides developers with real-time &#10; visibility and control where they can write and deploy code to push application &#10; logic to the edge. It supports modern application delivery processes, freeing &#10; developers to innovate without constraints. Our software-defined modern network &#10; is built for the software-defined future. It is powerful, efficient, and &#10; flexible, designed to enable us to rapidly scale to meet the needs of the most &#10; demanding customers and never be a barrier to their growth. Our 45 terabit edge &#10; network is located in 60 uniquely designed points-of-presence (POPs) across the &#10; world as of March 31, 2019. Finally, being developers ourselves, we empower &#10; customers to build great things while supporting their efforts through &#10; frictionless tools and a deeply technical support team that facilitates ongoing &#10; collaboration. &#10;  &#10; We serve both established enterprises and technology-savvy organizations. Our &#10; customers represent a diverse set of organizations across many industries with &#10; one thing in common: they are competing by using the power of software to build &#10; differentiation at the edge. With our edge cloud platform, our customers are &#10; disrupting existing industries and creating new ones. For example, several of &#10; our customers have reinvented digital publishing by connecting readers through &#10; subscription models to indispensable content, helping people understand the &#10; world through deeply reported independent journalism. Our customers software &#10; applications use our edge cloud platform to ensure concert goers can buy tickets &#10; to the live events they love, travelers can book flights seamlessly and embark &#10; on their next great adventure, and sports fans can stream events in real time, &#10; across all devices. The range of applications that developers build with our &#10; edge cloud platform continues to surpass our expectations. &#10;  &#10; So where do we go from here? Our vision is to create a trustworthy internet, &#10; where good thrives. We want all developers to have the ability to deliver the &#10; next transformative digital experience on a global scale. And because big ideas &#10; often start small, we love it when developers experiment and iterate on our edge &#10; cloud platform, coming up with exciting new ways to solve todays complex &#10; problems. &#10;  &#10; Our usage-based revenue grows as our customers websites and applications &#10; deliver, process, and protect more traffic, as they adopt more features of our &#10; edge platform and as they more broadly adopt our platform across their &#10; organizations. A meaningful indicator of the increased activity from our &#10; existing customers is our Dollar-Based Net Expansion Rate (DBNER), which was &#10; 147.3%, 132.0%, 140.3%, and 130.4% for the years ended December 31, 2017, &#10; December 31, 2018, and the three months ended March 31, 2018 and March 31, 2019, &#10; respectively. &#10; --- &#10;  &#10; We were initially incorporated under the laws of the State of Delaware in March &#10; 2011 under the name SkyCache, Inc. We changed our name to Fastly, Inc. in May &#10; 2012. &#10;  &#10; Our principal executive offices are located at 475 Brannan Street, Suite 300, &#10; San Francisco, California 94107. Our telephone number is 1-844-432-7859. Our &#10; website address is www.fastly.com.',\n",
       "   'useOfProceeds': 'We estimate that the net proceeds from our issuance and sale of shares of our &#10; Class A common stock in this offering will be approximately $150.9 million, or &#10; approximately $174.5 million if the underwriters exercise their option to &#10; purchase additional shares in full, based upon an assumed initial public &#10; offering price of $15.00 per share, the midpoint of the price range set forth on &#10; the cover page of this prospectus, after deducting underwriting discounts and &#10; commissions and estimated offering expenses payable by us. &#10;  &#10; Each $1.00 increase or decrease in the assumed initial public offering price of &#10; $15.00 per share, the midpoint of the price range set forth on the cover page of &#10; this prospectus, would increase or decrease the net proceeds to us from this &#10; offering by approximately $10.5 million, assuming that the number of shares &#10; offered by us, as set forth on the cover page of this prospectus, remains the &#10; same, and after deducting underwriting discounts and commissions and estimated &#10; offering expenses payable by us. We may also increase or decrease the number of &#10; shares we are offering. A 1,000,000 share increase or decrease in the number of &#10; shares offered by us would increase or decrease the net proceeds to us from this &#10; offering by approximately $14.0 million, assuming that the assumed initial &#10; offering price to the public remains the same, and after deducting underwriting &#10; discounts and commissions and estimated offering expenses payable by us. We do &#10; not expect that a change in the initial offering price to the public or the &#10; number of shares by these amounts would have a material effect on uses of the &#10; proceeds from this offering, although it may accelerate the time at which we &#10; will need to seek additional capital. &#10;  &#10; The principal purposes of this offering are to increase our financial &#10; flexibility, create a public market for our Class A common stock, and facilitate &#10; our future access to the capital markets. Although we have not yet determined &#10; with certainty the manner in which we will allocate the net proceeds of this &#10; offering, we expect to use the net proceeds from this offering for working &#10; capital and other general corporate purposes. We may use a portion of the net &#10; proceeds we receive from this offering to repay up to approximately $47.5 &#10; million of indebtedness under our credit facilities, which, to date, has been &#10; used for general operating expenses, including personnel related costs as we &#10; expanded our employee base, and capital expenditures for our network. We may &#10; also use a portion of the net proceeds from this offering for acquisitions or &#10; strategic investments in complementary businesses or technologies. We do not &#10; currently have any plans for any such acquisitions or investments. We have not &#10; allocated specific amounts of net proceeds for any of these purposes. &#10;  &#10; $27.5 million of the outstanding indebtedness that we may repay under our credit &#10; facilities is scheduled to mature in November 2021 and interest on such amount &#10; accrues at a rate of prime plus 1.75%. $20.0 million of the outstanding &#10; indebtedness that we may repay under our credit facilities is scheduled to &#10; mature in December 2021 and interest on such amount accrues at a rate of prime &#10; plus 4.25%. &#10;  &#10; The expected use of net proceeds from this offering represents our intentions &#10; based upon our present plans and business conditions. We cannot predict with &#10; certainty all of the particular uses for the proceeds of this offering or the &#10; amounts that we will actually spend on the uses set forth above. Accordingly, &#10; our management will have significant flexibility in applying the net proceeds of &#10; this offering. The timing and amount of our actual expenditures will be based on &#10; many factors, including cash flows from operations and the anticipated growth of &#10; our business. Pending their use, we intend to invest the net proceeds of this &#10; offering in a variety of capital-preservation investments, including short- and &#10; intermediate-term, interest-bearing, investment-grade securities.',\n",
       "   'competition': 'Our platform spans several markets from cloud computing and cloud security to &#10; CDNs. We segment the competitive landscape into four key categories: &#10;  &#10;  Legacy CDNs like Akamai, Limelight, EdgeCast (part of Verizon Digital Media), &#10;   Level3, and Imperva (for security); &#10;  &#10;  Small business focused CDNs like InStart, Cloudflare, StackPath, and &#10;   Section.io; &#10;  &#10;  Cloud providers who are starting to offer compute functionality at the edge &#10;   like Amazons CloudFront, AWS Lambda, and Google Cloud Platform; and &#10;  &#10;  Traditional data center and appliance vendors like F5, Citrix, A10 Networks, &#10;   Cisco, Imperva, Radware, and Arbor, as well as networks that offer a range of &#10;   on-premise solutions for load balancing, WAF, and DDoS. &#10;  &#10; The principle competitive factors in our market include: &#10;  &#10;  Platform scalability and performance; &#10;  &#10;  Global network coverage; &#10;  &#10;  Platform reliability and security; &#10;  &#10;  Ease of integration and programmability; &#10;  &#10;  Credibility with developers; &#10;  &#10;  Ability to support modern application development processes; &#10;  &#10;  Brand awareness, reputation, and trust; &#10;  &#10;  Strength of our sales and marketing efforts; &#10;  &#10;  Quality of customer support; and &#10;  &#10;  Price and network cost savings. &#10;  &#10; We believe we generally compete favorably with our competitors on the basis of &#10; these factors. Our edge cloud platform integrates many of the point products &#10; offered by our competitors which is a key differentiator. However, many of our &#10; competitors have substantially greater financial and technical resources in &#10; addition to larger sales and marketing budgets, broader market distribution, and &#10; more mature intellectual property portfolios.',\n",
       "   'amount': 168750000,\n",
       "   'percentOffered': '100.00'},\n",
       "  {'symbol': 'LK',\n",
       "   'companyName': 'LUCKIN COFFEE INC.',\n",
       "   'expectedDate': '2019-05-17',\n",
       "   'leadUnderwriters': ['China International Capital Corporation Hong Kong Securities...',\n",
       "    'Credit Suisse Securities (USA) LLC',\n",
       "    'Haitong International Securities Company Limited',\n",
       "    'Morgan Stanley & Co. LLC'],\n",
       "   'underwriters': ['KeyBanc Capital Markets Inc', 'Needham & Company, LLC'],\n",
       "   'companyCounsel': ['Davis Polk & Wardwell LLP'],\n",
       "   'underwriterCounsel': ['Cleary Gottlieb Steen & Hamilton LLP'],\n",
       "   'auditor': 'Not Specified',\n",
       "   'market': 'NASDAQ Global Select',\n",
       "   'cik': '0001767582',\n",
       "   'address': '17F BLOCK A, TEFANG PORTMAN TOWER',\n",
       "   'city': 'XIAMEN, FUJIAN 361008',\n",
       "   'state': '',\n",
       "   'zip': '',\n",
       "   'phone': '86 592 338 6666',\n",
       "   'ceo': 'Jenny Zhiya Qian',\n",
       "   'employees': 16645,\n",
       "   'url': 'www.luckincoffee.com',\n",
       "   'status': 'Filed',\n",
       "   'sharesOffered': 30000000,\n",
       "   'priceLow': 15,\n",
       "   'priceHigh': 17,\n",
       "   'offerAmount': None,\n",
       "   'totalExpenses': 6366788.6,\n",
       "   'sharesOverAlloted': 4500000,\n",
       "   'shareholderShares': None,\n",
       "   'sharesOutstanding': 34075688,\n",
       "   'lockupPeriodExpiration': '',\n",
       "   'quietPeriodExpiration': '',\n",
       "   'revenue': 71300000,\n",
       "   'netIncome': -82218000,\n",
       "   'totalAssets': 432221000,\n",
       "   'totalLiabilities': 160899000,\n",
       "   'stockholderEquity': -374341000,\n",
       "   'companyDescription': \"Our mission is to be part of everyone's everyday life, starting with coffee. &#10;  &#10; We are China's second largest and fastest-growing coffee network, in terms of &#10; number of stores and cups of coffee sold, according to the Frost & Sullivan &#10; Report. We have pioneered a technology-driven new retail model to provide coffee &#10; and other products with high quality, high affordability and high convenience to &#10; our customers. We believe that our disruptive model has fulfilled the large &#10; unmet demand for coffee and driven its mass market consumption in China, while &#10; allowing us to achieve significant scale and growth since our inception. &#10;  &#10; Driven by technology, our new retail model is built upon our mobile apps and &#10; store network. &#10;  &#10;  Mobile apps: Our mobile apps cover the entire customer purchase process, &#10;   offering our customers a 100% cashier-less environment. This enhances our &#10;   customer experience, improves our operating efficiency, and allows us to stay &#10;   connected with our customers and engage them anytime, anywhere. &#10;  &#10;  Store network: While operating three types of stores, we strategically focus &#10;   on pick-up stores, which accounted for 91.3% of our total stores as of March &#10;   31, 2019. Our pick-up stores have limited seating and are typically located in &#10;   areas with high demand for coffee, such as office buildings, commercial areas &#10;   and university campuses. This enables us to stay close to our target customers &#10;   and expand rapidly with low rental and decoration costs. &#10; --- &#10;  &#10; Our principal executive offices are located at 17F Block A, Tefang Portman &#10; Tower, No. 81 Zhanhong Road, Siming District, Xiamen, Fujian, People's Republic &#10; of China. Our telephone number at this address is +86-592-3386666. &#10;  &#10; Our registered office in the Cayman Islands is located at Conyers Trust Company &#10; (Cayman) Limited, Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, &#10; KY1-1111, Cayman Islands. &#10;  &#10; Our agent for service of process in the United States is Cogency Global Inc. &#10; located at 10 E. 40th Street, 10th Floor New York, New York 10016. Our principal &#10; website is www.luckincoffee.com.\",\n",
       "   'businessDescription': \"Our mission is to be part of everyone's everyday life, starting with coffee. &#10;  &#10; We are China's second largest and fastest-growing coffee network, in terms of &#10; number of stores and cups of coffee sold, according to the Frost & Sullivan &#10; Report. We have pioneered a technology-driven new retail model to provide coffee &#10; and other products with high quality, high affordability and high convenience to &#10; our customers. We believe that our disruptive model has fulfilled the large &#10; unmet demand for coffee and driven its mass market consumption in China, while &#10; allowing us to achieve significant scale and growth since our inception. &#10;  &#10; Driven by technology, our new retail model is built upon our mobile apps and &#10; store network. &#10;  &#10;  Mobile apps: Our mobile apps cover the entire customer purchase process, &#10;   offering our customers a 100% cashier-less environment. This enhances our &#10;   customer experience, improves our operating efficiency, and allows us to stay &#10;   connected with our customers and engage them anytime, anywhere. &#10;  &#10;  Store network: While operating three types of stores, we strategically focus &#10;   on pick-up stores, which accounted for 91.3% of our total stores as of March &#10;   31, 2019. Our pick-up stores have limited seating and are typically located in &#10;   areas with high demand for coffee, such as office buildings, commercial areas &#10;   and university campuses. This enables us to stay close to our target customers &#10;   and expand rapidly with low rental and decoration costs. &#10;  &#10; By disrupting the status quo of the traditional coffee shop model, we have &#10; gained significant cost advantages and provided attractive value propositions to &#10; our customers. &#10;  &#10; Technology is at the core of our business. With our centralized technology &#10; system, we are able to simplify and standardize our operations, which allows us &#10; to improve operational efficiency and quickly expand and scale up our business. &#10; We leverage big data analytics and AI to analyze our customer behavior and &#10; transaction data, which enables us to continuously enhance our products and &#10; services, implement dynamic pricing and improve customer retention. We also &#10; leverage our proprietary technologies in store operations and supply chain to &#10; support our business, such as new store selection, inventory management and &#10; workforce management. Our focus on technologies has enabled us to operate &#10; efficiently, grow rapidly while maintaining quality control. &#10; --- &#10;   &#10; We offer premium coffee and other high-quality products to our customers. We &#10; source premium Arabica coffee beans from prominent suppliers and engage World &#10; Barista Champion teams to design our coffee recipes. We procure coffee machines &#10; and coffee condiments from renowned global suppliers such as Schaerer. Our &#10; coffee has won numerous awards, including most recently the Gold Medal in the &#10; 2018 IIAC International Coffee Tasting competition. We also partner with &#10; reputable suppliers for our other products such as juices and light meals. Due &#10; to our scale, we are able to procure high-quality products from our suppliers at &#10; favorable prices. &#10;  &#10; Since inception, we have successfully built a brand of distinguished value &#10; propositionshigh quality, high affordability and high convenience. We have also &#10; been able to cultivate a large and loyal customer base and achieve strong &#10; growth. Within 18 months, we expanded from a single trial store in Beijing to &#10; 2,370 stores in 28 cities in China as of March 31, 2019. We had over 16.8 &#10; million of cumulative transacting customers as of March 31, 2019. In addition, &#10; our customer repurchase rate in 2018 was over 54%. &#10;  &#10; China's coffee market is highly underpenetrated. Inconsistent qualities, high &#10; prices and inconvenience have hampered the growth of the freshly brewed coffee &#10; market in China. We believe that our model has successfully driven the mass &#10; market coffee consumption in China by addressing these pain points. We aim to &#10; become the largest coffee network in China, in terms of number of stores, by the &#10; end of 2019. &#10; --- &#10;  &#10; Our principal executive offices are located at 17F Block A, Tefang Portman &#10; Tower, No. 81 Zhanhong Road, Siming District, Xiamen, Fujian, People's Republic &#10; of China. Our telephone number at this address is +86-592-3386666. &#10;  &#10; Our registered office in the Cayman Islands is located at Conyers Trust Company &#10; (Cayman) Limited, Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, &#10; KY1-1111, Cayman Islands. &#10;  &#10; Our agent for service of process in the United States is Cogency Global Inc. &#10; located at 10 E. 40th Street, 10th Floor New York, New York 10016. Our principal &#10; website is www.luckincoffee.com.\",\n",
       "   'useOfProceeds': 'We estimate that we will receive net proceeds from this offering and the &#10; concurrent private placement to Louis Dreyfus Company B.V. of approximately &#10; US$490.0 million, or approximately US$557.0 million if the underwriters exercise &#10; their option to purchase additional ADSs in full, after deducting underwriting &#10; discounts and commissions and the estimated offering expenses payable by us. &#10;  &#10; We plan to use the net proceeds of this offering and the concurrent private &#10; placement to Louis Dreyfus Company B.V. for general corporate purposes, which &#10; may include store network expansion, customer acquisition, research and &#10; development, sales and marketing, investment in our technology infrastructure, &#10; working capital, and other general and administrative matters. In utilizing the &#10; proceeds from this offering and the concurrent private placement to Louis &#10; Dreyfus Company B.V., we are permitted under PRC laws and regulations to provide &#10; funding to our PRC subsidiaries only through loans or capital contributions, and &#10; to our consolidated VIE only through loans, and only if we satisfy the &#10; applicable government registration and approval requirements. We cannot assure &#10; you that we will be able to meet these requirements on a timely basis, if at &#10; all. We expect that all the net proceeds from this offering and the concurrent &#10; private placement to Louis Dreyfus Company B.V. will be used in the PRC in the &#10; form of RMB and mainly by funding our PRC subsidiaries through capital &#10; contributions. In general, the relevant registration and approval procedures for &#10; capital contributions typically take approximately eight weeks to complete and &#10; there is no statutory limit on the amount of capital contributions under PRC &#10; laws and regulations. We currently see no material obstacles in completing the &#10; registration and approval procedures with respect to future capital &#10; contributions to our PRC subsidiaries. &#10;  &#10; Pending use of the net proceeds, we intend to hold our net proceeds in &#10; short-term, interest-bearing, financial instruments or demand deposits.',\n",
       "   'competition': \"We face intense competition in China's coffee industry. Our current or potential &#10; competitors are mainly coffee shop operators. &#10;  &#10; We believe that the principal competitive factors in China coffee industry &#10; include the following: &#10;  &#10;  Store network; &#10;  &#10;  Product quality and safety; &#10;  &#10;  Product pricing; &#10;  &#10;  Supply chain management and operating efficiency; &#10;  &#10;  Quality of customer services; &#10;  &#10;  Brand recognition and reputation; &#10;  &#10;  Effectiveness of sales and marketing; and &#10;  &#10;  Customer experience &#10;  &#10; We believe that we are well-positioned to effectively compete on the basis of &#10; the factors listed above. However, our competitors may have longer operating &#10; history, greater brand recognition, more capital, better supplier relationships &#10; and larger customer base.\",\n",
       "   'amount': 480000000,\n",
       "   'percentOffered': '88.04'}],\n",
       " 'viewData': [{'Company': 'PARSONS CORP',\n",
       "   'Symbol': 'PSN',\n",
       "   'Price': '$26.00 - 28.00',\n",
       "   'Shares': '18,518,500',\n",
       "   'Amount': '499,999,500',\n",
       "   'Float': '96,657,331',\n",
       "   'Percent': '19.16%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-08'},\n",
       "  {'Company': 'HEADHUNTER GROUP PLC',\n",
       "   'Symbol': 'HHR',\n",
       "   'Price': '$11.00 - 13.50',\n",
       "   'Shares': '16,304,348',\n",
       "   'Amount': '199,728,263',\n",
       "   'Float': '50,000,000',\n",
       "   'Percent': '32.61%',\n",
       "   'Market': 'NASDAQ Global Select',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'APPLIED THERAPEUTICS INC.',\n",
       "   'Symbol': 'APLT',\n",
       "   'Price': '$14.00 - 16.00',\n",
       "   'Shares': '4,000,000',\n",
       "   'Amount': '60,000,000',\n",
       "   'Float': '17,052,202',\n",
       "   'Percent': '23.46%',\n",
       "   'Market': 'NASDAQ Global',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'NEXTCURE, INC.',\n",
       "   'Symbol': 'NXTC',\n",
       "   'Price': '$14.00 - 16.00',\n",
       "   'Shares': '5,000,000',\n",
       "   'Amount': '75,000,000',\n",
       "   'Float': '21,935,381',\n",
       "   'Percent': '22.79%',\n",
       "   'Market': 'NASDAQ Global Select',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'SOUTH PLAINS FINANCIAL, INC.',\n",
       "   'Symbol': 'SPFI',\n",
       "   'Price': '$17.50 - 19.50',\n",
       "   'Shares': '3,380,000',\n",
       "   'Amount': '62,530,000',\n",
       "   'Float': '17,471,520',\n",
       "   'Percent': '19.35%',\n",
       "   'Market': 'NASDAQ Global Select',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'MAYVILLE ENGINEERING COMPANY, INC.',\n",
       "   'Symbol': 'MEC',\n",
       "   'Price': '$19.00 - 21.00',\n",
       "   'Shares': '6,250,000',\n",
       "   'Amount': '125,000,000',\n",
       "   'Float': '19,693,484',\n",
       "   'Percent': '31.74%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'CORTEXYME, INC.',\n",
       "   'Symbol': 'CRTX',\n",
       "   'Price': '$16.00 - 18.00',\n",
       "   'Shares': '4,412,000',\n",
       "   'Amount': '75,004,000',\n",
       "   'Float': '26,013,334',\n",
       "   'Percent': '16.96%',\n",
       "   'Market': 'NASDAQ Global Select',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'AXCELLA HEALTH INC.',\n",
       "   'Symbol': 'AXLA',\n",
       "   'Price': '$20.00 - 22.00',\n",
       "   'Shares': '3,571,428',\n",
       "   'Amount': '74,999,988',\n",
       "   'Float': '22,988,359',\n",
       "   'Percent': '15.54%',\n",
       "   'Market': 'NASDAQ Global',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'MILESTONE PHARMACEUTICALS INC.',\n",
       "   'Symbol': 'MIST',\n",
       "   'Price': '$14.00 - 16.00',\n",
       "   'Shares': '5,000,000',\n",
       "   'Amount': '75,000,000',\n",
       "   'Float': '23,147,589',\n",
       "   'Percent': '21.60%',\n",
       "   'Market': 'NASDAQ Global',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'DIAMOND EAGLE ACQUISITION CORP. \\\\ DE',\n",
       "   'Symbol': 'DEACU',\n",
       "   'Price': '$10.00',\n",
       "   'Shares': '35,000,000',\n",
       "   'Amount': '175,000,000',\n",
       "   'Float': '43,750,000',\n",
       "   'Percent': '80.00%',\n",
       "   'Market': 'NASDAQ Capital',\n",
       "   'Expected': '2019-05-09'},\n",
       "  {'Company': 'UBER TECHNOLOGIES, INC',\n",
       "   'Symbol': 'UBER',\n",
       "   'Price': '$44.00 - 50.00',\n",
       "   'Shares': '180,000,000',\n",
       "   'Amount': '8,460,000,000',\n",
       "   'Float': '1,676,959,021',\n",
       "   'Percent': '10.73%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-10'},\n",
       "  {'Company': 'POSTAL REALTY TRUST, INC.',\n",
       "   'Symbol': 'PSTL',\n",
       "   'Price': '$19.00 - 21.00',\n",
       "   'Shares': '5,000,000',\n",
       "   'Amount': '100,000,000',\n",
       "   'Float': '5,763,308',\n",
       "   'Percent': '86.76%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-10'},\n",
       "  {'Company': 'SONIM TECHNOLOGIES INC',\n",
       "   'Symbol': 'SONM',\n",
       "   'Price': '$13.00 - 15.00',\n",
       "   'Shares': '3,571,429',\n",
       "   'Amount': '50,000,006',\n",
       "   'Float': '19,509,611',\n",
       "   'Percent': '18.31%',\n",
       "   'Market': 'NASDAQ Global',\n",
       "   'Expected': '2019-05-10'},\n",
       "  {'Company': 'HEALTH SCIENCES ACQUISITIONS CORP',\n",
       "   'Symbol': 'HSACU',\n",
       "   'Price': '$10.00',\n",
       "   'Shares': '10,000,000',\n",
       "   'Amount': '50,000,000',\n",
       "   'Float': '12,500,000',\n",
       "   'Percent': '80.00%',\n",
       "   'Market': 'NASDAQ Capital',\n",
       "   'Expected': '2019-05-10'},\n",
       "  {'Company': 'CONVERSIONPOINT HOLDINGS, INC.',\n",
       "   'Symbol': 'CPTI',\n",
       "   'Price': '$6.00 - 7.00',\n",
       "   'Shares': '6,153,846',\n",
       "   'Amount': '39,999,999',\n",
       "   'Float': '28,153,846',\n",
       "   'Percent': '21.86%',\n",
       "   'Market': 'NASDAQ Capital',\n",
       "   'Expected': '2019-05-14'},\n",
       "  {'Company': 'BRICKTOWN BREWERY RESTAURANTS LLC',\n",
       "   'Symbol': 'BEER',\n",
       "   'Price': '$7.00 - 9.00',\n",
       "   'Shares': '1,875,000',\n",
       "   'Amount': '15,000,000',\n",
       "   'Float': '5,000,000',\n",
       "   'Percent': '37.50%',\n",
       "   'Market': 'NASDAQ Capital',\n",
       "   'Expected': '2019-05-15'},\n",
       "  {'Company': 'PIMCO MORTGAGE INCOME TRUST INC.',\n",
       "   'Symbol': 'PMTG',\n",
       "   'Price': '$20.00',\n",
       "   'Shares': '50,000,000',\n",
       "   'Amount': '500,000,000',\n",
       "   'Float': '50,000,000',\n",
       "   'Percent': '100.00%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-16'},\n",
       "  {'Company': 'AVANTOR, INC.',\n",
       "   'Symbol': 'AVTR',\n",
       "   'Price': '$18.00 - 21.00',\n",
       "   'Shares': '154,000,000',\n",
       "   'Amount': '3,003,000,000',\n",
       "   'Float': '426,444,907',\n",
       "   'Percent': '36.11%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-17'},\n",
       "  {'Company': 'FASTLY, INC.',\n",
       "   'Symbol': 'FSLY',\n",
       "   'Price': '$14.00 - 16.00',\n",
       "   'Shares': '11,250,000',\n",
       "   'Amount': '168,750,000',\n",
       "   'Float': '11,250,000',\n",
       "   'Percent': '100.00%',\n",
       "   'Market': 'NYSE',\n",
       "   'Expected': '2019-05-17'},\n",
       "  {'Company': 'LUCKIN COFFEE INC.',\n",
       "   'Symbol': 'LK',\n",
       "   'Price': '$15.00 - 17.00',\n",
       "   'Shares': '30,000,000',\n",
       "   'Amount': '480,000,000',\n",
       "   'Float': '34,075,688',\n",
       "   'Percent': '88.04%',\n",
       "   'Market': 'NASDAQ Global Select',\n",
       "   'Expected': '2019-05-17'}]}"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ipoUpcoming()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>address</th>\n",
       "      <th>amount</th>\n",
       "      <th>auditor</th>\n",
       "      <th>businessDescription</th>\n",
       "      <th>ceo</th>\n",
       "      <th>cik</th>\n",
       "      <th>city</th>\n",
       "      <th>companyCounsel</th>\n",
       "      <th>companyDescription</th>\n",
       "      <th>companyName</th>\n",
       "      <th>...</th>\n",
       "      <th>status</th>\n",
       "      <th>stockholderEquity</th>\n",
       "      <th>totalAssets</th>\n",
       "      <th>totalExpenses</th>\n",
       "      <th>totalLiabilities</th>\n",
       "      <th>underwriterCounsel</th>\n",
       "      <th>underwriters</th>\n",
       "      <th>url</th>\n",
       "      <th>useOfProceeds</th>\n",
       "      <th>zip</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>CHWY</th>\n",
       "      <td>1855 GRIFFIN ROAD, SUITE B-42</td>\n",
       "      <td>832000000</td>\n",
       "      <td>American Stock Transfer &amp; Trust Company, LLC</td>\n",
       "      <td>Our mission is to be the most trusted and conv...</td>\n",
       "      <td>Sumit Singh</td>\n",
       "      <td>0001766502</td>\n",
       "      <td>DANIA BEACH</td>\n",
       "      <td>[Kirkland &amp; Ellis LLP]</td>\n",
       "      <td>Our mission is to be the most trusted and conv...</td>\n",
       "      <td>CHEWY, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-335942000</td>\n",
       "      <td>541622000</td>\n",
       "      <td>5500000</td>\n",
       "      <td>877564000</td>\n",
       "      <td>[Davis Polk &amp; Wardwell LLP]</td>\n",
       "      <td>[Barclays Capital Inc, BofA Securities, Inc, J...</td>\n",
       "      <td>www.chewy.com</td>\n",
       "      <td>We expect to receive net proceeds from this of...</td>\n",
       "      <td>33004</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>STOK</th>\n",
       "      <td>3 PRESTON COURT</td>\n",
       "      <td>100500000</td>\n",
       "      <td>American Stock Transfer &amp; Trust Company, LLC</td>\n",
       "      <td>We are pioneering a new way to treat the under...</td>\n",
       "      <td>Edward M. Kaye</td>\n",
       "      <td>0001623526</td>\n",
       "      <td>BEDFORD</td>\n",
       "      <td>[Fenwick &amp; West LLP]</td>\n",
       "      <td>We are pioneering a new way to treat the under...</td>\n",
       "      <td>STOKE THERAPEUTICS, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>99581000</td>\n",
       "      <td>102934000</td>\n",
       "      <td>2450000</td>\n",
       "      <td>3353000</td>\n",
       "      <td>[Davis Polk &amp; Wardwell LLP]</td>\n",
       "      <td>[Canaccord Genuity LLC]</td>\n",
       "      <td>www.stoketherapeutics.com</td>\n",
       "      <td>We estimate that the net proceeds from our sal...</td>\n",
       "      <td>01730</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>PSNL</th>\n",
       "      <td>1330 O'BRIEN DRIVE</td>\n",
       "      <td>100000005</td>\n",
       "      <td>Computershare Trust Company, N.A</td>\n",
       "      <td>We are a growing cancer genomics company trans...</td>\n",
       "      <td>John West</td>\n",
       "      <td>0001527753</td>\n",
       "      <td>MENLO PARK</td>\n",
       "      <td>[Cooley LLP]</td>\n",
       "      <td>We are a growing cancer genomics company trans...</td>\n",
       "      <td>PERSONALIS, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-110523000</td>\n",
       "      <td>57647000</td>\n",
       "      <td>3200000</td>\n",
       "      <td>78766000</td>\n",
       "      <td>[Davis Polk &amp; Wardwell LLP]</td>\n",
       "      <td>[Oppenheimer &amp; Co. Inc.]</td>\n",
       "      <td>www.personalis.com</td>\n",
       "      <td>We estimate that we will receive net proceeds ...</td>\n",
       "      <td>94025</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>GO</th>\n",
       "      <td>5650 HOLLIS STREET</td>\n",
       "      <td>275000000</td>\n",
       "      <td>American Stock Transfer and Trust Company LLC</td>\n",
       "      <td>We are a high-growth, extreme value retailer o...</td>\n",
       "      <td>Eric J. Lindberg, Jr.</td>\n",
       "      <td>0001771515</td>\n",
       "      <td>EMERYVILLE</td>\n",
       "      <td>[Simpson Thacher &amp; Bartlett LLP]</td>\n",
       "      <td>We are a high-growth, extreme value retailer o...</td>\n",
       "      <td>GROCERY OUTLET HOLDING CORP.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>303851000</td>\n",
       "      <td>2059912000</td>\n",
       "      <td>8055476</td>\n",
       "      <td>1756061000</td>\n",
       "      <td>[Davis Polk &amp; Wardwell LLP]</td>\n",
       "      <td>[Barclays Capital Inc, Cowen and Company, LLC,...</td>\n",
       "      <td>www.groceryoutlet.com</td>\n",
       "      <td>We estimate that we will receive net proceeds ...</td>\n",
       "      <td>94608</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>DRMT</th>\n",
       "      <td>2398 E. CAMELBACK RD.</td>\n",
       "      <td>100100000</td>\n",
       "      <td>American Stock Transfer &amp; Trust Company, LLC</td>\n",
       "      <td>We are a clinical-stage biopharmaceutical comp...</td>\n",
       "      <td>Todd Zavodnick</td>\n",
       "      <td>0001753483</td>\n",
       "      <td>PHOENIX</td>\n",
       "      <td>[Cooley LLP]</td>\n",
       "      <td>We are a clinical-stage biopharmaceutical comp...</td>\n",
       "      <td>DERMAVANT SCIENCES LTD</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-106432163</td>\n",
       "      <td>18101609</td>\n",
       "      <td>3500000</td>\n",
       "      <td>124533772</td>\n",
       "      <td>[Latham &amp; Watkins LLP]</td>\n",
       "      <td>[]</td>\n",
       "      <td>www.dermavant.com</td>\n",
       "      <td>We estimate that the net proceeds from our iss...</td>\n",
       "      <td>85016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>PRVL</th>\n",
       "      <td>430 EAST 29TH STREET, SUITE 940</td>\n",
       "      <td>125001000</td>\n",
       "      <td>Computershare Trust Company, N.A</td>\n",
       "      <td>We are a gene therapy company leveraging break...</td>\n",
       "      <td>Asa Abeliovich</td>\n",
       "      <td>0001714798</td>\n",
       "      <td>NEW YORK</td>\n",
       "      <td>[Cooley LLP]</td>\n",
       "      <td>We are a gene therapy company leveraging break...</td>\n",
       "      <td>PREVAIL THERAPEUTICS INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-27750643</td>\n",
       "      <td>115194156</td>\n",
       "      <td>2900000</td>\n",
       "      <td>13400958</td>\n",
       "      <td>[Latham &amp; Watkins LLP]</td>\n",
       "      <td>[Wedbush Securities Inc]</td>\n",
       "      <td>www.prevailtherapeutics.com</td>\n",
       "      <td>We estimate that the net proceeds from this of...</td>\n",
       "      <td>10016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BCEL</th>\n",
       "      <td>500 SAGINAW DRIVE, FIRST FLOOR</td>\n",
       "      <td>124950000</td>\n",
       "      <td>Computershare Trust Company, N.A</td>\n",
       "      <td>We are a biopharmaceutical company utilizing o...</td>\n",
       "      <td>John A. Orwin</td>\n",
       "      <td>0001532346</td>\n",
       "      <td>REDWOOD CITY</td>\n",
       "      <td>[Cooley LLP]</td>\n",
       "      <td>We are a biopharmaceutical company utilizing o...</td>\n",
       "      <td>ATRECA, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-105795000</td>\n",
       "      <td>109126000</td>\n",
       "      <td>2378440</td>\n",
       "      <td>5253000</td>\n",
       "      <td>[Davis Polk &amp; Wardwell LLP]</td>\n",
       "      <td>[Brookline Capital Markets, a division of Arca...</td>\n",
       "      <td>www.atreca.com</td>\n",
       "      <td>We estimate that we will receive net proceeds ...</td>\n",
       "      <td>94063</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AKRO</th>\n",
       "      <td>170 HARBOR WAY</td>\n",
       "      <td>75000000</td>\n",
       "      <td>Computershare Trust Company, N.A</td>\n",
       "      <td>We are a clinical-stage biotechnology company ...</td>\n",
       "      <td>Andrew Cheng</td>\n",
       "      <td>0001744659</td>\n",
       "      <td>SOUTH SAN FRANCISCO</td>\n",
       "      <td>[Goodwin Procter LLP]</td>\n",
       "      <td>We are a clinical-stage biotechnology company ...</td>\n",
       "      <td>AKERO THERAPEUTICS, INC.</td>\n",
       "      <td>...</td>\n",
       "      <td>Filed</td>\n",
       "      <td>-55066000</td>\n",
       "      <td>72066000</td>\n",
       "      <td>2472451</td>\n",
       "      <td>2404000</td>\n",
       "      <td>[Cooley LLP]</td>\n",
       "      <td>[Roth Capital Partners, Inc]</td>\n",
       "      <td>www.akerotx.com</td>\n",
       "      <td>We estimate that the net proceeds to us from t...</td>\n",
       "      <td>94080</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>8 rows  39 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                address     amount  \\\n",
       "symbol                                               \n",
       "CHWY      1855 GRIFFIN ROAD, SUITE B-42  832000000   \n",
       "STOK                    3 PRESTON COURT  100500000   \n",
       "PSNL                 1330 O'BRIEN DRIVE  100000005   \n",
       "GO                   5650 HOLLIS STREET  275000000   \n",
       "DRMT              2398 E. CAMELBACK RD.  100100000   \n",
       "PRVL    430 EAST 29TH STREET, SUITE 940  125001000   \n",
       "BCEL     500 SAGINAW DRIVE, FIRST FLOOR  124950000   \n",
       "AKRO                     170 HARBOR WAY   75000000   \n",
       "\n",
       "                                              auditor  \\\n",
       "symbol                                                  \n",
       "CHWY     American Stock Transfer & Trust Company, LLC   \n",
       "STOK     American Stock Transfer & Trust Company, LLC   \n",
       "PSNL                 Computershare Trust Company, N.A   \n",
       "GO      American Stock Transfer and Trust Company LLC   \n",
       "DRMT     American Stock Transfer & Trust Company, LLC   \n",
       "PRVL                 Computershare Trust Company, N.A   \n",
       "BCEL                 Computershare Trust Company, N.A   \n",
       "AKRO                 Computershare Trust Company, N.A   \n",
       "\n",
       "                                      businessDescription  \\\n",
       "symbol                                                      \n",
       "CHWY    Our mission is to be the most trusted and conv...   \n",
       "STOK    We are pioneering a new way to treat the under...   \n",
       "PSNL    We are a growing cancer genomics company trans...   \n",
       "GO      We are a high-growth, extreme value retailer o...   \n",
       "DRMT    We are a clinical-stage biopharmaceutical comp...   \n",
       "PRVL    We are a gene therapy company leveraging break...   \n",
       "BCEL    We are a biopharmaceutical company utilizing o...   \n",
       "AKRO    We are a clinical-stage biotechnology company ...   \n",
       "\n",
       "                          ceo         cik                 city  \\\n",
       "symbol                                                           \n",
       "CHWY              Sumit Singh  0001766502          DANIA BEACH   \n",
       "STOK           Edward M. Kaye  0001623526              BEDFORD   \n",
       "PSNL                John West  0001527753           MENLO PARK   \n",
       "GO      Eric J. Lindberg, Jr.  0001771515           EMERYVILLE   \n",
       "DRMT           Todd Zavodnick  0001753483              PHOENIX   \n",
       "PRVL           Asa Abeliovich  0001714798             NEW YORK   \n",
       "BCEL            John A. Orwin  0001532346         REDWOOD CITY   \n",
       "AKRO             Andrew Cheng  0001744659  SOUTH SAN FRANCISCO   \n",
       "\n",
       "                          companyCounsel  \\\n",
       "symbol                                     \n",
       "CHWY              [Kirkland & Ellis LLP]   \n",
       "STOK                [Fenwick & West LLP]   \n",
       "PSNL                        [Cooley LLP]   \n",
       "GO      [Simpson Thacher & Bartlett LLP]   \n",
       "DRMT                        [Cooley LLP]   \n",
       "PRVL                        [Cooley LLP]   \n",
       "BCEL                        [Cooley LLP]   \n",
       "AKRO               [Goodwin Procter LLP]   \n",
       "\n",
       "                                       companyDescription  \\\n",
       "symbol                                                      \n",
       "CHWY    Our mission is to be the most trusted and conv...   \n",
       "STOK    We are pioneering a new way to treat the under...   \n",
       "PSNL    We are a growing cancer genomics company trans...   \n",
       "GO      We are a high-growth, extreme value retailer o...   \n",
       "DRMT    We are a clinical-stage biopharmaceutical comp...   \n",
       "PRVL    We are a gene therapy company leveraging break...   \n",
       "BCEL    We are a biopharmaceutical company utilizing o...   \n",
       "AKRO    We are a clinical-stage biotechnology company ...   \n",
       "\n",
       "                         companyName  ... status  stockholderEquity  \\\n",
       "symbol                                ...                             \n",
       "CHWY                     CHEWY, INC.  ...  Filed         -335942000   \n",
       "STOK        STOKE THERAPEUTICS, INC.  ...  Filed           99581000   \n",
       "PSNL                PERSONALIS, INC.  ...  Filed         -110523000   \n",
       "GO      GROCERY OUTLET HOLDING CORP.  ...  Filed          303851000   \n",
       "DRMT          DERMAVANT SCIENCES LTD  ...  Filed         -106432163   \n",
       "PRVL       PREVAIL THERAPEUTICS INC.  ...  Filed          -27750643   \n",
       "BCEL                    ATRECA, INC.  ...  Filed         -105795000   \n",
       "AKRO        AKERO THERAPEUTICS, INC.  ...  Filed          -55066000   \n",
       "\n",
       "       totalAssets totalExpenses totalLiabilities  \\\n",
       "symbol                                              \n",
       "CHWY     541622000       5500000        877564000   \n",
       "STOK     102934000       2450000          3353000   \n",
       "PSNL      57647000       3200000         78766000   \n",
       "GO      2059912000       8055476       1756061000   \n",
       "DRMT      18101609       3500000        124533772   \n",
       "PRVL     115194156       2900000         13400958   \n",
       "BCEL     109126000       2378440          5253000   \n",
       "AKRO      72066000       2472451          2404000   \n",
       "\n",
       "                 underwriterCounsel  \\\n",
       "symbol                                \n",
       "CHWY    [Davis Polk & Wardwell LLP]   \n",
       "STOK    [Davis Polk & Wardwell LLP]   \n",
       "PSNL    [Davis Polk & Wardwell LLP]   \n",
       "GO      [Davis Polk & Wardwell LLP]   \n",
       "DRMT         [Latham & Watkins LLP]   \n",
       "PRVL         [Latham & Watkins LLP]   \n",
       "BCEL    [Davis Polk & Wardwell LLP]   \n",
       "AKRO                   [Cooley LLP]   \n",
       "\n",
       "                                             underwriters  \\\n",
       "symbol                                                      \n",
       "CHWY    [Barclays Capital Inc, BofA Securities, Inc, J...   \n",
       "STOK                              [Canaccord Genuity LLC]   \n",
       "PSNL                             [Oppenheimer & Co. Inc.]   \n",
       "GO      [Barclays Capital Inc, Cowen and Company, LLC,...   \n",
       "DRMT                                                   []   \n",
       "PRVL                             [Wedbush Securities Inc]   \n",
       "BCEL    [Brookline Capital Markets, a division of Arca...   \n",
       "AKRO                         [Roth Capital Partners, Inc]   \n",
       "\n",
       "                                url  \\\n",
       "symbol                                \n",
       "CHWY                  www.chewy.com   \n",
       "STOK      www.stoketherapeutics.com   \n",
       "PSNL             www.personalis.com   \n",
       "GO            www.groceryoutlet.com   \n",
       "DRMT              www.dermavant.com   \n",
       "PRVL    www.prevailtherapeutics.com   \n",
       "BCEL                 www.atreca.com   \n",
       "AKRO                www.akerotx.com   \n",
       "\n",
       "                                            useOfProceeds    zip  \n",
       "symbol                                                            \n",
       "CHWY    We expect to receive net proceeds from this of...  33004  \n",
       "STOK    We estimate that the net proceeds from our sal...  01730  \n",
       "PSNL    We estimate that we will receive net proceeds ...  94025  \n",
       "GO      We estimate that we will receive net proceeds ...  94608  \n",
       "DRMT    We estimate that the net proceeds from our iss...  85016  \n",
       "PRVL    We estimate that the net proceeds from this of...  10016  \n",
       "BCEL    We estimate that we will receive net proceeds ...  94063  \n",
       "AKRO    We estimate that the net proceeds to us from t...  94080  \n",
       "\n",
       "[8 rows x 39 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ipoUpcomingDF()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Key Stats"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'week52change': 0.125945,\n",
       " 'week52high': 233.47,\n",
       " 'week52low': 142,\n",
       " 'marketcap': 959233158400,\n",
       " 'employees': 132000,\n",
       " 'day200MovingAvg': 192.36,\n",
       " 'day50MovingAvg': 191.93,\n",
       " 'float': 4594455231,\n",
       " 'avg10Volume': 29695469,\n",
       " 'avg30Volume': 27470517.9,\n",
       " 'ttmEPS': 11.99,\n",
       " 'ttmDividendRate': 2.92,\n",
       " 'companyName': 'Apple, Inc.',\n",
       " 'sharesOutstanding': 4601080000,\n",
       " 'maxChangePercent': 205.130117,\n",
       " 'year5ChangePercent': 1.463761,\n",
       " 'year2ChangePercent': 0.362525,\n",
       " 'year1ChangePercent': 0.125945,\n",
       " 'ytdChangePercent': 0.320162,\n",
       " 'month6ChangePercent': -0.007002,\n",
       " 'month3ChangePercent': 0.219609,\n",
       " 'month1ChangePercent': 0.041879,\n",
       " 'day30ChangePercent': 0.104588,\n",
       " 'day5ChangePercent': 0.03892,\n",
       " 'nextDividendDate': '2019-05-10',\n",
       " 'dividendYield': 0.014006139677666923,\n",
       " 'nextEarningsDate': '2019-07-22',\n",
       " 'exDividendDate': '2019-05-10',\n",
       " 'peRatio': 16.92,\n",
       " 'beta': 1.454167231727185}"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.keyStats(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>avg10Volume</th>\n",
       "      <th>avg30Volume</th>\n",
       "      <th>beta</th>\n",
       "      <th>companyName</th>\n",
       "      <th>day200MovingAvg</th>\n",
       "      <th>day30ChangePercent</th>\n",
       "      <th>day50MovingAvg</th>\n",
       "      <th>day5ChangePercent</th>\n",
       "      <th>dividendYield</th>\n",
       "      <th>employees</th>\n",
       "      <th>...</th>\n",
       "      <th>sharesOutstanding</th>\n",
       "      <th>ttmDividendRate</th>\n",
       "      <th>ttmEPS</th>\n",
       "      <th>week52change</th>\n",
       "      <th>week52high</th>\n",
       "      <th>week52low</th>\n",
       "      <th>year1ChangePercent</th>\n",
       "      <th>year2ChangePercent</th>\n",
       "      <th>year5ChangePercent</th>\n",
       "      <th>ytdChangePercent</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>29695469</td>\n",
       "      <td>27470517.9</td>\n",
       "      <td>1.454167</td>\n",
       "      <td>Apple, Inc.</td>\n",
       "      <td>192.36</td>\n",
       "      <td>0.104588</td>\n",
       "      <td>191.93</td>\n",
       "      <td>0.03892</td>\n",
       "      <td>0.014006</td>\n",
       "      <td>132000</td>\n",
       "      <td>...</td>\n",
       "      <td>4601080000</td>\n",
       "      <td>2.92</td>\n",
       "      <td>11.99</td>\n",
       "      <td>0.125945</td>\n",
       "      <td>233.47</td>\n",
       "      <td>142</td>\n",
       "      <td>0.125945</td>\n",
       "      <td>0.362525</td>\n",
       "      <td>1.463761</td>\n",
       "      <td>0.320162</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows  30 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   avg10Volume  avg30Volume      beta  companyName  day200MovingAvg  \\\n",
       "0     29695469   27470517.9  1.454167  Apple, Inc.           192.36   \n",
       "\n",
       "   day30ChangePercent  day50MovingAvg  day5ChangePercent  dividendYield  \\\n",
       "0            0.104588          191.93            0.03892       0.014006   \n",
       "\n",
       "   employees  ... sharesOutstanding  ttmDividendRate  ttmEPS  week52change  \\\n",
       "0     132000  ...        4601080000             2.92   11.99      0.125945   \n",
       "\n",
       "   week52high  week52low  year1ChangePercent year2ChangePercent  \\\n",
       "0      233.47        142            0.125945           0.362525   \n",
       "\n",
       "  year5ChangePercent  ytdChangePercent  \n",
       "0           1.463761          0.320162  \n",
       "\n",
       "[1 rows x 30 columns]"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.keyStatsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Largest Trades"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'price': 202.64,\n",
       "  'size': 29815,\n",
       "  'time': 1557259112641,\n",
       "  'timeLabel': '15:58:32',\n",
       "  'venue': 'XNGS',\n",
       "  'venueName': 'Nasdaq'},\n",
       " {'price': 201.49,\n",
       "  'size': 26229,\n",
       "  'time': 1557251006634,\n",
       "  'timeLabel': '13:43:26',\n",
       "  'venue': 'None',\n",
       "  'venueName': 'Off Exchange'},\n",
       " {'price': 201,\n",
       "  'size': 21100,\n",
       "  'time': 1557257999636,\n",
       "  'timeLabel': '15:39:59',\n",
       "  'venue': 'None',\n",
       "  'venueName': 'Off Exchange'},\n",
       " {'price': 202.11,\n",
       "  'size': 20243,\n",
       "  'time': 1557252084201,\n",
       "  'timeLabel': '14:01:24',\n",
       "  'venue': 'None',\n",
       "  'venueName': 'Off Exchange'},\n",
       " {'price': 205.64,\n",
       "  'size': 19334,\n",
       "  'time': 1557237644656,\n",
       "  'timeLabel': '10:00:44',\n",
       "  'venue': 'XNGS',\n",
       "  'venueName': 'Nasdaq'},\n",
       " {'price': 202.67,\n",
       "  'size': 18777,\n",
       "  'time': 1557259140544,\n",
       "  'timeLabel': '15:59:00',\n",
       "  'venue': 'XNGS',\n",
       "  'venueName': 'Nasdaq'},\n",
       " {'price': 203.69,\n",
       "  'size': 18710,\n",
       "  'time': 1557248941169,\n",
       "  'timeLabel': '13:09:01',\n",
       "  'venue': 'XNGS',\n",
       "  'venueName': 'Nasdaq'},\n",
       " {'price': 204.7,\n",
       "  'size': 17289,\n",
       "  'time': 1557246318742,\n",
       "  'timeLabel': '12:25:18',\n",
       "  'venue': 'XNGS',\n",
       "  'venueName': 'Nasdaq'},\n",
       " {'price': 201.61,\n",
       "  'size': 17200,\n",
       "  'time': 1557251024041,\n",
       "  'timeLabel': '13:43:44',\n",
       "  'venue': 'XPHL',\n",
       "  'venueName': 'Nasdaq PSX'},\n",
       " {'price': 206.92,\n",
       "  'size': 15760,\n",
       "  'time': 1557236001139,\n",
       "  'timeLabel': '09:33:21',\n",
       "  'venue': 'None',\n",
       "  'venueName': 'Off Exchange'}]"
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.largestTrades(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>price</th>\n",
       "      <th>size</th>\n",
       "      <th>timeLabel</th>\n",
       "      <th>venue</th>\n",
       "      <th>venueName</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>time</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-05-07 19:58:32.641</th>\n",
       "      <td>202.64</td>\n",
       "      <td>29815</td>\n",
       "      <td>15:58:32</td>\n",
       "      <td>XNGS</td>\n",
       "      <td>Nasdaq</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 17:43:26.634</th>\n",
       "      <td>201.49</td>\n",
       "      <td>26229</td>\n",
       "      <td>13:43:26</td>\n",
       "      <td>None</td>\n",
       "      <td>Off Exchange</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 19:39:59.636</th>\n",
       "      <td>201.00</td>\n",
       "      <td>21100</td>\n",
       "      <td>15:39:59</td>\n",
       "      <td>None</td>\n",
       "      <td>Off Exchange</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 18:01:24.201</th>\n",
       "      <td>202.11</td>\n",
       "      <td>20243</td>\n",
       "      <td>14:01:24</td>\n",
       "      <td>None</td>\n",
       "      <td>Off Exchange</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 14:00:44.656</th>\n",
       "      <td>205.64</td>\n",
       "      <td>19334</td>\n",
       "      <td>10:00:44</td>\n",
       "      <td>XNGS</td>\n",
       "      <td>Nasdaq</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 19:59:00.544</th>\n",
       "      <td>202.67</td>\n",
       "      <td>18777</td>\n",
       "      <td>15:59:00</td>\n",
       "      <td>XNGS</td>\n",
       "      <td>Nasdaq</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 17:09:01.169</th>\n",
       "      <td>203.69</td>\n",
       "      <td>18710</td>\n",
       "      <td>13:09:01</td>\n",
       "      <td>XNGS</td>\n",
       "      <td>Nasdaq</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 16:25:18.742</th>\n",
       "      <td>204.70</td>\n",
       "      <td>17289</td>\n",
       "      <td>12:25:18</td>\n",
       "      <td>XNGS</td>\n",
       "      <td>Nasdaq</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 17:43:44.041</th>\n",
       "      <td>201.61</td>\n",
       "      <td>17200</td>\n",
       "      <td>13:43:44</td>\n",
       "      <td>XPHL</td>\n",
       "      <td>Nasdaq PSX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-05-07 13:33:21.139</th>\n",
       "      <td>206.92</td>\n",
       "      <td>15760</td>\n",
       "      <td>09:33:21</td>\n",
       "      <td>None</td>\n",
       "      <td>Off Exchange</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                          price   size timeLabel venue     venueName\n",
       "time                                                                \n",
       "2019-05-07 19:58:32.641  202.64  29815  15:58:32  XNGS        Nasdaq\n",
       "2019-05-07 17:43:26.634  201.49  26229  13:43:26  None  Off Exchange\n",
       "2019-05-07 19:39:59.636  201.00  21100  15:39:59  None  Off Exchange\n",
       "2019-05-07 18:01:24.201  202.11  20243  14:01:24  None  Off Exchange\n",
       "2019-05-07 14:00:44.656  205.64  19334  10:00:44  XNGS        Nasdaq\n",
       "2019-05-07 19:59:00.544  202.67  18777  15:59:00  XNGS        Nasdaq\n",
       "2019-05-07 17:09:01.169  203.69  18710  13:09:01  XNGS        Nasdaq\n",
       "2019-05-07 16:25:18.742  204.70  17289  12:25:18  XNGS        Nasdaq\n",
       "2019-05-07 17:43:44.041  201.61  17200  13:43:44  XPHL    Nasdaq PSX\n",
       "2019-05-07 13:33:21.139  206.92  15760  09:33:21  None  Off Exchange"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.largestTradesDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## List"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'symbol': 'AMD',\n",
       "  'companyName': 'Advanced Micro Devices, Inc.',\n",
       "  'calculationPrice': 'close',\n",
       "  'open': 27.2,\n",
       "  'openTime': 1557235800425,\n",
       "  'close': 26.66,\n",
       "  'closeTime': 1557259200467,\n",
       "  'high': 27.35,\n",
       "  'low': 26.21,\n",
       "  'latestPrice': 26.66,\n",
       "  'latestSource': 'Close',\n",
       "  'latestTime': 'May 7, 2019',\n",
       "  'latestUpdate': 1557259200467,\n",
       "  'latestVolume': 75187428,\n",
       "  'iexRealtimePrice': 26.645,\n",
       "  'iexRealtimeSize': 140,\n",
       "  'iexLastUpdated': 1557259189758,\n",
       "  'delayedPrice': 26.66,\n",
       "  'delayedPriceTime': 1557259200467,\n",
       "  'extendedPrice': 26.69,\n",
       "  'extendedChange': 0.03,\n",
       "  'extendedChangePercent': 0.00113,\n",
       "  'extendedPriceTime': 1557260206139,\n",
       "  'previousClose': 27.42,\n",
       "  'change': -0.76,\n",
       "  'changePercent': -0.02772,\n",
       "  'iexMarketPercent': 0.010079384548172069,\n",
       "  'iexVolume': 757843,\n",
       "  'avgTotalVolume': 66639014,\n",
       "  'iexBidPrice': 0,\n",
       "  'iexBidSize': 0,\n",
       "  'iexAskPrice': 0,\n",
       "  'iexAskSize': 0,\n",
       "  'marketCap': 28835456000,\n",
       "  'peRatio': 96.84,\n",
       "  'week52High': 34.14,\n",
       "  'week52Low': 11.3,\n",
       "  'ytdChange': 0.428467},\n",
       " {'symbol': 'CHK',\n",
       "  'companyName': 'Chesapeake Energy Corp.',\n",
       "  'calculationPrice': 'close',\n",
       "  'open': 2.84,\n",
       "  'openTime': 1557235800151,\n",
       "  'close': 2.78,\n",
       "  'closeTime': 1557259360279,\n",
       "  'high': 2.86,\n",
       "  'low': 2.73,\n",
       "  'latestPrice': 2.78,\n",
       "  'latestSource': 'Close',\n",
       "  'latestTime': 'May 7, 2019',\n",
       "  'latestUpdate': 1557259360279,\n",
       "  'latestVolume': 61919727,\n",
       "  'iexRealtimePrice': 2.8,\n",
       "  'iexRealtimeSize': 100,\n",
       "  'iexLastUpdated': 1557259199970,\n",
       "  'delayedPrice': 2.78,\n",
       "  'delayedPriceTime': 1557259360289,\n",
       "  'extendedPrice': 2.8,\n",
       "  'extendedChange': 0.02,\n",
       "  'extendedChangePercent': 0.00719,\n",
       "  'extendedPriceTime': 1557260159151,\n",
       "  'previousClose': 2.89,\n",
       "  'change': -0.11,\n",
       "  'changePercent': -0.03806,\n",
       "  'iexMarketPercent': 0.022101728581587578,\n",
       "  'iexVolume': 1368533,\n",
       "  'avgTotalVolume': 40279387,\n",
       "  'iexBidPrice': 0,\n",
       "  'iexBidSize': 0,\n",
       "  'iexAskPrice': 0,\n",
       "  'iexAskSize': 0,\n",
       "  'marketCap': 4540018000,\n",
       "  'peRatio': 3.22,\n",
       "  'week52High': 5.6,\n",
       "  'week52Low': 1.71,\n",
       "  'ytdChange': 0.281575},\n",
       " {'symbol': 'BAC',\n",
       "  'companyName': 'Bank of America Corp.',\n",
       "  'calculationPrice': 'close',\n",
       "  'open': 30.16,\n",
       "  'openTime': 1557235823901,\n",
       "  'close': 29.92,\n",
       "  'closeTime': 1557259357613,\n",
       "  'high': 30.17,\n",
       "  'low': 29.63,\n",
       "  'latestPrice': 29.92,\n",
       "  'latestSource': 'Close',\n",
       "  'latestTime': 'May 7, 2019',\n",
       "  'latestUpdate': 1557259357613,\n",
       "  'latestVolume': 57900808,\n",
       "  'iexRealtimePrice': 29.895,\n",
       "  'iexRealtimeSize': 200,\n",
       "  'iexLastUpdated': 1557259193658,\n",
       "  'delayedPrice': 29.92,\n",
       "  'delayedPriceTime': 1557259357638,\n",
       "  'extendedPrice': 29.94,\n",
       "  'extendedChange': 0.02,\n",
       "  'extendedChangePercent': 0.00067,\n",
       "  'extendedPriceTime': 1557260174072,\n",
       "  'previousClose': 30.47,\n",
       "  'change': -0.55,\n",
       "  'changePercent': -0.01805,\n",
       "  'iexMarketPercent': 0.019121857504993713,\n",
       "  'iexVolume': 1107171,\n",
       "  'avgTotalVolume': 57036390,\n",
       "  'iexBidPrice': 0,\n",
       "  'iexBidSize': 0,\n",
       "  'iexAskPrice': 0,\n",
       "  'iexAskSize': 0,\n",
       "  'marketCap': 284485344000,\n",
       "  'peRatio': 10.96,\n",
       "  'week52High': 31.91,\n",
       "  'week52Low': 22.66,\n",
       "  'ytdChange': 0.202703},\n",
       " {'symbol': 'GE',\n",
       "  'companyName': 'General Electric Co.',\n",
       "  'calculationPrice': 'close',\n",
       "  'open': 10.31,\n",
       "  'openTime': 1557235807469,\n",
       "  'close': 10.11,\n",
       "  'closeTime': 1557259217691,\n",
       "  'high': 10.36,\n",
       "  'low': 10.06,\n",
       "  'latestPrice': 10.11,\n",
       "  'latestSource': 'Close',\n",
       "  'latestTime': 'May 7, 2019',\n",
       "  'latestUpdate': 1557259217691,\n",
       "  'latestVolume': 56597983,\n",
       "  'iexRealtimePrice': 10.115,\n",
       "  'iexRealtimeSize': 100,\n",
       "  'iexLastUpdated': 1557259190610,\n",
       "  'delayedPrice': 10.11,\n",
       "  'delayedPriceTime': 1557259217736,\n",
       "  'extendedPrice': 10.15,\n",
       "  'extendedChange': 0.04,\n",
       "  'extendedChangePercent': 0.00396,\n",
       "  'extendedPriceTime': 1557260206031,\n",
       "  'previousClose': 10.43,\n",
       "  'change': -0.32,\n",
       "  'changePercent': -0.03068,\n",
       "  'iexMarketPercent': 0.01441443593493429,\n",
       "  'iexVolume': 815828,\n",
       "  'avgTotalVolume': 65900696,\n",
       "  'iexBidPrice': 0,\n",
       "  'iexBidSize': 0,\n",
       "  'iexAskPrice': 0,\n",
       "  'iexAskSize': 0,\n",
       "  'marketCap': 88167389100,\n",
       "  'peRatio': -4.27,\n",
       "  'week52High': 15.59,\n",
       "  'week52Low': 6.66,\n",
       "  'ytdChange': 0.26497200000000004},\n",
       " {'symbol': 'MYL',\n",
       "  'companyName': 'Mylan NV',\n",
       "  'calculationPrice': 'close',\n",
       "  'open': 26.7,\n",
       "  'openTime': 1557235800219,\n",
       "  'close': 21.53,\n",
       "  'closeTime': 1557259200479,\n",
       "  'high': 26.95,\n",
       "  'low': 21.52,\n",
       "  'latestPrice': 21.53,\n",
       "  'latestSource': 'Close',\n",
       "  'latestTime': 'May 7, 2019',\n",
       "  'latestUpdate': 1557259200479,\n",
       "  'latestVolume': 50755023,\n",
       "  'iexRealtimePrice': 21.84,\n",
       "  'iexRealtimeSize': 150,\n",
       "  'iexLastUpdated': 1557259218048,\n",
       "  'delayedPrice': 21.77,\n",
       "  'delayedPriceTime': 1557260143481,\n",
       "  'extendedPrice': 21.78,\n",
       "  'extendedChange': 0.25,\n",
       "  'extendedChangePercent': 0.01161,\n",
       "  'extendedPriceTime': 1557260203532,\n",
       "  'previousClose': 28.26,\n",
       "  'change': -6.73,\n",
       "  'changePercent': -0.23815,\n",
       "  'iexMarketPercent': 0.025444693424727636,\n",
       "  'iexVolume': 1291446,\n",
       "  'avgTotalVolume': 4541439,\n",
       "  'iexBidPrice': 0,\n",
       "  'iexBidSize': 0,\n",
       "  'iexAskPrice': 0,\n",
       "  'iexAskSize': 0,\n",
       "  'marketCap': 11096949540,\n",
       "  'peRatio': 31.66,\n",
       "  'week52High': 42.5,\n",
       "  'week52Low': 21.52,\n",
       "  'ytdChange': -0.225972}]"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.list()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>avgTotalVolume</th>\n",
       "      <th>calculationPrice</th>\n",
       "      <th>change</th>\n",
       "      <th>changePercent</th>\n",
       "      <th>close</th>\n",
       "      <th>closeTime</th>\n",
       "      <th>companyName</th>\n",
       "      <th>delayedPrice</th>\n",
       "      <th>delayedPriceTime</th>\n",
       "      <th>extendedChange</th>\n",
       "      <th>...</th>\n",
       "      <th>latestVolume</th>\n",
       "      <th>low</th>\n",
       "      <th>marketCap</th>\n",
       "      <th>open</th>\n",
       "      <th>openTime</th>\n",
       "      <th>peRatio</th>\n",
       "      <th>previousClose</th>\n",
       "      <th>week52High</th>\n",
       "      <th>week52Low</th>\n",
       "      <th>ytdChange</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>AMD</th>\n",
       "      <td>66639014</td>\n",
       "      <td>close</td>\n",
       "      <td>-0.76</td>\n",
       "      <td>-0.02772</td>\n",
       "      <td>26.66</td>\n",
       "      <td>2019-05-07 20:00:00.467</td>\n",
       "      <td>Advanced Micro Devices, Inc.</td>\n",
       "      <td>26.66</td>\n",
       "      <td>2019-05-07 20:00:00.467</td>\n",
       "      <td>0.03</td>\n",
       "      <td>...</td>\n",
       "      <td>75187428</td>\n",
       "      <td>26.21</td>\n",
       "      <td>28835456000</td>\n",
       "      <td>27.20</td>\n",
       "      <td>2019-05-07 13:30:00.425</td>\n",
       "      <td>96.84</td>\n",
       "      <td>27.42</td>\n",
       "      <td>34.14</td>\n",
       "      <td>11.30</td>\n",
       "      <td>0.428467</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>CHK</th>\n",
       "      <td>40279387</td>\n",
       "      <td>close</td>\n",
       "      <td>-0.11</td>\n",
       "      <td>-0.03806</td>\n",
       "      <td>2.78</td>\n",
       "      <td>2019-05-07 20:02:40.279</td>\n",
       "      <td>Chesapeake Energy Corp.</td>\n",
       "      <td>2.78</td>\n",
       "      <td>2019-05-07 20:02:40.289</td>\n",
       "      <td>0.02</td>\n",
       "      <td>...</td>\n",
       "      <td>61919727</td>\n",
       "      <td>2.73</td>\n",
       "      <td>4540018000</td>\n",
       "      <td>2.84</td>\n",
       "      <td>2019-05-07 13:30:00.151</td>\n",
       "      <td>3.22</td>\n",
       "      <td>2.89</td>\n",
       "      <td>5.60</td>\n",
       "      <td>1.71</td>\n",
       "      <td>0.281575</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BAC</th>\n",
       "      <td>57036390</td>\n",
       "      <td>close</td>\n",
       "      <td>-0.55</td>\n",
       "      <td>-0.01805</td>\n",
       "      <td>29.92</td>\n",
       "      <td>2019-05-07 20:02:37.613</td>\n",
       "      <td>Bank of America Corp.</td>\n",
       "      <td>29.92</td>\n",
       "      <td>2019-05-07 20:02:37.638</td>\n",
       "      <td>0.02</td>\n",
       "      <td>...</td>\n",
       "      <td>57900808</td>\n",
       "      <td>29.63</td>\n",
       "      <td>284485344000</td>\n",
       "      <td>30.16</td>\n",
       "      <td>2019-05-07 13:30:23.901</td>\n",
       "      <td>10.96</td>\n",
       "      <td>30.47</td>\n",
       "      <td>31.91</td>\n",
       "      <td>22.66</td>\n",
       "      <td>0.202703</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>GE</th>\n",
       "      <td>65900696</td>\n",
       "      <td>close</td>\n",
       "      <td>-0.32</td>\n",
       "      <td>-0.03068</td>\n",
       "      <td>10.11</td>\n",
       "      <td>2019-05-07 20:00:17.691</td>\n",
       "      <td>General Electric Co.</td>\n",
       "      <td>10.11</td>\n",
       "      <td>2019-05-07 20:00:17.736</td>\n",
       "      <td>0.04</td>\n",
       "      <td>...</td>\n",
       "      <td>56597983</td>\n",
       "      <td>10.06</td>\n",
       "      <td>88167389100</td>\n",
       "      <td>10.31</td>\n",
       "      <td>2019-05-07 13:30:07.469</td>\n",
       "      <td>-4.27</td>\n",
       "      <td>10.43</td>\n",
       "      <td>15.59</td>\n",
       "      <td>6.66</td>\n",
       "      <td>0.264972</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>MYL</th>\n",
       "      <td>4541439</td>\n",
       "      <td>close</td>\n",
       "      <td>-6.73</td>\n",
       "      <td>-0.23815</td>\n",
       "      <td>21.53</td>\n",
       "      <td>2019-05-07 20:00:00.479</td>\n",
       "      <td>Mylan NV</td>\n",
       "      <td>21.77</td>\n",
       "      <td>2019-05-07 20:15:43.481</td>\n",
       "      <td>0.25</td>\n",
       "      <td>...</td>\n",
       "      <td>50755023</td>\n",
       "      <td>21.52</td>\n",
       "      <td>11096949540</td>\n",
       "      <td>26.70</td>\n",
       "      <td>2019-05-07 13:30:00.219</td>\n",
       "      <td>31.66</td>\n",
       "      <td>28.26</td>\n",
       "      <td>42.50</td>\n",
       "      <td>21.52</td>\n",
       "      <td>-0.225972</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  37 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        avgTotalVolume calculationPrice  change  changePercent  close  \\\n",
       "symbol                                                                  \n",
       "AMD           66639014            close   -0.76       -0.02772  26.66   \n",
       "CHK           40279387            close   -0.11       -0.03806   2.78   \n",
       "BAC           57036390            close   -0.55       -0.01805  29.92   \n",
       "GE            65900696            close   -0.32       -0.03068  10.11   \n",
       "MYL            4541439            close   -6.73       -0.23815  21.53   \n",
       "\n",
       "                     closeTime                   companyName  delayedPrice  \\\n",
       "symbol                                                                       \n",
       "AMD    2019-05-07 20:00:00.467  Advanced Micro Devices, Inc.         26.66   \n",
       "CHK    2019-05-07 20:02:40.279       Chesapeake Energy Corp.          2.78   \n",
       "BAC    2019-05-07 20:02:37.613         Bank of America Corp.         29.92   \n",
       "GE     2019-05-07 20:00:17.691          General Electric Co.         10.11   \n",
       "MYL    2019-05-07 20:00:00.479                      Mylan NV         21.77   \n",
       "\n",
       "              delayedPriceTime  extendedChange  ...  latestVolume    low  \\\n",
       "symbol                                          ...                        \n",
       "AMD    2019-05-07 20:00:00.467            0.03  ...      75187428  26.21   \n",
       "CHK    2019-05-07 20:02:40.289            0.02  ...      61919727   2.73   \n",
       "BAC    2019-05-07 20:02:37.638            0.02  ...      57900808  29.63   \n",
       "GE     2019-05-07 20:00:17.736            0.04  ...      56597983  10.06   \n",
       "MYL    2019-05-07 20:15:43.481            0.25  ...      50755023  21.52   \n",
       "\n",
       "           marketCap   open                openTime  peRatio  previousClose  \\\n",
       "symbol                                                                        \n",
       "AMD      28835456000  27.20 2019-05-07 13:30:00.425    96.84          27.42   \n",
       "CHK       4540018000   2.84 2019-05-07 13:30:00.151     3.22           2.89   \n",
       "BAC     284485344000  30.16 2019-05-07 13:30:23.901    10.96          30.47   \n",
       "GE       88167389100  10.31 2019-05-07 13:30:07.469    -4.27          10.43   \n",
       "MYL      11096949540  26.70 2019-05-07 13:30:00.219    31.66          28.26   \n",
       "\n",
       "        week52High week52Low  ytdChange  \n",
       "symbol                                   \n",
       "AMD          34.14     11.30   0.428467  \n",
       "CHK           5.60      1.71   0.281575  \n",
       "BAC          31.91     22.66   0.202703  \n",
       "GE           15.59      6.66   0.264972  \n",
       "MYL          42.50     21.52  -0.225972  \n",
       "\n",
       "[5 rows x 37 columns]"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.listDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Logo"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'url': 'https://storage.googleapis.com/iex/api/logos/AAPL.png'}"
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.logo(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<PIL.PngImagePlugin.PngImageFile image mode=RGB size=128x128 at 0x11EA413C8>"
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.logoPNG(symbol) # Not available for sandbox"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<img src=\"https://storage.googleapis.com/iex/api/logos/AAPL.png\"/>"
      ],
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.logoNotebook(symbol) # Not available for sandbox"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Market Volume"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'mic': 'TRF',\n",
       "  'tapeId': '',\n",
       "  'venueName': 'TRF Volume',\n",
       "  'volume': 2616598627,\n",
       "  'tapeA': 1188236034,\n",
       "  'tapeB': 547148220,\n",
       "  'tapeC': 881214373,\n",
       "  'marketPercent': 0.34625,\n",
       "  'lastUpdated': 1557259276121},\n",
       " {'mic': 'XNGS',\n",
       "  'tapeId': 'Q',\n",
       "  'venueName': 'NASDAQ',\n",
       "  'volume': 1442531109,\n",
       "  'tapeA': 498799249,\n",
       "  'tapeB': 251498694,\n",
       "  'tapeC': 692233166,\n",
       "  'marketPercent': 0.19089,\n",
       "  'lastUpdated': 1557259276074},\n",
       " {'mic': 'XNYS',\n",
       "  'tapeId': 'N',\n",
       "  'venueName': 'NYSE',\n",
       "  'volume': 869030484,\n",
       "  'tapeA': 755995804,\n",
       "  'tapeB': 61562727,\n",
       "  'tapeC': 51471953,\n",
       "  'marketPercent': 0.115,\n",
       "  'lastUpdated': 1557259276081},\n",
       " {'mic': 'ARCX',\n",
       "  'tapeId': 'P',\n",
       "  'venueName': 'NYSE Arca',\n",
       "  'volume': 751073908,\n",
       "  'tapeA': 215781374,\n",
       "  'tapeB': 351378614,\n",
       "  'tapeC': 183913920,\n",
       "  'marketPercent': 0.09939,\n",
       "  'lastUpdated': 1557259275920},\n",
       " {'mic': 'BATS',\n",
       "  'tapeId': 'Z',\n",
       "  'venueName': 'BATS BZX',\n",
       "  'volume': 448589733,\n",
       "  'tapeA': 190127101,\n",
       "  'tapeB': 125882003,\n",
       "  'tapeC': 132580629,\n",
       "  'marketPercent': 0.05936,\n",
       "  'lastUpdated': 1557259275613}]"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.marketVolume()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>lastUpdated</th>\n",
       "      <th>marketPercent</th>\n",
       "      <th>mic</th>\n",
       "      <th>tapeA</th>\n",
       "      <th>tapeB</th>\n",
       "      <th>tapeC</th>\n",
       "      <th>tapeId</th>\n",
       "      <th>venueName</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2019-05-07 20:31:39.915</td>\n",
       "      <td>0.34822</td>\n",
       "      <td>TRF</td>\n",
       "      <td>1246784428</td>\n",
       "      <td>581102068</td>\n",
       "      <td>907392466</td>\n",
       "      <td></td>\n",
       "      <td>TRF Volume</td>\n",
       "      <td>2735278962</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2019-05-07 20:31:40.061</td>\n",
       "      <td>0.18413</td>\n",
       "      <td>XNGS</td>\n",
       "      <td>499012364</td>\n",
       "      <td>253100508</td>\n",
       "      <td>694258064</td>\n",
       "      <td>Q</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>1446370936</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2019-05-07 20:05:42.778</td>\n",
       "      <td>0.13184</td>\n",
       "      <td>XNYS</td>\n",
       "      <td>922545920</td>\n",
       "      <td>61562727</td>\n",
       "      <td>51471953</td>\n",
       "      <td>N</td>\n",
       "      <td>NYSE</td>\n",
       "      <td>1035580600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2019-05-07 20:31:39.913</td>\n",
       "      <td>0.09622</td>\n",
       "      <td>ARCX</td>\n",
       "      <td>216171089</td>\n",
       "      <td>353817727</td>\n",
       "      <td>185859405</td>\n",
       "      <td>P</td>\n",
       "      <td>NYSE Arca</td>\n",
       "      <td>755848221</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2019-05-07 20:31:38.152</td>\n",
       "      <td>0.05723</td>\n",
       "      <td>BATS</td>\n",
       "      <td>190132470</td>\n",
       "      <td>126607178</td>\n",
       "      <td>132769027</td>\n",
       "      <td>Z</td>\n",
       "      <td>BATS BZX</td>\n",
       "      <td>449508675</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>2019-05-07 20:31:39.830</td>\n",
       "      <td>0.04346</td>\n",
       "      <td>EDGX</td>\n",
       "      <td>136947635</td>\n",
       "      <td>86977615</td>\n",
       "      <td>117419147</td>\n",
       "      <td>K</td>\n",
       "      <td>EDGX</td>\n",
       "      <td>341344397</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2019-05-07 20:31:39.911</td>\n",
       "      <td>0.04140</td>\n",
       "      <td>BATY</td>\n",
       "      <td>165891929</td>\n",
       "      <td>84816806</td>\n",
       "      <td>74521476</td>\n",
       "      <td>Y</td>\n",
       "      <td>BATS BYX</td>\n",
       "      <td>325230211</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>2019-05-07 20:31:39.876</td>\n",
       "      <td>0.02721</td>\n",
       "      <td>IEXG</td>\n",
       "      <td>125519569</td>\n",
       "      <td>22730355</td>\n",
       "      <td>65468302</td>\n",
       "      <td>V</td>\n",
       "      <td>IEX</td>\n",
       "      <td>213718226</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2019-05-07 20:31:20.684</td>\n",
       "      <td>0.02213</td>\n",
       "      <td>EDGA</td>\n",
       "      <td>88540625</td>\n",
       "      <td>36241995</td>\n",
       "      <td>49029969</td>\n",
       "      <td>J</td>\n",
       "      <td>EDGA</td>\n",
       "      <td>173812589</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2019-05-07 20:31:29.492</td>\n",
       "      <td>0.01898</td>\n",
       "      <td>XBOS</td>\n",
       "      <td>70222534</td>\n",
       "      <td>39354884</td>\n",
       "      <td>39494008</td>\n",
       "      <td>B</td>\n",
       "      <td>NASDAQ BX</td>\n",
       "      <td>149071426</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>2019-05-07 20:29:49.955</td>\n",
       "      <td>0.01303</td>\n",
       "      <td>XCIS</td>\n",
       "      <td>50009154</td>\n",
       "      <td>29678270</td>\n",
       "      <td>22669202</td>\n",
       "      <td>C</td>\n",
       "      <td>NYSE National</td>\n",
       "      <td>102356626</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2019-05-07 20:31:24.011</td>\n",
       "      <td>0.00803</td>\n",
       "      <td>XPHL</td>\n",
       "      <td>18399868</td>\n",
       "      <td>27414148</td>\n",
       "      <td>17263713</td>\n",
       "      <td>X</td>\n",
       "      <td>NASDAQ PSX</td>\n",
       "      <td>63077729</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2019-05-07 20:14:57.051</td>\n",
       "      <td>0.00481</td>\n",
       "      <td>XCHI</td>\n",
       "      <td>12108510</td>\n",
       "      <td>19595843</td>\n",
       "      <td>6093800</td>\n",
       "      <td>M</td>\n",
       "      <td>CHX</td>\n",
       "      <td>37798153</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2019-05-07 20:29:42.681</td>\n",
       "      <td>0.00331</td>\n",
       "      <td>XASE</td>\n",
       "      <td>8135366</td>\n",
       "      <td>13855176</td>\n",
       "      <td>4042741</td>\n",
       "      <td>A</td>\n",
       "      <td>NYSE American</td>\n",
       "      <td>26033283</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               lastUpdated  marketPercent   mic       tapeA      tapeB  \\\n",
       "0  2019-05-07 20:31:39.915        0.34822   TRF  1246784428  581102068   \n",
       "1  2019-05-07 20:31:40.061        0.18413  XNGS   499012364  253100508   \n",
       "2  2019-05-07 20:05:42.778        0.13184  XNYS   922545920   61562727   \n",
       "3  2019-05-07 20:31:39.913        0.09622  ARCX   216171089  353817727   \n",
       "4  2019-05-07 20:31:38.152        0.05723  BATS   190132470  126607178   \n",
       "5  2019-05-07 20:31:39.830        0.04346  EDGX   136947635   86977615   \n",
       "6  2019-05-07 20:31:39.911        0.04140  BATY   165891929   84816806   \n",
       "7  2019-05-07 20:31:39.876        0.02721  IEXG   125519569   22730355   \n",
       "8  2019-05-07 20:31:20.684        0.02213  EDGA    88540625   36241995   \n",
       "9  2019-05-07 20:31:29.492        0.01898  XBOS    70222534   39354884   \n",
       "10 2019-05-07 20:29:49.955        0.01303  XCIS    50009154   29678270   \n",
       "11 2019-05-07 20:31:24.011        0.00803  XPHL    18399868   27414148   \n",
       "12 2019-05-07 20:14:57.051        0.00481  XCHI    12108510   19595843   \n",
       "13 2019-05-07 20:29:42.681        0.00331  XASE     8135366   13855176   \n",
       "\n",
       "        tapeC tapeId      venueName      volume  \n",
       "0   907392466            TRF Volume  2735278962  \n",
       "1   694258064      Q         NASDAQ  1446370936  \n",
       "2    51471953      N           NYSE  1035580600  \n",
       "3   185859405      P      NYSE Arca   755848221  \n",
       "4   132769027      Z       BATS BZX   449508675  \n",
       "5   117419147      K           EDGX   341344397  \n",
       "6    74521476      Y       BATS BYX   325230211  \n",
       "7    65468302      V            IEX   213718226  \n",
       "8    49029969      J           EDGA   173812589  \n",
       "9    39494008      B      NASDAQ BX   149071426  \n",
       "10   22669202      C  NYSE National   102356626  \n",
       "11   17263713      X     NASDAQ PSX    63077729  \n",
       "12    6093800      M            CHX    37798153  \n",
       "13    4042741      A  NYSE American    26033283  "
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.marketVolumeDF()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## News"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'datetime': 1560440040000,\n",
       "  'headline': \"How to lock apps on your iPhone using Apple's 'Screen Time' feature for limiting app usage\",\n",
       "  'source': 'Business Insider',\n",
       "  'url': 'https://cloud.iexapis.com/v1/news/article/f887d15a-1446-4293-a95e-684531fda4b8',\n",
       "  'summary': 'If you\\'d like to limit the use of some or all apps on your iPhone , Apple\\'s Screen Time function allows you to lock apps with a passcode-protected time limit. You can lock apps on your iPhone using Screen Time to prevent access to any apps containing sensitive information or provide privacy on shared devices. Visit Business Insider\\'s homepage for more stories . Whether you\\'re looking to spend some time away from your iPhone but can\\'t seem to drag yourself away from the grasp of social media apps, or just need some quiet from work emails while on vacation, Apple\\'s Screen Time feature is here to assist you. When Apple introduced iOS 12 last year , it also introduced Screen Time and its ability to limit certain iPhone apps to \"make more informed decisions about how you use your devices.\" Using the Screen Time function, you can also essentially \"lock\" any iPhone apps that you\\'re looking to prevent yourself or others from accessing. Here\\'s how to do it. How to lock apps on an iPhone using Screen Time 1.',\n",
       "  'related': 'AAPL',\n",
       "  'image': 'https://cloud.iexapis.com/v1/news/image/f887d15a-1446-4293-a95e-684531fda4b8',\n",
       "  'lang': 'en',\n",
       "  'hasPaywall': False},\n",
       " {'datetime': 1560438291000,\n",
       "  'headline': 'How An Antitrust Ruling Could Help Apple Lower The Price Of Its Modem Chips And Patents',\n",
       "  'source': 'Seeking Alpha',\n",
       "  'url': 'https://cloud.iexapis.com/v1/news/article/1ff50ea7-da75-40be-ba40-3bc40dec6c14',\n",
       "  'summary': \"Apple's dispute with Qualcomm looks to have been settled, but a court ruling may still shake things up in Apple's favor. Qualcomm used a two-pronged approach to\",\n",
       "  'related': 'AAPL',\n",
       "  'image': 'https://cloud.iexapis.com/v1/news/image/1ff50ea7-da75-40be-ba40-3bc40dec6c14',\n",
       "  'lang': 'en',\n",
       "  'hasPaywall': False},\n",
       " {'datetime': 1560433177000,\n",
       "  'headline': 'Huawei is furiously working to get its new operating system off the ground, trademarking it across the world and shipping 1 million test devices',\n",
       "  'source': 'Business Insider',\n",
       "  'url': 'https://cloud.iexapis.com/v1/news/article/8388baac-9688-4581-92ad-3039dba28f18',\n",
       "  'summary': 'Huawei is working furiously to get its homemade operating system, Hongmeng, off the ground. Reuters reported that it has filed a trademark for the software in nine countries, as well as Europe. China Daily also said Huawei is shipping 1 million test devices. Huawei wants to release Hongmeng early next year after being blacklisted by the US government. Visit Business Insider\\'s homepage for more stories. Huawei is working furiously to get its new operating system off the ground amid the serious threat that Google will sever all ties with the Chinese tech company. US President Donald Trump\\'s administration blacklisted Huawei last month amid fears it is a proxy for Chinese surveillance. It meant Google took the decision to cut off Huawei \\'s access to its Android operating system. In response, Huawei  the world\\'s second-biggest phone maker  has been ramping up plans for its own operating system, which it wants to release by early 2020, according to Richard Yu, the CEO of Huawei\\'s consumer division . \"Today, Huawei, we are still committed to Microsoft Windows and Google Android.',\n",
       "  'related': 'AAPL',\n",
       "  'image': 'https://cloud.iexapis.com/v1/news/image/8388baac-9688-4581-92ad-3039dba28f18',\n",
       "  'lang': 'en',\n",
       "  'hasPaywall': False},\n",
       " {'datetime': 1560427200000,\n",
       "  'headline': \"'Alexa, what ETF should I buy?' Asset managers like BlackRock and Invesco are testing out voice assistants  but it's too early to tell if customers will actually use them\",\n",
       "  'source': 'Business Insider',\n",
       "  'url': 'https://cloud.iexapis.com/v1/news/article/342128d9-b46b-4c25-aac3-5b04798fd120',\n",
       "  'summary': \"Asset managers' websites are difficult to navigate. Soon institutional and retail investors could ask questions and access their portfolios via voice assistants like Siri and Alexa. Some of the largest fund managers, including BlackRock, Invesco, JPMorgan, State Street, and T. Rowe Price, are laying the foundations for voice programs, which they could roll out as soon as next year. It's unclear how much investors will use these programs, and some advisers are worried about privacy and encouraging short-term behavior. Click here for more BI Prime stories . With just a few spoken words, you can schedule doctors' appointments on Alexa , order groceries on Google Home, and ask Siri for flight updates . Soon people will be able to interact just as easily with the companies that manage their investment and retirement accounts. Big asset managers such as BlackRock, Invesco, State Street, T. Rowe Price, and JPMorgan are preparing to roll out tools on platforms like Alexa and Siri as soon as next year, top digital and marketing executives told Business Insider.\",\n",
       "  'related': 'AAPL',\n",
       "  'image': 'https://cloud.iexapis.com/v1/news/image/342128d9-b46b-4c25-aac3-5b04798fd120',\n",
       "  'lang': 'en',\n",
       "  'hasPaywall': False},\n",
       " {'datetime': 1560423600000,\n",
       "  'headline': 'Apple And The New Chip Paradigm With Mark Hibben (Podcast)',\n",
       "  'source': 'Seeking Alpha',\n",
       "  'url': 'https://cloud.iexapis.com/v1/news/article/4e7f27a1-ccb4-4a94-9926-2588a96f31e9',\n",
       "  'summary': \"On the latest Marketplace Roundtable podcast, Mark Hibben (of Rethink Technology) sits down with Seeking Alpha's Jonathan Liss to walk listeners through his uni\",\n",
       "  'related': 'AAPL',\n",
       "  'image': 'https://cloud.iexapis.com/v1/news/image/4e7f27a1-ccb4-4a94-9926-2588a96f31e9',\n",
       "  'lang': 'en',\n",
       "  'hasPaywall': False}]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.news(symbol)[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasPaywall</th>\n",
       "      <th>headline</th>\n",
       "      <th>image</th>\n",
       "      <th>lang</th>\n",
       "      <th>related</th>\n",
       "      <th>source</th>\n",
       "      <th>summary</th>\n",
       "      <th>url</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>datetime</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2019-06-13 15:34:00</th>\n",
       "      <td>False</td>\n",
       "      <td>How to lock apps on your iPhone using Apple's ...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/image/f887d1...</td>\n",
       "      <td>en</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>Business Insider</td>\n",
       "      <td>If you'd like to limit the use of some or all ...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/article/f887...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-06-13 15:04:51</th>\n",
       "      <td>False</td>\n",
       "      <td>How An Antitrust Ruling Could Help Apple Lower...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/image/1ff50e...</td>\n",
       "      <td>en</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>Seeking Alpha</td>\n",
       "      <td>Apple's dispute with Qualcomm looks to have be...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/article/1ff5...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-06-13 13:39:37</th>\n",
       "      <td>False</td>\n",
       "      <td>Huawei is furiously working to get its new ope...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/image/8388ba...</td>\n",
       "      <td>en</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>Business Insider</td>\n",
       "      <td>Huawei is working furiously to get its homemad...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/article/8388...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-06-13 12:00:00</th>\n",
       "      <td>False</td>\n",
       "      <td>'Alexa, what ETF should I buy?' Asset managers...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/image/342128...</td>\n",
       "      <td>en</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>Business Insider</td>\n",
       "      <td>Asset managers' websites are difficult to navi...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/article/3421...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2019-06-13 11:00:00</th>\n",
       "      <td>False</td>\n",
       "      <td>Apple And The New Chip Paradigm With Mark Hibb...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/image/4e7f27...</td>\n",
       "      <td>en</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>Seeking Alpha</td>\n",
       "      <td>On the latest Marketplace Roundtable podcast, ...</td>\n",
       "      <td>https://cloud.iexapis.com/v1/news/article/4e7f...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     hasPaywall  \\\n",
       "datetime                          \n",
       "2019-06-13 15:34:00       False   \n",
       "2019-06-13 15:04:51       False   \n",
       "2019-06-13 13:39:37       False   \n",
       "2019-06-13 12:00:00       False   \n",
       "2019-06-13 11:00:00       False   \n",
       "\n",
       "                                                              headline  \\\n",
       "datetime                                                                 \n",
       "2019-06-13 15:34:00  How to lock apps on your iPhone using Apple's ...   \n",
       "2019-06-13 15:04:51  How An Antitrust Ruling Could Help Apple Lower...   \n",
       "2019-06-13 13:39:37  Huawei is furiously working to get its new ope...   \n",
       "2019-06-13 12:00:00  'Alexa, what ETF should I buy?' Asset managers...   \n",
       "2019-06-13 11:00:00  Apple And The New Chip Paradigm With Mark Hibb...   \n",
       "\n",
       "                                                                 image lang  \\\n",
       "datetime                                                                      \n",
       "2019-06-13 15:34:00  https://cloud.iexapis.com/v1/news/image/f887d1...   en   \n",
       "2019-06-13 15:04:51  https://cloud.iexapis.com/v1/news/image/1ff50e...   en   \n",
       "2019-06-13 13:39:37  https://cloud.iexapis.com/v1/news/image/8388ba...   en   \n",
       "2019-06-13 12:00:00  https://cloud.iexapis.com/v1/news/image/342128...   en   \n",
       "2019-06-13 11:00:00  https://cloud.iexapis.com/v1/news/image/4e7f27...   en   \n",
       "\n",
       "                    related            source  \\\n",
       "datetime                                        \n",
       "2019-06-13 15:34:00    AAPL  Business Insider   \n",
       "2019-06-13 15:04:51    AAPL     Seeking Alpha   \n",
       "2019-06-13 13:39:37    AAPL  Business Insider   \n",
       "2019-06-13 12:00:00    AAPL  Business Insider   \n",
       "2019-06-13 11:00:00    AAPL     Seeking Alpha   \n",
       "\n",
       "                                                               summary  \\\n",
       "datetime                                                                 \n",
       "2019-06-13 15:34:00  If you'd like to limit the use of some or all ...   \n",
       "2019-06-13 15:04:51  Apple's dispute with Qualcomm looks to have be...   \n",
       "2019-06-13 13:39:37  Huawei is working furiously to get its homemad...   \n",
       "2019-06-13 12:00:00  Asset managers' websites are difficult to navi...   \n",
       "2019-06-13 11:00:00  On the latest Marketplace Roundtable podcast, ...   \n",
       "\n",
       "                                                                   url  \n",
       "datetime                                                                \n",
       "2019-06-13 15:34:00  https://cloud.iexapis.com/v1/news/article/f887...  \n",
       "2019-06-13 15:04:51  https://cloud.iexapis.com/v1/news/article/1ff5...  \n",
       "2019-06-13 13:39:37  https://cloud.iexapis.com/v1/news/article/8388...  \n",
       "2019-06-13 12:00:00  https://cloud.iexapis.com/v1/news/article/3421...  \n",
       "2019-06-13 11:00:00  https://cloud.iexapis.com/v1/news/article/4e7f...  "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.newsDF(symbol).head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.marketNews()[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: []\n",
       "Index: []"
      ]
     },
     "execution_count": 103,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.marketNewsDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## OHLC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'open': {'price': 205.86, 'time': 1557235800311},\n",
       " 'close': {'price': 202.86, 'time': 1557259200243},\n",
       " 'high': 207.417,\n",
       " 'low': 200.825,\n",
       " 'symbol': 'AAPL'}"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ohlc(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>close.price</th>\n",
       "      <th>close.time</th>\n",
       "      <th>high</th>\n",
       "      <th>low</th>\n",
       "      <th>open.price</th>\n",
       "      <th>open.time</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>202.86</td>\n",
       "      <td>2019-05-07 20:00:00.243</td>\n",
       "      <td>207.417</td>\n",
       "      <td>200.825</td>\n",
       "      <td>205.86</td>\n",
       "      <td>1557235800311</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   close.price              close.time     high      low  open.price  \\\n",
       "0       202.86 2019-05-07 20:00:00.243  207.417  200.825      205.86   \n",
       "\n",
       "       open.time symbol  \n",
       "0  1557235800311   AAPL  "
      ]
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ohlcDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Open/Close Price"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'open': {'price': 205.86, 'time': 1557235800311},\n",
       " 'close': {'price': 202.86, 'time': 1557259200243},\n",
       " 'high': 207.417,\n",
       " 'low': 200.825,\n",
       " 'symbol': 'AAPL'}"
      ]
     },
     "execution_count": 111,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ohlc(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>close.price</th>\n",
       "      <th>close.time</th>\n",
       "      <th>high</th>\n",
       "      <th>low</th>\n",
       "      <th>open.price</th>\n",
       "      <th>open.time</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>202.86</td>\n",
       "      <td>2019-05-07 20:00:00.243</td>\n",
       "      <td>207.417</td>\n",
       "      <td>200.825</td>\n",
       "      <td>205.86</td>\n",
       "      <td>2019-05-07 13:30:00.311</td>\n",
       "      <td>AAPL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   close.price              close.time     high      low  open.price  \\\n",
       "0       202.86 2019-05-07 20:00:00.243  207.417  200.825      205.86   \n",
       "\n",
       "                open.time symbol  \n",
       "0 2019-05-07 13:30:00.311   AAPL  "
      ]
     },
     "execution_count": 117,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ohlcDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Options"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['201905',\n",
       " '201906',\n",
       " '201907',\n",
       " '201908',\n",
       " '201909',\n",
       " '201910',\n",
       " '202001',\n",
       " '202006',\n",
       " '202009',\n",
       " '202101',\n",
       " '202106']"
      ]
     },
     "execution_count": 118,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "exps = c.optionExpirations(symbol)\n",
    "exps"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'symbol': 'AAPL',\n",
       "  'id': 'AAPL20190517C00210000',\n",
       "  'expirationDate': '20190517',\n",
       "  'contractSize': 100,\n",
       "  'strikePrice': 210,\n",
       "  'closingPrice': 3.72,\n",
       "  'side': 'call',\n",
       "  'type': 'equity',\n",
       "  'volume': 6162,\n",
       "  'openInterest': 19277,\n",
       "  'bid': 3.65,\n",
       "  'ask': 3.75,\n",
       "  'lastUpdated': '2019-05-03'},\n",
       " {'symbol': 'AAPL',\n",
       "  'id': 'AAPL20190517C00100000',\n",
       "  'expirationDate': '20190517',\n",
       "  'contractSize': 100,\n",
       "  'strikePrice': 100,\n",
       "  'closingPrice': 113.900002,\n",
       "  'side': 'call',\n",
       "  'type': 'equity',\n",
       "  'volume': 0,\n",
       "  'openInterest': 18,\n",
       "  'bid': 111,\n",
       "  'ask': 112.25,\n",
       "  'lastUpdated': '2019-05-03'},\n",
       " {'symbol': 'AAPL',\n",
       "  'id': 'AAPL20190517C00090000',\n",
       "  'expirationDate': '20190517',\n",
       "  'contractSize': 100,\n",
       "  'strikePrice': 90,\n",
       "  'closingPrice': 110.93,\n",
       "  'side': 'call',\n",
       "  'type': 'equity',\n",
       "  'volume': 0,\n",
       "  'openInterest': 95,\n",
       "  'bid': 120.699997,\n",
       "  'ask': 122.550003,\n",
       "  'lastUpdated': '2019-05-03'},\n",
       " {'symbol': 'AAPL',\n",
       "  'id': 'AAPL20190517C00160000',\n",
       "  'expirationDate': '20190517',\n",
       "  'contractSize': 100,\n",
       "  'strikePrice': 160,\n",
       "  'closingPrice': 50.880001,\n",
       "  'side': 'call',\n",
       "  'type': 'equity',\n",
       "  'volume': 3,\n",
       "  'openInterest': 1458,\n",
       "  'bid': 51.5,\n",
       "  'ask': 52,\n",
       "  'lastUpdated': '2019-05-03'},\n",
       " {'symbol': 'AAPL',\n",
       "  'id': 'AAPL20190517C00270000',\n",
       "  'expirationDate': '20190517',\n",
       "  'contractSize': 100,\n",
       "  'strikePrice': 270,\n",
       "  'closingPrice': 0.01,\n",
       "  'side': 'call',\n",
       "  'type': 'equity',\n",
       "  'volume': 0,\n",
       "  'openInterest': 261,\n",
       "  'bid': 0,\n",
       "  'ask': 0.01,\n",
       "  'lastUpdated': '2019-05-03'}]"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.options(symbol, exps[0])[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ask</th>\n",
       "      <th>bid</th>\n",
       "      <th>closingPrice</th>\n",
       "      <th>contractSize</th>\n",
       "      <th>expirationDate</th>\n",
       "      <th>id</th>\n",
       "      <th>lastUpdated</th>\n",
       "      <th>openInterest</th>\n",
       "      <th>side</th>\n",
       "      <th>strikePrice</th>\n",
       "      <th>symbol</th>\n",
       "      <th>type</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3.750000</td>\n",
       "      <td>3.650000</td>\n",
       "      <td>3.720000</td>\n",
       "      <td>100</td>\n",
       "      <td>2019-05-17</td>\n",
       "      <td>AAPL20190517C00210000</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>19277</td>\n",
       "      <td>call</td>\n",
       "      <td>210.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>equity</td>\n",
       "      <td>6162</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>112.250000</td>\n",
       "      <td>111.000000</td>\n",
       "      <td>113.900002</td>\n",
       "      <td>100</td>\n",
       "      <td>2019-05-17</td>\n",
       "      <td>AAPL20190517C00100000</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>18</td>\n",
       "      <td>call</td>\n",
       "      <td>100.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>equity</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>122.550003</td>\n",
       "      <td>120.699997</td>\n",
       "      <td>110.930000</td>\n",
       "      <td>100</td>\n",
       "      <td>2019-05-17</td>\n",
       "      <td>AAPL20190517C00090000</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>95</td>\n",
       "      <td>call</td>\n",
       "      <td>90.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>equity</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>52.000000</td>\n",
       "      <td>51.500000</td>\n",
       "      <td>50.880001</td>\n",
       "      <td>100</td>\n",
       "      <td>2019-05-17</td>\n",
       "      <td>AAPL20190517C00160000</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>1458</td>\n",
       "      <td>call</td>\n",
       "      <td>160.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>equity</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.010000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.010000</td>\n",
       "      <td>100</td>\n",
       "      <td>2019-05-17</td>\n",
       "      <td>AAPL20190517C00270000</td>\n",
       "      <td>2019-05-03</td>\n",
       "      <td>261</td>\n",
       "      <td>call</td>\n",
       "      <td>270.0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>equity</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          ask         bid  closingPrice  contractSize expirationDate  \\\n",
       "0    3.750000    3.650000      3.720000           100     2019-05-17   \n",
       "1  112.250000  111.000000    113.900002           100     2019-05-17   \n",
       "2  122.550003  120.699997    110.930000           100     2019-05-17   \n",
       "3   52.000000   51.500000     50.880001           100     2019-05-17   \n",
       "4    0.010000    0.000000      0.010000           100     2019-05-17   \n",
       "\n",
       "                      id lastUpdated  openInterest  side  strikePrice symbol  \\\n",
       "0  AAPL20190517C00210000  2019-05-03         19277  call        210.0   AAPL   \n",
       "1  AAPL20190517C00100000  2019-05-03            18  call        100.0   AAPL   \n",
       "2  AAPL20190517C00090000  2019-05-03            95  call         90.0   AAPL   \n",
       "3  AAPL20190517C00160000  2019-05-03          1458  call        160.0   AAPL   \n",
       "4  AAPL20190517C00270000  2019-05-03           261  call        270.0   AAPL   \n",
       "\n",
       "     type  volume  \n",
       "0  equity    6162  \n",
       "1  equity       0  \n",
       "2  equity       0  \n",
       "3  equity       3  \n",
       "4  equity       0  "
      ]
     },
     "execution_count": 121,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.optionsDF(symbol, exps[0]).head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Peers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['MSFT', 'NOK', 'IBM', 'HPQ', 'GOOGL', 'BB']"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.peers(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>peer</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>MSFT</th>\n",
       "      <td>MSFT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NOK</th>\n",
       "      <td>NOK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>IBM</th>\n",
       "      <td>IBM</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>HPQ</th>\n",
       "      <td>HPQ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>GOOGL</th>\n",
       "      <td>GOOGL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BB</th>\n",
       "      <td>BB</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         peer\n",
       "symbol       \n",
       "MSFT     MSFT\n",
       "NOK       NOK\n",
       "IBM       IBM\n",
       "HPQ       HPQ\n",
       "GOOGL   GOOGL\n",
       "BB         BB"
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.peersDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Previous Day Price"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'date': '2019-05-06',\n",
       " 'open': 204.29,\n",
       " 'close': 208.48,\n",
       " 'high': 208.84,\n",
       " 'low': 203.5,\n",
       " 'volume': 32443113,\n",
       " 'uOpen': 204.29,\n",
       " 'uClose': 208.48,\n",
       " 'uHigh': 208.84,\n",
       " 'uLow': 203.5,\n",
       " 'uVolume': 32443113,\n",
       " 'change': 0,\n",
       " 'changePercent': 0,\n",
       " 'changeOverTime': 0,\n",
       " 'symbol': 'AAPL'}"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.yesterday(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>change</th>\n",
       "      <th>changeOverTime</th>\n",
       "      <th>changePercent</th>\n",
       "      <th>close</th>\n",
       "      <th>date</th>\n",
       "      <th>high</th>\n",
       "      <th>low</th>\n",
       "      <th>open</th>\n",
       "      <th>uClose</th>\n",
       "      <th>uHigh</th>\n",
       "      <th>uLow</th>\n",
       "      <th>uOpen</th>\n",
       "      <th>uVolume</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>AAPL</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>208.48</td>\n",
       "      <td>2019-05-06</td>\n",
       "      <td>208.84</td>\n",
       "      <td>203.5</td>\n",
       "      <td>204.29</td>\n",
       "      <td>208.48</td>\n",
       "      <td>208.84</td>\n",
       "      <td>203.5</td>\n",
       "      <td>204.29</td>\n",
       "      <td>32443113</td>\n",
       "      <td>32443113</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        change  changeOverTime  changePercent   close       date    high  \\\n",
       "symbol                                                                     \n",
       "AAPL         0               0              0  208.48 2019-05-06  208.84   \n",
       "\n",
       "          low    open  uClose   uHigh   uLow   uOpen   uVolume    volume  \n",
       "symbol                                                                    \n",
       "AAPL    203.5  204.29  208.48  208.84  203.5  204.29  32443113  32443113  "
      ]
     },
     "execution_count": 125,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.yesterdayDF(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'A',\n",
       " 'date': '2019-02-19',\n",
       " 'open': 78,\n",
       " 'high': 78.32,\n",
       " 'low': 77.41,\n",
       " 'close': 77.52,\n",
       " 'volume': 2967968,\n",
       " 'uOpen': 78,\n",
       " 'uHigh': 78.32,\n",
       " 'uLow': 77.41,\n",
       " 'uClose': 77.52,\n",
       " 'uVolume': 2967968,\n",
       " 'change': None,\n",
       " 'changePercent': None}"
      ]
     },
     "execution_count": 126,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.marketYesterday()['A']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>change</th>\n",
       "      <th>changePercent</th>\n",
       "      <th>close</th>\n",
       "      <th>date</th>\n",
       "      <th>high</th>\n",
       "      <th>low</th>\n",
       "      <th>open</th>\n",
       "      <th>uClose</th>\n",
       "      <th>uHigh</th>\n",
       "      <th>uLow</th>\n",
       "      <th>uOpen</th>\n",
       "      <th>uVolume</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>A</th>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>77.52</td>\n",
       "      <td>2019-02-19</td>\n",
       "      <td>78.32</td>\n",
       "      <td>77.41</td>\n",
       "      <td>78.0</td>\n",
       "      <td>77.52</td>\n",
       "      <td>78.32</td>\n",
       "      <td>77.41</td>\n",
       "      <td>78.0</td>\n",
       "      <td>2967968</td>\n",
       "      <td>2967968</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAALF</th>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>31.70</td>\n",
       "      <td>2019-02-19</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>31.70</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAALY</th>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>34.00</td>\n",
       "      <td>2016-06-13</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>34.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAAG</th>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>0.42</td>\n",
       "      <td>2016-06-27</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AAADX</th>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>15.85</td>\n",
       "      <td>2019-02-19</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>15.85</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       change changePercent  close       date   high    low  open  uClose  \\\n",
       "symbol                                                                      \n",
       "A        None          None  77.52 2019-02-19  78.32  77.41  78.0   77.52   \n",
       "AAALF    None          None  31.70 2019-02-19   0.00   0.00   0.0   31.70   \n",
       "AAALY    None          None  34.00 2016-06-13   0.00   0.00   0.0   34.00   \n",
       "AAAG     None          None   0.42 2016-06-27   0.00   0.00   0.0    0.42   \n",
       "AAADX    None          None  15.85 2019-02-19   0.00   0.00   0.0   15.85   \n",
       "\n",
       "        uHigh   uLow  uOpen  uVolume   volume  \n",
       "symbol                                         \n",
       "A       78.32  77.41   78.0  2967968  2967968  \n",
       "AAALF    0.00   0.00    0.0        0        0  \n",
       "AAALY    0.00   0.00    0.0        0        0  \n",
       "AAAG     0.00   0.00    0.0        0        0  \n",
       "AAADX    0.00   0.00    0.0        0        0  "
      ]
     },
     "execution_count": 127,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.marketYesterdayDF().head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Price"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "202.86"
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.price(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>price</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>202.86</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    price\n",
       "0  202.86"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.priceDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Price Target"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'updatedDate': '2019-05-03',\n",
       " 'priceTargetAverage': 214.13,\n",
       " 'priceTargetHigh': 245,\n",
       " 'priceTargetLow': 150,\n",
       " 'numberOfAnalysts': 33}"
      ]
     },
     "execution_count": 130,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.priceTarget(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>numberOfAnalysts</th>\n",
       "      <th>priceTargetAverage</th>\n",
       "      <th>priceTargetHigh</th>\n",
       "      <th>priceTargetLow</th>\n",
       "      <th>symbol</th>\n",
       "      <th>updatedDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33</td>\n",
       "      <td>214.13</td>\n",
       "      <td>245</td>\n",
       "      <td>150</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>2019-05-03</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   numberOfAnalysts  priceTargetAverage  priceTargetHigh  priceTargetLow  \\\n",
       "0                33              214.13              245             150   \n",
       "\n",
       "  symbol updatedDate  \n",
       "0   AAPL  2019-05-03  "
      ]
     },
     "execution_count": 131,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.priceTargetDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Quote"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'companyName': 'Apple, Inc.',\n",
       " 'calculationPrice': 'close',\n",
       " 'open': 205.86,\n",
       " 'openTime': 1557235800311,\n",
       " 'close': 202.86,\n",
       " 'closeTime': 1557259200243,\n",
       " 'high': 207.417,\n",
       " 'low': 200.825,\n",
       " 'latestPrice': 202.86,\n",
       " 'latestSource': 'Close',\n",
       " 'latestTime': 'May 7, 2019',\n",
       " 'latestUpdate': 1557259200243,\n",
       " 'latestVolume': 38391956,\n",
       " 'iexRealtimePrice': 202.89,\n",
       " 'iexRealtimeSize': 100,\n",
       " 'iexLastUpdated': 1557259199899,\n",
       " 'delayedPrice': 203.08,\n",
       " 'delayedPriceTime': 1557260100013,\n",
       " 'extendedPrice': 203.035,\n",
       " 'extendedChange': 0.175,\n",
       " 'extendedChangePercent': 0.00086,\n",
       " 'extendedPriceTime': 1557260433062,\n",
       " 'previousClose': 208.48,\n",
       " 'change': -5.62,\n",
       " 'changePercent': -0.02696,\n",
       " 'iexMarketPercent': 0.022649614414019435,\n",
       " 'iexVolume': 869563,\n",
       " 'avgTotalVolume': 27470518,\n",
       " 'iexBidPrice': 0,\n",
       " 'iexBidSize': 0,\n",
       " 'iexAskPrice': 0,\n",
       " 'iexAskSize': 0,\n",
       " 'marketCap': 933375088800,\n",
       " 'peRatio': 16.92,\n",
       " 'week52High': 233.47,\n",
       " 'week52Low': 142,\n",
       " 'ytdChange': 0.293202}"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.quote(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>avgTotalVolume</th>\n",
       "      <th>calculationPrice</th>\n",
       "      <th>change</th>\n",
       "      <th>changePercent</th>\n",
       "      <th>close</th>\n",
       "      <th>closeTime</th>\n",
       "      <th>companyName</th>\n",
       "      <th>delayedPrice</th>\n",
       "      <th>delayedPriceTime</th>\n",
       "      <th>extendedChange</th>\n",
       "      <th>...</th>\n",
       "      <th>latestVolume</th>\n",
       "      <th>low</th>\n",
       "      <th>marketCap</th>\n",
       "      <th>open</th>\n",
       "      <th>openTime</th>\n",
       "      <th>peRatio</th>\n",
       "      <th>previousClose</th>\n",
       "      <th>week52High</th>\n",
       "      <th>week52Low</th>\n",
       "      <th>ytdChange</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>symbol</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>AAPL</th>\n",
       "      <td>27470518</td>\n",
       "      <td>close</td>\n",
       "      <td>-5.62</td>\n",
       "      <td>-0.02696</td>\n",
       "      <td>202.86</td>\n",
       "      <td>2019-05-07 20:00:00.243</td>\n",
       "      <td>Apple, Inc.</td>\n",
       "      <td>203.08</td>\n",
       "      <td>2019-05-07 20:15:00.013</td>\n",
       "      <td>0.175</td>\n",
       "      <td>...</td>\n",
       "      <td>38391956</td>\n",
       "      <td>200.825</td>\n",
       "      <td>933375088800</td>\n",
       "      <td>205.86</td>\n",
       "      <td>2019-05-07 13:30:00.311</td>\n",
       "      <td>16.92</td>\n",
       "      <td>208.48</td>\n",
       "      <td>233.47</td>\n",
       "      <td>142</td>\n",
       "      <td>0.293202</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows  37 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        avgTotalVolume calculationPrice  change  changePercent   close  \\\n",
       "symbol                                                                   \n",
       "AAPL          27470518            close   -5.62       -0.02696  202.86   \n",
       "\n",
       "                     closeTime  companyName  delayedPrice  \\\n",
       "symbol                                                      \n",
       "AAPL   2019-05-07 20:00:00.243  Apple, Inc.        203.08   \n",
       "\n",
       "              delayedPriceTime  extendedChange  ...  latestVolume      low  \\\n",
       "symbol                                          ...                          \n",
       "AAPL   2019-05-07 20:15:00.013           0.175  ...      38391956  200.825   \n",
       "\n",
       "           marketCap    open                openTime  peRatio  previousClose  \\\n",
       "symbol                                                                         \n",
       "AAPL    933375088800  205.86 2019-05-07 13:30:00.311    16.92         208.48   \n",
       "\n",
       "        week52High week52Low  ytdChange  \n",
       "symbol                                   \n",
       "AAPL        233.47       142   0.293202  \n",
       "\n",
       "[1 rows x 37 columns]"
      ]
     },
     "execution_count": 133,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.quoteDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Recommendation Trends"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Sector Performance"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'sector',\n",
       "  'name': 'Utilities',\n",
       "  'performance': -0.0031,\n",
       "  'lastUpdated': 1557259200308},\n",
       " {'type': 'sector',\n",
       "  'name': 'Energy',\n",
       "  'performance': -0.00871,\n",
       "  'lastUpdated': 1557259200354},\n",
       " {'type': 'sector',\n",
       "  'name': 'Consumer Staples',\n",
       "  'performance': -0.00994,\n",
       "  'lastUpdated': 1557259200271},\n",
       " {'type': 'sector',\n",
       "  'name': 'Consumer Discretionary',\n",
       "  'performance': -0.01516,\n",
       "  'lastUpdated': 1557259200279},\n",
       " {'type': 'sector',\n",
       "  'name': 'Communication Services',\n",
       "  'performance': -0.0162,\n",
       "  'lastUpdated': 1557259200247},\n",
       " {'type': 'sector',\n",
       "  'name': 'Financials',\n",
       "  'performance': -0.0165,\n",
       "  'lastUpdated': 1557259200339},\n",
       " {'type': 'sector',\n",
       "  'name': 'Real Estate',\n",
       "  'performance': -0.01713,\n",
       "  'lastUpdated': 1557259200244},\n",
       " {'type': 'sector',\n",
       "  'name': 'Materials',\n",
       "  'performance': -0.01754,\n",
       "  'lastUpdated': 1557259200264},\n",
       " {'type': 'sector',\n",
       "  'name': 'Health Care',\n",
       "  'performance': -0.0192,\n",
       "  'lastUpdated': 1557259200331},\n",
       " {'type': 'sector',\n",
       "  'name': 'Industrials',\n",
       "  'performance': -0.02022,\n",
       "  'lastUpdated': 1557259200022},\n",
       " {'type': 'sector',\n",
       "  'name': 'Technology',\n",
       "  'performance': -0.02148,\n",
       "  'lastUpdated': 1557259200308}]"
      ]
     },
     "execution_count": 134,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.sectorPerformance()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>lastUpdated</th>\n",
       "      <th>performance</th>\n",
       "      <th>type</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>name</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Utilities</th>\n",
       "      <td>2019-05-07 20:00:00.308</td>\n",
       "      <td>-0.00310</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Energy</th>\n",
       "      <td>2019-05-07 20:00:00.354</td>\n",
       "      <td>-0.00871</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Consumer Staples</th>\n",
       "      <td>2019-05-07 20:00:00.271</td>\n",
       "      <td>-0.00994</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Consumer Discretionary</th>\n",
       "      <td>2019-05-07 20:00:00.279</td>\n",
       "      <td>-0.01516</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Communication Services</th>\n",
       "      <td>2019-05-07 20:00:00.247</td>\n",
       "      <td>-0.01620</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Financials</th>\n",
       "      <td>2019-05-07 20:00:00.339</td>\n",
       "      <td>-0.01650</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Real Estate</th>\n",
       "      <td>2019-05-07 20:00:00.244</td>\n",
       "      <td>-0.01713</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Materials</th>\n",
       "      <td>2019-05-07 20:00:00.264</td>\n",
       "      <td>-0.01754</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Health Care</th>\n",
       "      <td>2019-05-07 20:00:00.331</td>\n",
       "      <td>-0.01920</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Industrials</th>\n",
       "      <td>2019-05-07 20:00:00.022</td>\n",
       "      <td>-0.02022</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Technology</th>\n",
       "      <td>2019-05-07 20:00:00.308</td>\n",
       "      <td>-0.02148</td>\n",
       "      <td>sector</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   lastUpdated  performance    type\n",
       "name                                                               \n",
       "Utilities              2019-05-07 20:00:00.308     -0.00310  sector\n",
       "Energy                 2019-05-07 20:00:00.354     -0.00871  sector\n",
       "Consumer Staples       2019-05-07 20:00:00.271     -0.00994  sector\n",
       "Consumer Discretionary 2019-05-07 20:00:00.279     -0.01516  sector\n",
       "Communication Services 2019-05-07 20:00:00.247     -0.01620  sector\n",
       "Financials             2019-05-07 20:00:00.339     -0.01650  sector\n",
       "Real Estate            2019-05-07 20:00:00.244     -0.01713  sector\n",
       "Materials              2019-05-07 20:00:00.264     -0.01754  sector\n",
       "Health Care            2019-05-07 20:00:00.331     -0.01920  sector\n",
       "Industrials            2019-05-07 20:00:00.022     -0.02022  sector\n",
       "Technology             2019-05-07 20:00:00.308     -0.02148  sector"
      ]
     },
     "execution_count": 135,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.sectorPerformanceDF()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Splits"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 136,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.splits(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: []\n",
       "Index: []"
      ]
     },
     "execution_count": 137,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.splitsDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Upcoming Events"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Volume By Venue"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 138,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'volume': 58855,\n",
       "  'venue': 'XASE',\n",
       "  'venueName': 'NYSE American',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.001550432278327238,\n",
       "  'avgMarketPercent': 0.0013988667649070885},\n",
       " {'volume': 128014,\n",
       "  'venue': 'XCIS',\n",
       "  'venueName': 'NYSE National',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.003372305457102762,\n",
       "  'avgMarketPercent': 0.0027233833629648333},\n",
       " {'volume': 104690,\n",
       "  'venue': 'XCHI',\n",
       "  'venueName': 'CHX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.0035884340065768876,\n",
       "  'avgMarketPercent': 0.019839707033233366},\n",
       " {'volume': 274061,\n",
       "  'venue': 'XPHL',\n",
       "  'venueName': 'Nasdaq PSX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.007219658833245114,\n",
       "  'avgMarketPercent': 0.00758794843446839},\n",
       " {'volume': 366666,\n",
       "  'venue': 'EDGA',\n",
       "  'venueName': 'Cboe EDGA',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.009659175970862884,\n",
       "  'avgMarketPercent': 0.012147458463215965},\n",
       " {'volume': 372534,\n",
       "  'venue': 'BATY',\n",
       "  'venueName': 'Cboe BYX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.009813758191731532,\n",
       "  'avgMarketPercent': 0.02030662022159324},\n",
       " {'volume': 409110,\n",
       "  'venue': 'XBOS',\n",
       "  'venueName': 'Nasdaq BX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.010777289089906657,\n",
       "  'avgMarketPercent': 0.01684399071131908},\n",
       " {'volume': 869563,\n",
       "  'venue': 'IEXG',\n",
       "  'venueName': 'IEX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.022907119925903798,\n",
       "  'avgMarketPercent': 0.02803983675894908},\n",
       " {'volume': 1304584,\n",
       "  'venue': 'XNYS',\n",
       "  'venueName': 'NYSE',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.03722274089130869,\n",
       "  'avgMarketPercent': 0.022422897396352538},\n",
       " {'volume': 1576346,\n",
       "  'venue': 'EDGX',\n",
       "  'venueName': 'Cboe EDGX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.04107767067556842,\n",
       "  'avgMarketPercent': 0.03890235960676351},\n",
       " {'volume': 2378623,\n",
       "  'venue': 'BATS',\n",
       "  'venueName': 'Cboe BZX',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.06198421041385122,\n",
       "  'avgMarketPercent': 0.0683246566594053},\n",
       " {'volume': 2782747,\n",
       "  'venue': 'ARCX',\n",
       "  'venueName': 'NYSE Arca',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.07251343848555453,\n",
       "  'avgMarketPercent': 0.08024871602164509},\n",
       " {'volume': 13039388,\n",
       "  'venue': 'XNGS',\n",
       "  'venueName': 'Nasdaq',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.339789958255991,\n",
       "  'avgMarketPercent': 0.28313339012738925},\n",
       " {'volume': 14710396,\n",
       "  'venue': 'TRF',\n",
       "  'venueName': 'Off Exchange',\n",
       "  'date': '2019-05-07',\n",
       "  'marketPercent': 0.38332673148336127,\n",
       "  'avgMarketPercent': 0.39808016843779326}]"
      ]
     },
     "execution_count": 138,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.volumeByVenue(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>avgMarketPercent</th>\n",
       "      <th>date</th>\n",
       "      <th>marketPercent</th>\n",
       "      <th>venueName</th>\n",
       "      <th>volume</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>venue</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>XASE</th>\n",
       "      <td>0.001399</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.001550</td>\n",
       "      <td>NYSE American</td>\n",
       "      <td>58855</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>XCIS</th>\n",
       "      <td>0.002723</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.003372</td>\n",
       "      <td>NYSE National</td>\n",
       "      <td>128014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>XCHI</th>\n",
       "      <td>0.019840</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.003588</td>\n",
       "      <td>CHX</td>\n",
       "      <td>104690</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>XPHL</th>\n",
       "      <td>0.007588</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.007220</td>\n",
       "      <td>Nasdaq PSX</td>\n",
       "      <td>274061</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>EDGA</th>\n",
       "      <td>0.012147</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.009659</td>\n",
       "      <td>Cboe EDGA</td>\n",
       "      <td>366666</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BATY</th>\n",
       "      <td>0.020307</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.009814</td>\n",
       "      <td>Cboe BYX</td>\n",
       "      <td>372534</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>XBOS</th>\n",
       "      <td>0.016844</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.010777</td>\n",
       "      <td>Nasdaq BX</td>\n",
       "      <td>409110</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>IEXG</th>\n",
       "      <td>0.028040</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.022907</td>\n",
       "      <td>IEX</td>\n",
       "      <td>869563</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>XNYS</th>\n",
       "      <td>0.022423</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.037223</td>\n",
       "      <td>NYSE</td>\n",
       "      <td>1304584</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>EDGX</th>\n",
       "      <td>0.038902</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.041078</td>\n",
       "      <td>Cboe EDGX</td>\n",
       "      <td>1576346</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BATS</th>\n",
       "      <td>0.068325</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.061984</td>\n",
       "      <td>Cboe BZX</td>\n",
       "      <td>2378623</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ARCX</th>\n",
       "      <td>0.080249</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.072513</td>\n",
       "      <td>NYSE Arca</td>\n",
       "      <td>2782747</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>XNGS</th>\n",
       "      <td>0.283133</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.339790</td>\n",
       "      <td>Nasdaq</td>\n",
       "      <td>13039388</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>TRF</th>\n",
       "      <td>0.398080</td>\n",
       "      <td>2019-05-07</td>\n",
       "      <td>0.383327</td>\n",
       "      <td>Off Exchange</td>\n",
       "      <td>14710396</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       avgMarketPercent       date  marketPercent      venueName    volume\n",
       "venue                                                                     \n",
       "XASE           0.001399 2019-05-07       0.001550  NYSE American     58855\n",
       "XCIS           0.002723 2019-05-07       0.003372  NYSE National    128014\n",
       "XCHI           0.019840 2019-05-07       0.003588            CHX    104690\n",
       "XPHL           0.007588 2019-05-07       0.007220     Nasdaq PSX    274061\n",
       "EDGA           0.012147 2019-05-07       0.009659      Cboe EDGA    366666\n",
       "BATY           0.020307 2019-05-07       0.009814       Cboe BYX    372534\n",
       "XBOS           0.016844 2019-05-07       0.010777      Nasdaq BX    409110\n",
       "IEXG           0.028040 2019-05-07       0.022907            IEX    869563\n",
       "XNYS           0.022423 2019-05-07       0.037223           NYSE   1304584\n",
       "EDGX           0.038902 2019-05-07       0.041078      Cboe EDGX   1576346\n",
       "BATS           0.068325 2019-05-07       0.061984       Cboe BZX   2378623\n",
       "ARCX           0.080249 2019-05-07       0.072513      NYSE Arca   2782747\n",
       "XNGS           0.283133 2019-05-07       0.339790         Nasdaq  13039388\n",
       "TRF            0.398080 2019-05-07       0.383327   Off Exchange  14710396"
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.volumeByVenueDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Alternative"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## crypto"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {},
   "outputs": [],
   "source": [
    "# c.crypto()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "metadata": {},
   "outputs": [],
   "source": [
    "# c.cryptoDF()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## sentiment"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 142,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'sentiment': -0.03152100238663484,\n",
       " 'totalScores': 838,\n",
       " 'positive': 0.69,\n",
       " 'negative': 0.31}"
      ]
     },
     "execution_count": 142,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.sentiment(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>negative</th>\n",
       "      <th>positive</th>\n",
       "      <th>sentiment</th>\n",
       "      <th>totalScores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.31</td>\n",
       "      <td>0.69</td>\n",
       "      <td>-0.031521</td>\n",
       "      <td>838</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   negative  positive  sentiment  totalScores\n",
       "0      0.31      0.69  -0.031521          838"
      ]
     },
     "execution_count": 143,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.sentimentDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## CEO Compensation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'symbol': 'AAPL',\n",
       " 'name': 'Tim Cook',\n",
       " 'companyName': '',\n",
       " 'location': 'Cupertino, CA',\n",
       " 'salary': 3057692,\n",
       " 'bonus': 0,\n",
       " 'stockAwards': 0,\n",
       " 'optionAwards': 0,\n",
       " 'nonEquityIncentives': 9327000,\n",
       " 'pensionAndDeferred': 0,\n",
       " 'otherComp': 440374,\n",
       " 'total': 12825066,\n",
       " 'year': '2017'}"
      ]
     },
     "execution_count": 144,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ceoCompensation(symbol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>bonus</th>\n",
       "      <th>companyName</th>\n",
       "      <th>location</th>\n",
       "      <th>name</th>\n",
       "      <th>nonEquityIncentives</th>\n",
       "      <th>optionAwards</th>\n",
       "      <th>otherComp</th>\n",
       "      <th>pensionAndDeferred</th>\n",
       "      <th>salary</th>\n",
       "      <th>stockAwards</th>\n",
       "      <th>symbol</th>\n",
       "      <th>total</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>Cupertino, CA</td>\n",
       "      <td>Tim Cook</td>\n",
       "      <td>9327000</td>\n",
       "      <td>0</td>\n",
       "      <td>440374</td>\n",
       "      <td>0</td>\n",
       "      <td>3057692</td>\n",
       "      <td>0</td>\n",
       "      <td>AAPL</td>\n",
       "      <td>12825066</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   bonus companyName       location      name  nonEquityIncentives  \\\n",
       "0      0              Cupertino, CA  Tim Cook              9327000   \n",
       "\n",
       "   optionAwards  otherComp  pensionAndDeferred   salary  stockAwards symbol  \\\n",
       "0             0     440374                   0  3057692            0   AAPL   \n",
       "\n",
       "      total  year  \n",
       "0  12825066  2017  "
      ]
     },
     "execution_count": 145,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "c.ceoCompensationDF(symbol)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Forex"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Exchange Rates"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# IEX Data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## TOPS"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Last"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Auction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Book"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Operational Halt Status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Official Price"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Security Event"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Short Sale Price Test Status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP System Event"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Trades"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Trade Break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## DEEP Trading Status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Listed Regulation SHO Threshold Securities List In Dev"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Listed Short Interest List In Dev"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Stats Historical Daily In Dev"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Stats Historical Summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Stats Intraday"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Stats Recent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Stats Records"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# API Metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
